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C H A P T E R   1 




Nutrition [noun]: ‘‘The process by which living things receive the food necessary for them to grow 
and be healthy’’ – Oxford dictionary 
Introduction 
Optimal nutrition during childhood is one of the essential prerequisites for normal growth, 
development and providing lifelong health. A healthy and well-balanced diet, rich in fruits, 
vegetables and whole grains, helps to protect against malnutrition in all its forms, as well as 
a range of diseases.1 During critical illness the child is subjected to neuro-endocrine, 
immunologic and metabolic changes, commonly referred to as acute stress response, which 
temporarily inhibits the normal developmental process in order to survive.2 Admission to 
the paediatric intensive care unit (PICU) may result in harmful consequences prolonging 
long after PICU admission. The goal of nutritional support is to provide an appropriate 
amount of feeding in order to accelerate recovery and to have beneficial effects on both 
short-term outcome and long-term physical, neurocognitive and mental health. Both 
undernutrition and overfeeding have been associated with impaired outcomes.3-5 Critically 
ill infants and children are thought to be particularly vulnerable for development of 
nutritional deficiencies due to their limited body reserves and increased energy expenditure. 
Acute stress response 
The acute stress response to critical illness can be categorised into an acute, stable and 
recovery phase and the nutritional goals differ throughout the phases of the disease.6 The 
first phase of critical illness, the acute phase, is characterised by (escalating) requirement of 
viral organ support after admission to the paediatric intensive care unit (PICU) and may last 
up to several days. This is followed by a stable phase, where stabilisation or weaning of vital 
organ response occurs. The final phase, the recovery phase, is characterised by 
normalisation of stress response and clinical mobilisation. The awareness of the changes in 
metabolism during the different phase of critical illness is fundamental in determining 
metabolic and nutritional support. Thereby, during the complete course of admission both 
underfeeding and overfeeding should be avoided. Although optimal nutrition is considered 
an essential therapy during critical illness, there is a lack of causal evidence favouring specific 
strategies. 
Neuro-endocrine stress response 
The neuroendocrine response to critical illness predominantly involves enhanced activation 
of the hypothalamic function without activation of the peripheral pathways. This evolves to 
a reduction in pulsatile secretion of adrenocorticotropic hormone (ACTH), thyroid-
stimulating hormone (TSH), growth hormone (GH), prolactin, and luteinising hormone 
when the child enters the stable phase of illness. 
Hypothalamic-pituitary-thyroid axis 
Paediatric critical illness is typically presented with reduced plasma concentrations of 
triiodothyronine (T3), without physiological increase of TSH, as well as increase of inactive 
hormone reverse T3 (rT3) and decreased or normal thyroxine (T4). This phenomenon is 
commonly referred to as non-thyroidal illness syndrome (NTIS) and holds a strong 
correlation with the severity of illness.7,8 During acute stress non-thyroidal illness syndrome 
seems to be the result of increased peripheral inactivation of thyroid hormones and is a 
beneficial adaptation of the body to reduce energy expenditure and activate the innate 
immune response in order to survive. These plasma alterations can be variable and are 
believed to be adaptive in response to environmental factors, including nutritional support 
and inflammatory stimuli.9-11 
Hypothalamic-pituitary-adrenal axis 
The production of endogenous glucocorticoids, predominantly cortisol, are essential for 
normal homeostasis and play an essential role in the acute stress response.12,13 Cortisol 
levels normally fluctuate throughout the day in a circadian rhythm. Due to illness related 
factors, such as inflammation, splanchnic nerve output, and central nervous system control 
affect the pulsatile release and negative feedback system.14,15 In response to critical illness, 
corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) are increasingly 
released by the hypothalamus. This stimulates the release of ACTH from the pituitary into 
the circulation, which increases the rate of synthesis and secretion of cortisol from the 
adrenal cortex.16 In critically ill children the increase in cortisol availability is temporary and 
low levels of ACTH and high levels of cortisol are associated with worsened recovery.17 
Somatotropic Axis 
Growth hormones (GH) play a pivotal role in paediatric growth during health and induces 
a metabolic effect in a physiologic response to food intake and circadian rhythm.18 The 
release of GH is regulated by hypothalamic growth hormone releasing hormone (GHRH), 
the gut hormone ghrelin and the inhibitory hormone somatostatin. During stress the GH 
secretion is enhanced due to GH resistance in peripheral tissue, which is seen by a decrease 
in plasma concentrations of insulin-like growth factor I (IGF-I), which affects lipolysis and 
insulin antagonism.19 During prolonged critical illness GH secretion and low IGF-I 
concentrations occurs, which is associated with enhances protein catabolism and 
preservation of fat tissue.20 
Immunologic and metabolic stress response  
The immunologic and metabolic stress response is mediated by catabolic hormones 
(glucagon, catecholamines and corticosteroids), insulin resistance and local mediators 
(cytokines, eicosanoid and oxygen radicals). The acute phase is characterised by an enhanced 
metabolic rate associated with increased release of endogenous substrates for energy 
metabolism and increased inter-organ substrate exchanges. Increased pro-inflammatory 
cytokines cause a release of catabolic hormones stimulating a release of glucose and due to 
depletion in glycogen storages as a result of low intake this glucose is mainly formed via 
gluconeogenesis in the liver, kidney and muscle, which is the production of glucose from 
non-carbohydrate sources (i.e. protein, triacylglycerol).21-23 Peripheral insulin resistance 
together with increased gluconeogenesis result in hyperglycaemia, which is often seen during 
critical illness. During this catabolic state the amount of protein degraded for 
gluconeogenesis can be measured by increased excretion of nitrogen from the body. 
Carbohydrates are the preferred energy substrate over fat; however, stress hormones and 
glucagon can activate lipolysis resulting in a release of fatty acids and glycerol from adipose 
tissue as an alternative form of energy into the bloodstream.24,25 These fatty acids are 
produced into ketone bodies via ketogenesis by the liver. In most peripheral tissue cells 
these ketone bodies can be oxidised via the citric acid cycle in the mitochondria into 
energy.26 Furthermore, ketone bodies can cross the blood-brain barrier and are a main 
source of energy during fasting for the central nervous system.27 During stable and recovery 
phase the metabolic response shift towards an anabolic phase and is characterised by 
restoration of amino acid and lipid stores and normalization of nitrogen balance.28  
Underfeeding and overfeeding 
Acute phase 
Observational studies have found that malnourishment and nutritional deficits, often as a 
result of feeding intolerance, prolonged fasting around procedures and fluid restriction, are 
associated with delayed wound healing, reduced immune response, malabsorption, bacterial 
overgrowth and increased morbidity and mortality, as well as neurological and psychological 
long-term development disorders.3,29,30  
Two large observational studies involving 500 and 1200 critically ill ventilated children who 
received nutritional support via EN and PN presented an association between insufficient 
nutritional support and worse clinical outcomes. The first study found an association 
between improvement in 60 day mortality and higher enteral energy intake (energy goal 
achievement of >67% as compared with <33%).3 The second study found a similar 
association between reaching higher protein goals via enteral route and lower mortality 
rates, in which the found beneficial effect of protein was independent of the energy intake 
(protein goal achievement of 20-60% or >60% as compared with <20%).4 Due to the 
observational nature of these studies a cautious interpretation is necessary, as children who 
are less critical ill might tolerate EN better, and therefore already have an accelerated 
recovery. Without randomised controlled trials it is impossible to know if the impact on 
clinical outcome is caused by lower enteral intake, gastrointestinal dysfunction or other 
factors affected due to the underlying illness.  
Overfeeding in its turn may lead to fatty liver disease, hyperglycaemia and increased 
respiratory burden due to the increase in CO2 production present by lipogenesis from 
carbohydrates. The risk of overfeeding is considerably prominent during the acute phase, 
especially when PN is provided to supplement nutrition in children with intolerance to 
feeding or other barriers. A small retrospective study actually showed that overfeeding 
(defined as >110% of measured REE) was associated with worse outcome as compared with 
children who received nutrition within or below (<90% REE) range.5 Nonetheless, additional 
investigation is warranted to find the balance between overfeeding and underfeeding during 
the acute phase. 
Stable and recovery phase  
During the stable and recovery phase the body can shift from catabolism to anabolism and 
nutritional support should focus on increasing protein and energy intake to enable recovery, 
growth and even catch-up development. The focus during this phase should be to allow 
restoration of lean body mass and prevent muscle loss as a result of prolonged 
immobilisation. There are indications based upon observational studies that during the stable 
and recovery phase nutritional requirements rise markedly and even increase above normal 
requirements of a healthy growing child.31-34 
Identification of barriers in nutritional therapy 
The gastrointestinal tract is the preferred route of nutritional support. Enteral nutrition 
(EN) is considered safe, cost effective and more physiologic compared to Parenteral 
Nutrition (PN). Guideline recommendations for caloric and protein targets are often not 
achieved via enteral route and discrepancies between the amount prescribed and delivered 
ranged up to 60%.3,4,35,36 There have been numerous studies describing reasons for these 
discrepancies, with (perceived) feeding intolerance as a result of gastrointestinal dysfunction, 
fluid restriction, fasting around extubation and (bedside) procedures as most frequently 
reported.37-39 To improve EN delivery these barriers need to be identify and addressed 
earlier during the course of PICU admission. 
Gastrointestinal dysfunction 
In order to provide optimal enteral nutrition, the ‘‘gut’’ needs to function appropriately. 
During critical illness the gut is subjected to numerous adverse influences such as ischemia, 
altered blood flow, lack of EN and medication resulting in gastrointestinal dysfunction. In 
addition, during critical illness the gastrointestinal function may be affected by 
impoverishment of the microbiome and intestinal inflammation. As such the metabolic 
utilisation and assimilation of amino acids, carbohydrates and fats and micronutrients may 
be altered. Failure of the gastrointestinal tract to digest and absorb nutrients is commonly 
referred to by the descriptive term “feeding intolerance” and is associated with adverse 
clinical outcomes.40-42 Feeding intolerance may arise from a diversity of mechanisms including 
intestinal inflammation, altered enterocyte function and/or impaired gastrointestinal 
motility, including delayed gastric emptying.  
Identification of feeding intolerance  
Even though feeding intolerance is one of the most reported reasons for insufficient enteral 
intake in critically ill children, there is currently no consensus on when we should consider 
a child feeding intolerant. Table 1 presents an overview of symptoms used by clinicians to 
describe (perceived) feeding intolerance in critically ill children. Many of these symptoms 
are subjective.43 The definition used in research are also vague and elusive. Without a more 
uniform and objective definition we cannot provide insight on the possible magnitude, causes 
and consequences of feeding intolerance, or more importantly, adequately compare 
nutritional intervention in studies to overcome feeding intolerance as a barrier for optimal 
nutritional support.  
Enteral feeding practices 
Besides human milk, different types of EN formula including different protein and fat 
contents are available in children. These formulas can be classified into polymeric, semi-
elemental (oligomeric), elemental (monomeric) or disease specialised. Traditionally human 
milk or polymeric standard enteral feeds are used as first line. However, when full EN to 
account for high nutritional requirements is not tolerated or possible because due to PICU 
barriers, a protein and energy-enriched or semi-elemental (hydrolysed) protein and energy-
enriched formulas can be considered.44  
Protein and energy-enriched formula may have an additional value in children with fluid-
restriction i.e. after congenital heart surgery, or during recovery phase when energy 
requirements may rise remarkably. Previously, it has been shown that protein balances were 
positive in infants during the first days after PICU admission with the use of protein and 
energy-enriched formula compared to standard formula, however, this trial was not 
designed to provide evidence of the impact of these results on clinical outcome.45 While 
this formula is recommended to be considered by the guidelines when energy and protein 
goals cannot be reached with standard formula, currently, little data are available on feeding 
tolerance, recovery and growth in critically ill children during stable and recovery phase.  
Semi-elemental formulas are partially pre-digested (hydrolysed) and contain peptides of 
varying chain length, simple carbohydrates, and primarily medium chain triglycerides. These 
formulas have been used to treat non-critically ill children with feeding intolerance for many 
years and are also advised in critically ill children presenting with feeding intolerance, as they 
are believed to result in better absorption, are less allergenic and are better tolerated in 
patients with a malabsorptive state.46 There is a lack of evidence for the use of this type of 
formula in critically ill infants. However. a recent RCT in 180 children above 1 year showed 
a decrease in feeding interruptions and abdominal distention with faster achievement of EN 
targets and improved weight gain with semi-elemental formula as compared with polymeric 
formula.47  
Enteral feeding can be provided continuously via post-pyloric route or gastric or 
intermittently (bolus) via gastric route. Overall, gastric feeding can be considered safe in the 
majority of patients with no evidence favouring continuous or intermittent feeding in regards 
to feeding intolerance or achievement of nutrient targets.48-50 Furthermore, post-pyloric 
feeding may be considered in children with a high risk for aspiration or if nutritional target 
are not achieved via gastric feeding.51,52  
Table 1. Signs to define perceived feeding intolerance in critically ill children. 
Sign/ Symptom Comment 
Gastric residual 
volume (GRV)  
 
Most commonly used parameter, invalid marker of delayed gastric 
emptying, definitions highly variable and no evidence to support ‘‘high’’ 
GRV and prone to measurement error 
Colour of gastric 
aspirate 
Very subjective  
Vomiting (emesis)  May be induced by coughing, opiates and other drugs, withdrawal 
syndrome 
Diarrhoea Definition problematic in infants and can be induced by infections, drugs, 
bowel ischemia, withdrawal syndrome 
Stool output  
 
May be useful if being fed enterally 
Abdominal 
distention  
Subjective unless girth measured accurately over time and may be 
induced by other factors; no clear threshold 
Bowel sounds  No evidence relates to feed tolerance, are objective, but often poorly 
assessed 




No research in critically ill children in relation to feed tolerance 
Adapted with permission from Tume et al.43 
 
Supplemental parenteral nutrition 
In critically ill children with insufficient enteral intake due to gastrointestinal dysfunction or 
PICU barriers, parenteral nutrition (PN) is often initiated to reach recommended target 
nutritional intake. PN usually contains numerous components, including macronutrients 
(carbohydrates, amino acids, lipids) and micronutrients (electrolytes, trace elements and 
vitamins). PN guidelines historically had to base their recommendation for optimal timing, 
amount and composition upon very few studies in paediatric critical care and all using 
intermediate or surrogate endpoints, such as inflammation markers or nitrogen balances, 
thereby PN appeared to positively influence those surrogate markers.53,54 Furthermore, 
underfeeding has been associated with unfavourable outcome in many studies, thus based 
on expert consensus and observational studies, PN was advised during the acute, stable and 
recovery phase of critical illness to achieve early and high nutritional goals.55  
It was not until the paediatric early versus late PN in critically ill children (PEPaNIC) 
randomised controlled trial (RCT) that the recommendations to reach high and early 
macronutrient goals via PN were reassessed.56 This large multicentre RCT involving 1440 
critically ill children showed that withholding supplemental macronutrients (amino acids, 
carbohydrates and lipids) via PN for seven days (late PN), as compared with initiating PN 
within 24 hours after admission (early PN), improved short-term outcome in critically ill 
children.56,57 Children allocated to the late PN group, thus excepting lower than 
recommended macronutrient intake, had a lower incidence of new acquired infections and 
shorter length of stay (PICU and hospital). This was independent of confounders such as 
illness severity, age and malnutrition upon admission. Moreover, secondary analyses of the 
PEPaNIC RCT showed that also term neonates and undernourished children who are 
thought to be more vulnerable to nutritional deficiencies benefited from the acute phase 
parenteral macronutrient restriction.58,59  
In addition, recent studies have shown that restriction of parenteral macronutrients during 
the acute phase ameliorates the neuro-endocrine response shown by further reduction in 
plasma concentrations of TSH, total T4, T3, and the ratio of T3 (active) to reverse T3 
(inactive), which was not seen in patients receiving early feeding.11 Furthermore, the 
inactivation of T4 to reverse T3 and T3 to T2, altering the T3/reverse T3 ratio, might be a 
beneficial adaptation during acute illness as a result of caloric restriction associated with 
improved outcome in critically ill children.11,17,60 
Except for the PEPaNIC RCT, there are no other interventional studies that have focused 
on optimal timing or amount of PN in critically ill children and, therefore, recent updated 
SCCM/ESICM61, ESPNIC44 and ESPGHAN/ESPEN/ESPR/CSPEN62 guidelines advise to 
consider withholding parenteral macronutrients during the first week of paediatric critical 
illness, while continue to provide micronutrients in children. 
Long-term developmental outcome 
The improvements of medical devices and therapy has led to a substantial decrease in 
mortality rates over the past decades. Children, especially young infants, are in the 
fundamental phase of development. After admission to the PICU children may experience 
new or deteriorating impairments in their psychical, neurocognitive and mental health status 
for months or even years, which is defined as the post-intensive care syndrome (PICS).63,64 
Due to the increasing number of PICU survivors, it becomes increasingly important to 
consider long-term developmental physical and neurocognitive complications post-intensive 
care in addition to short-term improvements. Overall, studies investigating PICU survivors 
find lower scores for neurocognitive and mental health compared to the healthy population, 
with several risk factors identified to influence the degree of neurocognitive impairment 
including younger age at admission, need for high oxygen requirements and duration of 
mechanical ventilation, sedation and opioid therapy.65 The consequences of the post-
intensive care syndrome does not only cause growing health care costs but also reduces 
health-related quality of life.66 
Both underfeeding and overfeeding have been associated with impaired growth, cognitive 
functioning and emotional and behavioural problems in non-critically ill children.67,68 
However, there is a lack of evidence regarding long-term developmental outcomes of 
optimal enteral and/or parenteral nutrition. Due to this increasing number of survivors 
together with a gaining knowledge on the long-term legacy of paediatric critical illness, it 
seems imperative to incorporate long-term psychical and neurocognitive development 
before implementation or de-implementation of certain nutritional interventions. 
 
  
A I M S   A N D   O U T L I N E   O F  T H E S I S   
Part I: Introduction  
Admission to the PICU has detrimental consequences on morbidity and mortality. 
Nutritional therapy plays an important role in accelerating recovery and maintaining normal 
physical and neurocognitive development. The aim of this thesis is to provide insight on 
optimal nutritional therapy for critically ill children concerning the route, timing and amount.  
 
Part II: Identification of barriers in nutritional therapy 
~the acute phase 
The second part of this thesis is devoted to barriers in (enteral) nutritional therapy and 
aimed to find solutions to overcome these barriers. Chapter 2 aims to find PICU related 
barriers via a world survey and develops a tool to find and possible overcome these barriers 
on individual PICU sites. Non-invasive ventilation as a possible barrier for EN delivery is 
investigated in Chapter 3 and (perceived) feeding intolerance in critically ill children is 
systematically reviewed in Chapter 4. In Chapter 5 the amount of enteral intake during the 
acute phase of critical illness is associated with short-term clinical outcomes.  
 
~the stable and recovery phase 
The use of protein and energy-enriched or hydrolysed protein and energy-enriched enteral 
formulas during the recovery phase of critical illness are reviewed in Chapter 7. Chapter 8 
aims to find associations between protein and energy-enriched formula and feeding 
intolerance. These findings are followed by Chapter 9 which aims to find similar associations 
with hydrolysed protein and energy-enriched formula. 
 
Part III: Parenteral nutrition: macronutrients and micronutrient 
supplementation 
The third part of the thesis aims to review the role of parenteral macronutrients and 
micronutrients as a nutritional therapy in Chapter 9, and to answer how to provide 
parenteral micronutrients in Chapter 10.  
 
Part IV: Long-term developmental outcome of parenteral nutrition 
Children are in the fundamental phase of development and before implementation of a 
nutritional therapy in clinical practise the long-term developmental, physical and 
neurocognitive consequences have to be investigated. The developmental outcomes of the 
nutritional intervention of omitting parenteral nutrition during the acute phase of critical 





Part V: General discussion, future perspectives and summary 
The final part of this thesis is dedicated to the general discussion and places the results in 
broader perspectives and areas of current and future research are described (Chapter 13). 
The thesis is summarised in Chapter 14.  
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A B S T R A C T  
Objectives: To explore the perceived barriers by paediatric intensive care healthcare 
professionals (nurses, dieticians, and physicians) in delivering enteral nutrition to critically ill 
children across the world. 
 
Design: Cross-sectional international online survey adapted for use in paediatric settings. 
 
Setting: PICUs across the world. 
 
Subjects: PICU nurses, physicians, and dietitians. 
 
Interventions: The 20-item adult intensive care “Barriers to delivery of enteral nutrition” 
survey was modified for paediatric settings, tested, and translated into 10 languages. The 
survey was distributed online to paediatric intensive care nurses, physicians, and dieticians 
via professional networks in March 2019 to June 2019. Professionals were asked to rate 
each item indicating the degree to which they perceived it hinders the provision of enteral 
nutrition in their PICUs with a 7-point Likert scale from 0 “not at all a barrier” to 6 “an 
extreme amount.” 
 
Measurement and Main Results: Nine-hundred twenty paediatric intensive care 
professionals responded from 57 countries; 477 of 920 nurses (52%), 407 of 920 physicians 
(44%), and 36 of 920 dieticians (4%). Sixty-two percent had more than 5 years PICU 
experience and 49% worked in general PICUs, with 35% working in combined cardiac and 
general PICUs. The top three perceived barriers across all professional groups were as 
follows: 1) enteral feeds being withheld in advance of procedures or operating department 
visits, 2) none or not enough dietitian coverage on weekends or evenings, and 3) not enough 
time dedicated to education and training on how to optimally feed patients. 
 
Conclusions: This is the largest survey that has explored perceived barriers to the delivery 
of enteral nutrition across the world by physicians, nurses, and dietitians. There were some 
similarities with adult intensive care barriers. In all professional groups, the perception of 
barriers reduced with years PICU experience. This survey highlights implications for PICU 
practice around more focused nutrition education for all PICU professional groups. 
  
 
I N T R O D U C T I O N  
Successfully achieving delivery of enteral nutrition (EN) to critically ill children is associated 
with improved clinical outcomes.1,2 Yet, multiple barriers remain to achieving adequate 
nutrition enterally in the critically ill child. Some of these are common to all PICUs, but for 
some, the barrier is organization and unit specific.3,4 Recently, a survey instrument was 
developed and validated for adult ICUs (AICUs)5-7 to assess EN barriers in an ICU. This tool 
allowed clinicians to directly assess and address the perceived barriers in their ICU, with an 
aim to optimise EN delivery. In the adult survey, 20 known barriers to delivering EN 
identified in the literature are rated on a Likert scale relating to the perception of the item 
being a barrier. The aim of our study was to explore the barriers in providing optimal 
nutrition to children in PICU settings worldwide, as viewed by nurses, doctors, and 
dieticians using this survey tool, modified for the paediatric setting. 
 
M E T H O D S  
A cross-sectional electronic survey design was used. The 20-item adult survey instrument5-
7 was examined and modifications were made based on previously identified paediatric 
barriers from the literature. The modified survey was then pilot tested in a single U.K. PICU 
with 62 PICU staff (physicians, nurses, and dieticians). All items from the adult survey were 
considered relevant and therefore no items were deleted; however, the wording of some 
items was revised for clarification. Four additional barrier items specific for PICU population 
were identified and added to the survey. Afterward, pilot testing with nine professionals in 
a second PICU (in France) using the same method yielded one additional barrier item, 
resulting in a new 25-item barrier of EN in PICU survey (Appendix). Added items were as 
follows: 1) severe fluid restriction; 2) conservative PICU feeding protocol; 3) feeding tube 
or pomp delivery problems; 4) enteral feeds withheld for bedside procedures; and 5) lack 
of staff knowledge and support around breastfeeding mothers. 
In addition to the 25 barriers, basic demographic data was collected; PICU experience, PICU 
type and country, with one open-ended question asking if there were any other barriers not 
listed. The survey was translated from English by bi-lingual clinicians into 10 languages 
(French, Italian, Dutch, German, Latvian, Chinese, Spanish, Arabic, Polish, and Portuguese) 
using a recognised cultural adaptation process8 and tested by local clinicians for face validity. 
SurveyMonkey (San Mateo, CA) was used for distribution. Given the nature of distribution 
of this survey, there was no anticipated survey response. However, we aimed for an equal 
spread across continents and near equal among professional groups (acknowledging that the 
dietician numbers would be lower based on the number of dietitians compared with 
physicians and nurses). The inclusion criteria were as follows: nurses, assistant nurses, 
dieticians, and doctors who are working in a PICU and make decisions around feeding in 
 
critically ill children. The exclusion criteria were as follows: nonclinical nurses or staff who 
worked permanently outside clinical PICU setting. Neonatal and adult intensive care staff 
were excluded. If PICUs were mixed (neonates or adults), the introduction letter made it 
clear that the questions were to be answered regarding feeding in children 0 (term infants) 
to 17 years old. 
Data Collection 
The e-survey was sent out via established professional networks to PICU nurses, doctors, 
and dieticians via country leads and via organizational newsletters (The European Society of 
Paediatric and Neonatal Intensive Care [ESPNIC], the U.K. Paediatric Intensive Care Society 
[PICS], and the World Federation of Paediatric Intensive Care Societies in March 2019 to 
June 2019). Reminders were sent to country leads with low responses to improve response 
rates. No identifiable staff, patient, or PICU data were collected, and consent was implied 
by completing the survey. Country leads were responsible for ensuring ethical requirements 
were obtained according to their country regulation. In the United Kingdom (where data 
were gathered and analysed), this study was approved by the PICS study group and was 
approved as an audit by University Hospitals Bristol. Ethical approval was provided in the 
Netherlands by the Institutional Review Board of the Erasmus Medical Centre (MEC-2019-
0065). 
Data Analysis 
The datasets (one for each language version) from SurveyMonkey were downloaded, 
checked, and combined into one dataset and imported into IBM SPSS Version 25 (IBM Corp., 
Armonk, NY) for analysis. All data were categorical data or ordinal data (Likert scale) and 
were first analysed descriptively and then inferential analysis undertaken to test relationships 
between categorical variables including continents/geographical regions, professional 
groups, PICU type regarding perceived barriers using chi-square tests. The Likert scale 
ranged from 0 (not at all) to 6 (an extreme amount). Median (interquartile range) refers to 
the full Likert scale. However, barriers were further categorised as not a barrier 
(respondents who scored 0), moderate barrier (respondents who scored 1–3), and 
important barrier (respondents who scored score 4–6) consistent with the adult survey 
analysis (5,6). For subgroup analysis, the Europe countries were classified into three 
European regions as in the End-of-life Practices in European Intensive Care Units: The 
Ethicus Study (9): northern (Ireland, Latvia, Lithuania, the Netherlands, Sweden, and United 
Kingdom); central (Austria, Belgium, Germany, France, Luxembourg, Poland, and 
Switzerland); and southern (Bulgaria, Italy, Portugal, Spain). When a statically significant level 
was obtained using chi-square test, differences between the variable were further compared 
using a z test with Bonferroni correction. A p value of less than 0.05 was considered 
significant and two-tailed tests were used. 
 
 
R E S U L T S  
There were 920 survey responses from 57 countries (Figure 1). Most respondents were 
nurses (52%) and physicians (44%), followed by dieticians (4%). Sixty-two percent of 
respondents had more than 5 years PICU experience, and half (49%) worked in a general 
PICU with 32% in a mixed cardiac and general PICU (Table 1). 
The top five perceived barriers were as follows: 1) Enteral feeds being withheld in advance 
of procedures or operating department visits (43%); 2) No dietician coverage on weekends, 
evenings, or holidays (38%); 3) Not enough time dedicated to education and training on 
optimal feeding of patients (34%); 4) In stable resuscitated patients, other aspects of 
caretaking priority over nutrition (33%); and 5) Delays in obtaining small bowel access in 
patients intolerant of nutrition (31%). Table 2 presents the perceived importance of all 
barriers. However, these perceived barriers differed by professional group (Tables 3 and 4). 
Importantly, dietitians perceived severe fluid restriction as the most significant barrier (69%), 
whereas for physicians, it was withholding feeds before procedures (46%) and for nurses, it 
was insufficient dietician coverage on weekends, evenings, and holidays (44%). 
Comparing different PICU types: general PICUs compared with units which admitted cardiac 
surgical children and combined PICU-neonatal ICUs (NICUs) showed little differences in 
perceived barriers (Table 5) with severe fluid restriction being rated highly as a barrier 
across all PICU types (general 27% vs general and cardiac 31% vs PICU and NICU 26%; 
p=0.354). The two highest perceived barriers were consistent among the PICU types: Not 
enough (or no) dietician coverage during weekends, evenings, and holidays (p=0.664) and 
not enough time dedicated to education and training on how to optimally feed patients 
(p=0.701). When we examined perceived barriers by years of PICU experience, in all 
groups, we found a reduction in perceived barriers as PICU experience increased 
(Appendix). This was statistically significant for seven barriers. 
There were also significant differences in 14 perceived barriers when comparing continents 
(Appendix). Across all continents, the biggest perceived barrier was enteral feeds being 
withheld for procedures and operating department visits, and this was the highest perceived 
barrier in Southern America. A lack of knowledge around breastfeeding mothers was also 
significantly different between continents with the barrier perceived almost three times 
more in Northern America (48%) compared with Australasia (17%) (p=0.001). Most 
strikingly, was the perceived lack of dietician support and coverage in PICUs, which varied 
across countries, but even in units with a dietician (many had no dietitian input at all). 
  
 
Table 1. Characteristics of the responders  
Characteristics No. of surveys (N=920) 
Continent  
Europe 
    Northern region 
    Central region 
    Southern region 
517 (56%) 
    220 (24%) 
    171 (19%) 
    126 (14%) 
Asia 314 (34%) 
Latin America 48 (5%) 
North America 31 (3%) 
Oceania 8 (1%) 
Africa 2 (0%) 
Type of PICU  
General 453 (49%) 
General and Cardiac 319 (35%) 
PICU and NICU combined 125 (14%) 
Other or missing 23 (3%) 
Primary clinical specialty  
Nurse 477 (52%) 
Physician 407 (44%) 
Dietitian 36 (4%) 
Years of working experience  
0 – 5 years 356 (39%) 
6 – 10 years 215 (24%) 
11 – 15 years 133 (15%) 
> 15 years 211 (23%) 
Missing 5 (1%) 
















Delivery of Enteral Nutrition to the Patient    
1. Delay in physicians ordering the initiation of EN. 2 [1-3] 11.9% 20.1% 
2. Waiting for physician to order and check x-ray to confirm tube placement. 1 [0-2] 29.8% 13.6% 
3. Frequent displacement of feeding tube, requiring reinsertion. 1 [1-1] 17.1% 12.1% 
4. Delays in initiating motility agents in patients not tolerating enteral nutrition (i.e. high gastric 
residual volumes). 
2 [1-3] 11.0% 19.1% 
5. Delays and difficulties in obtaining small bowel access in patients not tolerating enteral 
nutrition (i.e. high gastric residual volumes). 
3 [2-4] 5.1% 30.9% 
6. In resuscitated, hemodynamically stable patients, other aspects of patient care still take priority 
over nutrition. 
3 [1-4] 8.1% 33.0% 
7. Nutrition therapy not routinely discussed on ward rounds. 1 [0-3] 30.1% 18.5% 
8. Severe fluid restriction (especially post-operative cardiac surgery). 2 [1-4] 9.8% 29.2% 
9. Conservative PICU feeding protocol. 2 [1-3] 23.2% 16.4% 
10. Difficulty in delivering enteral feed due to feeding tube obstruction or pump delivery problems 
with thickened formula. 
1 [0-2] 26.9% 10.8% 
Dietitian Support (Only if dietitian present; N=728) 
11. Waiting for the dietitian to assess the patient. 2 [1-3] 17.2% 15.2% 
12. Dietitian not routinely present on weekday patient rounds. 2 [1-4] 24.2% 29.6% 
13. No or not enough dietitian coverage during evenings, weekends and holidays. 3 [1-4] 11.5% 38.4% 
14. Not enough time dedicated to education and training on how to optimally feed patients. 3 [1-4] 9.7% 33.7% 
PICU Resources    
15. Delays to preparing or obtaining non-standard enteral feeds  2 [1-3] 13.6% 15.7% 
16. No or not enough feeding pumps on the unit. 
 
1 [0-2] 49.7% 12.0% 
 
Healthcare Professional Attitudes and Behaviour    
17. Non-PICU physicians (i.e. surgeons, gastroenterologists) requesting patients not be fed 
enterally. 
2 [1-3] 12.1% 17.4% 
18. Nurses failing to progress feeds as per the feeding protocol. 1 [0-2] 28.2% 10.3% 
19. Enteral feeds withheld due to diarrhoea. 2 [1-3] 12.6% 13.0% 
20. Fear of adverse events due to aggressively enterally feeding patients.  2 [1-3] 13.4% 18.4% 
21. Enteral feeds withheld for bedside procedures, such as physiotherapy, turns, and 
administration of certain medications. 
2 [1-3] 12.0% 20.5% 
22. Enteral feeds being withheld in advance of procedures or operating department visits. 3 [2-4] 4.6% 42.7% 
23. Lack of familiarity with current guidelines for nutrition in the PICU. 2 [1-3] 14.9% 22.9% 
24. General belief among PICU team that provision of adequate nutrition does not affect patient 
outcomes. 
1 [0-2] 36.1% 15.4% 
25. Lack of staff knowledge and support around breastfeeding mothers 2 [1-3] 23.0% 19.7% 
EN, Enteral Nutrition; PICU, Paediatric intensive care unit 
Responders answered the questionnaire through Likert scale (range 0-6). Median [IQR] refers to the full Likert scale (0-6). 
Not a barrier were the percentage of  responders who answered with ‘’not a barrier (0)’’.Important barrier is indicated by the percentage of 
responders who answered with ‘‘a lot (4)’’, ‘‘a great deal (5)’’, and ‘‘an extreme amount (6)’’ 
  
 
Table 3. Top 3 barriers to deliver enteral nutrition in the PICU reported per clinical specialty 








1. No or not enough dietitian coverage during evenings, weekends and holidays. 44.0% 3 [2-4] 
2. Enteral feeds being withheld in advance of procedures or operating department visits 40.3% 3 [2-4] 
3. In resuscitated, hemodynamically stable patients, other aspects of patient care still take priority 
over nutrition. 
33.5% 3 [2-4] 
Physician (N=407)   
1. Enteral feeds being withheld in advance of procedures or operating department visits. 46.4% 3 [2-5] 
2. Not enough time dedicated to education and training on how to optimally feed patients. 38.1% 3 [1-4] 
3. Delays and difficulties in obtaining small bowel access in patients not tolerating enteral nutrition 
(i.e. high gastric residual volumes). 
36.7% 3 [2-4] 
Dietitian (N=36)   
1. Severe fluid restriction (especially post-operative cardiac surgery) 68.6% 5 [3-6] 
2. No or not enough dietitian coverage during evenings, weekends and holidays. 41.2% 3 [1-5] 
3. Enteral feeds being withheld in advance of procedures or operating department visits. 33.3% 3 [1-4] 
PICU, Paediatric intensive care unit 
Responders answered the questionnaire through Likert scale (range 0-6). Median [IQR] refers to the full Likert scale (0-6) 





Table 4. Differences in perceived important barriers by professional group 









Delivery of Enteral Nutrition to the Patient     
1. Delay in physicians ordering the initiation of EN. 20.1% 21.1% 20.3% 5.6% 0.081 
2. Waiting for physician to order and check x-ray to confirm tube 
placement. 
13.6% 9.6%a 16.8%b 17.1%a,b 0.006 
3. Frequent displacement of feeding tube, requiring reinsertion. 12.1% 10.6% 14.1% 2.9% 0.066 
4. Delays in initiating motility agents in patients not tolerating 
enteral nutrition (i.e. high gastric residual volumes). 
19.1% 15.5%a 22.5%b 14.3%a,b 0.023 
5. Delays and difficulties in obtaining small bowel access in patients 
not tolerating enteral nutrition (i.e. high gastric residual volumes). 
30.9% 36.7%a 26.7%b 20.0%a,b 0.002 
6. In resuscitated, hemodynamically stable patients, other aspects of 
patient care still take priority over nutrition. 
33.0% 31.9% 33.5% 37.1% 0.763 
7. Nutrition therapy not routinely discussed on ward rounds. 18.5% 19.9% 18.3% 5.7% 0.144 
8. Severe fluid restriction (especially post-operative cardiac 
surgery). 
29.2% 27.8%a 27.5%a 68.6% <0.001 
9. Conservative PICU feeding protocol. 16.4% 15.7% 16.4% 22.9% 0.547 
10. Difficulty in delivering enteral feed due to feeding tube 
obstruction or pump delivery problems with thickened formula. 
10.8% 5.9%a 15.4%b 5.7%a,b <0.001 
Dietitian Support (Only if dietitian present; N=728)     
11. Waiting for the dietitian to assess the patient. 15.2% 10.6%a 18.9%b 14.7%a,b 0.008 
12. Dietitian not routinely present on weekday patient rounds. 29.6% 25.7% 33.5% 20.6% 0.037 
13. No or not enough dietitian coverage during evenings, weekends 
and holidays. 
38.4% 31.0%a 44.0%b 41.2%a,b 0.002 
14. Not enough time dedicated to education and training on how to 
optimally feed patients. 
33.7% 38.1% 30.7% 29.4% 0.100 
PICU Resources     
15. Delays to preparing or obtaining non-standard enteral feeds  15.7% 15.6% 16.1% 11.4% 0.757 
16. No or not enough feeding pumps on the unit. 12.0% 6.9% 15.7%a 19.4%a <0.001 
 
Healthcare Professional Attitudes and Behaviour     
17. Non-PICU physicians (i.e. surgeons, gastroenterologists) 
requesting patients not be fed enterally. 
17.4% 21.0%a 14.7%b 13.9%a,b 0.041 
18. Nurses failing to progress feeds as per the feeding protocol. 10.3% 12.1% 9.4% 2.8% 0.136 
19. Enteral feeds withheld due to diarrhoea. 13.0% 13.6% 11.9% 19.4% 0.385 
20. Fear of adverse events due to aggressively enterally feeding 
patients.  
18.4% 23.2%a 14.7%b 13.9%a,b 0.004 
21. Enteral feeds withheld for bedside procedures, such as 
physiotherapy, turns, and administration of certain medications. 
20.5% 22.0% 19.3% 19.4% 0.608 
22. Enteral feeds being withheld in advance of procedures or 
operating department visits. 
42.7% 46.4% 40.3% 33.3% 0.093 
23. Lack of familiarity with current guidelines for nutrition in the 
PICU. 
22.9% 26.4% 20.3% 19.4% 0.089 
24. General belief among PICU team that provision of adequate 
nutrition does not affect patient outcomes. 
15.4% 16.0% 15.3% 8.3% 0.468 
25. Lack of staff knowledge and support around breastfeeding 
mothers 
19.7% 17.3% 21.2% 28.6% 0.143 
EN, Enteral Nutrition; PICU, Paediatric intensive care unit 
Responders answered the questionnaire through Likert scale (range 0-6). Important barrier is indicated by the percentage of respondents who 
answered with ‘‘a lot (4)’’, ‘‘a great deal (5)’’, and ‘‘an extreme amount (6)’’ 















Delivery of Enteral Nutrition to the Patient      
1. Delay in physicians ordering the initiation of EN. 21.1% 19.7% 16.0% 0.435 
2. Waiting for physician to order and check x-ray to confirm tube placement. 16.0% 11.9% 8.0% 0.043 
3. Frequent displacement of feeding tube, requiring reinsertion. 12.4% 11.9% 11.3% 0.942 
4. Delays in initiating motility agents in patients not tolerating enteral nutrition (i.e. high 
gastric residual volumes). 
16.9% 20.1% 22.4% 0.286 
5. Delays and difficulties in obtaining small bowel access in patients not tolerating 
enteral nutrition (i.e. high gastric residual volumes). 
29.8% 32.0% 34.4% 0.574 
6. In resuscitated, hemodynamically stable patients, other aspects of patient care still 
take priority over nutrition. 
35.0% 31.7% 30.4% 0.494 
7. Nutrition therapy not routinely discussed on ward rounds. 19.1% 15.0% 20.8% 0.234 
8. Severe fluid restriction (especially post-operative cardiac surgery). 27.4% 31.4% 25.8% 0.354 
9. Conservative PICU feeding protocol. 16.5% 17.4% 10.6% 0.198 
10. Difficulty in delivering enteral feed due to feeding tube obstruction or pump delivery 
problems with thickened formula. 
13.1%a 7.2%b 12.0%a,b 0.033 
Dietitian Support (Only if dietitian present; N=728)      
1. Waiting for the dietitian to assess the patient. 16.5% 14.1% 12.2% 0.505 
11. Dietitian not routinely present on weekday patient rounds. 28.2% 30.5% 33.3% 0.590 
12. No or not enough dietitian coverage during evenings, weekends and holidays. 39.5% 36.3% 40.0% 0.664 
13. Not enough time dedicated to education and training on how to optimally feed 
patients. 
32.6% 34.2% 37.1% 0.701 
PICU Resources      
14. Delays to preparing or obtaining non-standard enteral feeds  15.7% 16.4% 12.9% 0.661 
15. No or not enough feeding pumps on the unit. 12.8%a 7.9%a 15.3% 0.035 
Healthcare Professional Attitudes and Behaviour      
 
16. Non-PICU physicians (i.e. surgeons, gastroenterologists) requesting patients not be 
fed enterally. 
18.3% 16.4% 16.1% 0.723 
17. Nurses failing to progress feeds as per the feeding protocol. 9.9% 8.5% 12.9% 0.373 
18. Enteral feeds withheld due to diarrhoea. 11.5% 13.8% 13.7% 0.579 
19. Fear of adverse events due to aggressively enterally feeding patients.  15.0%a 20.2%a,b 26.6%b 0.008 
20. Enteral feeds withheld for bedside procedures, such as physiotherapy, turns, and 
administration of certain medications. 
22.7% 17.9% 21.0% 0.268 
21. Enteral feeds being withheld in advance of procedures or operating department 
visits. 
43.3% 44.3% 38.7% 0.555 
22. Lack of familiarity with current guidelines for nutrition in the PICU. 23.4% 21.4% 25.8% 0.588 
23. General belief among PICU team that provision of adequate nutrition does not affect 
patient outcomes. 
15.0% 13.1% 20.2% 0.185 
24. Lack of staff knowledge and support around breastfeeding mothers 19.0% 19.5% 23.4% 0.551 
EN, Enteral Nutrition; PICU, Paediatric intensive care unit 
Responders answered the questionnaire through Likert scale (range 0-6). Important barrier is indicated by the percentage of responders who 
answered with ‘‘a lot (4)’’, ‘‘a great deal (5)’’, and ‘‘an extreme amount (6)’’. 
The subscript letters ‘’a’’ and ‘’b’’ denote categories in which proportions did not significantly differ from each other. 
















Delivery of Enteral Nutrition to the Patient     
1. Delay in physicians ordering the initiation of EN. 18.2% 22.8% 20.6% 0.527 
2. Waiting for physician to order and check x-ray to confirm tube placement. 10.9% 4.7% 6.3% 0.062 
3. Frequent displacement of feeding tube, requiring reinsertion. 10.0% 14.9% 8.7% 0.187 
4. Delays in initiating motility agents in patients not tolerating enteral nutrition (i.e. high 
gastric residual volumes). 
21.0% 17.9% 23.0% 0.537 
5. Delays and difficulties in obtaining small bowel access in patients not tolerating enteral 
nutrition (i.e. high gastric residual volumes). 
36.5% 38.8% 30.2% 0.290 
6. In resuscitated, hemodynamically stable patients, other aspects of patient care still take 
priority over nutrition. 
25.5% 37.6% 34.9% 0.026 
7. Nutrition therapy not routinely discussed on ward rounds. 10.5% 25.3%a 24.6%a <0.001 
8. Severe fluid restriction (especially post-operative cardiac surgery) 28.1% 30.8% 26.8% 0.740 
9. Conservative PICU feeding protocol 8.4% 13.6% 18.3% 0.026 
10. Difficulty in delivering enteral feed due to feeding tube obstruction or pump delivery 
problems with thickened formula 
5.5% 14.8% 6.3% 0.003 
Dietitian Support (Only if dietitian present; N=465)     
11. Waiting for the dietitian to assess the patient. 7.3% 17.9%a 19.4%a 0.004 
12. Dietitian not routinely present on weekday patient rounds. 27.0%a 31.6%a 58.1% <0.001 
13. No or not enough dietitian coverage during evenings, weekends and holidays. 33.8%a 33.3%a,b 50.8%b 0.038 
14. Not enough time dedicated to education and training on how to optimally feed 
patients. 
29.9% 43.6%a 56.5%a <0.001 
PICU Resources     
15. Delays to preparing or obtaining non-standard enteral feeds  19.1% 12.9% 12.0% 0.112 
16. No or not enough feeding pumps on the unit. 11.8% 12.9% 7.2% 0.274 
 
Healthcare Professional Attitudes and Behaviour     
17. Non-PICU physicians (i.e. surgeons, gastroenterologists) requesting patients not be fed 
enterally. 
17.3% 17.0% 25.6% 0.112 
18. Nurses failing to progress feeds as per the feeding protocol. 10.9% 9.9% 8.0% 0.684 
19. Enteral feeds withheld due to diarrhoea. 6.8%a 14.0%a,b 16.7%b 0.015 
20. Fear of adverse events due to aggressively enterally feeding patients.  16.8% 22.2% 16.0% 0.394 
21. Enteral feeds withheld for bedside procedures, such as physiotherapy, turns, and 
administration of certain medications. 
13.2%a 28.1%b 18.4%a,b 0.001 
22. Enteral feeds being withheld in advance of procedures or operating department visits. 42.3%a 43.3%a 57.6% 0.014 
23. Lack of familiarity with current guidelines for nutrition in the PICU. 16.4% 31.6%a 28.0%a 0.001 
24. General belief among PICU team that provision of adequate nutrition does not affect 
patient outcomes. 
11.8% 17.0% 17.6% 0.231 
25. Lack of staff knowledge and support around breastfeeding mothers 17.3% 21.6% 20.8% 0.516 
EN, Enteral Nutrition; PICU, Paediatric intensive care unit 
Responders answered the questionnaire through Likert scale (range 0-6). Important barrier is indicated by the percentage of respondents who 
answered with ‘‘a lot (4)’’, ‘‘a great deal (5)’’, and ‘‘an extreme amount (6)’’ 
The subscript letters ‘’a’’ and ‘’b’’ denote categories in which proportions did not significantly differ from each other. 
  
 
D I S C U S S I O N  
This is the largest survey undertaken to identify perceived barriers to the delivery of EN in 
PICU settings across the world. It is also only the second survey to include all three 
professional groups responsible for the delivery of EN in the ICU (nurses, physicians, and 
dieticians). With permission, we adapted and tested a new paediatric version of the survey 
tool validated for adult intensive care,5-7 providing a new paediatric version of this quality 
improvement tool. 
We identified the main perceived barriers of EN in PICU that were related to fasting for 
procedures, dietician coverage, inadequate education, care priorities, and delays in gained 
small bowel access. However, there was variability in perceived barriers between the 
professional groups. In PICU, the first observational study to describe barriers to EN10 found 
severe fluid restriction in children with congenital heart disease the main barrier, followed 
by the interruption of feeds for procedures. In our study, only the dieticians perceived this 
as the most important barrier, and overall it ranked sixth. Interestingly, we did not find any 
significant difference between PICUs that admitted cardiac surgical children and those that 
did not, even though the fluid restriction for postoperative cardiac children is greater. 
Cahill et al.5 used the adult barriers survey to explore the views of 138 critical care nurses 
across five AICUs in the United States and Canada. Three of these are consistent with our 
top five PICU perceived barriers but ranked differently. However, another AICU survey11 
found different barriers: with the main barrier being insufficient nursing staff to deliver EN 
(60%) followed by a fear of adverse events by feeding aggressively (56%). 
The problem of feed interruption is well recognised.3,4,12 Mehta et al.12, in a prospective 
observational study of 117 children, found interruptions occurred in 30% of PICU patients, 
and 58% of these interruptions were classed as avoidable. A Canadian survey of physicians 
and dieticians3 also found fasting for procedures a major barrier. Fasting for procedures, 
both in the PICU (such as for extubation) or outside the PICU (for radiological procedures) 
and to the operating department, are considerable problems for most intensive care 
patients. No evidence exists regarding “safe” fasting times for critically ill children and 
specifically which procedures require fasting for. The fear driving the fasting is potentially 
having a “full stomach” and the risk of pulmonary aspiration associated with emergency 
reintubation (if the endotracheal tube became dislodged). Despite recent Early 
Rehabilitation after Surgery recommendations for “well” children being fasted 
preoperatively, which have considerably reduced fasting times,13 there is no evidence for 
fasting times in critically ill children, being fed, often minimally and already intubated. New 
techniques, such as gastric antral ultrasound,14,15 need to be examined in the PICU 
population, to determine a more accurate way to individualise fasting times to critically ill 
children, with a view to avoiding the blanket 6 hour fasting rule. 
 
In a U.K.-wide survey of PICU physicians, nurses, and dieticians,4 the top five barriers were 
as follows: severe fluid restriction (60%), the child being “too ill” to feed (17%), surgical 
postoperative orders (17%), nursing staff being slow in starting feeds (7%), and hemodynamic 
instability (7%) including children with hemodynamic instability requiring pressor support, 
those with fluid restrictions, and those with major degrees of injury severity. 
More recently, a retrospective study of 444 children in six PICUs in the United States,16 
identified the biggest risk factors for delayed EN were noninvasive ventilation (NIV), 
followed by invasive ventilation, increasing severity of illness, impending procedures, and 
gastrointestinal disturbances within the first 48 hours. Interestingly, NIV was not listed as 
barrier in our survey (nor is it in the adult survey), and only two people mentioned being 
on NIV as a barrier in free-text responses. Children requiring noninvasive respiratory 
support are at risk of requiring escalation of care to intubation. Many early guidelines 
recommended avoiding or limiting EN in respiratory distress (American Bronchiolitis 
Guidelines); however, NIV is no longer a barrier to enteral feeding, in accordance with 
recent updated guidelines.17 
Only 4% of the respondents were dieticians and the perceived inadequacy of dietician 
coverage in PICUs was identified by dieticians and physicians. Specialist dieticians and their 
educational level vary significantly across countries. Additionally, there are relatively few of 
these individuals compared with other healthcare professionals, with many European units 
reporting having no dietician at all.18 Nutritional support teams (NSTs) (including a dietitian) 
have been shown to be beneficial in optimising nutrition in PICUs.19 This has been shown in 
a Latin American and Spanish survey on nutrition in paediatric intensive care where 68% of 
the participant PICUs had a NST and the availability of an NST was associated with better 
nutritional practices.19 A perceived lack of education around nutrition (and the optimal 
feeding of critically ill patients) is concerning. In the United Kingdom, “nutrition” is a 
required component of both specialist PICU nursing education and PICU medical trainees; 
however, how it is taught is variable. In some countries, specialist PICU training programs 
for doctors or nurses do not exist, and individuals train in adult critical care or anaesthesia, 
further contributing to their lack of knowledge around paediatric nutrition. In this context, 
the ESPNIC and its nutrition section has a major role to play in providing education for all 
professionals. 
The lack of prioritization of nutrition over other aspects of care has been identified as a 
problem in a recent Australian AICU nursing survey.20 In this study, nurses identified their 
main perceived role related to EN was the care, maintenance and management of EN and 
being an advocate for EN. When asked to rank their care priorities; however, nutrition 
support and management ranked sixth after physiologic monitoring of other systems, but 
before hygiene and psychologic support. They concluded that education (as well as reducing 
other barriers) could improve nurses’ understanding of the importance of nutrition and thus 
improve the prioritization of nutrition within the competing demands of their workload. 
 
Additionally, a survey investigating barriers in an Israeli hospital found the time it takes to 
prescribe nutritional therapy, lack of protocols, and awareness of the staff of the nutritional 
therapy as the main barriers and highlighted the importance of collaboration between the 
clinical specialties.21 The role of a nutrition support nurse could also be a valuable aspect in 
a NST, especially in PICUs without a dietician. This nurse can act as an important player for 
patients and the healthcare organization by having enough knowledge, attitudes, and 
competences to fulfil the role of a clinical nutrition expert.21 
We found delays in obtaining small bowel access was also reported as a barrier. Although 
the paediatric evidence does not show superiority in post-pyloric feeding as the primary 
feeding method, some units do utilise this method successfully in all patients.23-25 However, 
most units reserve this method for children intolerant of gastric feeding.23 In the only 
randomised controlled trial of EN via gastric versus post-pyloric feeding,25 there was 
significant crossover and drop out reported in the post-pyloric arm because of inability to 
place the pyloric tube. Newer devices26 may assist in ease of correct placement of these 
tubes in larger children, but others have simply implemented intensive nurse training to 
achieve high placement success. 
One of the most common reasons for failure to deliver EN in PICUs is that of feed 
intolerance,3-12 yet this was not a survey item, and its definition remains problematiC.27,28 
The Canadian Critical Care Nutrition network (https://www.criticalcarenutrition.com/ 
resources/strategies-for-improving) developed the barriers survey as part of a larger 
nutrition improvement program focused around: auditing your own practice, standardising 
care, identifying barriers, improving nutrition knowledge, and having nutrition champions. 
Thus, this quality improvement survey tool sought to identify modifiable ICU organizational 
and healthcare team barriers to the delivery of EN, rather than patient-related factors such 
as this. 
The differences in perceived barriers by professional groups is interesting and has not been 
examined before. All three groups perceived fasting prior to procedures and operating 
department visits as a significant problem. The lack of dietician input was identified by both 
physicians and dieticians (in the top three barriers), but not nurses. This shows some 
consistency among the three professional groups but reflects their specific professional role 
around nutrition. Future education and interventions to improve EN in PICUs must involve 
all three of these professional groups. This freely available survey (available in eleven 
languages on the ESPNIC website: https://espnic-online.org/Education/Professional-
Resources) can now be used by PICUs to first identify barriers in their unit, and then target 
these barriers to improve the delivery of EN, as part of a unit-based quality improvement 
program. This survey tool was adapted to a PICU population and deliberately excluded 
neonatal wards, as the organizational, behavioural, clinical, and pathophysiological aspects 
could be different. It would be interesting to evaluate these aspects in future research. 
 
There are some limitations to our study that warrant highlighting. First, due to our 
distribution method via professional networks and organizational websites and newsletters, 
we are unable to know a denominator and thus calculate a response rate or rule out possible 
selection bias. Second, because of this, we were also unable to control for the variation in 
response rates from different countries; thus, we had significantly more European 
responses. However, the strengths of our study are our extensive responses (920 across 
57 countries) and in our inclusion of all three professional groups involved in the delivery 
of EN. Unfortunately, the responses from dietitians were lower, which prevented us making 
firm conclusions regarding this group. Furthermore, our translation into multiple languages 
ensured the survey did not just reach an English-speaking group, a bias in many other 
surveys. 
 
C O N C L U S I O N S 
This study has demonstrated that many perceived barriers to enteral feeding remain in 
PICUs internationally. These are similar, but not the same as those in AICUs. These barriers 
relate to organizational and staff factors as well as patient factors relating to their clinical 
status. Whether the barrier is real or not, if clinicians believe these, then this still inhibits 
the delivery of EN. Generating evidence to support or refute these perceived barriers is 
ongoing, but further education to improve awareness of the existing evidence and facilitate 
the implementation of best evidence into local unit guidelines is required. The use of local 
feeding guidelines with or without nutrition support teams have been shown to be effective 
in promoting EN and as such should be encouraged. Physicians, nurses, and dieticians must 
all be involved in this process and in actively addressing barriers in their PICU.
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A P P E N D I X 
  
 
Figure S1. Countries of which the survey correcspondents work; 920 responses from 57 countries  
Created with: https://www.amcharts.com/visited_countries/# 
 
Argentina , Austria, Australia, Belgium, Bolivia, Brazil, Bulgaria , Canada, Chile, China, Cuba, Colombia, 
Ecuador, France, Germany, Guatemala, Honduras, Hong Kong, India, Iraq, Ireland, Israel, Italy, Latvia, 
Lebanon, Lithuania, Luxembourg, Malaysia, Mexico, the Netherlands, Nicaragua, Panama, Paraguay, 
Peru, Philippines, Poland, Portugal, Puerto Ricco, Republic Dominica, Reunion, Russia, Saudi Arabia, 
Singapore, Spain, South Africa, Surinam, Sweden, Switzerland, Taiwan, Thailand,  Turkey, Unites States 
of America, Uruguay, Uzbekistan, United Kingdom, Vatican, Vietnam 
 
 
Table S1. Differences in perceived important barrier divided by years of experience (N=920) 













 Delivery of Enteral Nutrition to the Patient      
1. Delay in physicians ordering the initiation of EN. 21.1% 20.9% 23.3% 15.6% 0.288 
2. Waiting for physician to order and check x-ray to confirm tube placement. 15.7% 16.3% 10.6% 9.0% 0.060 
3. Frequent displacement of feeding tube, requiring reinsertion. 18.3%a 12.1%a,b 6.0%b 5.8%b <0.001 
4. Delays in initiating motility agents in patients not tolerating enteral nutrition 
(i.e. high gastric residual volumes). 
24.4%a 15.0%a,b 18.9%a,b 14.8%b 0.013 
5. Delays and difficulties in obtaining small bowel access in patients not 
tolerating enteral nutrition (i.e. high gastric residual volumes). 
32.7% 29.3% 31.8% 29.0% 0.760 
6. In resuscitated, hemodynamically stable patients, other aspects of patient 
care still take priority over nutrition. 
34.6% 32.1% 36.8% 28.6% 0.359 
7. Nutrition therapy not routinely discussed on ward rounds. 19.7% 20.9% 19.5% 13.8% 0.229 
8. Severe fluid restriction (especially post-operative cardiac surgery) 27.9% 31.8% 30.2% 26.9% 0.672 
9. Conservative PICU feeding protocol 19.3%a 16.9%a,b 17.4%a,b 10.1%b 0.040 
10. Difficulty in delivering enteral feed due to feeding tube obstruction or pump 
delivery problems with thickened formula 
14.9%a 11.2%a,b 7.5%a,b 5.8%b <0.001 
Dietitian Support (Only if dietitian present; N=465)      
11. Waiting for the dietitian to assess the patient. 20.1%a 15.0%a,b 16.2%a,b 6.5%b 0.002 
12. Dietitian not routinely present on weekday patient rounds. 33.9% 28.7% 30.6% 22.2% 0.065 
13. No or not enough dietitian coverage during evenings, weekends and holidays. 40.9% 37.1% 38.2% 34.7% 0.595 
14. Not enough time dedicated to education and training on how to optimally 
feed patients. 
34.6% 35.6% 34.2% 30.4% 0.746 
PICU Resources      
15. Delays to preparing or obtaining non-standard enteral feeds  18.8% 14.0% 17.4% 11.1% 0.079 
16. No or not enough feeding pumps on the unit. 13.8% 13.5% 10.6% 8.1% 0.188 
      
 
Healthcare Professional Attitudes and Behaviour      
17. Non-PICU physicians (i.e. surgeons, gastroenterologists) requesting patients 
not be fed enterally. 
19.4% 18.1% 20.5% 11.9% 0.099 
18. Nurses failing to progress feeds as per the feeding protocol. 10.4% 9.8% 12.1% 10.0% 0.908 
19. Enteral feeds withheld due to diarrhoea. 14.3% 14.9% 12.1% 9.5% 0.314 
20. Fear of adverse events due to aggressively enterally feeding patients.  19.4% 19.6% 19.7% 15.2% 0.579 
21. Enteral feeds withheld for bedside procedures, such as physiotherapy, turns, 
and administration of certain medications. 
22.5%a 22.3%a 25.8%a 12.4% 0.007 
22. Enteral feeds being withheld in advance of procedures or operating 
department visits. 
41.6% 47.9% 50.0% 35.7% 0.022 
23. Lack of familiarity with current guidelines for nutrition in the PICU. 23.9% 23.7% 25.8% 19.2% 0.531 
24. General belief among PICU team that provision of adequate nutrition does 
not affect patient outcomes. 
16.9% 15.8% 11.4% 15.2% 0.521 
25. Lack of staff knowledge and support around breastfeeding mothers 18.5% 25.6% 17.6% 16.2% 0.070 
EN, Enteral Nutrition; PICU, Paediatric intensive care unit 
Responders answered the questionnaire through Likert scale (range 0-6). Important barrier is indicated by the percentage of responders who 
answered with ‘‘a lot (4)’’, ‘‘a great deal (5)’’, and ‘‘an extreme amount (6)’’ 
The subscript letters ‘’a’’ and ‘’b’’ denote categories in which proportions did not significantly differ from each other. 
  
 














Delivery of Enteral Nutrition to the Patient      
1. Delay in physicians ordering the initiation of EN. 29.0% 20.8% 20.3% 18.6% 0.572 
2. Waiting for physician to order and check x-ray to confirm tube 
placement. 
22.6%a,b 12.5%a,b 7.8%b 22.4%a <0.001 
3. Frequent displacement of feeding tube, requiring reinsertion. 12.9% 8.3% 11.3% 14.0% 0.564 
4. Delays in initiating motility agents in patients not tolerating enteral 
nutrition (i.e. high gastric residual volumes). 
19.4% 12.5% 20.5% 17.7% 0.496 
5. Delays and difficulties in obtaining small bowel access in patients not 
tolerating enteral nutrition (i.e. high gastric residual volumes). 
35.5%a,b 31.9%a,b 35.7%b 22.4%a <0.001 
6. In resuscitated, hemodynamically stable patients, other aspects of patient 
care still take priority over nutrition. 
41.9% 35.4% 31.8% 33.9% 0.647 
7. Nutrition therapy not routinely discussed on ward rounds. 35.5%a 27.1%a,b 18.8%a,b 15.2%b 0.014 
8. Severe fluid restriction (especially post-operative cardiac surgery) 35.5% 29.8% 28.7% 29.2% 0.881 
9. Conservative PICU feeding protocol 41.9%a 8.3%b,c 12.5%c 21.3%a,b <0.001 
10. Difficulty in delivering enteral feed due to feeding tube obstruction or 
pump delivery problems with thickened formula 
16.1%a,b 4.2%a,b 8.8%b 14.6%a 0.017 
Dietitian Support (Only if dietitian present; N=465)      
11. Waiting for the dietitian to assess the patient. 16.0% 5.0% 12.5% 19.6% 0.017 
12. Dietitian not routinely present on weekday patient rounds. 44.0%a 12.5%b 33.4%a 25.9%a,b 0.005 
13. No or not enough dietitian coverage during evenings, weekends and 
holidays. 
56.0%a 22.5%b 36.4%a,b 41.4%a,b 0.024 
14. Not enough time dedicated to education and training on how to 
optimally feed patients. 
56.0%a 30.0%a,b 38.4%a 26.5%b 0.001 
PICU Resources      
15. Delays to preparing or obtaining non-standard enteral feeds  25.8% 19.6% 15.3% 14.3% 0.326 
16. No or not enough feeding pumps on the unit. 29.0%a 14.9%a,b 11.0%b 11.5%b 0.024 
 
Healthcare Professional Attitudes and Behaviour      
17. Non-PICU physicians (i.e. surgeons, gastroenterologists) requesting 
patients not be fed enterally. 
29.0% 14.9% 19.2% 13.7% 0.060 
18. Nurses failing to progress feeds as per the feeding protocol. 22.6% 12.8% 9.9% 9.6% 0.134 
19. Enteral feeds withheld due to diarrhoea. 19.4% 14.9% 11.4% 14.6% 0.376 
20. Fear of adverse events due to aggressively enterally feeding patients.  35.5%a 21.3%a,b 19.0%a,b 15.6%b 0.044 
21. Enteral feeds withheld for bedside procedures, such as physiotherapy, 
turns, and administration of certain medications. 
22.6% 21.3% 19.8% 21.4% 0.932 
22. Enteral feeds being withheld in advance of procedures or operating 
department visits. 
45.2%a,b 53.2%a,b 46.3%b 35.4%a 0.008 
23. Lack of familiarity with current guidelines for nutrition in the PICU. 38.7%a 29.8%a,b 24.2%a,b 18.3%b 0.019 
24. General belief among PICU team that provision of adequate nutrition 
does not affect patient outcomes. 
32.3% 12.8% 14.9% 14.9% 0.067 
25. Lack of staff knowledge and support around breastfeeding mothers 48.4% 19.1%a 19.6%a 17.4%a 0.001 
EN, Enteral Nutrition; PICU, Paediatric intensive care unit 
Responders answered the questionnaire through Likert scale (range 0-6). Important barrier is indicated by the percentage of responders who 
answered with ‘‘a lot (4)’’, ‘‘a great deal (5)’’, and ‘‘an extreme amount (6)’’. 
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A B S T R A C T  
Objectives: To explore enteral feeding practices and the achievement of energy targets in 
children on non-invasive respiratory support, in four European PICUs. DESIGN: A four-
centre retrospective cohort study.  
 
Setting: Four PICUs: Bristol, United Kingdom; Lyon, France; Madrid, Spain; and Rotterdam, 
The Netherlands.  
 
Patients: Children in PICU who required acute non--invasive respiratory support in the 
first 7 days. The primary outcome was achievement of standardised kcal/goal.  
 
Measurements and main results: A total of 325 children were included (Bristol 104; 
Lyon 99; Madrid 72; and Rotterdam 50). The median (interquartile range) age and weight 
were 3 months (1–16 months) and 5kg (4–10 months), respectively, with 66% admitted with 
respiratory failure. There were large between-centre variations in practices. Overall, 
190/325 (58.5%) received non-invasive respiratory support in order to prevent intubation 
and 41.5% after extubation. The main modes of non-invasive respiratory support used were 
high-flow nasal cannula 43.6%, bilevel positive airway pressure 33.2%, and continuous 
positive airway pressure 21.2%. Most children (77.8%) were fed gastrically (48.4% 
continuously) and the median time to the first feed after non-invasive respiratory support 
initiation was 4 hours (interquartile range, 1–9hr). The median percentage of time a child 
was nil per oral while on non-invasive respiratory support was 4 hours (2–13hr). Overall, 
children received a median of 56% (25–82%) of their energy goals compared with a 
standardised target of 0.85 of the recommended dietary allowance. Patients receiving step-
up non-invasive respiratory support (p< 0.001), those on bilevel positive airway pressure or 
continuous positive airway pressure (compared with high-flow nasal cannula) (p< 0.001), 
and those on continuous feeds (p< 0.001) achieved significantly more of their kcal goal. 
Gastrointestinal complications varied from 4.8—20%, with the most common reported 
being vomiting in 54/325 (16.6%), other complications occurred in 40/325 (12.3%) children, 
but pulmonary aspiration was rare 5/325 (1.5%).  
 
Conclusions: Children on non-invasive respiratory support tolerated feeding well, with 
relatively few complications, but prospective trials are now required to determine the 
optimal timing and feeding method for these children  
 
I N T R O D U C T I O N  
Enteral nutrition (EN) delivery in children on non-invasive respiratory support (NRS; 
highflow nasal cannula [HFNC], bilevel positive airway pressure [BLPAP], and continuous 
positive airway pressure [CPAP]) remains challenging. Clinical staff are concerned about the 
potential need for escalation of treatment and subsequent intubation and of the risk of 
aspiration. A large study of risk factors for delayed EN in the United States PICUs found 
that non-invasive ventilation was the most significant risk factor for delayed EN.1 
Furthermore, a single-centre U.S. study reported that enteral feeding was possible in these 
children, with 64% children receiving EN within 24 hours (54% orally, 30%  transpylorically, 
and 7% gastric feeding).2 This contrasts with a multicentre adult ICU study in France, which 
found three-fifths of patients receiving non-invasive ventilation fasted for the first 2 days.3  
 
The use of NRS is increasing in children worldwide, in efforts to reduce the need for 
intubation and invasive ventilation.4 Despite the lack of an accurate and clinically available 
method of predicting energy expenditure in children on NRS, they are likely to have a higher 
work of breathing (and higher energy expenditure) than those on invasive ventilation. As 
increasing evidence shows associations between the inadequate nutrition intake and the 
impaired clinical outcomes in invasively ventilated children,7-10 the impact of this for children 
on NRS may be worse, particularly in infants and already malnourished children. Efforts to 
prevent faltering growth occurrence on PICU are recommended in both the ASPEN 2017 
and ESPNIC 2020 guidelines. However, these are based on the studies in invasively 
ventilated children, rather than in children on non-invasive ventilation. We lack evidence in 
this subgroup of critically ill children; thus, we wanted to investigate practices with regard 
to EN in children receiving NRS across four European PICUs as a first step.  
 
First, we wanted to examine the child’s achievement of energy goals while on NRS. Second, 
we wanted to describe the time to initiate EN after NRS commencement, the duration of 
nil per oral times on NRS, the EN site and delivery method, and reported gastrointestinal 
complications on NRS. Then, we explored whether any associations existed between the 
main NRS modes, or whether step-up or down on EN delivery and percentage of energy 
targets achieved. 
 
M E T H O D S  
Study population 
A retrospective cohort study was undertaken to describe current practices around the 
enteral feeding of all consecutive children who met the study inclusion criteria in four 
European PICUs receiving some form of acute NRS: HFNC, CPAP, and BLPAP between 
2018 and March 2019. We only included children 0–17 years old receiving acute NRS with 
 
no limitation on the duration of NRS and collected data for the first 7 days of NRS and 
excluded children on chronic long-term respiratory support and preterm infants (< 37-wk 
gestational age).This period of NRS may have been before or after intubation and it may 
occur at any time point in the child’s PICU stay. 
 
Data collected included age, weight, gender, reason for PICU admission, primary diagnostic 
category, severity of illness score at admission (Paediatric Index of Mortality 2 [PIM2]), mode 
of NRS—step-up or down and specific type (CPAP, BLPAP, and HFNC) and starting 
pressures, flows, and Fio2 . Nutritional data collected included gastric tube type, route and 
feeding method, estimated (by equation) energy requirements at the initiation of NRS, hours 
nil per oral during the first 7 days, the time from initiation of NRS to the first enteral feed, 
and the child’s total nutritional intake (kcal) during the first 7 days of NRS, along with any 
documented gastrointestinal complications (vomiting, diarrhoea, constipation, and high 
gastric residual volumes) and any documented aspiration. In all units, these data were 
retrieved from the electronic health records.  
 
Four European centres participated (Bristol, United Kingdom; Lyon, France; Madrid, Spain; 
and Rotterdam, The Netherlands) and collected data on 50–100 patients per centre. 
Settings included the following: Bristol PICU is an 18-bedded combined general and cardiac 
PICU, Lyon is a 23-bedded general PICU, Rotterdam is a 24-bedded combined general and 
cardiac PICU, and Madrid is an 11-bedded combined general and cardiac PICU. All units 
deliver NRS regularly. Local unit protocols and practices was summerized in the appendix. 
 
Ethical approval for the study was obtained separately in each country. In the United 
Kingdom, ethical approval was gained through the University of the West of England (August 
2017), and in France, ethical approval was granted by Comite d’Ethique de Chu de Lyon 
(References 19–82). In The Netherlands, ethical approval was granted from Erasmus Medical 
Centre (MEC-2019-0182), and in Madrid, ethical approval was granted from Hospital 
General Universitario Gregorio Marañón (23/2017).  
 
Outcomes  
An important goal of our study was to examine the child’s achievement of both their unit 
derived energy goal and a standardised energy goal (85% recommended daily allowance 
[RDA]) on NRS across the four sites. As no current recommendation exists on how much 
and how to feed NRS children, we used 85% of RDA as an assumption based on the mean 
of Schofield (in critically ill intubated sedated children) and RDA (healthy children).This was 
calculated as follows: ([total feeds given during NRS in mL, max 7 d] × [feed concentration 
in kcal/mL]) × 100/(number of days of NRS in days)/(85% RDA as goal in kcal/d). The 




Statistical Analysis  
Data were collected in Microsoft Excel, checked, anonymised, and cleaned before combining 
into one database and exported directly into IBM SPSS v22 for analysis. Descriptive statistics 
were summarised by median (interquartile range [IQR]) and mean (SD) if appropriate and 
numbers (percentages). Data were tested for normality using the Shapiro-Wilk test. 
Nonparametric tests (Spearman rho) were used for testing associations between the non-
normal variables with the primary outcome, and Mann-Whitney or Kruskall-Walis to test 
between the categorical variables and the non-normally distributed primary outcome. 
Stepwise multivariate linear regression analysis was used to identify if any patient or practice 
variables were associated with the percentage of achieved energy targets (% energy intake 
compared with 85% RDA goal). Investigated variables were age, PIM2 score, NRS initiation, 
main mode used, starting Fio2), inspiratory positive airway pressure (IPAP), expiratory 
positive airway pressure (EPAP), highest Fio2, IPAP, and EPAP, the child’s feeding method, 
and route. Variables were included in the multivariate model if the univariate association 
with the outcome % achieved energy targets had a significance of p ≤ 0.1. The multivariate 
models included the PICU site as a fixed effect to account for. Multicollinearity was assessed 
using Spearman correlation with a cut-off value of 0.5. The constant, unstandardised beta 
values with their corresponding standard errors, 95% CIs, and p values were reported for 
multivariate linear regression model. The normality assumption was not met for the main 
outcome variable energy achievement; however, due the large cohort group, it was 
considered acceptable under the central limit theorem.5 Results are reported as 
standardised beta, standard error, or beta values, and corresponding 95% CI. All p values 
were two-sided and less than 0.05 were considered as statistically significant. 
 
R E S U L T S  
Three-hundred twenty-five children were included (104 in Bristol, 99 in Lyon, 72 in Madrid, 
and 50 in Rotterdam). The median (IQR) age and weight were 3 months (1–16 months) and 
5 kg (4–10 kg), respectively, and weight for age z score 0.74 (–1.8 to –0.39) with 66% 
children admitted with respiratory failure (Table 1). The patient recruitment number and 
profile were significantly different between the centres (Table 2). The median duration of 
NRS was 3 days (IQR, 2–5 d) and 190/325 (58.5%) received NRS to prevent intubation and 
41.5% as a step-down after extubation. Across the four units, the main mode of NRS used 
was HFNC 43.7%, BLPAP 33.2%, and CPAP 21.2%, with 1.8% patients on neurally adjusted 
ventilatory assist. 
 
Overall, children received a median of 56% (25– 82%) of their energy goals (compared with 
a standardised 85% RDA) target while they were receiving NRS. However, large variability 
was seen across centres (Table 3). Across all centres, the median (IQR) time to first EN 
after NRS initiation was 4 hours (1–12hr) but varied between the centres. The median 
 
percentage of time nil per oral while on NRS was 5 hours (IQR, 2–14.5). Of the children 
enterally fed, most children (93.8%) were fed via the gastric route, with 48.4% of these fed 
continuously. Only 6.2% were fed post-pyloric. Relatively few (10.8%) received normal 
oral/bottle and 17 (5.3%) were nil per oral (Table 3). Children receiving continuous feeds 
achieved significantly more of their energy goals than bolus feeds (mean 70.5% vs 47.8%, 
respectively (p< 0.001). Of the 6.2% children fed via the post-pyloric route, they received 
significantly more of their energy goal (mean 76.8% post-pyloric vs 57.6%; p=0.012); 
however, these factors were not significant in the multivariate model. Overall, children 
receiving HFNC achieved less of their mean energy goal achievement (42.1%) compared 
with those on BLPAP (68.5%) or CPAP (63.2%) (p< 0.001), but this was highly centre-
dependent and not significant in the multivariate model. Children in whom NRS was initiated 
as “step-down” received less than those in whom it was “step-up” (mean 49% vs 61.9%, 
respectively; p=0.001) and this was significant only in univariate analysis (p< 0.001). In our 
multivariate analysis, only a higher age and bolus feeding were associated with lower 
achievement of standardised target energy goals (Table 4). 
 
In terms of gastrointestinal complications, the rate varied between the centres from 4.8% 
to 20%. The most common reported gastrointestinal complication was vomiting in 54/325 
(16.6%) and other reported complications occurred in only 40/325 (12.3%) children, with 
pulmonary aspiration rare 5/325 (1.5%) (Table 3). Overall, children received a median of 
56.2% (24.7–79%) of their centre-predicted energy goal and 55.9% (24.9–81.8%) compared 
with a standardised energy goal of 0.85% RDA. 
 
D I S C U S S I O N  
Our results showed significant differences in patient characteristics, NRS, and nutrition 
practices between the centres. Despite these differences, EN was commonly used and 
started early after NRS commencement; nutrition complications were infrequent and non-
severe in most cases. However, target energy goals were rarely reached. This is the first 
study to examine practices around EN and NRS across four centres in Europe. 
 
Delivering adequate nutrition in PICUs is challenging. An international study of 800 
mechanically ventilated children in 31 PICUs showed only 37% of children received their 
prescribed energy intake.6 On average, critically ill children receive less than half of their 
predicted energy requirements.7 This is problematic, because inadequate nutrition delivery 
to critically ill children is associated with prolonged mechanical ventilation, impaired wound 
healing (and time to sternal closure in postoperative cardiac babies), increased healthcare 
acquired infections, increased mortality, and longer PICU stays.8-15 However, in our study, 
energy achievement in children on NRS did not appear worse than those studies reporting 
this in invasively ventilated children. 
 
Despite the variations between the four European centres, the time to initiation of EN was 
still better than previous studies. A North American cross-sectional analysis of barriers to 
delayed enteral feeding in six PICUs showed NIV as the predominant factor for EN delay,1 
with the odds ratio of delayed EN compared with those with no respiratory support that 
was 3.37 (95% CI, 1.69–6.72) and a median of 20 hours (IQR, 6–42hr) for EN initiation after 
PICU admission.1 A single-centre U.S. retrospective study of 562 children on non-invasive 
ventilation found 64% were fed within the first 24 hours.2 Compared with this, EN was 
initiated in 80% of our patients in less than 24 hours. 
 
In our study, no NRS parameter was significantly associated with a lower achievement of 
energy targets, whereas Leroue et al2 found BLPAP itself was a significantly factor for delayed 
EN with the reported median IPAP at initiation (16 cm H2 O). However, only 18% of 
children in this U.S. study received HFNC compared with nearly half (44%) of our sample. 
Surprisingly, in our study, the children receiving HFNC received significantly less of their 
energy goal compared with children on BLAP and CPAP. There was significant between-
centre variation in the use of HFNC; however, when corrected for centre, there was no 
significant effect, and in the multivariate analysis, mode of NRS was not significant. Two 
centres (both having a cardiac surgical population) used significantly more HFNC and more 
step-down HFNC than the other two centres. It may be the impact these fluid restricted 
postoperative cardiac surgical children may have affected this on this finding of lower energy 
targets.  
 
We found on univariate analysis that children receiving “step-down” NRS after extubation 
received significantly less of their energy goal compared with step-up NRS to prevent 
intubation. This was, however, not significant in the multivariate model. No other studies 
have examined this. This is also unexpected, as one might expect that the clinical team may 
be more cautious in starting EN in NRS initiated in children with respiratory distress to 
prevent intubation. A possible explanation is that one centre used significantly more step-
down NRS than others, and this centre also had significantly more postoperative cardiac 
surgical patients, who were severely fluid-restricted, thus potentially affecting the EN 
allowance.  
 
Few children in our study reached their nutritional targets during NRS: this may be partly 
due to the centre practices consisting of a progressive increase of EN during the first 
hours/days of PICU stay and ventilation support and affected also by the severe fluid 
restriction of children with cardiac failure and postoperative cardiac surgery. However, we 
did see a significantly higher achievement of energy goal in children continuously fed, 
compared with those fed by intermittent bolus feeds. However, this practice varied by 
centre, and future prospective studies are needed to investigate this further in children on 
NRS. In ventilated children, recent recommendations found neither method was superior, 
but this may be different in children on NRS. Similarly, in the few patients receiving post-
 
pyloric feeding (in only two centres), they achieved higher energy goals, but these are small 
numbers. In the same review,16 they found no difference in energy goals by either method 
in invasively ventilated children.  
 
Recent guidelines recommend targeting at least two-thirds of energy expenditure in 
invasively ventilated children within the first week.17 Due to the difficulty of measuring 
energy expenditure in NRS children, no clear recommendation exists regarding children on 
acute NRS. The percentage of predefined energy goal reached differed significantly between 
the centres (14–82%), even when considering a standard goal (85% of RDA) or locally 
defined goals; this was mainly attributable to centres differences in patient recruitment and 
nutrition practices.  
 
A study of adult on non-invasive ventilation and18 airway complications found the rate of 
airway complications was higher in those adults receiving EN. However, vomiting alone and 
gastrointestinal complications were not reported. In our study, gastrointestinal 
complications were relatively low and mainly consisted of minor signs of feed intolerance: 
vomiting was less than 17% and others (non-severe) were less than 12%. Neither paediatric 
study examined gastrointestinal complications. Leroue et al2 did record “new” pneumonia 
(reflecting aspiration) with an incidence of 9.6% (54/562). Our recorded aspiration 
occurrence was rare; however, these data may not be reliable when defined and collected 
retrospectively.  
 
Our study suggests that enteral feeding can be initiated early after NRS commencement, 
with a low-to-moderate rate of complications. The ideal timing for initiation of EN and the 
optimal method for children on NRS, however, remain based on the experience and 
confidence of the team managing the child. Our study found large variations among the four 
European canters, both in NRS practices and EN initiation and titration.  
 
This study has several limitations that warrant mentioning. There were significant differences 
in recruitment numbers between the centres and significant variations in both NRS and EN 
practices, along with a skewed population in terms of age, all of which may affect our findings. 
In addition, the retrospective nature of the data collection may have introduced selection 
bias, even though we had agreed definitions and used an agreed data extraction tool. Due 
to the observational nature of the study, EN initiation was biased by the clinical team local 
practice and protocols and we did not collect data on sedative use during NRS and the lack 
of a control group is also a weakness. Finally, we used estimated energy target prediction 
on the day NRS started as the goal and did not reassess this in the 7-day NRS period, and 
we only studied patients for the first 7 days of NRS. Despite these limitations, this is the 
first study to examine real practices around the issue of enteral feeding in children on NRS 
in a European context and provides us with new knowledge, giving us some idea of energy 
targets achieved in this group of children. 
 
C O N C L U S I O N S 
Despite variations between the centres in terms of NRS use, nutrition targets, and delivery 
practices, our study suggests that early enteral feeding is possible during NRS, even if energy 
targets are not met. We found a low–to-moderate incidence of gastrointestinal 
complications such as vomiting; however, documented aspiration was rare. Further 
conclusions regarding the association between different NRS methods and EN initiation 
cannot be drawn from this retrospective study. Further prospective trials are needed to 
determine both the optimal timing and feeding method for children on NRS using a 
consistent approach to enteral feeding. 
 
 
Table 1. Patient demographics variation by centre and overall  
Patient characteristic Bristol Lyon Madrid Rotterdam Total 
Number 104 99 72 50 325 
Sex male 58 (55.8%) 46 (46.5%) 40 (55.5%) 26 (52.0%) 104/203 (51.2%) 
Weight (kg) 5.9 (3.5-11.0) 4.0 (3.4-5.1) 5.5 (4.4-9.9) 9.6 (4.7-24.4) 5.0 (3.7-10.0) 
Median (IQR) WAZ score -1.3 (-2.3 - -0.27) -.34 (-1.7 -0.7) -3.0 (-1.6 – 0.5) -0.86 (-1.95 – 0.21) -0.74 (-1.8 -0.39) 
PIM2 score 2.9 (1.7-8.3) 1.4 (1.1-3.7) 0.3 (0.2-1.7) 2.8 (1.6-7.8) 1.8 (1.0-4.5) 
Age (months) 5.0 (1.0-18.3) 1.3 (0.8-3.5) 3.0 (1.5-16.0) 15.0 (3.0-78.1) 3.0 (1.0-16.1) 
Cause of Admission N 104 N 99 N 72 N 50 N 325 
Circulatory failure 16 (15.4%) 0 1 (1.4%) 2 (4%) 19 (5.8%) 
Trauma 1 (1%) 2 (2%) 0 2 (4%) 5 (15.4%) 
Respiratory failure 49 (47.1%) 90 (90.1%) 55 (76.4%) 21 (42%) 215 (66.2%) 
Neurological failure 4 (3.8%) 3 (3%) 0 2 (4%) 9 (2.8%) 
Post op cardiac surgery 33 (31.7%) 0 12 (16.7%) 9 (18%) 54(16.6%) 
Post op other 0 4 (4%) 0 4 (8%) 8 (2.5%) 
Renal failure 1 (1%) 0 1 (1.4%) 6 (12%) 8 (2.5%) 
Metabolic 0 0 1 (1.4%) 2 (4%) 3 (0.9%) 
Sepsis 0 0 2 (2.8%) 0 2 (0.6%) 
Other 0 0 0 2 (4%) 2 (0.6%) 
Primary Diagnostic group N 104 N 99 N 72 N 50 N 325 
Gastroenterology 0 1 (1%) 0 6 (12%) 7 (2.2%) 
Neurology 13 (12.5%) 5 (5%) 0 2 (4%) 20 (6.2%) 
Oncology haematology 1 (1%) 3 (3%) 0 1 (2%) 5 (1.5%) 
Respiratory infection 35 (33.6%) 84 (84.8%) 55 (76.4%) 14 (28%) 188 (57.8%) 
Trauma 1 (1%) 1 (1%) 0 2 (4%) 4 (1.2%) 
Cardiac failure 8 (7.7%) 0 2 (2.8%) 1 (2%) 11(3.4%) 
Congenital heart disease 42 (40.4%) 0 11 (15.3%) 11 (22%) 64 (19.7%) 
Metabolic/Endocrine 2 (2%) 0 2 (2.8%) 2 (4%) 6 (1.8%) 
Sepsis 1 (1%) 0 2 (2.8%) 0 3 (0.9%) 
Other 1 (1%) 5 (5%) 0 11 (22%) 17 (5.2%) 
PIM, pediatric index of mortality; WAZ, weight-for-age Z-score 
 
 
Table 2. Variation by centre in Non-Invasive Respiratory support practices 
Variable Bristol (N=104) Lyon (N=99) Madrid (N=72) Rotterdam (N=50) Total (M=325) 
Total days NRS (max 7d)  2.0 (1.0-3) 4 (3-6) 3 (2-4) 2.0 (1.0-3.0) 3.0 (2.0-5.0) 
NRS initiation  N=104 N=99 N=72 N=50 N=325 
Step up  24 (23%) 82 (82.8%) 55 (76.4%) 29 (58.0%) 190 (58.5%) 
Step down  80 (76.9%) 17 (17.1%) 17 (23.6%) 21 (42.0%) 135 (41.5%) 
Main mode NIRS used N=104 N=99 N=72 N=50 N=325 
CPAP  16 (15.4%) 45 (45.4%) 3 (4.2%) 5 (10.0%) 69 (21.2%) 
BIPAP  23 (22.1%) 24 (24.2%) 61 (84.7%) 0 108 (33.2%) 
HFNC  64 (61.5%) 25 (25.2%) 8 (11.1%) 45 (90.0%) 142 (43.7%) 
NAVA  1 (0.9%) 5 (5%) 0 0 6 (1.8%) 
Starting Fio2 40 (30-50) 30 (25-40) 60 (40-100) 60 (40-100) 40 (30-60) 
Starting IPAP 14 (11.5-15.3) 14 (13.3-14) 10 (8-12) NA 12 (10-14) 
Starting EPAP 6.5 (6-8) 7 (7-7) 6 (5-6) 5 (5-5.5) 7 (6-7) 
Starting Flow (L/min) 10.0 (8-16) 10 (8-20) 12 (10-15) 15 (9-25) 12 (8-20) 
Highest Fio2 40 (35-52.8) 40 (30-50) 60 (47.3-100) 100 (50-100) 45 (35-65) 
Highest IPAP 16 (14-18) 14 (14-15) 12 (12-14) NA 14 (12-15) 
Highest EPAP 8 (6-8) 7 (7-7) 6 (6-8) 6.(5.5-6.5) 7 (6-8) 
Highest flow (L/min) 12 (8-20) 10 (8-20) 12 (11.5-15) 15 (9-25) 12 (8-20) 
Main patient interface used  N=103 N=99 N=72 N=48 N=322 
Nasal mask 5 (4.9%) 65 (65.7%) 1 (1.4%) 3 (6.2%) 74 (23.0%) 
Nasal cannula 73 (70.9%) 26 (26.3%) 51 (70.8%) 44 (91.7%) 194 (60.2%) 
Face mask 6 (5.8%) 8 (8.0%) 2 (2.8%) 1 (2.1%) 17 (52.8%) 
Full face mask 19 (18.4%) 0 18 (25.0%) 0 37 (11.5%) 
Data in median (IQR) or numbers (%) 
BIPAP, Bilevel Positive Airway pressure, CPAP, Continuous Positive Airway pressure; EPAP, Expiratory positive airway pressure; Fi02, Fraction of 
inspired oxygen, HFNC, High Flow Nasal Cannula, IPAP, Inspiratory positive airway pressure; NA, Not available; NAVA, Neurally Adjusted Ventilatory 
Assist; NRS, Non-invasive Respiratory Support 
  
 
Table 3. Variation across centres in Enteral Nutrition Practices  











Feeding tube tip site N 95 N 99 N55 N 40 N 289 <0.01 
   Gastric 85 (89.5%) 98 (99.0%) 40 (72.7%) 31 (77.5%) 254 (87.9%)  
   Post pyloric 0 0 13 (23.6%) 5 (12.5%) 18 (6.2%)  
   Gastrostomy 10 (10.5%) 1 (1.0%) 2 (3.6%) 4 (10%) 17 (5.9%)  
Feeding route N 104 N 99 N 72 N 50 N 325 <0.01 
   Enteral 89 (85.6%) 99 (100%) 55 (76.4%) 30 (60%) 273 (84.0%)  
   Oral 11 (10.6%) 0 16 (22.2%) 8 (16%) 35 (10.8%)  
   NBM 4 (3.8%) 0 1 (1.4%) 12 (24%) 17 (5.2%)  
Main enteral feed method 
during NRS 
N 88 N 99 N 55 N 30 272 <0.01 
   Continuous 2 (2.3%) 96 (97.0%) 46 (83.6%) 12 (40.0%) 156 (57.3%)  
   Bolus/Intermittent  86 (97.7%) 3 (3.0%) 9 (16.3%) 18 (60.0%) 116 (42.6%)  
Energy targets used 85% RDA 85% RDA 85% RDA Individualised*   
Energy goals and fasting Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)  
   0.85% of RDA as energy    
   goal (kcal/d) 
497 (297-900) 340 (291-429) 467.5 (377.2-837.3) 817.9 (396.3-1355.8) 425.0 (314.5-850.0) <0.01 
   At initiation of NIRS  
   estimated energy  
   requirements (kcal/d) 
497 (297-900) 340 (291-429) 467.5 (377.2-837.3) 529.9 (241.3-974.3) 442.0 (320.0-782.0) <0.01 
   Time (hours) first EN 3 (2-5) 3 (1-15) 6 (1-14) 11.5 (2.0-21.1) 4 (1-12) <0.01 
   NBM hours during NRS 4 (2-6) 5 (1-16) 6 (1-16) 13.5 (4.5-24) 5 (2-14.5) <0.01 
   Percentage of hours NBM  
   during total NRS 
12.5 (4.1-25) 6.4 (1.2-19.3) 9 (2.0-26.2) 37 (15.4-100) 11.8 (2.9-27.6) 0.02 
   Energy received  
   compared to centre goal   
   (%)  
 
34.5 (17.6-59) 70.8 (51.9-85.2) 81.9 (50.5-95.8) 22.3 (0-72.7) 56.2 (24.7-79) <0.01 
 
   Energy received     
   compared to 0.85%RDA  
   (%)  
34.5 (17.6-59) 70.8 (51.9-85.2) 81.9 (50.5-95.8) 14.4 (0-53.2) 55.9 (24.9-81.8) <0.01 
Gastrointestinal effects       
   Any vomiting (yes/no) 13/104 12.5%) 19/99 (19.2%) 15/72 (20.8%) 7/50 (14.0%) 54/325 (16.6%) 0.4 
   Any other 
Gastrointestinal 
complications?  
5/104 (4.8%) 11/99 (11.1%) 14/72 (19.4%) 10/50 (20.0%) 40/325 (12.3%) <0.01 
   If Any, other GI  
   complications? 
N 5 (4.8%) N 11 (11.1%) N 14 (19.4%) N 10 (20%) 40 (12.3%) <0.01 
   Regurgitation 0 11 (100%) 0 0 11 (27.5%)  
   Diarrhoea 0/104 0/99 0/72 2 (20.0%) 2 (5.0%)  
   High GRV 3 (60%) 0 0 7 (70.0%) 10 (25.0%)  
   Abdominal distension 2 (40%) 0 5 (35.5%) 1 (10.0%) 8 (20.0%)  
   Constipation  0 0 9 (64.3%) 0 9 (22.5%)  
   Aspiration 0/104 5/99 (5.0%) 0/72 0/50 5/325 (1.5%) <0.01 
*Rotterdam energy goals for enteral nutrition are based on the Schofield equation for weight for the first day of admission and on the 
Recommended Dietary Allowances (RDA, Dutch Health Council) for the subsequent days. Data in median (IQR) or numbers (%) 
EN, Enteral Nutrition; IQR, Interquartile Range; GI, Gastrointestinal; GRV, Gastric Residual Volume; NBM, Nil by mouth; NRS, Non-invasive 
Respiratory Support;  RDA, Recommended Daily Allowance 
 
Table 4. Impact of variables on the achievement of energy targets  
 Univariate Multivariate 
  Adjusted R2=0.126 
Variable Factor  Mean % 
energy target 
achievement  










<0.001 1.2 (-3.5 – 5.9) 0.609 
Age (months)  Rs -0.27 <0.001 -0.2 (-0.3 to -0.1) 0.001 
PIM2  Rs -0.27 <0.001   
NRS initiation: Step up or Step down Step up  
Step down  
62.0 
49.0 
0.001   






<0.001   
Starting Fio2  Rs -0.07 0.231   
Starting IPAP  Rs -0.16 0.101   
Starting EPAP   Rs -0.09 0.238   
Highest Fio2  Rs -0.05 0.445   
Highest IPAP  Rs -0.17 0.096   
Highest EPAP   Rs 0.02 0.781   




<0.001 -21.5 (-30.9 to -12.1) <0.001 




0.012   
All values univariate with P<0.1 were placed in the multivariate model including centre as fixed variable, except for highest IPAP which could not be 
included due to the large number of missing data and feeding route due to the high correlation with feeding method. Excluding variables were: PIM2, 
main NRS mode and NRS initiation. BLPAP, Bilevel Positive Airway pressure; CPAP, Continuous Positive Airway Pressure; FiO2, Fraction of Inspired 
Oxygen; HFNC, High Flow Nasal Cannulae; NRS, Non-invasive respiratory support; PIM2 Paediatric Index of Mortality 2 Score.  
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A P P E N D I X 
Table S1. Nutritional protocols across sites 
Practices Bristol Lyon Madrid Rotterdam 
EN protocol Yes Yes Yes Yes 
Time to initiate 
EN   
Within 24 hours 
of admission 
Within 24 hours 
of admission  







Gastric Gastric Transpyloric Gastric 
Default Feeding 
method 
Bolus 3 hourly Continuous Continuous Continuous 



































Based on IV fluid 
allowances and 



































Start at 5ml/3 
hourly and 
increased by 2ml 
per Kg every 3-





target within 2 to 
4 days, daily 
stepwise increase 
Start at 1 ml/kg 
(max. 10 ml) per 
hour first 3 hours 
and increased by 
5 ml every 3- 
hourly feed until 
the maximum 




at the end of 






Practices Bristol Lyon Madrid Rotterdam 
Definition of 
intolerance 









times a day but it 
is not a criterion 
to stop enteral 
feeding 
Large GRV 
>50% of intake 
Vomiting >2 
times or 







pain and emesis 



























get a high fibre 













and Macrogol at 












EN, Enteral Nutrition; GRV, Gastric Residual Volume; REE, Resting Energy Expenditure; RDA, 
Recommended Daily Allowance; NIV, Non-invasive ventilation 
  
 
Table S2. Definition of terms 
Term Defined as 
Patient age In months to one decimal place  
Patient weight In Kg to one decimal place 
Cause of PICU 
admission 
Main reason for PICU admission: Drop down box options: 
Post-op cardiac surgery 
Post-op other surgery 
Respiratory failure 




















Total hours NRS Up to a maximum of 7 days  
PIM 2 score  All using standard PIM 2 scoring 
Date patient started 
NRS 
 
Date patient stopped 
NRS 
 
Total days NRS  Defined from the dates above: up to a maximum of 7 days 
Total hours NIV Within the period above: Up to a maximum of 168 hours 
Total hours HFNC Within the period above: Up to a maximum of 168 hours 
NRS initiation Drop down box options: 
Step up or Step down  
Main mode used The NRS mode used for the majority of the time spend on NRS 
Drop down box options: 
HFNC, CPAP, BLPAP or NAVA 
Second mode If a secondary mode used, what was this 
Drop down box options: 
HFNC, CPAP, BLPAP or NAVA 
Starting Fio2 Starting Fio2 
Starting IPAP If on BLPAP inspiratory pressure at start  
Starting EPAP/PEEEP For CPAP/BLPAP the lower pressure at start 
Starting flow  For HFNC in l/min  
Highest Fio2 Highest Fio2 recorded during NRS 
Highest IPAP If on BLPAP highest inspiratory pressure during NRS support  
Highest EPAP/PEEP For CPAP/BLPAP the highest value of the lower pressure during NRS 
support 
Highest flow For HFNC the highest flow during NRS support 
 
 
Term Defined as 
Main patient interface 
used 
Drop down box options: 
Face mask, nasal cannulae, full face mask,  
Secondary interface 
used 
Drop down box options: 
Face mask, nasal cannulae, full face mask, 
Feeding tube insitu at 
NRS 
Was a feeding tube insitu at the start of NRS 
Yes or No options 
Type Type: Drop down box options: 
Gastric, post-pyloric, gastrostomy  
Feeding tube site Options: nasal, oral or gastrostomy  
Main feeding method Main feeding method used whilst on NRS 
Drop down box options: 
Continuous, bolus or Not applicable e.g. Nil per oral  
Enteral or normal oral 
feeding 
Options: normal oral feeding/diet or enteral feeds 
Feed formula used Brand name 
Concentration  Kcal/ml of this feed  
0.85 of RDA as energy 
goal  
85% of the RDA energy goal calculated by: 
Based on expert opinion only we defined this using the mean between 
invasively ventilated children (Scofield +/- = 65% RDA) 
and RDA 
 
kcal requirements At initiation of NRS estimated kcal requirements  
Predictive equation 
used 
Predictive equation or formula used to calculate these requirements  
Any vomiting Any recorded vomiting episodes during NRS (yes or No) 
If yes, number If yes, the number of recorded vomiting episodes 
Any other GI 
complications? 
If yes please record along with number of episodes 
Any recorded 
aspiration? 
Any recorded aspiration episodes (yes or No) 
NPO during whole 
NRS 
Nil per oral during whole NRS (1st 7 days) Yes or No 
Time to first EN Hours from initiation of NRS to first EN 
NPO time  Total Nil per oral time during 1st 7 days of NRS 
% NRS time NPO Percentage of time nil per oral per time on NRS (in 1st 7 days)  
Total mls feed  Total mls of feed given during 1st 7 days of NRS 
Any supplemental PN Was any supplemental PN started specifically due to poor enteral 
intake during 1st 7 days of NRS (not for other reasons) 
Total kcal in  total (kcal) feed given during NRS: (kcal/mL) x (total feeds in mL) during 
the 1st 7 days of NRS  
Total kcal in per hours 
of NRS  
(kcal/mL) x (total feeds in mL)/ days of NIV (based on hours) 
Total kcal in days of 
NRS 
(kcal/mL) x (total feeds in mL) / days of NIV 
 
% energy goal kcal received compared to centre goal (%) 
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A B S T R A C T  
Background & aims: Clinicians and researchers often use feeding intolerance (FI) as main 
cause for insufficient enteral nutrition (EN). However, there is no uniform definition for FI. 
A uniform definition is essential for future studies focusing on predictors and outcomes of 
FI and enteral nutrition. A systematic review was performed to investigate the definitions, 
prevalence, predictors and outcomes of FI in critically ill children. 
 
Methods: The databases Medline, Embase, Cochrane CENTRAL, Web of Science were 
searched. Inclusion criteria were interventional, observational or case-control studies (>10 
patients) in which a definition of FI was reported in critically ill children (0-21 years). 
 
Results: FI was defined in 31 unique studies performed in 2973 critically ill children. FI was 
most commonly defined as presence of gastrointestinal (GI) symptoms and/or large gastric 
residual volume (GRV) (n=21), followed by discontinuation of EN due to GI symptoms (n=7) 
and inadequate delivery of EN (n=3). Median prevalence of FI was 20.0% [IQR 7.4%-33.0%]. 
Large GRV, abdominal distention, diarrhoea and vomiting/emesis, were the predominantly 
reported GI symptoms to define FI. FI was associated with severity of illness, mortality and 
nosocomial infections. 
 
Conclusions: Feeding intolerance is inconsistently defined in the current literature, but 
appears to be a prevalent concern in critically ill children. FI is most frequently defined by 
the presence of GI symptoms. A standardised definition is needed for both clinical and 
research purpose to determine the consequences of FI in relation to short-term and long-
term outcomes. The new proposed definition for FI entails the inability to achieve enteral 





I N T R O D U C T I O N  
The preferred route to administer nutritional support in the paediatric intensive care unit 
(PICU) is through enteral nutrition (EN) and achieving adequate energy and protein target 
intakes via enteral nutrition is associated with improved outcome. In clinical practice 
nutritional targets are often not reached during critical illness.1,2 Failure to achieve enteral 
target intakes in the PICU can be caused by a diversity of reasons, of which fear for poor 
gut function, interruptions around procedures, fluid restriction and feeding intolerance (FI) 
are frequently reported.2,3 
Although FI is declared a main reason for insufficient enteral intake, it is inconsistently 
defined among the different PICUs.3 A standardised definition is essential from a clinical and 
scientific perspective, providing insight into possible causes and consequences of difficulties 
with enteral intake in critically ill children. Furthermore, such a definition is needed to 
compare interventions in studies to optimise enteral intake during critical illness. 
A systematic review was performed to evaluate the definitions and to investigate the 
prevalence, predictors and outcomes of FI in critically ill children. Our primary aim was to 
evaluate all the reported definitions in research. Furthermore, the prevalence of FI, and 
associated predictors and outcomes of the different definitions were evaluated. Finally, we 
aimed to propose a definition for further validation. 
 
M E T H O D S  
The study protocol and objectives were established a priori (PROSPERO protocol number: 
CRD42018092967) and performed in line with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) statement.4 
 
Eligibility criteria 
Studies were included if the following eligibility criteria were met: 1) the study had an 
interventional, observational cohort or case-control design; 2) study participants were 
admitted to a paediatric intensive care unit (PICU); 3) investigators provided a definition of 
‘feeding intolerance’ or derivative terms (combination of the following terms: (in)tolerance, 
enteral, nutritional, GI, difficulties, complications). All studies reporting a definition were 
included, feeding intolerance was not necessarily the main topic of investigation. Studies 
were excluded if they: 1) were case reports or case series including <10 patients; 2) included 






The search was conducted in the following databases: Medline Ovid, Embase, Cochrane 
Central Register of Controlled Trials (CENTRAL), Web of Science and Google scholar. The 
search strategy was first developed by a Biomedical Information Specialist of the Medical 
Library of the Erasmus Medical Centre in Medline and adapted for the other databases. The 
search was limited to English language, and data published as conference abstract, letter, 
note or editorial were excluded. The search was performed on 11 January 2018 and updated 
on 07 Sept 2018. It included a citation review of all eligible articles (Appendix). All articles 
were independently screened on title and abstract by two reviewers and followed by full-
text screening (RE, SV). When reviewers disagreed a third investigator made the final 
decision (KJ). 
 
Data extraction and risk of bias assessment 
Data were extracted from eligible articles by two reviewers (RE; SV). The following data 
were extracted: 1) study design and setting; 2) inclusion criteria; 3) population; 4) study 
objective; 5) interventions; 6) definition of FI; 7) incidence or prevalence of FI; 8) predictors 
and/or presumed causes of FI; and 9) clinical outcome measures (mortality, infection, 
mechanical ventilation, use of vasoactive agents, or other adverse events). Only data of 
unique studies were extracted to report the definitions or prevalence. However, secondary 
analysis of previous published populations were included in the predictors and outcomes 
sections of this systematic review. 
 
The risk of bias was assessed by description of study design, feeding route, description of 
nutritional policy and the clearness in the definition of FI. The investigated PICU population 
was reported to determine the clinical heterogeneity of the studies, which potentially could 
result into bias. Methodological quality of nonrandomised studies was evaluated using the 
STROBE checklist.5 Quality of randomised trials were assessed with the Cochrane risk of 
bias tool.6 This tool assesses the different types of bias for RCTs, divided into selection, 
performance, detection, attrition, reporting and other bias. 
 
Statistical analysis 
Descriptive statistics are reported as number (percentages), mean (standard deviation (SD)) 
if normally distributed or as median (interquartile range (IQR)) if not normally distributed. 
A random effect meta-analysis was used to calculate the pooled prevalence of FI and the 
95% confidence intervals (CI) using R studio version 3.4.1 (Boston, USA). Heterogeneity 
was clinically and statistically assessed using Cochran's Q homogeneity and I-squared 
inconsistency statistics. Due to the clinical heterogeneity of the definition categories, 
separate analyses were performed for the different FI definitions. The Agresti-Coull (AC) 
binominal CI was used if only one prevalence per definition was reported. 
 
 
R E S U L T S  
A total of 3572 unique studies were identified and after reviewing title and abstract 101 
potentially relevant studies remained (Figure 1). After full-text screening 39 articles met the 
full eligibility criteria,7-45 of which 10 were identified with possible overlapping participants.7-
14,29,45 After contact with the authors, the two primary studies with the largest population 
and a clear definition of FI were selected for the data pooling analyses.7,45 Therefore, 31 
unique studies, reporting definitions of FI on 2973 critically ill children, were included in the 
analysis. Of these studies, 9 studies were RCTs, 5 non-randomised interventional trials, 8 
were prospective observational and 9 retrospective observational studies. The majority of 
the included studies were performed in a mixed PICU population and reported a median 
participant size of 60 (range 20–526). In all studies, EN was the main topic of investigation, 
whereas in 17 studies (54%) FI was the main objective of the study. 
 
Risk of bias assessment 
The majority of the studies included a mixed PICU population. Two studies were performed 
in term neonates; one with neonates receiving venoarterial extracorporeal membrane 
oxygenation (VA-ECMO) treatment19 and one receiving prostaglandin medication.20 Other 
studies with non-mixed population included infants with respiratory diagnosis,24,40 post-
surgery for congenital heart diseases (CHD),21,22,24 and children with a hypoplastic left heart 
syndrome (HLHS).23 
 
In the nine RCTs, FI was either the primary or secondary objective of the study.24-28,30,43-45 
The risk of bias from the randomization process (selection bias), selective reporting or 
incomplete outcome data was generally low, however, in three studies there might be 
selection bias because of exclusion or switching of patients to the other treatment arm after 
the randomization process due to the inability to place a post-pyloric tube.25,43,44 There was 
potential performance and detection bias in four studies due to the inability to blind the 
participants, clinicians and investigators25,26,43,45 and one study did not report if investigators 
were blinded for outcome data (detection bias).24 
 
The methodological quality varied among the observational and non-randomised 
interventional studies but was overall medium to poor. The highest score obtained from 
the STROBE checklist5 was 12 of a maximum of 22 points. Most studies did not report the 
method section according to the checklist and information on selection and inclusion of 
participants, methods of data assessment, bias, quantitative variables and/or detailed 
statistical plan were missing. 
 
EN was provided in the majority of studies via the combination of gastric, post-pyloric and 
oral route. Ten studies (32%) investigated exclusive gastric feeding and four (13%) post-
pyloric feeding. In three studies no information on feeding route was provided. Also, not all 
 
studies provided information on patient characteristics. Three studies (10%) did not report 
an age range in method or result section.15,18,26 Detailed description of nutritional policy was 
reported in 23 studies (74%). The majority of the studies reported exclusion criteria, which 
were expected limited admission duration (range 12 h to 5 days), GI-disorders or surgery, 
congenital or genetic abnormalities, renal or liver failure. Seven studies (23%) excluded 
children if GI symptoms or pro-kinetic agents were present at baseline.22,24,37,39,44-46 
 
Definitions of feeding intolerance 
There was a wide variety in definitions used to determine FI, which were classified into 
three main categories: 
1) Discontinuations of EN due to gastrointestinal (GI) symptoms (n=7 studies); 
2) Presence of GRV and/or GI symptoms, divided in 
a. GRV and GI symptoms (n=12 studies) 
b. Only GI symptoms (n=6 studies) 
c. Only GRV (n=3 studies); 
3) Inability to achieve enteral target intake (n=3 studies). 
 
Gastrointestinal symptoms 
Table 1 presents an overview of the reported GI symptoms used to describe FI in the studies 
from category 1 (discontinuations of EN due to gastrointestinal (GI) symptoms) and 
category 2 (Presence of GRV and/or GI symptoms), which were reported in 28 studies 
(90%) in total. Most reported symptoms were diarrhoea, large GRV, abdominal distention 
and vomiting. Twenty studies (65%) reported large GRV as a marker for feeding intolerance 
(category 1, 2a and 2c), but this was defined inconsistently among the studies. Four studies 
reported large GRV as >50% of previous 4 h of feeding7,42,46. All other cut-off values for large 
GRV were used only once per study, i.e. 100–150% of previous 4 h of feeding, > 300% of 
previous 3 h of feeding, >66% of previous feeding, >125% after 4 h feed challenge, > 2 ml/kg 
per 3 h, >3 ml/kg/day, >5 ml/kg per 4–5 h, >10 ml/kg per 4 h, >100 ml per 4 h or >150  ml 
per hour. In the remaining six studies large GRV was not specified. No values or definitions 
were provided in the majority of the studies regarding the other GI symptoms. Diarrhoea 
was specified in eight studies as having more than 3, 4 or 6 loose stools per day or exciding 
the amount of 2.5 L per day.15,24,25,37,40,44-46 Four studies mentioned a threshold value for 
abdominal girth, which were ≥2 times increase,34,38 >3 cm increase20 or ≥15% increase.40 
Emesis or vomiting was defined in two studies as having two or more episodes of spitting-
up gastric content.34,38 
 
Enteral target intake 
Inability to achieve enteral target intake was used to determine FI in the remaining three 
studies (10%) (category 3) and GI-symptoms were not part of the definitions. In one study 
FI was defined by not reaching 75% of target intake (estimated energy expenditure * 1.3) 







Figure 1. Flow chart depicting search for eligible studies for inclusion in systematic review about 
feeding intolerance in critically ill children. 
  
 
Table 1. Number of times gastrointestinal symptoms were used to define feeding intolerance 
(N=28 studies) 
Definition category Category 1 Category 2  Category 1 and 2  
 Discontinuation of EN 
due to GI symptoms 
GRV and/or GI 
symptoms 
All GI symptoms 
reported 
Diarrhoea 5 17 22 
Large GRV 5 15 20 
Vomiting/emesis 5 15 20 
Abdominal distention 5 13 18 
Constipation 3 2 5 
Aspiration 2 3 5 
GI-bleeding 1 3 4 
Abdominal discomfort - 3 3 
NEC 1 1 2 
Reflux - 2 2 
Hemoccult positive stool - 1 1 
Absent bowel sounds - 1 1 










Table 2. Prevalence of FI with use of different definitions 














ty I2 % (95% 
CI) 
1.   EN discontinued due to GI 
symptoms 
6 1026 119 NA 0.15 (0.07-0.30) 91 (87-96) 
2a. GI symptoms including large GRV 7 854 238 NA 0.22 (0.09-0.44) 85 (71-92) 
2b. GI symptoms without large GRV 1 59 7 0.12 (0.05-0.23) NA NA 
2c. Large GRV 2 83 35 NA 0.42 (0.30-0.54) NA 
3.   Insufficient enteral intake 1 50 0 0.00 (0.00-0.09) NA NA 
     Total 17 2072 339 NA 0.19 (0.11-0.30) 90 (86-93) 
EN, Enteral nutrition; FI, feeding intolerant GI, gastrointestinal; GRV, gastric residual volume 
aSubanalyses of studies with a reported prevalence; bPooled proportion calculated when >1 study was included and binominal proportion when 




Table 3. Causes of feeding intolerance investigated in 8 randomised interventional trials 
Author, year Definition of FI N Population  Study design  Objective Causes of FI 
Cui et al., 2018 
[24] 
Large GRV (> 3 times 
feeding volume delivered 
in 3h), intolerable 
vomiting, diarrhoea (>4 










effects and tolerance of 
the 2 different formulas 
in infants after congenital 
heart surgery. 
Tolerable diarrhoea 
higher in PE-formula 
group 69.2% vs 33.3% 
No difference in other 
parameters 
Fayazi et al., 
2016 [43] 




5 – 17 years 
Intermitted vs 
continuous gastric EN 
Compare intermitted vs 
continuous feeding in 
terms of time to reach 
caloric goal and 
complications 
FI higher in intermittent 
feeding group (p=0.02) 
No significant difference 
in vomiting and 
diarrhoea 
Jacobs et al., 
2013 [30] 
Achieved energy goal less 
than 75% of estimated 
energy expenditure x 1,3 
within 48 hours of 
initiation of EN 
26 Respiratory 
failure 
1 - 18 years 
Eicosapentaenoic acid, 
ƴ-linolenic acid and 
antioxidants vs 
standard formula via 
gastric or post-pyloric 
route 
Pilot study to determine 
feasibility of 
eicosapentaenoic acid, ƴ-
linolenic acid and 
antioxidants feeding 
Achievement of energy 
goal comparable for 
both formulas (28-30 
hours) 
Simakachorn et 
al., 2011 [27] 
Inability to reach target 
caloric intake (70 kcal * 







1 - 3 years 
Probiotic vs standard 
formula via oral or 
gastric route 
Demonstrate the 
tolerance and safety of 
an enteral formula 
containing a synbiotic 
blend and to investigate 
its effect on the intestinal 
microbiota 
1) Median time to reach 
target caloric goal 
comparable between 
probiotic (4.13d) vs 
standard (4.36d) formula 
(p=0.999) 
2) No difference in 
abdominal distention 
(p=0.83), vomiting 





et al., 2009 [28] 
Large GRV (> 50% of 4h 
feeding volume 
delivered), distension, 
vomiting or diarrhoea (>4 
watery stools per day 
leading to a negative fluid 






4 weeks – 
12 months 
PE-formula vs 
standard formula via 
gastric or post-pyloric 
route 
Compare nutritional 




balances, amino acid 
profiles). Secondary aims 
were assessing tolerance 
and safety 
No vomiting, distention, 
diarrhoea in both 
groups. GRV higher in 
PE-group vs standard 
group (9.8±2.8 vs 
4.7±2.4 ml/kg; p<0.01) 
 
Meert et al., 
2004 [25] 
Aspiration, vomiting, 
diarrhoea (> 3 liquid 









Evaluate the effect of 
feeding tube position on 
nutrient delivery and 
feeding complications 
Presence of each 
symptom did not differ 
between gastric and 
post-pyloric EN group 
(NS) 
Horn et al., 
2003 [45] 
Number of stools, 
diarrhoea (>3 stools in a 
24h period) or vomiting  
45 Mixed 
0 – 13 years 
Intermittent vs 
continuous gastric EN 
Assessing tolerance of 
continuous vs 
intermitted feeding 
The number of stools 
per day and the 
prevalence’s of 
diarrhoea and vomiting 
did not differ between 
the two groups (NS) 












pyloric feeding during 
extubation  
Examine the safety and 
efficacy of continuous 
feeding compared with 
interrupted post-pyloric 
feeding at the time of 
extubation. 
No difference between 
continuation vs 
withholding EN prior to 
extubation (NS) 
CHD, Congenital heart disease; EN, Enteral nutrition; FI, Feeding Intolerance; GA, gestational age; GI, gastro-intestinal; GRV, gastric residual 
volume; NEC, necrotising enterocolitis; NPO, Nil per os; PE, protein and energy enriched; RCT, randomised controlled trial 
  
 
Table 4. Feeding intolerance associated with outcome in 3 non randomised studies 
Author, year Definition of FI N Population  Study design Objective Clinical 
outcomes of FI 
Sánchez et al., 
2000* [14]  
EN discontinued 
due to abdominal 
distention, large 










Assess the use 
and complications 
of post-pyloric EN 
- Pulmonary 
infections (25% vs 
8.6%; p<0.05) 
- Altered hepatic 
function (100% vs 
9.5%; p<0.01) 
- Hypokalaemia 
(19 vs 5.5%; 
p<0.05) 
- Hypocalcaemia 
(19% vs 9.5; 
p<0.05) 













Analyse the utility 
and complications 
of post-pyloric EN 
Mortality higher in 
FI patients 30% vs 
13% (NS) 







in ≥ 24h EN 
discontinuation. 












FI associated with 
sepsis (p<0.001) 
FI associated with 
mortality (p<0.05) 
* Studies are secondary analysis of previous published studies with possible overlay in population. 
EN, Enteral nutrition; FI, Feeding Intolerance; GRV, gastric residual volume 
 
Table 5. Feeding intolerance associated with energy delivery investigated in 4 non randomised studies 
Author, 
year 




Large GRV (>3ml/kg or >150 
ml), ≥ 2 increases in 
abdominal girth, ≥ 2 emesis 
episodes, ≥ 3 loose stools or 
subjective abdominal 






receiving gastric EN 
Explored the feasibility of 
performing the 
acetaminophen absorption 
test and examined its 
correlation with FI 
GRV did not predict 
delayed vs normal 
gastric emptying 
(p=0.964) 
Other FI signs did 









< 21 years 
Prospective cross-
sectional, receiving 
oral, gastric or post-
pyloric EN 
Reviewed nutritional 
practices in six medical-
surgical PICUs and 
determined risk factors 
associated with delayed EN 
Risk factor for 
delayed EN 









< 21 years 
Prospective cross-
sectional, receiving 
oral, gastric or post-
pyloric EN 
Reviewed nutritional 
practices in six medical-
surgical PICUs and 
determined risk factors 
associated with delayed EN 
Risk factor for 
delayed EN 





Large GRV (> 125% of 4h 
feeding volume delivered) 
 
23 Mixed 




receiving gastric EN 
Determine the relationship 
between amylin levels and 
gastric emptying 
Delayed gastric 









120 ml/kg/day of continuous enteral feeds without interruption.23 The third study defined FI 
as the inability to reach target caloric intake (70 kcal * kg * day) in children aged 1–3 years.27 
 
Prevalence of feeding intolerance 
Prevalence of FI was reported in 17 studies (55%) and ranged from 0.0 to 57.1% with a 
median prevalence of 20.0% [IQR 7.4–33.0]. Due to the clinical heterogeneity within the 
category definitions, a pooled prevalence was calculated per group category (Table 2). The 
pooled percentage of children with feeding intolerance was 15% (95% CI 7–30%) in six 
studies with the FI definition EN discontinuation, 22% (95% CI 9–44%) in seven studies with 
the FI definition of GI symptoms including large GRV and 42% (95% CI 30–54%) in two 
studies defining FI with large GRV. However, the heterogeneity of the pooled prevalence 
was considered large in the definitions, with an I-squared of 91% in studies which used 
discontinuation of EN and 85% in studies using GI symptoms and GRV. 
 
Predictors associated with feeding intolerance 
Causes and predictors of FI were mentioned in 23 studies (74%) and are presented in Table 
3 and Appendix. Eight studies were randomised controlled trials (RCTs) with a primary 
focus on FI (Table 3), 10 studies had a prospective design and 5 studies a retrospective 
design (Appendix). In the 8 RCTs that were identified, various nutritional interventions were 
compared in critically ill children. In one study comparing intermittent versus continuous 
gastric feeding a significant higher prevalence of FI was found in the intermittent group 
(p=0.02) [43]. The other studies comparing gastric versus post-pyloric25 and intermittent 
versus continuous feeding, did not find differences in FI.26,45 Also studies comparing standard 
frmula with formulas that were enriched with either pre- and probiotics,27 with 
immunomodulators30 or with protein and energy did not report differences in FI.24,46 
 
Clinical outcome measures associated with feeding intolerance 
There were three observational studies associating clinical outcomes with FI and no 
interventional trials (Table 4).13-15 In one study mortality was higher in children with FI (30% 
versus 13%); however this was not significant.13 A retrospective study in 91 severely burned 
children receiving post-pyloric EN did find a significant association between feeding 
intolerance and mortality (p<0.05).15 In 2 studies, FI in critically ill children was also 
associated with pulmonary infections (p<0.05)14 and sepsis (p<0.001).15 The association of FI 
and enteral energy delivery was investigated in four non randomised studies and are 
reported in Table 5. FI was associated with lower energy delivery37 and delayed achievement 
of full EN.33,39 
 
 
D I S C U S S I O N  
Our systematic review revealed several nutritional studies in critically ill children with a 
focus on the descriptive term “feeding intolerance”. However, the methodological quality 
of these studies was moderate to poor. As hypothesised, FI was inconsistently defined, 
which precludes any firm conclusions on prevalence, predictors and outcomes. FI was most 
commonly based on a wide variety of gastrointestinal symptoms. FI was sometimes 
addressed as not reaching target intakes, however, in other studies this was the outcome 
determinant of FI. It is remarkable that there is no standardised definition for FI, especially 
considering the substantial impact it presumably is declared to have on morbidity and 
mortality during critical illness.14,47 Unfortunately, no overall prevalence could be calculated 
to assess the burden if FI in critically ill children. Aside from inconsistency in the use of 
determinants for a definition the overall poor description of how these determinants were 
assessed was of greater concern, leading to a high risk of bias in almost all studies included 
in our review. This resulted in a large statistical heterogeneity of our pooled prevalence 
within the definitions (I-squared 85% and 91%).48 Despite the substantial heterogeneity of 
the definitions, the current literature search showed that FI is prevalent (median prevalence 
20.0%) in the PICU. 
 
The variety of definitions used in the studies, in combination with the risk of bias of the 
studies describing them, precluded making even cautious conclusions on potential 
predictors of feeding intolerance. However, there appeared to be an association between 
FI and severity of illness.17,39 Our review further showed that current literature does not 
provide causation in relation to feeding intolerance. No studies were identified which 
compared polymeric versus (semi)-elemental formulas. This is remarkable as these formulas 
are advised in nutritionally vulnerable patients who are unable to achieve adequate nutrition 
from standard oral diets.49,50 Despite the high burden and prevalence, no studies investigated 
motility agents or other treatment for FI. Thus, the current literature does not provide any 
evidence that feeding intolerance can be influenced by feeding route, mode or the type or 
composition of enteral nutrition. 
 
Considering feeding intolerance as an aggregate of symptoms of yet another organ failing 
during critical illness is, again taking the methodological issues into consideration, supported 
by a few studies which associated feeding intolerance with increased morbidity and even 
mortality.13-15 Whether GI dysfunction in itself can determine outcome independent of 
nutrient intake is an important question. It is unclear if the impact on clinical outcome is 
caused by the consequences of FI as expression of organ (intestinal) failure, or if it reflects 
an underlying severity of illness. The studies in our systematic review that defined FI as an 
inability to achieve enteral target intake did not make associations with outcome. There are 
two large observational cohorts who have showed that enteral intake below two-third of 
what was prescribed during the first 10 days of admission in the PICU impaired clinical 
 
outcome in critically ill children.51,52 Unfortunately, these studies did not describe any GI 
symptoms or gave a description of feeding intolerance otherwise and where therefore not 
included in our systematic review. 
 
Diverse pathophysiological pathways leading to FI might play a part in the variations in 
definitions and prevalence at the PICU. Both the GI morphology and function can be altered 
and aside from nutritional processing the intestines have other immunological, endocrine 
and barrier functions.22,53,54 The aetiology of abnormal GI function in critically ill children is 
largely unknown, but is most likely multifactorial. GI peptides and neurohormones play an 
important role in the motor function and increased levels of GI peptides (CCK, PYY) have 
been associated with GI dysfunction .55,56 A study in cardiac surgery patients found an 
association between GI symptoms as definition of feeding intolerance, and intestinal barrier 
function (I-FABP, citrulline, claudin 3). Plasma biomarkers reflecting the epithelial barrier 
function, together with pro- and anti-inflammatory cytokines, were altered in relation with 
severity of illness.22 There is a high need for studies investigating the potential mechanisms 
of FI during critical illness and unravel the largely unknown aetiology. 
 
A recently published narrative review discusses the need for a consistent definition of FI 
among the international PICU community.57 Unfortunately, the evidence from the current 
paediatric literature is insufficient to provide such definition. Therefore, we want to propose 
a definition, which can be used for further validation (Table 6). The term feeding intolerance 
implies a patient who does not tolerate full enteral nutrition due to gastrointestinal 
symptoms. Thus, in our opinion the descriptive definition of FI should start with the inability 
to achieve enteral target intakes and secondly should include GI symptoms which indicate 
GI dysfunction according to expert clinicians and researchers. As previously reported, the 
evidence of insufficient enteral intake is sparse, however, an intake below two-third of target 
has been associated with poor clinical outcome.51,52 Furthermore, the new SCCM-ASPEN 
clinical guidelines suggest to achieve an energy delivery of at least two-thirds of the 
prescribed daily requirement by the end of the first week in the PICU.58 Therefore, this 
could be a starting point for a proposed definition. We would like to state that the GI 
symptoms are a direct symptom of the pathophysiological mechanism causing FI, and 
therefore reflect problems with gastric emptying, motility, enterocyte dysfunction and 
nutrient absorption or are related to intestinal inflammation or dysfunction of enteric 
endocrine system. Frequently described GI symptoms (≥10 times) were large GRV, 
abdominal distention, diarrhoea and vomiting, and these have to be considered in the 
definition. Also, serious adverse GI symptoms, such as intestinal ischemia and bloody stool 
have to be taken into account.41 Usually no cut-off thresholds for frequency and/or volumes 
of symptoms were reported. Without reporting these thresholds in the definition, besides 
the issues with inter- and intra-observer reliability, validation will be difficult. The impact of 
each individual symptom is uncertain, but will probably vary between symptoms. Also, no 
attempts were made to report the sensitivity or specificity of the symptoms in the included 
 
studies of our review. In our review, large GRV was often reported as one of the GI 
symptoms, which is comparable with the systematic review performed in adults.47 The 
implications of GRV measurements in standard practice are debated. Recent studies found 
no association between GRV measurements and clinical outcome and current guidelines on 
critically ill children start to challenge the use of GRV as a marker for feeding intolerance.59-
62 Due to the previously mentioned limitations, further validation of any proposed definitions 
is needed in critically ill children. 
 
Taking all these concerns into consideration, we propose the definition for enteral feeding 
intolerance as presented in Table 6, to be used as clinical and research tool. This definition 
includes the combination of the inability to achieve target intake and the presence of GI-
symptoms. For this definition it is essential that EN is indicated and attempted. Additional 
research is needed for validation of this proposed definition, including cut-off thresholds for 
enteral target intake and GI symptoms. Furthermore, the impact of each individual criterion 
needs to be investigated. 
 
There are several limitations of our systematic review that need to be addressed. As 
described before, the methodological quality of the included studies was overall moderate 
to poor and conclusions based on these studies need to be made with considerations. 
Furthermore, our systematic review might be subjected to bias, as a large proportion of our 
included studies were retrospective observational studies. Our primary aim was to report 
the most commonly used definitions of FI, and if possible, provide a universal and standard 
definition. Unfortunately, the evidence from the current paediatric literature is insufficient 
to provide such definition and we therefore proposed a definition for further validation 
based on expert opinion. Despite our elaborate literature search, no causal relationship 
could be addressed in regard with short-term or long-term effects of FI. 
 
C O N C L U S I O N S 
Feeding intolerance is inconsistently defined in the current literature, but appears to be a 
realistic and prevalent problem in critically ill children. FI is mostly defined in studies by the 
presence of gastrointestinal symptoms, without describing associations between predictors 
and outcome with FI. We would propose that a definition for FI should include the inability 
to achieve enteral nutrition target intakes in combination with the presence of GI symptoms 




Table 6. Proposed definition for enteral feeding intolerance in critically ill children in whom EN 
is indicated and attempted; registered over a 24h period 
1) Insufficient enteral 
intake  
Defined as enteral intake two-third of prescribed daily target 
or  
EN is withheld for ≥ 48 hours or  
EN is not increased for ≥ 48 hours 
Excluding interruptions due to procedures 
AND 
2) Presence of at least 
one of the following 
criteria 
 
a GI-symptoms  
 Large GRV  Defined as ≥ 50% of the EN delivered in the last 4 hours 
 Presence of vomiting Defines as ≥ 2 times with gastric content in 24h period 
 Presence of diarrhoea  Defined as ≥ 4 times loose stool with negative fluid balance in 
24h period 
b Severe GI-symptoms with 
concern for intestinal 
ischemia  
- Abdominal distention 
- Abdominal pain 
- Melena 
- Haematochezia 
Critically ill children must both fulfil the first and second criteria to be classified as feeding 
intolerant according to this definition.  
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A P P E N D I X 
Supplement file 1. Search strategy in different databases.  
Embase.com  
('critically ill patient'/de OR 'critical illness'/de OR 'intensive care'/de OR 'intensive care 
unit'/de OR 'coronary care unit'/exp OR 'medical intensive care unit'/exp OR 'neurological 
intensive care unit'/exp OR 'pediatric intensive care unit'/exp OR 'surgical intensive care 
unit'/exp OR 'artificial feeding'/de OR 'enteric feeding'/de OR 'digestive tract intubation'/exp 
OR 'nose feeding'/de OR 'artificial ventilation'/de OR 'digestive tube'/de OR 'enterostomy 
tube'/exp OR 'esophagus tube'/exp OR 'jejunostomy tube'/exp OR 'nasobiliary tube'/exp 
OR 'nasogastric tube'/exp OR 'stomach tube'/exp OR 'nutritional support'/de OR 
(((critical*) NEAR/3 (ill*)) OR (intensive* NEAR/3 care*) OR ((artificial* OR enter* OR 
nose OR tube OR support*) NEAR/3 (feed* OR nutrition*)) OR ((digestiv* OR duoden* 
OR esophag* OR oesophag* OR stomach* OR gastr* OR enterostom* OR jejunostom* 
OR nasobiliar* OR nasogastric* OR Nasojejun*) NEAR/3 (intubat* OR tube*)) OR picu OR 
icu OR ((mechanic* OR artificial* OR controlled* OR support*) NEAR/3 (respirat* OR 
ventilat*))):kw,ab,ti) AND ('nutritional intolerance'/de OR 'stomach emptying'/de OR 
'gastric residual volume'/de OR 'caloric intake'/exp OR (((nutrition* OR food OR feeding* 
OR feed OR gastrointestin* OR enter*) NEAR/6 (intoleran* OR toleran*)) OR ((enter* OR 
tube) NEAR/3 fail*) OR ((stomach OR gastric*) NEAR/3 (empty* OR residu*)) OR ((energy 
OR calor* OR enteral*) NEAR/3 (intake* OR goal*))):kw,ab,ti) AND (child/exp OR 
adolescent/exp OR adolescence/exp OR pediatrics/exp OR childhood/exp OR 'child 
development'/de OR 'child growth'/de OR 'child health'/de OR 'child health care'/de OR 
'child care'/exp OR 'childhood disease'/exp OR 'pediatric ward'/de OR 'pediatric hospital'/de 
OR 'pediatric intensive care unit'/exp OR (adolescen* OR infan* OR newborn* OR (new 
NEXT/1 born*) OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* 
OR teen* OR boy* OR girl* OR minors OR underag* OR (under NEXT/1 (age* OR aging)) 
OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR 
prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR highschool* OR 
picu):kw,ab,ti) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR 
[Editorial]/lim) AND [english]/lim 
Medline Ovid   
(Critical Illness/ OR Critical Care/ OR Intensive Care Units/ OR Coronary Care Units/ OR 
Intensive Care Units, Pediatric/ OR Respiratory Care Units/ OR Nutritional Support/ OR 
Enteral Nutrition/ OR Intubation, Gastrointestinal/ OR Respiration, Artificial/ OR 
(((critical*) ADJ3 (ill*)) OR (intensive* ADJ3 care*) OR ((artificial* OR enter* OR nose OR 
tube OR support*) ADJ3 (feed* OR nutrition*)) OR ((digestiv* OR duoden* OR esophag* 
OR oesophag* OR stomach* OR gastr* OR enterostom* OR jejunostom* OR nasobiliar* 
OR nasogastric* OR Nasojejun*) ADJ3 (intubat* OR tube*)) OR picu OR icu OR 
((mechanic* OR artificial* OR controlled* OR support*) ADJ3 (respirat* OR 
 
ventilat*))).kw,ab,ti.) AND (Gastric Emptying/ OR Energy Intake/ OR (((nutrition* OR food 
OR feeding* OR feed OR gastrointestin* OR enter*) ADJ6 (intoleran* OR toleran*)) OR 
((enter* OR tube) ADJ3 fail*) OR ((stomach OR gastric*) ADJ3 (empty* OR residu*)) OR 
((energy OR calor* OR enteral*) ADJ3 (intake* OR goal*))).kw,ab,ti.) AND (exp Child/ OR 
exp Infant/ OR exp Adolescent/ OR exp "Pediatrics"/ OR "Child Nutrition Sciences"/ OR 
"Infant nutritional physiological phenomena"/ OR "Child Development"/ OR exp "Child 
Health Services"/ OR exp "Child Care"/ OR "Hospitals, Pediatric"/ OR exp "Intensive Care 
Units, Pediatric"/ OR (adolescen* OR infan* OR newborn* OR (new ADJ born*) OR baby 
OR babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR 
girl* OR minors OR underag* OR (under ADJ (age* OR aging)) OR juvenil* OR youth* OR 
kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR 
paediatric* OR school* OR preschool* OR highschool* OR picu).kw,ab,ti.)  
Cochrane CENTRAL  
((((critical*) NEAR/3 (ill*)) OR (intensive* NEAR/3 care*) OR ((artificial* OR enter* OR 
nose OR tube OR support*) NEAR/3 (feed* OR nutrition*)) OR ((digestiv* OR duoden* 
OR esophag* OR oesophag* OR stomach* OR gastr* OR enterostom* OR jejunostom* 
OR nasobiliar* OR nasogastric* OR Nasojejun*) NEAR/3 (intubat* OR tube*)) OR picu OR 
icu OR ((mechanic* OR artificial* OR controlled* OR support*) NEAR/3 (respirat* OR 
ventilat*))):ab,ti) AND ((((nutrition* OR food OR feeding* OR feed OR gastrointestin* OR 
enter*) NEAR/6 (intoleran* OR toleran*)) OR ((enter* OR tube) NEAR/3 fail*) OR 
((stomach OR gastric*) NEAR/3 (empty* OR residu*)) OR ((energy OR calor* OR enteral*) 
NEAR/3 (intake* OR goal*))):ab,ti) AND ((adolescen* OR infan* OR newborn* OR (new 
NEXT/1 born*) OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* 
OR teen* OR boy* OR girl* OR minors OR underag* OR (under NEXT/1 (age* OR aging)) 
OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR 
prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR highschool* OR 
picu):ab,ti)  
Web of science   
TS=(((((critical*) NEAR/2 (ill*)) OR (intensive* NEAR/2 care*) OR ((artificial* OR enter* 
OR nose OR tube OR support*) NEAR/2 (feed* OR nutrition*)) OR ((digestiv* OR duoden* 
OR esophag* OR oesophag* OR stomach* OR gastr* OR enterostom* OR jejunostom* 
OR nasobiliar* OR nasogastric* OR Nasojejun*) NEAR/2 (intubat* OR tube*)) OR picu OR 
icu OR ((mechanic* OR artificial* OR controlled* OR support*) NEAR/2 (respirat* OR 
ventilat*)))) AND ((((nutrition* OR food OR feeding* OR feed OR gastrointestin* OR 
enter*) NEAR/5 (intoleran* OR toleran*)) OR ((enter* OR tube) NEAR/2 fail*) OR 
((stomach OR gastric*) NEAR/2 (empty* OR residu*)) OR ((energy OR calor* OR enteral*) 
NEAR/2 (intake* OR goal*)))) AND ((adolescen* OR infan* OR newborn* OR (new 
NEAR/1 born*) OR baby OR babies OR neonat* OR child* OR kid OR kids OR toddler* 
OR teen* OR boy* OR girl* OR minors OR underag* OR (under NEAR/1 (age* OR aging)) 
OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* OR prepubescen* OR 
 
prepubert* OR pediatric* OR paediatric* OR school* OR preschool* OR highschool* OR 
picu)) ) AND DT=(article) AND LA=(english) 
Google scholar  













Table S1. Predictors associated with of feeding intolerance investigated in 14 non randomised studies 
Author, 
year 
Definition of FI N Population 
and age 
range 
Study design  Objective Associated predictors of 
FI 
Haney et 
al., 2018 40 
EN discontinued due to 
increased abdominal girth 
(>15 % increase), vomiting 
or diarrhoea (>4 stools) in 
a 24h period 
106 Respiratory 
failure 37 





Investigate the impact of 
early EN in patients with 
respiratory failure 
No association with use of 
motility agents or degree of 
respiratory failure and FI 
FI higher in patients receiving 
vasoactive agents (33% vs 9%; 
p=0.02) 
Qi et al., 
2017 21 
EN discontinued due to 
vomiting, GI bleeding, 











Determine the causes of 
interruptions in 
postoperative EN in 
CHD patients and 
discuss clinical counter 
measures 
Interruptions higher in 
younger patients (age 1 - 12 
months vs 1 - 6 years; 
p=0.053) 
Toms et al., 
2015 23 
Intake less than 120 
ml/kg/d from continuous 
enteral feeds or per os 




GA > 35 
weeks 
Retrospective, 
receiving oral or 
gastric EN pre-
operative vs NPO 
Determine if 
preoperative trophic 
feeds can improve 
outcomes after 
Norwood palliation. 
Infants with pre-operative 
tropic feeds achieved 
postoperative PO feeds 8 
days sooner than NPO pre-
operative group (p=0.01) 
Sánchez et 
al., 2009 17 
Abdominal distention, large 
GRV or diarrhoea 
209 Mixed 






between the clinical 
severity at the time of 
starting post-pyloric EN 
and the onset of GI 
complications 
- Risk of mortality and large 
GRV and/or abdominal 
distention  
(PRISM p=0.4; PELOD p=0.8; 
PIM2 p=0.5) 
- Risk of mortality and 
diarrhoea 
(PRISM p=0.04; PELOD 
p=0.06; PIM2 p=0.42) 
Lopez-
Herce et al., 
2008* 11 
Abdominal distention, large 
GRV (>50% of 4h feeding 
volume delivered), 
diarrhoea or NEC 
526 Mixed 





Study risk factors for GI 
complications related to 
EN 
Higher in patients with shock 




al., 2007* 12 
EN discontinued due to 
abdominal distensions 
and/or increased abdominal 
pressure, large GRV (>50% 
of 4h), diarrhoea (> 5 loose 
stools in 24h period), NEC 
526 Mixed 





Compared the tolerance 
of early (<24ht) and late 
post-pyloric EN 
Early EN (<24h) associated 
with less abdominal 
distention (3.5%) vs late EN 
(7.8%) p=0.05 
No association between early 
of late EN and diarrhoea 




al., 2006 18 
EN discontinued due to 
abdominal distention, 
aspiration, vomiting, 
diarrhoea or constipation 




implementation of an 
early, aggressive, EN 
protocol improves time 
to goal feedings and 
results in fewer GI 
complications 
Not significantly different 
after implementation of 
feeding protocol 30% vs 19% 
(p=0.10) 
Lopez-
Herce et al., 
2006* 10 
 
Abdominal distention, large 
GRV (>50% of 4h feeding 
volume delivered), 
diarrhoea (> 5 loose stools 
in 24h period), NEC 
526 Mixed 





Analyse the tolerance of 
post-pyloric EN in 
children with renal failure 
compared with other 
critically ill children 
Higher in patients with acute 
renal failure 24.5% vs 9.9% 
(p=0.01) 
Sánchez et 
al., 2006* 8 
EN discontinued due to 
abdominal distention, 
severe diarrhoea, NEC or 
large GRV (>50% of 4h 









Assess the utility of post-
pyloric EN after cardiac 
surgery 
No difference between post 
cardiac surgery and mixed 
patients (NS) 
Hanekamp 
et al., 2005 
19 
EN discontinued due to 
gastric retention, bilious 
vomiting, aspiration, NEC-
related symptoms, such as 
blood-stained stool, 
abdominal distention or 
number of positive blood 










Evaluate over a 5-yr 
period the feasibility and 
tolerance of a protocol 




No association between 
Apgar scores, gestational age, 
time to beginning of enteral 
nutrition, vasoactive drugs, 
morphine dosage, and type of 
feeding tube and FI (p=0.63) 
 
Sánchez et 
al., 2005* 9 
EN discontinued due to 
abdominal distensions, 
large GRV ( >50% of 4h 
feeding volume delivered), 
diarrhoea or NEC 
42 Mixed 







nutritional status and 
evaluate the short-term 
effects of EN 
No association between FI 
and anthropometric or 
biochemical parameters 
Rogers et 
al., 2003 32 
 
Large GRV (100-150% of 
4h feeding volume 
delivered), vomiting, 
abdominal distention or 
diarrhoea 
42 Cardiac vs 
mixed 




receiving EN, not 
specified 
Asses adequacy of 
nutrition support and 
identify barriers impeding 
the delivery of estimated 
energy requirement  
Higher in patients with 
cardiac diagnosis 57.1% vs 
non-cardiac diagnosis 38.9% 
(p=0.04)  
Mayer et al., 
2002 39 
Large GRV (> 125% of 4h 
feeding volume delivered) 
 
23 Mixed 








amylin levels and gastric 
emptying 
 
Higher risk of mortality 
score in FI patients 21% vs 
6.6% (p=0.006) 
Higher serum amylin 
concentration in FI patients 
(47.0 pmol/l vs 22.7 pmol/l, 
p<0.0001) 
Panadero et 
al., 1998* 13 
Vomiting, abdominal 









Analyse the utility and 
complications of post-
pyloric EN 
Higher in post-surgery 
patients 33% vs 0% 
(P<0.001). Age, diagnosis, 
type of formula, medication 
not significant 
* Studies are secondary analysis of previous published studies with possible overlay in population. 
ECMO, extracorporeal membrane oxygenation; EN, Enteral nutrition; FI, Feeding Intolerance; GA, gestational age; GI, gastro-intestinal; GRV, gastric 
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A B S T R A C T  
Background & aims: In the absence of methodologically sound randomised controlled 
trials (RCTs), current recommendations for timing and amount of enteral nutrition (EN) in 
critically ill children are based on observational studies. These studies have associated 
achievement of a higher EN intake in critically ill children with improved outcome. Inherent 
to the observational design of these underlying studies, thorough insight in possible 
confounding factors to correct for is essential. We evaluated the associations between EN 
intake and 1) patient and daily clinical characteristics and 2) clinical outcomes adjusted for 
these patient and clinical characteristics during the first week of critical illness with a 
multivariable mixed model. 
 
Methods: This secondary analysis of the multicentre PEPaNIC RCT investigated a subgroup 
of critically ill children with daily prospectively recorded gastrointestinal symptoms and EN 
intake during the first week with multivariable analyses using two-part mixed effect models, 
including multiple testing corrections using Holm's method. These models combined a 
mixed-effects logistic regression for the dichotomous outcome EN versus no EN, and a 
linear mixed-effects model for the patients who received any EN intake. EN intake per 
patient was expressed as mean daily EN as % of predicted resting energy expenditure (% of 
EN/REE). Model 1 included 40 fixed effect baseline patient characteristics, and daily 
parameters of illness severity, feeding, medication and gastrointestinal symptoms. Model 2 
included these patient and daily variables as well as clinical outcomes. 
 
Results: Complete data were available for 690 children. EN was provided in 503 (73%) 
patients with a start after a median of 2 (IQR 2-3) days and a median % of EN/REE of 38.8 
(IQR 14.1-79.5) over the first week. Multivariable mixed model analyses including all patients 
showed that admission after gastrointestinal surgery (-49%EN/REE; p=0.002), gastric feeding 
(-31% EN/REE; p<0.001), treatment with inotropic agents (-22%EN/REE; p=0.026) and large 
gastric residual volume (-64%EN/REE; p<0.001) were independently associated with a low 
mean EN intake. In univariable analysis, low mean EN intake was associated with new 
acquired infections, hypoglycaemia, duration of PICU and hospital stay and duration of 
mechanical ventilation. However, after adjustment for confounders, these associations were 
no longer present, except for low EN and hypoglycaemia (-39%EN/REE; p=0.018). 
 
Conclusions: Several patient and clinical characteristics during the first week of critical 
illness were associated with EN intake. No independent associations were found between 
EN intake and clinical outcomes such as mortality, new acquired infection and duration of 
stay. These data emphasise the necessity of adequate multivariable adjustment in nutritional 
support research and the need for future RCTs investigating optimal EN intake. 
 
I N T R O D U C T I O N  
Critically ill children are vulnerable to become undernourished, which has been associated 
with increased mortality, prolonged hospital stay, as well as neurological and psychological 
development disorders.1-4 However, feeding a critically ill child is a challenge and 
nutritional targets are often not achieved.1-3 Different studies in various paediatric 
intensive care unit (PICU) settings have shown that the actual delivery of enteral nutrition 
(EN) is usually much less (40–75%) than is prescribed and reported barriers are the lack of 
feeding protocols, fluid restriction and stopping EN in anticipation of procedures.1,5,6 One 
of the main factors for not reaching caloric goals is (presumed) intolerance to EN, where 
intolerance itself is also associated with adverse outcomes.1,7 We recently performed a 
systematic review to seek the definition of feeding intolerance in critically ill children.8 
Unfortunately, feeding intolerance was highly inconsistently defined throughout the 
literature and most often based upon a wide variety of gastrointestinal symptoms. This 
inconsistency precludes any firm conclusions on its prevalence, predictors and outcomes 
and its relationship with enteral intake. 
 
Despite the recognised difficulties to feed, current paediatric critical care guidelines agree 
to start EN early (<24–48 h) and to target caloric goals between 67% and 100% of Resting 
Energy Expenditure (REE) at the end of the first week.9,10,11 In the absence of 
methodologically sound randomised controlled trials (RCTs) these recommendations for 
timing and amount of EN in critically ill children are based upon large observational studies 
which showed associations between early achievement of nutritional goals and improved 
outcome.9,12-15 However, the observational design of these studies calls for cautiousness in 
assuming a causal relationship between higher EN intake and improved outcomes, as 
children who tolerate EN might be less critically ill and inherently have a better outcome. 
Up to now, observational nutritional studies commonly interpreted associations with 
outcomes from univariable analyses or with limited adjustments for confounders.9,12-15 No 
RCTs are currently scheduled to investigate the impact of achieving enteral intake targets 
with clinical outcome in a paediatric intensive care setting.16 Multivariable adjustment with 
relevant confounding factors is deemed imperative for interpreting observational studies 
with clinical outcome based on the hypotheses that predictors, clinical outcomes and EN 
intake are correlated. Therefore, we aimed to first explore the patient and clinical 
characteristics independently associated with amount of EN achieved during the first week 
of PICU admission, followed by an investigation of the associations between EN intake and 
clinical outcomes with multivariable mixed models. 
 
 
M E T H O D S  
Subjects 
For this study we included a subgroup of critically ill children who participated in the 
multicentre PEPaNIC RCT (University Hospital KU Leuven, Leuven, Belguim; Erasmus MC 
- Sophia Children's Hospital, Rotterdam, the Netherlands; Stollery Children's Hospital, 
Edmonton, Canada; ClinicalTrials.gov: NCT01536275), and for whom gastrointestinal 
symptoms and EN intake were recorded daily during the first week. The method and 
outcomes of the PEPaNIC RCT have been published previously.1718 In brief, the PEPaNIC 
RCT was a multicentre trial involving 1440 critically ill children (term - 17 years) investigating 
short- and long-term outcome of late parenteral nutrition (PN) (initiation after one week) 
as compared with early PN to complete insufficient EN (initiation within 24 h).17,18 The 723 
patients assigned to the early PN group received PN within the first 24 h after PICU 
admission according to the local standard care. For the 717 patients in the late PN group, 
PN was withheld for the first 7 days. If at day 8 the required caloric goal was not reached, 
supplemental PN was started. In both groups EN was provided according to local protocol 
with an intended start 6 h after admission if possible. All children received micronutrients 
intravenously until the amount of EN provided was above 80% of the caloric target. The 
institutional ethical review boards of the participating centres approved the study and 
written informed consent was obtained from the parents or legal guardians (Belgium: 
ML8052; The Netherlands: NL38772.000.12; and Canada Pro00038098). Children with 
inborn metabolic diseases requiring specific diets or patients with short bowel syndrome or 
other medical condition requiring home PN for over 7 days prior to admission were 
excluded in the PEPaNIC RCT. 
 
Nutritional protocol 
The local EN protocol, including caloric goal achievement, differed per research centre. The 
initiation and incline of EN, the type and methods, as well as the use of gastroprokinetics 
were prescribed via standing orders in each centre and prospectively collected in the study 
database for each patient.17 Nutritional and fluid practises of the three research centres 
which were valid during the PEPaNIC trial is presented in the appendix. 
 
In Leuven, Belgium, enteral intake was assessed based upon fluid allowance. For patients 
who required fluid restriction, total fluid intake was 50 ml/m2/h on days 1 and 2 and 60 
ml/m2/h on day 3, corresponding generally with an enteral intake of 50 kcal/m2/h and 60 
kcal/m2/h, respectively. Patients not requiring fluid restriction received 100 kcal/kg/d for the 
first 10 kg bodyweight, 50 kcal/kg/d for the next 10 kg, and 20 kcal/kg/d for the bodyweight 
> 20 kg. Gastric feeding was considered first choice and provided continuously over 10 h 
including a 2 h rest in children and via slow bolus in infants. 
 
 
In Rotterdam, The Netherlands, the energy goals for EN were based on the body weight 
and calculated with the Schofield equation19 for the first day of admission and on the 
Recommended Dietary Allowances (Dutch Health Council) for the remaining duration of 
admission.20 This translated to up to 2 times predicted resting energy expenditure (REE) in 
neonates to 1.5 times REE in adolescents. In patients who required fluid restriction or who 
were intubated, a protein and energy enriched formula or human milk was started as first 
choice and provided via post-pyloric tube and in non-ventilated patients standard formula 
was indicated. 
 
In Edmonton, Canada, energy expenditure of patients was assessed by indirect calorimetry 
upon admission to the PICU when possible, and used for estimating patient specific caloric 
goals for the first day of admission. If indirect calorimetry measurement was not possible, 
the prescribed caloric goal was set on 65% of basal metabolic rate estimated by the equation 
of the Food and Agriculture Organisation – World Health Organisation.21 For the 
subsequent days, caloric goals were assessed daily by a dietitian based on clinical information 
and acute phase response. In general, the caloric goal was 65% of Basal Metabolic Rate 
(BMR) when the patient was intubated, BMR when patient has been extubated and Total 
Energy Expenditure (REE adjusted for activity) when the patient had been extubated and 
ambulatory. Furthermore, type of feeding and location of feeding tube was prescribed at the 
discretion of the dietician and local protocol; common practise was to prescribe feeding via 
post-pyloric tube, especially in hemodynamic unstable patients and patient receiving (non-
invasive) ventilatory support. 
 
Each centre aimed to reach the caloric target from day 2 onwards via EN. When EN was 
below 80% of the target, supplemental PN was provided to reach the local goal in the early 
PN group. Initiation and incline of EN was based on the discretion of the clinical team in 
both study groups and (supplemental) PN was prescribed by the study team to reach the 
daily caloric goal in the early PN group only. 
 
Data collection 
Data on patient characteristics and gastrointestinal symptoms were prospectively collected 
and registered in the PEPaNIC RCT database. Characteristics investigated were 
demographics (early PN randomisation, age, sex, weight or BMI Z-score (defined as weight-
for-age Z-score in children <1 year old and BMI-for-age Z-score in children ≥1 year old, as 
described previously4), emergency admission, diagnosis upon admission, centre, 
STRONGkids, PeLOD score (Paediatric Logistic Organ Dysfunction score), PIM 3 
(Paediatric Index of Mortality) and Paediatric Risk of Mortality III (PRISM) score). Prior 
medical conditions and co-morbidities upon admission were also extracted (syndrome or 
genetic abnormality, malignancy, chronic disease, mechanical ventilatory or hemodynamic 
support and infection upon admission). At each day of admission, the nutritional intake, 
including initiation of EN and the total caloric and protein intake through enteral and 
 
parenteral route were recorded. Daily gastrointestinal symptoms recorded were vomiting 
or aspiration (yes/no), abdominal distension (yes/no), diarrhoea (≥4 times loose stool; 
defined watery or mushy) and large gastric residual volume (GRV; ≥50% of delivered EN 
over 24 h). Furthermore, clinical and feeding characteristics and treatment with 12 different 
medications were also collected daily. Clinical outcomes investigated were mortality, 
duration of PICU stay, duration of hospital stay, duration of mechanical ventilation, new 
acquired infections and incidence of hypoglycaemia (plasma glucose <40 mg/dl) during the 
first 7 days of admission. A complete list of investigated parameters is presented in the 
apendix. 
 
The current study investigated the enteral intake in association with baseline patient 
characteristics and daily clinical and feeding characteristics, gastrointestinal symptoms, 
medication and clinical outcome. The randomisation of the primary study was only 
addressed as a covariate. For this secondary analysis, the subgroup of critically ill children 
with complete daily recorded gastrointestinal symptoms and EN intake during the first week 
was included. In order to account for differences in caloric goals across the centres, a 
general benchmark for the quantification of enteral intake was used for all patients, i.e. 
enteral intake from EN as % of predicted REE based on Schofield formula according to age 
and weight [16]. Mean daily EN as % of predicted REE (% EN/REE) was calculated for each 
patient for the duration of his or her stay. 
 
Statistical analyses 
Characteristics were described as numbers and percentages for categorical variables or as 
mean and standard deviation (SD, if normally distributed) or as median and interquartile 
range (IQR, if not normally distributed) for continuous variables. To account for the 
correlations in the repeated measurements of enteral intake for each child, a mixed-effects 
model has been used. Due to the fact that many patients had zero enteral nutrition intake, 
the specific model was specified into a two-part mixed model. This combines a mixed-effects 
logistic regression for the dichotomous outcome zero or positive enteral intake, and a linear 
mixed-effects model for the natural logarithm of only the positive EN intake measurements. 
For both models the random-effects structure was random intercepts. 
 
For the univariable associations, the main effect of the follow-up time variable was included 
in the model together with clinical outcome variables. For the multivariable association, in 
the fixed effects of the linear mixed model we included the main effect of the follow-up time 
variable, as well as baseline patient characteristics (including PICU site and early PN 
randomisation), daily admission-level clinical characteristics, feeding characteristics, 
gastrointestinal symptoms and treatment with medication. A second model included all fixed 
effect baseline and daily clinical variables and the clinical outcome variable of interest. The 
duration of stay and duration of mechanical ventilation variables were penalised for mortality 
as a competitive risk. Data on EN intake and gastrointestinal symptoms needed to be 
 
complete, however, multiple imputation has been used to impute missing covariate 
information using 30 imputed datasets.22-24 Each imputed dataset has been separately 
analysed using the two-part mixed model, and the results were pooled using the formulas 
of multiple imputation. The fit of the model was assessed using scaled simulated residuals. 
No variable selection has been performed and all models. We hypothesised that patients 
admitted after gastrointestinal surgery had a different a priori feeding strategy, where EN 
would be withheld based on the discretion of the surgeons rather than EN intolerance or 
PICU related reasons. Therefore, sensitivity analyses were performed excluding this patient 
group (n=100). 
 
The reported coefficients, the corresponding 95% confidence intervals and p-values are for 
the marginalised mean of EN intake. The marginalised mean is the sum of possible values of 
one variable to determine the contribution of another variable. Correction for multiple 
testing was performed using Holm's method.25 The exponent of the coefficients is in the 
original scale of the main outcome, thus % EN compared to REE. Hence, the exponent of 
the coefficients quantifies the multiplicative increase in the average of the main outcome. 
For example, if the exponent of the coefficient for age is 0.98 it means that the average main 
outcome is decreased by 2% EN/REE for every unit increase of age. The reported 95% 
confidence intervals are for the exponentiated coefficients. These confidence intervals are 
not corrected for multiple testing. The mixed model analysis has been performed in R 
(version 3.6.2) using packages GLMMadaptive, mice, mitools, and DHARMa. 
 
R E S U L T S  
Of the total PEPaNIC patient population, 690 patients (58.1% male; 50.7% surgical diagnosis) 
had a complete recording of gastrointestinal symptoms and nutritional assessment during 
the first 7 days of admission or until discharge if discharge < 7 days and were included in 
the analyses. Table 1 presents the baseline patient characteristics. The median age was 1.2 
(IQR: 0.1–6.5) year, mean PIM3 score was −2.9 (±1.9) and 76% of the patients had an 
emergency admission. Nutritional risk, assessed by STRONGkids, was high in 16.4% of 
patients and medium in 83.6%, whereas the median weight Z-score was −0.5 (IQR: −1.7 to 
0.4), with a weight Z-score < -2 in 137 (19.8%) patients. A total of 50.7% was randomised 
to Early PN, with no differences between baseline patient characteristics (data not shown). 
Enteral intake and gastro-intestinal symptoms were collected on a total of 3208 admission 
days (median of 5 (IQR 2–7) days per patient). The presence of at least one gastrointestinal 
symptom occurred on 631 (19.7%) days, with vomiting or aspiration being the most 




Table 1. Baseline characteristics of the 690 critically ill children included in the present study 
Characteristics upon PICU admission  N=690 
Early PN randomisation  350 (50.7%) 
Age, y, median (IQR),   1.2 (0.1 - 6.5) 
Infant (age<1y)   339 (49.1%) 
Male sex  401 (58.1%) 
Weight or BMI Z-score, median (IQR)d  -0.7 (± 1.8) 
      Acute undernourished 
      Severe acute undernourished 
 59 (9.1%) 
70 (10.8%) 
Emergency admission  535 (77.5%) 
Diagnostic group   
     Surgical   
          Gastrointestinal  100 (14.5%) 
          Cardiac  111 (16.1%) 
          Neurosurgery-Traumatic brain 
          injury 
 54 (7.8%) 
          Other  85 (12.3%) 
     Medical   
          Cardiac  45 (6.5%) 
          Neurologic  64 (9.3%) 
          Respiratory  161 (23.3%) 
          Other  70 (10.1%) 
STRONGkids risk levela   
     Medium  577 (83.6%) 
     High  113 (16.4%) 
PeLOD score, first 24h in PICU, median (IQR)b  12 (2 - 21) 
PIM3 score, mean (SD)c  -2.9 (1.9) 
PRISM III (IQR)  8 (5 - 14) 
Malignancy   44 (6.4%) 
Confirmed syndrome or genetic abnormality 
Suspected syndrome or genetic abnormality 
 75 (10.9%) 
29 (4.2%) 
Chronic disease  474 (68.7%) 
Infection upon PICU admission  368 (53.3%) 
Mechanical ventilatory support upon PICU admission  592 (85.8%) 
Mechanical hemodynamic support on PICU admission  32 (4.6%) 
Data are n (%), median (IQR) or mean (SD). a (STRONGkids scores range from 0 to 5, with a score 
of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score of 4 to 
5 indicating high risk. b Paediatric Logistic Organ Dysfunction (PeLOD) scores range from 0 to 71, 
with higher scores indicating more severe illness. c Paediatric Index of Mortality 3 (PIM3) scores, with 
higher scores indicating a higher risk of mortality. d weight of BMI Z-score was defined as weight-for-
age Z-score in children <1 year old and BMI-for-age Z-score in children ≥1 year old, acute under-
nourished was defined as z-score between ≥ -3 and < −2, severely acute undernourished was defined 
as z- score less than −3 (<1 year) or body mass index-for-age z score less than −3 (if aged≥ 1 year). 
BMI, body mass index; : IQR, interquartile range; PeLOD, paediatric logistic organ dysfunction score; 
PICU, paediatric intensive care unit; PIM3, paediatric index of mortality 3 score; PN, parenteral 
nutrition; PRISM Paediatric Risk of Mortality III;  SD, standard deviation; STRONGkids, Screening 
Tool for Risk on Nutritional Status and Growth 
 
Figure 1. Mean daily enteral energy intake as % of predicted resting energy expenditure of crtically 
ill children during the first week of PICU admission 
 
A. Daily mean enteral energy intake (expressed as % of predicted resting energy expenditure (REE)) 
of critically ill children during first week of paediatric intensive care unit (PICU) admission. Bars 
represent the mean and the whiskers represent the 95% confidence interval (CI); B. Percentage of 
critically ill children who reached a daily mean enteral energy intake (expressed as % of predicted 
REE) of 100% during first week of PICU admission. Bars represent the percentage of children who 











































































































The mean daily EN as % of predicted REE provided during the first week of PICU admission 
is presented in Figure 1a. EN was provided in 503 (72.9%) patients with an overall median 
intake/day of 4.9 (IQR: 0.0–39.2) kcal/kg/d (Appendix). Reasons for not receiving EN were 
short admission duration ≤2 days (45%), gastrointestinal surgery (21%), gastrointestinal 
surgery and short admission stay (≤2 days) (17%), and other reasons (17%). In 314 (45.5%) 
patients EN was initiated within 48 h. The median daily enteral intake as % of predicted REE 
was 10.9% [IQR:0.0–84.0] and 28.3% [IQR 0.0–100.9] for the whole group (n=690) and the 
group of patients that had EN provided (n=503), respectively. A total of 139/425 (32.3%) 
and 120/275 (43.6%) patients achieved at least 100% of predicted REE via EN on day 4 and 
on day 7 respectively (Figure 1b). A total of 197/503 (39.2%) patients received enteral 
feeding via a post-pyloric tube. Mixed model analyses showed a mean EN/REE increase of 
21.3% (95%CI 18.8; 23.8%; p<0.001) per day of admission for all patients. 
 
Predictors for EN intake 
Table 2 presents the multivariable associations between baseline patient characteristics and 
daily parameters with daily mean enteral energy intake as percentage of predicted REE of 
critically ill children during the first week of PICU admission. Mixed model analyses including 
all patients showed that 15 predictors were independently associated with the amount of 
EN intake. Early PN randomisation had no effect on the EN intake (p=0.418). After 
correction for multiple testing, 5 predictors remained significantly associated with EN intake. 
Mean enteral intake was 30.9% (95%CI -16.5; −47.0%) EN/REE lower with gastric feeding as 
compared with post-pyloric feeding (p<0.001), and 21.5% (95% CI -31.6; −9.9%) EN/REE 
lower in children when treated with inotropic agents as compared with no inotropic support 
(p<0.001). Patients admitted after gastrointestinal surgery and patients admitted to the 
centre Edmonton had 48.9% (95%CI -63.1; −29.3%, p<0.001) and 36.6% (95%CI -48.4; 
−22.2%, p<0.001) EN/REE lower intake respectively. Of the analysed daily recorded gastro-
intestinal symptoms, after correction for multiple testing, only large GRV was significantly 
associated with 64.4% lower enteral intake EN/REE (p<0.001). Sensitivity analyses, which 
excluded patients admitted after gastrointestinal surgery, did not result in different results 
(Appendix). 
 
EN intake and outcomes 
Of the 690 patients, 44 (6.4%) died during PICU admission and 90-day mortality was 52 
(7.5%). Median duration of PICU stay was 5 (IQR 2–10) days, median duration of hospital 
stay was 13 (IQR 6–25) days and median duration of mechanical ventilation was 3 (IQR 2–
7) days. Hypoglycaemia occurred in 23 (3.3%) patients during the first 7 days of PICU 
admission and 123 (17.8%) had a new acquired infection. 
  
 
Table 2. Multivariable associations between baseline patient characteristics and daily parameters with daily mean enteral energy intake as percentage 
of predicted resting energy expenditure of critically ill children during first week of admission 
  Coefficient4 % EN/REE 95% CI  p-value
5 
(Intercept) 2.961   <0.001 
Baseline characteristics     
Randomisation to late vs early initiation of PN 0.043 +4.4% -6.0; +16.0% 0.418 
Day of admission 0.190 +21.0% +18.2; +23.8% <0.001* 
Age in years -0.018 -1.8% -3.1; -0.7% 0.010 
Female vs male sex 0.078 +8.1% -2.6; +20.0% 0.145 
Malnourishment1 (as compared with normal)     
    Acute malnourished  0.147 +15.8% -2.4; +37.5% 0.093 
    Severe acute malnourished  0.165 +17.9% -2.2; +40.6% 0.067 
Urgent vs elective admission -0.143 -13.3% -28.8; +5.6% 0.156 
Diagnostic category (as compared with cardiac surgery)     
   Surgical - Neurosurgery 0.169 +18.4% -12.8; +60.9% 0.279 
   Surgical - Gastrointestinal -0.672 -48.9% -63.1; -29.3% <0.001* 
   Surgical - Other -0.044 -4.3% -22.5; +18.1% 0.680 
   Medical - Cardiac 0.069 +7.2% -16.8; +38.1% 0.592 
   Medical - Neurologic 0.371 +45.0% +10.3; +90.7% 0.008 
   Medical - Respiratory 0.328 +38.8% +9.7; +75.7% 0.006 
   Medical - Other 0.114 +12.0% -16.5; +50.3% 0.448 
Centre Edmonton vs Rotterdam -0.456 -36.6% -48.4; -22.2% <0.001* 
STRONGkids score high risk vs medium risk 0.179 +19.6% +2.7; +39.2% 0.021 
PIM3 score (per point added) -0.071 -6.8% -10.9; -2.6% 0.002 
PRISM score (per point added) -0.000 +0.0% -1.0; +1.0% 0.925 
Malignancy vs no malignancy -0.027 -2.7% -24.3; +25.0% 0.831 
Syndrome or genetic abnormality vs no syndrome 0.148 +15.9% -2.2; +37.4% 0.088 
Suspicion or genetic abnormality  for syndrome vs no syndrome -0.019 -1.9% -21.6; +22.7% 0.865 
Chronic disease vs no chronic disease 0.010 +1.0% -11.9; +15.8% 0.883 
Admitted with infection -0.047 -4.6% -17.4%; +10.2% 0.522 
 
Admitted with mechanical ventilation support 0.222 +24.9% +2.0%; +52.9% 0.032 
Admitted with hemodynamic support -0.185 -16.9% -36.5%; +8.8% 0.178 
Daily clinical characteristics     
PeLOD score (per point added) -0.007 -0.7% -1.2%; -0.3% 0.002 
Maximum CRP in mg/L (per point added) -0.000 +0.0% -0.1%; +0.0% 0.150 
Maximum WBC in 10^9/L (per point added) -0.005 -0.5% -1.0%; +0.0% 0.044 
Maximum Lactate in mmol/L(per point added) -0.001 -0.1% -2.3%; +2.1% 0.909 
Daily feeding characteristics     
Location Tube (as compared with nasogastric tube)     
   post-pyloric tube 0.269 +30.9% +16.5;+47.0% <0.001* 
   No tube -0.175 -16.1% -35.6; +9.9% 0.202 
Main type of feeding (as compared with no Standard formula)     
   Human Milk 0.012 +01.2% -12.3; +16.8% 0.866 
   Energy enriched formula 0.220 +24.6% +7.7; +44.2% 0.003 
   Peptide formula 0.287 +33.2% +5.5; +68.3% 0.016 
   Oral intake -0.249 -22.0% -37.7; -2.5% 0.029 
   No formula -1.284 -72.3% -84.9; -49.3% <0.001* 
Daily gastro-intestinal symptoms     
Large Gastric residual volume2 (>50% of EN intake) -1.032 -64.4% -71.7; -55.2% <0.001* 
Presence of diarrhoea3 0.096 +10.1% -8.3; +32.1% 0.302 
Presence of vomit and/or aspiration 0.124 +13.2% -10.2; +42.7% 0.293 
Presence of abdominal distention -0.314 -27.0% -48.7; +3.9% 0.081 
Presence of ≥ EN intolerance parameter -0.053 -5.2% 0.784; +14.7% 0.584 
Daily treatment with medication      
Treatment with anti-emetics -0.119 -11.2% -24.3; +4.2% 0.144 
Treatment with oral laxation 0.175 +19.1% +4.9; +35.3% 0.007 
Treatment with acid suppression -0.057 -5.5% -15.4; +5.5% 0.313 
Treatment with rectal enema 0.086 +8.9% -7.2; +27.8% 0.294 
Treatment with corticosteroids -0.084 -8.0% -17.9; +3.0% 0.147 
Treatment with antibiotics -0.114 -10.8% -20.2; -0.3% 0.045 
 
Treatment with benzodiazepines -0.110 -10.4% -19.6; -0.2% 0.045 
Treatment with opiates -0.097 -9.2% -18.5; +1.2% 0.081 
Treatment with vasopressors -0.217 -19.5% -30.6; -6.7% 0.004 
Treatment with inotropic agents -0.242 -21.5% -31.6; -9.9% <0.001* 
Treatment with hypnotics and/or barbiturates -0.005 -0.5% -9.9; +9.8% 0.922 
Treatment with Alpha-2 antagonist -0.055 -5.3% -18.2; +9.6% 0.465 
1Children younger than 1 year: weight-for-age Z-score; children 1 year or older: body mass index–for-age Z-score; 2 Large gastric residual volume 
was defined as volume in ml more than 50% of prescribed EN feeding per 24 hours; 3Diarrhoea was defined as four or more loose stools per 24 
hours 4The reported coefficients, and the corresponding 95% confidence intervals and p-values are for the marginalised mean of enteral nutrition 
intake. The exponent of the coefficients quantifies the multiplicative increase in the average of the main outcome. Hence, an exponent of the 
coefficients of 0.90 reflect an 10% lower mean enteral intake expressed as a % Of REE. 5. *Statistically significant after correction for multiple 
comparisons using Holms method. 
CRP, C-reactive protein; EN, enteral nutrition; GRV, gastric residual volume; PeLOD, Paediatric Logistic Organ Dysfunction; PIM, paediatric index of 
mortality; PN, parenteral nutrition; PRISM, Paediatric Risk of Mortality; REE, resting energy expenditure; WBC, white blood count 
 
Table 3. Multivariable association between mean daily enteral energy intake as % of predicted REE and clinical outcomes during the first week of 
admission to the paediatric intensive care unit corrected adjusted for baseline and daily clinical parameters 
  Coefficient1 % EN/REE 95% CI  p-value
2 
Clinical outcomes     
New acquired infection vs no infection -0.031 -3.1% -15.4; +11.1% 0.652 
Hypoglycaemia <40mg/dl within the first 7 days of    
       admission vs no hypoglycaemia 
-0.494 -39.0% -53.5; -19.9% <0.001* 
Duration of PICU stay (per day) 0.000 +0.0% -0.2; +0.3% 0.687 
Duration of hospital stay (per day) -0.001 -0.1% -0.2; +0.1% 0.331 
Duration of mechanical ventilation (per day) 0.000 +0.0% -0.2; +0.3% 0.729 
First week non-survivor vs survivor 0.160 +17.3% -23.4; +79.7% 0.462 
PICU non-survivor vs survivor 0.218 +24.3% -3.3; +59.9% 0.090 
Hospital non-survivor vs survivor 0.159 +17.2% -6.8; +47.4% 0.175 
90 day non-survivor vs survivor 0.104 +11.0% -12.7; +41.1% 0.395 
1The reported coefficients, and the corresponding 95% confidence intervals and p-values are for the marginalised mean of enteral nutrition intake. 
The exponent of the coefficients quantifies the multiplicative increase in the average of the main outcome. Hence, an exponent of the coefficients of 
0.90 reflect a 10% lower mean enteral intake expressed as a % of REE. 2 *Statistically significant after adjusting for multiple comparisons using Holms 
method. Appendix presents the complete list of included baseline and daily parameters for multivariate correction 
PICU, paediatric intensive care unit. REE, Resting energy expenditure 
 
 
Univariable associations between mean daily enteral intake as % of predicted REE during the 
first week and clinical outcomes showed that low EN intake was associated with new 
acquired infection (p<0.001), incidence of hypoglycaemia (P<0.001), duration of PICU stay 
(p=0.017), duration of hospital stay (p<0.001) and duration of mechanical ventilation 
(p=0.024). EN was not associated with mortality on any of the time-points (Appendix). 
However, after multivariable adjustment for confounders and multiple testing, the mixed 
model analyses did not show any significant associations between lower mean EN intake 
and duration of PICU or hospital stay, duration of mechanical ventilation or new acquired 
infection. Patients with an episode of hypoglycaemia during the first 7 days of admission had 
a 39% lower EN/REE intake as compared with children without hypoglycaemia (p<0.001) 
(Table 3). Sensitivity analyses, which excluded patients admitted after gastrointestinal 
surgery, did not result in different results (Appendix). 
 
D I S C U S S I O N  
Our study reported possible predictors and outcomes associated with higher achievement 
of enteral nutrition during the first week of paediatric critical illness. Multivariable mixed 
model analyses showed that five clinical characteristics, i.e. admission after gastrointestinal 
surgery, centre, gastric tube feeding, receiving treatment with inotropic agents, and large 
GRV, were independently and negatively associated with lower enteral intake. Regarding 
outcomes, low EN during the first week was univariably associated with new acquired 
infection, hypoglycaemia, duration of PICU and hospital stay and duration of mechanical 
ventilation. However, after adjustment for confounders and multiple testing, these 
associations were no longer present, except for the risk of developing hypoglycaemia. 
Hence, these findings emphasise the necessity of adequate multivariable adjustment for 




Whereas, five independent predictors for lower EN intake were recognised, the lack of 
relevance of higher EN achievement to clinical outcomes puts these predictors into 
perspective. Nonetheless, feeding provided via post-pyloric tube was associated with higher 
enteral intake as compared with gastric feeding. Current paediatric critical care guidelines 
advise gastric feeding as first choice and suggest to administer feeding via post-pyloric route 
on indication in children with signs of intolerance or high risk for aspiration.10 However, 
despite the lack of studies investigating EN feeding route in relation to clinical outcomes, 
one small RCT involving 62 critically ill ventilated children found a 17% lower intake with 
gastric feeding,26 whereas another small RCT involving 44 children found delayed EN 
initiation.27 The associations found in our study might indicate that post-pyloric feeding could 
increase EN intake in patients who are a priori identified at risk for low enteral intake. 
 
 
Furthermore, large GRV (defined as > 50% of delivered EN) was independently associated 
with lower mean enteral intake. In contradiction, abdominal distention, vomiting and/or 
aspiration and diarrhoea were not independently associated with mean enteral intake. Low 
EN is often a consequence of (perceived) feeding intolerance in critically ill children which 
is most often described by the presence of a combination of gastrointestinal symptoms, such 
as large GRV, diarrhoea, vomiting and abdominal distention.8 No previous studies have 
explored the effect of individual parameters of feeding intolerance other than large GRV, 
such as abdominal distention, vomiting or diarrhoea on inadequate enteral intake. Studies 
on (routine) GRV measurements have shown inconsistent associations between GRV and 
enteral intake in critically ill children, possibly related to the small number of subjects within 
these studies].28-30 GRV appears to influence bed-site decision making around initiating and 
withholding of EN and is the most commonly reported gastrointestinal symptom for 
(perceived) feeding intolerance .31 The necessity of GRV measurements are complicated by 
the lack of standardization for large GRV to define intolerance as well as by differences in 
measurement technique that are also affected by post-pyloric versus gastric feeding policies 
and patients posture.26,32 Furthermore, recent studies found no association between large 
GRV and clinical outcomes, and as a result, the current guidelines challenged the use of 
routine GRV as a sign for feeding intolerance.9,33,34 Studies in critically ill adults report similar 
inconsistencies and the adult guidelines advise not to use GRV measurement for bed side 
decisions.35 Nonetheless, large GRV is still reported as a major factor for not initiating or 
increasing EN in current studies and it is also the most important gastrointestinal symptom 
of influence in our population.8,36 
 
Receiving vasopressors or inotropic agents was associated with a lower mean enteral intake, 
which is in agreement with previous observational studies.37 However, a retrospective study 
investigating safety of EN while receiving vasoactive agents found no difference in the 
presence of gastrointestinal symptoms between children with and without EN.38 The 
current recommendations state that EN is feasible in hemodynamically stable children and 
neonates with inotropic support. In our study we were not able to subdivide patients into 
stable on inotropic or vasopressor medication and patients with escalating support. 
 
The gut serves multiple functions including absorption of nutrients, immunologic defence 
and microbiome to maintain health. Whether our reported independent predictors for low 
enteral intake reflect true effect on insufficient gut function as a result of critical 
gastrointestinal organ failure or merely perceived feeding intolerance based on the 
physicians judgment prescribing lower intake remains to be answered. Patients admitted 
after gastrointestinal surgery had a significantly lower mean intake, which is potentially 
influenced by preference of the physician/surgeon rather than feeding intolerance resulting 
in lower intake. Sensitivity analyses without this group resulted in similar results indicating 
the robustness of the predictors. Lastly, centre was also associated with the amount of EN 
 
intake, with a higher EN intake in Rotterdam. This is most likely the result of differences in 
local enteral feeding protocols and thereby differences in caloric targets during the acute 
phase of illness. 
 
Due to the large number of predictors included in the model, correction for multiple testing 
was required. Holms correction methods can be considered strict, and combined with the 
assumption that several daily and baseline characteristics might be correlated, it is more 
likely that our correction is too extensive rather than too little. As such, the predictors 
before multiple correction should not be discarded.25 Before correction for multiple testing, 
a total of 15 predictors were identified with a potential effect on achieving EN intake, e.g. 
age, diagnosis, STRONGkids malnutrition risk score, white blood count marker and type of 
feeding (Table 2). Also, a worse mortality/illness severity score (PeLOD, PIM 3) was found 
to be associated with lower mean enteral intake. This is in line with previous studies 
suggesting that the degree of illness is related to the degree of gastrointestinal 
intolerance.28,39 These factors may play a significant role in the clinicians judgement to 
prescribe or enhance EN and for interpreting each sign of (perceived) feeding intolerance, 
thus it is important that these associations should not be interpreted literally. Hypothesis 
generating, we would like to argue that these baseline and daily characteristics are 
predictors for low EN intake and should be taken into account as confounding factors in 
future research investigating relationships with clinical outcomes. 
 
Outcomes 
Our study presents the second largest observational study on achievement of enteral intake 
and clinical outcome. In contrast with published observational studies1,5 our analyses were 
performed with a multivariable mixed model showing no association between enteral intake 
during the first week of paediatric critical illness and several clinical outcomes including 
mortality and PICU duration of stay. Current recommendations for early and high enteral 
intake are mostly based upon two large multicentre observational cohorts (paediatric 
international nutrition study (PINS) 1 and PINS 2) showing an association between enteral 
intake above two-third (as compared with below 1/3) of prescribed goal during the first 10 
days of admission and an improved 60-day survival and PICU duration-of-stay.1,5 
 
Methodological differences between the PIN studies and our study could explain the 
differences in results. Most importantly, the availability of extensive prospectively collected 
detailed daily characteristics and the large number of children enabled us to perform 
methodologically sound multivariable analyses adjusting for 40 baseline and daily clinical 
parameters with a potential mediating effect on clinical outcomes. Selecting only a small 
number of variables into the model based on the univariable coefficient quantities can 
provide misleading conclusions due to inappropriate adjustment of variables needed for 
control in the model.40 Univariable analyses from our study showed indeed the frequently 
referenced association between higher achievement of EN and improved outcome.1,5 
 
However, multivariable adjustment without pre-selection deemed imperative due to raised 
concerns on the potential influence of predictors on the amount of energy and protein 
intake as well as on clinical outcome. The PIN studies used pre-selection methods and 
included only a small number of confounders in their model. As such, EN intake could 
directly be related to outcome or indirectly reflect one or more underlying predictors, such 
as illness severity, resulting in worsened feeding intolerance and subsequently lower intake 
in the sickest children. Second, in both PIN studies data collection was not complete with 
illness severity scores reported to be missing in up to 31% of the participants.1,5 Additionally, 
illness severity was found to be a significant confounder between the association of protein 
intake and 60-day mortality.5 Hence, the influence of the severity of illness or other possible 
predictors cannot be ruled out in the observational PIN studies. A third important difference 
is the categorisation of essential continuous variables. For instance, the variable EN intake 
was categorised into three groups (energy/goal <33%, 33–67% and >67% or protein/goal 
<20%, 20–60% and >60%). Also, illness severity was categorised due to different scores used 
in different research centres in the PIN studies. 
 
Inadequate enteral intake can be the consequence of (perceived) feeding intolerance during 
critical illness. Without interventional trials it is impossible to know if the perceived adverse 
impact on clinical outcome is caused by lower enteral intake or by the underlying 
confounders such as medication and severity of illness or bed site decisions resulting in 
lower enteral intake. A small retrospective study in fact found that overfeeding, defined as 
>110% of measured REE, was found to be unfavourable as compared with caloric restriction 
in 139 critically ill children.41 Due to the differences in associations within the literature and 
our study, we believe further investigation is warranted, preferably with an RCT on timing 
and/or amount of EN where a trophic feeding strategy deserves to be taken into account. 
 
Besides the lack of benefit of higher caloric goals achievement on most short-term 
outcomes, lower enteral intake remained associated with the risk for developing 
hypoglycaemia during the first seven days of PICU admission after multivariate correction. 
Although, the consequences of a short and transitory occurrence of hypoglycaemia are 
debatable, several studies involving neonates or critically ill children did not find a negative 
effect on long-term neurocognitive development.42-44 The PEPaNIC RCT previously showed 
that lower artificial caloric and macronutrients intake during the first week of admission 
resulted in improved long-term physical and neurocognitive outcome.45,46 Whether the 
amount of enteral caloric and macronutrients intake has long-term consequences was not 
investigated in these studies, therefore, long-term physical as well as neurocognitive follow-
up of EN itself remains warranted. 
 
Some limitations of the present study should be addressed. First, our study was limited to 
the first 7 days of admission and the effect of nutrition on outcome beyond this point could 
not be investigated. Second, due to differences in EN protocol and caloric goals between 
 
centres we had to use a general benchmark for EN delivery.19 The golden standard to assess 
energy expenditure and determine patients' caloric goal is via indirect calorimetry 
measurement in stable patients, however, the optimal method to determine energy 
expenditure during the acute phase remains debatable. Current guidelines recommend to 
consider performing indirect calorimetry beyond the acute phase, while using calculated 
REE with the use of the Schofield equation during the first 7 days of admission.11,19 This 
calculated Schofield equation for weight was used in our study. Ideally, investigation of the 
amount of gastrointestinal failure should be monitored by means of assessing its function 
such as the ability to digest and absorb nutrients by recording patients’ growth achievement 
or alterations in the gut microbiome. Our study was not designed to include additional 
makers for gastrointestinal dysfunction other than EN intake. Furthermore, it is important 
to consider that potential fluid restrictions placed on the individual patient, could have 
hampered the ability to achieve REE without signs of feeding intolerance present. 
Unfortunately, data on fluid restrictions were not available and could not be incorporated 
into the mixed model. Furthermore, many of our variables are based upon bed-site decision 
making, (e.g. location of feeding tube or type of feeding), and warrant further investigation 
with the use of RCTs to obtain a causal relationship with EN intake. Lastly, this study was 
limited in investigating only short-term outcomes. To validate our results and provide 
evidence on the burden of critical illness, future studies should incorporate functional 
outcomes (e.g. anthropometrics, muscle wasting, PICU acquired weakness), long-term 
neurocognitive development and quality of life post PICU admission. 
C O N C L U S I O N S 
Enteral intake was low in the majority of critically ill children and gastrointestinal surgery 
diagnosis, gastric feeding tube, treatment with inotropic agents and large GRV was 
independently and negatively associated with successfully achieving enteral nutrition using 
multivariable mixed models. After multivariable adjustment, there were no associations 
between achievement of enteral intake and clinical outcomes, suggesting that the impact on 
clinical outcome reported in previous studies might reflect insufficient adjustment for 
confounders. These data substantiate the requirement of sound multivariable adjustment in 




R E F E R E N C E S  
1. Mehta NM, Bechard LJ, Cahill N, et al. 
Nutritional practices and their relationship to 
clinical outcomes in critically ill children--an 
international multicenter cohort study*. Crit 
Care Med 2012; 40(7): 2204-11. 
2. Bagri NK, Jose B, Shah SK, Bhutia TD, Kabra 
SK, Lodha R. Impact of Malnutrition on the 
Outcome of Critically Ill Children. Indian J 
Pediatr 2015; 82(7): 601-5. 
3. Matsuyama M, Bell K, White M, et al. 
Nutritional Assessment and Status of 
Hospitalized Infants. J Pediatr Gastroenterol 
Nutr 2017. 
4. van Puffelen E, Hulst JM, Vanhorebeek I, et al. 
Outcomes of Delaying Parenteral Nutrition 
for 1 Week vs Initiation Within 24 Hours 
Among Undernourished Children in Pediatric 
Intensive Care: A Subanalysis of the PEPaNIC 
Randomized Clinical Trial. JAMA Netw Open 
2018; 1(5): e182668. 
5. Mehta NM, Bechard LJ, Zurakowski D, 
Duggan CP, Heyland DK. Adequate enteral 
protein intake is inversely associated with 60-
d mortality in critically ill children: a 
multicenter, prospective, cohort study. Am J 
Clin Nutr 2015; 102(1): 199-206. 
6. de Neef M, Geukers VG, Dral A, Lindeboom 
R, Sauerwein HP, Bos AP. Nutritional goals, 
prescription and delivery in a pediatric 
intensive care unit. Clin Nutr 2008; 27(1): 65-
71. 
7. Blaser AR, Starkopf J, Kirsimagi U, Deane AM. 
Definition, prevalence, and outcome of 
feeding intolerance in intensive care: a 
systematic review and meta-analysis. Acta 
Anaesthesiol Scand 2014; 58(8): 914-22. 
8. Eveleens RD, Joosten KFM, de Koning BAE, 
Hulst JM, Verbruggen S. Definitions, 
predictors and outcomes of feeding 
intolerance in critically ill children: A 
systematic review. Clin Nutr 2019. 
9. Mehta NM, Skillman HE, Irving SY, et al. 
Guidelines for the Provision and Assessment 
of Nutrition Support Therapy in the Pediatric 
Critically Ill Patient: Society of Critical Care 
Medicine and American Society for Parenteral 
and Enteral Nutrition. JPEN J Parenter Enteral 
Nutr 2017; 41(5): 706-42. 
10. Tume LN, Valla FV, Joosten K, et al. 
Nutritional support for children during critical 
illness: European Society of Pediatric and 
Neonatal Intensive Care (ESPNIC) 
metabolism, endocrine and nutrition section 
position statement and clinical 
recommendations. Intensive Care Med 2020; 
46(3): 411-25. 
11. Joosten K, Embleton N, Yan W, Senterre T, 
nutrition EEECwgopp. 
ESPGHAN/ESPEN/ESPR/CSPEN guidelines on 
pediatric parenteral nutrition: Energy. Clin 
Nutr 2018; 37(6 Pt B): 2309-14. 
12. Mikhailov TA, Kuhn EM, Manzi J, et al. Early 
enteral nutrition is associated with lower 
mortality in critically ill children. JPEN J 
Parenter Enteral Nutr 2014; 38(4): 459-66. 
13. Kerklaan D, Fivez T, Mehta NM, et al. 
Worldwide Survey of Nutritional Practices in 
PICUs. Pediatr Crit Care Med 2016; 17(1): 10-
8. 
14. Velazco CS, Zurakowski D, Fullerton BS, 
Bechard LJ, Jaksic T, Mehta NM. Nutrient 
delivery in mechanically ventilated surgical 
patients in the pediatric critical care unit. J 
Pediatr Surg 2017; 52(1): 145-8. 
15. Srinivasan V, Hasbani NR, Mehta NM, et al. 
Early Enteral Nutrition Is Associated With 
Improved Clinical Outcomes in Critically Ill 
Children: A Secondary Analysis of Nutrition 
Support in the Heart and Lung Failure-
Pediatric Insulin Titration Trial. Pediatr Crit 
Care Med 2020; 21(3): 213-21. 
16. Clinicaltrials.gov. https://clinicaltrials.gov/ 
(accessed 04/08/2020. 
17. Fivez T, Kerklaan D, Verbruggen S, et al. 
Impact of withholding early parenteral 
nutrition completing enteral nutrition in 
pediatric critically ill patients (PEPaNIC trial): 
study protocol for a randomized controlled 
trial. Trials 2015; 16: 202. 
18. Fivez T, Kerklaan D, Mesotten D, et al. Early 
versus Late Parenteral Nutrition in Critically 
Ill Children. N Engl J Med 2016; 374(12): 1111-
22. 
19. Schofield WN. Predicting basal metabolic rate, 
new standards and review of previous work. 
Hum Nutr Clin Nutr 1985; 39 Suppl 1: 5-41. 
 
20. Dietary Reference Intakes: energy, proteins, 
fats and digestible carbohydrates. : The Hague: 
Health Council of the Netherlands, 2001. 
21. Energy and protein requirements. Report of a 
joint FAO/WHO/UNU Expert Consultation. 
World Health Organ Tech Rep Ser 1985; 724: 
1-206. 
22. Fichman M, Cummings JN. Multiple Imputation 
for Missing Data: Making the most of What 
you Know. Organizational Research Methods 
2003; 6(3): 282-308. 
23. Schafer JL. Multiple imputation: a primer. 
Statistical Methods in Medical Research 1999; 
8(1): 3-15. 
24. Wulff J, Jeppesen L. Multiple imputation by 
chained equations in praxis: Guidelines and 
review. The Lancet Respiratory medicine 
2017; 15(1): 41-56. 
25. Holm S. A Simple Sequentially Rejective 
Multiple Test Procedure. Scandinavian Journal 
of Statistics 1979; 6(2): 65-70. 
26. Meert KL, Daphtary KM, Metheny NA. 
Gastric vs small-bowel feeding in critically ill 
children receiving mechanical ventilation: a 
randomized controlled trial. Chest 2004; 
126(3): 872-8. 
27. Kamat P, Favaloro-Sabatier J, Rogers K, 
Stockwell JA. Use of methylene blue 
spectrophotometry to detect subclinical 
aspiration in enterally fed intubated pediatric 
patients. Pediatr Crit Care Med 2008; 9(3): 
299-303. 
28. Mayer AP, Durward A, Turner C, et al. Amylin 
is associated with delayed gastric emptying in 
critically ill children. Intensive Care Med 2002; 
28(3): 336-40. 
29. Martinez EE, Pereira LM, Gura K, et al. Gastric 
Emptying in Critically Ill Children. JPEN J 
Parenter Enteral Nutr 2017: 
148607116686330. 
30. Tume LN, Bickerdike A, Latten L, et al. 
Routine gastric residual volume measurement 
and energy target achievement in the PICU: a 
comparison study. Eur J Pediatr 2017; 176(12): 
1637-44. 
31. Tume LN, Latten L, Kenworthy L. Paediatric 
intensive care nurses' decision-making around 
gastric residual volume measurement. Nurs 
Crit Care 2017; 22(5): 293-7. 
32. Martinez EE, Douglas K, Nurko S, Mehta NM. 
Gastric Dysmotility in Critically Ill Children: 
Pathophysiology, Diagnosis, and Management. 
Pediatr Crit Care Med 2015; 16(9): 828-36. 
33. Tume L, Carter B, Latten L. A UK and Irish 
survey of enteral nutrition practices in 
paediatric intensive care units. Br J Nutr 2013; 
109(7): 1304-22. 
34. Kuppinger DD, Rittler P, Hartl WH, Ruttinger 
D. Use of gastric residual volume to guide 
enteral nutrition in critically ill patients: a brief 
systematic review of clinical studies. Nutrition 
2013; 29(9): 1075-9. 
35. McClave SA, Taylor BE, Martindale RG, et al. 
Guidelines for the Provision and Assessment 
of Nutrition Support Therapy in the Adult 
Critically Ill Patient: Society of Critical Care 
Medicine (SCCM) and American Society for 
Parenteral and Enteral Nutrition (A.S.P.E.N.). 
JPEN J Parenter Enteral Nutr 2016; 40(2): 159-
211. 
36. Martinez EE, Bechard LJ, Mehta NM. Nutrition 
algorithms and bedside nutrient delivery 
practices in pediatric intensive care units: an 
international multicenter cohort study. Nutr 
Clin Pract 2014; 29(3): 360-7. 
37. Haney A, Burritt E, Babbitt CJ. The impact of 
early enteral nutrition on pediatric acute 
respiratory failure. Clin Nutr ESPEN 2018; 26: 
42-6. 
38. Panchal AK, Manzi J, Connolly S, et al. Safety 
of Enteral Feedings in Critically Ill Children 
Receiving Vasoactive Agents. JPEN J Parenter 
Enteral Nutr 2016; 40(2): 236-41. 
39. Sanchez C, Lopez-Herce J, Mencia S, Urbano 
J, Carrillo A, Maria Bellon J. Clinical severity 
scores do not predict tolerance to enteral 
nutrition in critically ill children. Br J Nutr 
2009; 102(2): 191-4. 
40. Heinze G, Dunkler D. Five myths about 
variable selection. Transpl Int 2017; 30(1): 6-
10. 
41. Larsen BMK, Beggs MR, Leong AY, Kang SH, 
Persad R, Garcia Guerra G. Can energy intake 
alter clinical and hospital outcomes in PICU? 
Clin Nutr ESPEN 2018; 24: 41-6. 
42. Mesotten D, Gielen M, Sterken C, et al. 
Neurocognitive development of children 4 
years after critical illness and treatment with 
tight glucose control: a randomized controlled 
trial. Jama 2012; 308(16): 1641-50. 
43. McKinlay CJD, Alsweiler JM, Anstice NS, et al. 
Association of Neonatal Glycemia With 
 
Neurodevelopmental Outcomes at 4.5 Years. 
JAMA Pediatr 2017; 171(10): 972-83. 
44. Tin W, Brunskill G, Kelly T, Fritz S. 15-year 
follow-up of recurrent "hypoglycemia" in 
preterm infants. Pediatrics 2012; 130(6): 
e1497-503. 
45. Verstraete S, Verbruggen SC, Hordijk JA, et al. 
Long-term developmental effects of 
withholding parenteral nutrition for 1 week in 
the paediatric intensive care unit: a 2-year 
follow-up of the PEPaNIC international, 
randomised, controlled trial. Lancet Respir 
Med 2019; 7(2): 141-53. 
46. Jacobs A, Dulfer K, Eveleens RD, et al. Long-
term developmental effect of withholding 
parenteral nutrition in paediatric intensive 
care units: a 4-year follow-up of the PEPaNIC 
randomised controlled trial. The Lancet Child 
& Adolescent Health 2020; 4(7): 503-14. 
  
 
A P P E N D I X 
File S1. Prescription of parameters included in mixed model analyses. 
Day of admission: Day 1 up to 7 days 
Baseline characteristics 
1. Randomisation to late or early initiation of PN 
2. Age in years 
3. Sex: female or male  
4. Malnourishment: 
a. Acute undernourished was defined as weight-for-age z-score between -3 
and −2 (aged <1 year) or body mass index-for-age z-score between -3 and 
−2 (if aged ≥ 1) 
b. Severely acute undernourished was defined as weight-for-age z-score less 
than −3 (<1 year) or body mass index-for-age z-score less than −3 (if 
aged≥ 1 year). 
5. Emergency or elective admission 
6. Diagnostic groups: categorised into 4 surgical (cardiac, neurologic, gastrointestinal 
and other) and 4 medical (cardiac, neurologic, respiratory and other) diagnoses 
7. Centre: Leuven, Rotterdam or Edmonton 
8. Screening Tool for Risk on Nutritional Status and Growth (STRONGkids) score: 
range from 0 to 5, with a score of 0 indicating low risk of malnutrition, 1 to 3 
indicating medium risk, and 4 to 5 indicating high risk 
9. Paediatric Index of Mortality 3 (PIM3) score: higher scores indicate higher risk of 
mortality 
10. Paediatric Risk of Mortality III (PRISM) score: higher scores indicate higher risk of 
mortality 
11. Active malignancy upon admission 
12. Syndrome or genetic abnormality upon admission: divided in confirmed or 
suspected abnormality 
13. Chronic disease upon admission: cardiac, respiratory, renal, diabetes mellitus  
14. Infection prior to admission 
15. Mechanical ventilatory support upon PICU admission 
16. Mechanical hemodynamic support on PICU admission 
Daily clinical characteristics 
17. Paediatric Logistic Organ Dysfunction (PeLOD) score: range from 0 to 71, higher 
scores indicate higher severity of illness 
18. Maximum registered C-reactive protein (CRP) in mg/L 
19. Maximum registered white blood count (WBC) in 10^9/L 
20. Maximum registered lactate in mmol/L 
Daily feeding characteristics 
21. Location of feeding type: nasogastric tube, post-pyloric tube or no tube 
 
22. Main type of feeding: Human milk, Standard formula, Protein and energy enriched 
formula, Peptide formula, oral intake or no intake 
Daily gastro-intestinal symptoms 
23. Large gastric residual volume (GRV): defined as ≥ 50% ml gastric residue of 
provided enteral feeding intake over 24 hours 
24. Presence of diarrhoea: defined as ≥ 4 loose stools over 24 hours 
25. Presence of vomiting and/or aspiration: classified into yes or no over 24 hours 
26. Presence of abdominal distention: classified into yes or no over 24 hours 
27. Presence of ≥ 1 EN intolerance parameter: combination of large GRV, diarrhoea, 
vomiting and/or aspiration and abdominal distention 
Daily treatment with medication  
28. Anti-emetics 
29. Laxatives 
30. Acid suppression 






37. Inotropic agents 
38. Hypnotics and/or barbiturates 
39. Alpha-2 antagonist 
Clinical outcomes 
1. New acquired infection 
2. Hypoglycaemia <40mg/dl within the first 7 days of admission  
3. Length of PICU stay (days) 
4. Length of hospital stay (days) 
5. Length of mechanical ventilatory support (days) 
6. First week survival  
7. PICU survival 
8. Hospital survival 




Table S1. Overview of nutritional and fluid practices in the three research centres during the PEPaNIC RCT. 
Practices Leuven Rotterdam Edmonton 
EN protocol 
present 
Yes Yes Yes 
Fluid allowance 100 ml/kg/d for the first 10 kg 
bodyweight, 50 ml/kg/d for the next 
10 kg, and 20 ml/kg/d for the 
bodyweight > 20 kg 
<3m: 150-180 ml/kg/d 
3-6m: 150 ml/kg/d 
6-9m: 140 ml/kg/d 
9-12m: 120 ml/kg/d 
> 1y: 100 ml/kg/d for the first 10 kg 
bodyweight, 50 ml/kg/d for the next 
10 kg, and 20 ml/kg/d for the 
bodyweight > 20 kg 
(This will be considered Total Fluid 
Intake, TFI) 
100 ml/kg/d for the first 10 kg bodyweight, 50 
ml/kg/d for the next 10 kg, and 20 ml/kg/d for 
the bodyweight > 20 kg 
(This will be considered Total Fluid Intake, TFI) 
Fluid allowance in 
restricted patients 
80-110 ml/kg/d Post-op cardiac patients: day 1 50% 
TFI and day 2 75% 
Other patients around 75%, 
however Individually adjusted 
75% TFI for intubated patients 
50% TFI for post-op cardiac patients 
Time to initiate 
EN   
Within 24-48 hours of admission  Within 24 hours of admission  Within 24 hours of admission  
Preferred feeding 
location 
Gastric Post-pyloric Post-pyloric 
Preferred feeding 
method 
Infants: Slow bolus feed 
Children: Continuous over 10 
hours, followed by 2 hours rest 
Continuous Continuous 
Formula Infants: Human milk or polymeric 
infant feeding  
Children: Polymeric age-based 
formula (+/- fibre) 
Infants: Human milk or polymeric 
infant formula with fibre 
Children: Polymeric age-based 
formula with fibre 
Infants: Human milk or 
semi-elemental infant formula 
Children:  
>12 months-10 years: Semi-elemental age-
based formula  
 
Semi-elemental indicated by 
‘intolerance’ 
All children: Energy-protein 
enriched age-based formula (with 
fibre) if fluid restricted or 
mechanical ventilated   
Semi-elemental indicated by 
‘intolerance ‘ 
> 10 years: Semi-elemental energy-protein 
enriched age-based formula  
Energy goals used 100 kcal/kg/d for the first 10 kg 
bodyweight, 50 kcal/kg/d for the 
next 10 kg, and 20 kcal/kg/d for the 
bodyweight > 20 kg 
Predicted REE according to 
Schofield equation (200% in infants 
declining to 130% REE in 
adolescents)  
Indirect calorimetry. Otherwise 65% of BMR 
when the patient was intubated, BMR when 
patient is extubated and TEE when the patient 
had been extubated and ambulatory. 




No Performed in ventilated patients on 
day 7 or 8 
Used to guide energy goal from admission 
onwards 
Feed advancement Stepwise incline based on tolerance  
 
Stepwise incline based on tolerance. 
Protocol allows for half EN on day 1 
and full EN from day 2 onwards 
Stepwise incline based on tolerance. Protocol 
allows for full energy goal from day 1.  
Routine GRV 
measurement 
Before starting the next planned 
feeding 
Every 4 hours; amount GRV is 





Based on clinicians judgement and 
large GRV (>50% of bolus intake or 
previous 4 hours when continuously 
fed) 
Based on clinicians judgement and 
large GRV (>50% of bolus intake or 
previous 4 hours when continuously 
fed) 
Based on clinical judgement: nausea, vomiting, 
diarrhoea, bloody stool and/or abdominal 
distention. 
GI reasons for 
stopping feeds 
Signs of intestinal ischemia of 
discomfort and ≥ 2 times large GRV 
Signs of intestinal ischemia of 
discomfort and ≥ 2 times large GRV 
Vomiting, significant abdominal distention, 
bloody stool suspicion or NEC 
BMR, basal metabolic rate; EN, enteral nutrition; GI, gastrointestinal; GRV, gastric residual volume; NEC, Necrotising enterocolitis; REE, resting 
energy expenditure; TEE, total energy expenditure; TFI: Total fluid intake 
  
 
Table S2. Sensitivity analyses of the multivariate associations between baseline patient characteristics and daily parameters with daily mean daily 
enteral energy intake as percentage of predicted REE of critically ill children during first week of admission excluding children admitted after 
gastrointestinal surgery (N=590).   
  Coefficient4 % EN/REE 95% CI  p-value
5 
(Intercept) 3.101   <0.001 
Baseline characteristics     
Randomisation to late vs early initiation of PN 0.049 +5.0% -5.6; +16.7% 0.368 
Day of admission 0.193 +21.3% +18.5; +24.2% <0.001* 
Age in years -0.019 -1.9% -3.2%: -0.6% 0.006 
Female vs male sex 0.105 +11.1% -0.4% +23.8 0.058 
Malnourishment1 (as compared with normal)     
    Acute malnourished  0.133 +14.2% -3.9; +35.6% 0.131 
    Severe acute malnourished  0.199 +22.0% +1.6; +46.5% 0.033 
Urgent vs elective admission -0.174 -16.0% -31.7; +3.4% 0.100 
Diagnostic category (as compared with cardiac surgery)     
   Surgical - Neurosurgery 0.192 +21.2% -9.5; +62.3% 0.198 
   Surgical - Other -0.014 -1.4% -20.8; +22.9% 0.903 
   Medical - Cardiac 0.090 +9.5 -16.1; +42.8% 0.505 
   Medical - Neurologic 0.411 +50.8 +12.9; +101.4% 0.005 
   Medical - Respiratory 0.363 +43.7 +12.7; +83.4% 0.004 
   Medical - Other 0.154 +16.7 -11.7; +54.2% 0.279 
Centre Edmonton vs Rotterdam -0.405 -33.3% -45.7; -18.0% <0.001* 
STRONGkids score high risk vs medium risk 0.162 +17.6 +0.8; +37.1% 0.040 
PIM3 score (per point added) -0.062 -6.1% -10.4; -1.5% 0.010 
PRISM score (per point added) -0.000 +0.0 -1.1; +1.0% 0.931 
Malignancy vs no malignancy -0.042 -4.1% -26.5; +25.1% 0.755 
Syndrome vs no syndrome 0.152 +16.4 -1.5; +37.5% 0.074 
Suspicion for syndrome vs no syndrome -0.022 -2.1% -22.0; +22.9% 0.852 
Chronic disease vs no chronic disease 0.003 +0.3% -13.3; +16.1% 0.967 
Admitted with infection -0.056 -5.5% -18.1; +9.1% 0.442 
 
Admitted with respiratory support 0.220 +24.6% +0.7; +54.2% 0.042 
Admitted with hemodynamic support -0.212 -19.1% -38.1; +5.6% 0.119 
Daily clinical characteristics     
PeLOD score (per point added) -0.007 -0.7% -1.1; -0.2% 0.007 
Maximum CRP (per point added) -0.000 +0.0% -0.1; +0.0% 0.100 
Maximum WBC (per point added) -0.005 -0.5% -1.0; +0.0% 0.042 
Maximum Lactate (per point added)  -0.001 -0.1% -2.2; +2.0% 0.912 
Daily feeding characteristics     
Location Tube (as compared with nasogastric tube)     
   post-pyloric tube 0.268 +30.7% +16.7; +46.4% <0.001* 
   No tube -0.198 -17.9% -37.0; +7.0% 0.144 
Main type of feeding (as compared with no Standard formula)     
   Human Milk 0.021 +2.1 -12.1; +18.7% 0.784 
   Energy enriched formula 0.218 +24.4 +7.9; +43.5% 0.003 
   Peptide formula 0.248 +28.1 +0.8; +62.8% 0.043 
   Oral intake -0.226 -20.2% -36.3; +0.0% 0.050 
   No formula -1.326 -73.5% -85.7; -50.7% <0.001* 
Daily gastro-intestinal symptoms     
Large Gastric residual volume2 (>50% of EN intake) -0.998 -63.1% -41.0; -53.1% <0.001* 
Presence of diarrhoea3 0.098 +10.3% -8.3; +32.7% 0.297 
Presence of vomit and/or aspiration 0.116 +12.3% -10.8; +41.4% 0.324 
Presence of abdominal distention -0.398 -32.9% -53.9; -2.3% 0.038 
Presence of ≥ EN intolerance parameter -0.069 -6.7% -23.2; +13.5% 0.487 
Daily treatment with medication      
Treatment with anti-emetics -0.127 -11.9% -24.7; +3.0% 0.113 
Treatment with oral laxation 0.175 +19.2% +5.3; +34.9% 0.006 
Treatment with acid suppression -0.036 -3.5% -13.8; +7.9% 0.530 
Treatment with rectal enema 0.072 +7.5% -7.8; +25.3% 0.358 
Treatment with corticosteroids -0.095 -9.0% -18.6; +1.6% 0.094 
Treatment with antibiotics -0.121 -11.4% -20.6; -1.2% 0.030 
 
Treatment with benzodiazepines -0.104 -9.9% -19.3; +0.7% 0.067 
Treatment with opiates -0.100 -9.5% -18.6; +0.6% 0.066 
Treatment with vasopressors -0.214 -19.2% -30.1; -6.7% 0.004 
Treatment with inotropic agents -0.258 -22.8% -32.4; -11.8% <0.001* 
Treatment with hypnotics and/or barbiturates -0.004 -0.4% -9.5; +9.5% 0.928 
Treatment with Alpha-2 antagonist -0.050 -4.9% -18.1; +10.4% 0.507 
1Children younger than 1 year: weight-for-age z-score; children 1 year or older: body mass index–for-age z-score; 2 Large gastric residual volume 
was defined as volume in ml more than 50% of prescribed EN feeding per 24 hours; 3Diarrhoea was defined as four or more loose stools per 24 
hours 4The reported coefficients, and the corresponding 95% confidence intervals and p-values are for the marginalised mean of enteral nutrition 
intake. The exponent of the coefficients quantifies the multiplicative increase in the average of the main outcome. Hence, an exponent of the 
coefficients of 0.90 reflect an 10% lower mean enteral intake expressed as a % Of REE. 5. *Statistically significant after correction for multiple 
comparisons using Holms method. 
CRP, C-reactive protein; EN, enteral nutrition; GRV, gastric residual volume; PeLOD, Paediatric Logistic Organ Dysfunction; PIM, paediatric index 




Table S3. Univariable association between mean daily enteral energy intake as % of predicted REE during the first week of PICU 
admission and clinical outcomes  
  Coefficient1 % EN/REE 95% CI  p-value
 
Clinical outcomes     
New acquired infection vs no infection -0.370 -30.9% -41.9; -17.9% <0.001 
Hypoglycaemia <40 mg/dl within the first 7 days of admission 
vs no hypoglycaemia 
-0.906 -69.6% -72.7; -40.3% <0.001 
Duration of PICU stay (per day) -0.004 -0.4% -0.7; -0.1% 0.020 
Duration of hospital stay (per day) -0.004 -0.4% -0.6; -0.2% <0.001 
Duration of mechanical ventilation (per day) -0.004 -0.4% -0.8; +0.1% 0.029 
First week non-survivor vs survivor -0.171 -15.7% -53.0; +51.1% 0.565 
PICU non-survivor vs survivor -0.066 -6.4% -35.0; +34.7% 0.722 
Hospital non-survivor vs survivor -0.090 -8.7% -34.4; +27.3% 0.593 
90 day non-survivor vs survivor -0.172 -15.8% -39.6; +17.4% 0.311 
1The reported coefficients, and the corresponding 95% confidence intervals and p-values are for the marginalised mean of enteral nutrition intake. 
The exponent of the coefficients quantifies the multiplicative increase in the average of the main outcome. Hence, an exponent of the coefficients of 
0.90 reflect an 10% lower mean enteral intake expressed as a % of REE  







Table S4. Sensitivity analyses of the univariable associations between mean daily enteral energy intake as % of predicted REE during the 
first week of PICU admission and clinical outcomes, excluding children admitted after gastrointestinal surgery (N=590).   
  Coefficient1 % EN/REE 95% CI  p-value
 
Clinical outcomes     
New acquired infection vs no infection -0.382 -31.8% -42.4; -19.2% <0.001 
Hypoglycaemia <40 mg/dl within the first 7 days of admission 
vs no hypoglycaemia 
-0.943 -61.0% -73.7; -42.3% <0.001 
Time to live PICU discharge (days) -0.003 -0.3% -0.7; +0.1% 0.201 
Time to live hospital discharge (days) -0.003 -0.3% -0.6; -0.1% 0.006 
Time to live weaning form ventilation (days) -0.004 -0.4% -1.0; +0.3% 0.267 
First week non-survivor vs survivor -0.225 -20.1% -55.2; +42.4% 0.446 
Non-ICU survivor vs survivor -0.102 -9.7% -36.3; +28.2% 0.569 
Non-hospital survivor vs survivor -0.114 -10.8% -34.8; +22.0% 0.474 
90 day non-survivor vs survivor -0.207 -18.7% -40.8; +11.6% 0.201 
1The reported coefficients, and the corresponding 95% confidence intervals and p-values are for the marginalised mean of enteral nutrition intake. 
The exponent of the coefficients quantifies the multiplicative increase in the average of the main outcome. Hence, an exponent of the coefficients of 
0.90 reflect an 10% lower mean enteral intake expressed as a % of REE. 




Table S5. Sensitivity analyses of the multivariable associations between mean daily enteral energy intake as % of predicted REE during 
the first week of PICU admission and clinical outcomes excluding children admitted after gastrointestinal surgery (N=590).   
  Coefficient1 % EN/REE 95% CI  p-value
2 
Clinical outcomes     
New acquired infection vs no infection -0.039 -3.8% -16.3; +10.4% 0.581 
Hypoglycaemia <40mg/dl within the first 7 days of admission 
vs no hypoglycaemia 
-0.519 -40.5% -55.1; -21.1% <0.001* 
Time to live PICU discharge (days) 0.002 +0.2% -0.1; +0.5% 0.300 
Time to live hospital discharge (days) -0.000 +0.0% -0.2; +0.1% 0.606 
Time to live weaning form ventilation (days) 0.002 +0.2% -0.2; +0.6% 0.260 
First week non-survivor vs survivor 0.169 +18.4% -23.5; +83.3% 0.448 
Non-ICU survivor vs survivor 0.220 +24.6% -3.7; +61.1% 0.094 
Non-hospital survivor vs survivor 0.159 +17.3% -6.2; +46.5% 0.161 
90 day non-survivor vs survivor 0.100 +10.5% -13.1; +40.6% 0.415 
1The reported coefficients, and the corresponding 95% confidence intervals and p-values are for the marginalised mean of enteral nutrition intake. 
The exponent of the coefficients quantifies the multiplicative increase in the average of the main outcome. Hence, an exponent of the coefficients of 
0.90 reflect a 10% lower mean enteral intake expressed as a % of REE. 2 *Statistically significant after correction for multiple comparisons using Holms 
method. Appendix presents the complete list of included baseline and daily parameters for multivariable adjustment. 
PICU, paediatric intensive care unit. REE, Resting energy expenditure 
 


















































































































Daily amount of mean enteral energy in kcal/kg/day, and the daily amounts of mean enteral 
macronutrient substrates in g/kg/day are shown for the first 7 days in the paediatric intensive care 
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A B S T R A C T  
Purpose of review: The metabolic stress response of a critically ill child evolves over time 
and thus it seems reasonable that nutritional requirements change during their course of 
illness as well. This review proposes strategies and considerations for nutritional support 
during the recovery phase to gain optimal (catch-up) growth with preservation of lean body 
mass. 
 
Recent findings: Critical illness impairs nutritional status, muscle mass and function, and 
neurocognition, but early and high intakes of artificial nutrition during the acute phase 
cannot resolve this. Although (parenteral) nutrient restriction during the acute phase 
appears to be beneficial, persistent nutrient restriction, when the metabolic stress response 
resolves, has short-term and long-term detrimental consequences. Requirements increase 
markedly during the recovery phase to enable recovery and catch-up growth. Such large 
amounts of intake demand for alternate approach, especially when intestinal problems 
constitute a barrier for full enteral feeding. As part of the nutritional recovery, mobilization 
and exercise are essential to achieve catch-up growth with an optimal body composition. 
 
Summary: During the recovery phase of paediatric critical illness (catch-up) growth and 





I N T R O D U C T I O N  
Owing to scientific and clinical progress during the past two decades, most critically ill 
children nowadays survive the initial life-threatening event that required admission to the 
paediatric ICU (PICU).1 However, although acute outcome has improved, many children 
who survived are often confronted with long-lasting physical, neurocognitive, and 
psychological problems.2 Consequently, research focus is shifting from improving short-term 
vital outcomes to improving long-term morbidity and quality of life, years after PICU 
discharge. Although undernourishment during and after PICU stay are associated with 
worse outcome, nutritional support during critical illness has not been shown to improve 
short-term and long-term outcome.3,4 Such nutritional interventions have traditionally been 
done during the acute phase of critical illness. Following this acute phase, critical illness 
generally evolves into a stable and recovery phase. Each of these three phases is 
characterised by a cascade of neuro-endocrine, immunologic, and metabolic responses that 
change over time.5 The characterization of these phases is arbitrary and artificial, as no 
method currently exists to determine when and how patients evolve through these phases. 
In this review, the focus will be on nutritional interventions during the recovery phase 
critical illness and the potential long-term consequences. 
 
Nutritional support during the acute phase 
During the acute phase of critical illness, the metabolic stress response is characterised by 
severe catabolism. No evidence currently exists that the acute catabolic response can, or 
should, be countered with nutritional support. In fact, the Paediatric ’Early versus Late 
Parenteral Nutrition in the Paediatric Intensive Care Unit’ (PEPaNIC) trial has shown that 
withholding supplemental parenteral nutrition during the first week in PICU, when enteral 
nutrition was insufficient, prevented infections and accelerated recovery with shorter stay 
in the PICU and the hospital.6 These results corroborated with trials performed in the adult 
ICU which did not show any harm, and possibly even benefit, when they were fed with low 
nutritional macronutrient intakes during the acute phase.7-11 In contrast to the concerns that 
withholding parenteral nutrition would be detrimental in critically ill children considered 
most vulnerable to low nutritional intakes because of low reserves, it proved also beneficial 
in term neonates and children already undernourished upon admission to PICU.12,13 
However, the optimum length of time how parenteral nutrition should be withheld is 
unknown. 
 
A leading explanation for the counterintuitive benefits of lower nutritional intake during the 
acute phase might be the activation of autophagy.11,14,15 Autophagy is an essential survival 
mechanism by which cells break down their own (damaged) components to recycle 
intracellular nutrients and generate energy during starvation, which is inactivated with 
nutritional intake.16,17 When suppressed by forced mandatory overfeeding during the acute 
phase of critical illness, the risk of organ failure and cell death increases, resulting in worse 
 
clinical outcome.15,18 There are indications that during the recovery phase nutritional 
requirements rise markedly and even overshoot normal requirements of a healthy growing 
child.19 No method currently exists to determine the exact point at which well-tolerated 
starvation during the acute phase ends and malnutrition-related complications begin in the 
recovery phase. 
 
Consequences of prolonged undernutrition  
Nutritional status 
Undernourishment upon or during PICU admission are both associated with impaired 
outcome such as prolonged PICU stay, increased duration of mechanical ventilation, and 
even higher risk of mortality.13,20-22 An observational study in critically ill children found 
significant cumulative nutritional deficits compared to recommended dietary allowance at 
14 days after admission. These deficits were on average 20 and 12kcal/kg and 0.3 and 0.2 
g/kg of protein per day for term neonates (n=91) and older children (n=67), respectively. 
These deficits were associated with declines in z-scores for weight and arm circumference 
from admission to discharge, which recovered within 6 months after discharge.23 
Additionally, lower enteral intake was associated with deterioration of the nutritional 
status.24-26 In a study of 325 children who stayed at least 4 days in the PICU, 19% were 
acutely undernourished upon admission and in a subgroup of 223 with registered weight at 
discharge, this was still 26%.27 However, this study was not designed to make an association 
between nutritional intake and outcome.27 In a recent study, a longer length of PICU stay 
was associated with faltering growth (defined as deceleration of >-1 z-score within 3 
months) during the first year after PICU admission.28 There is a scarcity of data addressing 
the evolution of body composition during admission and at follow-up, and the effect of 
nutrition hereon. 
 
Muscle wasting and weakness  
The reported incidence of muscle weakness in critically ill children varies from 1.7 to 30%.29-
31 Furthermore, it was shown that muscle mass, as measured by thickness of the femoral 
quadriceps, decreased up to 13% during PICU stay.32 Also, decrease in muscle mass was 
associated with increased length of mechanical ventilation and PICU stay.33 Anabolic 
resistance of muscle during the acute phase of critical illness is now generally accepted. In 
fact, it has been recently shown that early supplementation of parenteral nutrition did not 
prevent muscle wasting and actually withholding parenteral nutrition during the first week 
of critical illness, through the activation of autophagy, improved muscle architecture and 
functioning.11,14,34,35 
 
Cognitive development  
Nutrition is a major factor affecting cognitive development and health of brain structure and 
function.36-38 Indeed, proper building blocks need to be provided to the brain for creation 
and maintenance of connections to improve cognition and academic performance,39 
 
particularly in the phase of rapid growth in the first 2 years of life 40. But nutrition 
continuously plays an important role throughout childhood into adulthood.36 There are 
some indications that even short nutritional interventions impact neurocognition and 
psychological health. Healthy adults undergoing a semi-starvation study developed 
neurocognitive and psychiatric problems only after a few weeks.41,42 One patient who ended 
the study prematurely because of psychological problems recovered after only a few days 
of a normal diet.42 Both undernutrition and overnutrition have been related with impaired 
cognitive health and poorer scholastic performance,39 as well as behavioural problems.40 
Importantly, early effects of nutrition may not only immediately impact on structural and 
functional development of the brain, but may also affect other body functions in which the 
brain is involved, including endocrine and inflammatory signalling that regulates metabolic 
processes involved in growth and development.40,43 In critically ill children, withholding 
parenteral nutrition for 1 week in the PICU improved certain domains of neurocognitive 
development at follow-up 2 years later, as compared with children who received parenteral 
nutrition early during critical illness.38 In fact, in children who did not receive parenteral 
nutrition during the first week overall executive functioning, inhibition, meta-cognition, and 
externalising problems as reported by parents were not different any more than in healthy 
children.38 
 
Figure 1. Energy requirements in different phases of critical illness; % of REE 
  
 
Table 1. Indications for targeted Indirect Calorimetry  
- PICU stay > 1 week 
- >10% weight change during PICU stay 
- Inappropriate weight z-score change during stable or recovery phase 
- Failure to consistently meet prescribed energy goals in stable or recovery phase 
- Suspicion of hypermetabolism (burns, traumatic brain injury, systemic inflammatory 
response syndrome, dysautonomic storms, persistent fever) 
- Suspicion to be hypometabolism (hypothermia, (medicational induced) coma) 
PICU, Paediatric ICU 
 
 
Nutritional support in recovery phase  
During the acute phase, endogenous energy production can cover a substantial (up to 75%) 
part of energy requirements, irrespective of the exogenous energy provision.44 In the 
recovery phase, resting energy expenditure (REE) values are the optimal guide for 
determining energy requirements. If possible, targeted indirect calorimetry is recommended 
in critically ill children with specific conditions (Table 1). However, in most clinical settings 
the lack of availability of indirect calorimetry means that prediction equations have to be 
used.45 Reasonable values for REE can be derived from Schofield’s prediction equation for 
REE using the actual weight of the patient.46 In contrast to the acute phase, the recovery 
phase does necessitate to add stress and activity factors to REE to account for tissue repair, 
growth, and for catch-up growth and physical activity during mobilization. To further 
understand the concept of energy requirements in the recovery phase, we can learn from 
existing data of severely malnourished, sick children and malnourished adults who were 
previously healthy.41,42 The WHO recommended, in children aged 6–59 months recovering 
from severe malnutrition in developing countries, to feed according to three evolving phases 
as well. In the first phase low protein-based milk formula should be provided, whereas in 
the second phase higher protein/energy content is necessary. Once children are ready to 
move into the third phase of rehabilitation to correct the emerged growth deficits energy 
intake up to 100–135 kcal/kg/day are required.47 Also, in older children recovering from 
severe malnutrition because of anorexia nervosa supraphysiological energy intakes up to 
3000–5000 kcal/day were needed for a weight gain of 0.5–1.0 kg/week.48 Interestingly, in line 
with treatment of children with anorexia nervosa it has been shown in healthy adults (70 
kg) that after significant weight loss (±25%), requirements reached 4000– 5000 kcal/day 
(approximately 60–70 kcal/kg/day = 2–3x REE) to fully regain weight after 6 months to 
2years.41,42 
 
Overall, in the recovery phase of critical illness, the body experiences a massive increase in 
metabolic needs with energy expenditure increasing as much as 2x REE, which increases 
even further up to 3–4x REE taking into account physical activity and catch-up growth. Figure 
1 depicts the concept of energy requirements during the different phases of critical illness. 
 
 
Table 2. Total energy requirement recorded in the recovery phase of specific disease states  
Disease or disease state Total energy requirement 
Critically ill infants 49 2 x REE 
Severe malnutrition 47,48 2-3 x REE 
Congenital heart disease 50,51 2-4 x REE 
Burns 52-55 2-2.5 x REE 
Traumatic brain injury 56,57 1.3-1.6 x REE 
 
 
Nutritional support in specific diseases  
Only few studies have investigated the energy requirements in the recovery phase in 
critically ill children, mostly with specific diagnoses (Table 2). In critically ill infants with a 
prolonged (>14 days) PICU stay normal weight gain was achieved by following a nutritional 
protocol with energy target set at 2x REE.49 In infants recovering from surgical repair of a 
congenital heart disease, energy requirements were 2–3x REE (120–150 kcal/kg/ day) to 
obtain a weight gain of 20–30 g/day, which might increase to 4x REE (200kcal/kg/day) when 
a haemodynamically significant lesion remains after surgery.50,51 Children with burns52-55 and 
traumatic brain injury56,57 develop a hypermetabolic state lasting from 1 week to 1 year after 
the injury, which increases energy requirements to 2.5x REE. 
 
Protein requirements 
The acute catabolic phase is characterised by extraordinary whole body protein breakdown 
and muscle loss (in adults up to 1kg per day). Beyond the acute phase, muscle wasting often 
persists because of disease-related factors, but also iatrogenic factors such as medication, 
immobilization, and undernourishment 58. Increased length of stay in the PICU is associated 
with cumulative protein depletion 59. In the recovery phase, protein requirements increase 
to replenish depleted stores but also to account for tissue repair and (catch-up) growth. 
American Society for Parenteral and Enteral Nutrition guidelines state that a minimum of 
1.5 g/kg/day enteral protein, and in young children even 2.5–3.0 g/kg/day, is required to 
achieve a positive protein balance 60. In the recovery phase, one has to account for the 
protein energy ratio of the prescribed formula. The WHO recommends 9–11.5% energy 
from protein for infants who are acutely malnourished and 11–15% for those with chronic 
malnutrition.61 The protein energy content of most standard enteral formula is 10–11% and 
this will be sufficient to deliver an adequate amount of protein in the recovery phase. 
 
Optimal feeding 
Enteral nutrition also remains the preferred route to meet energy and nutrient 
requirements in the recovery phase. Due to markedly increasing requirements, this is even 
in the recovery phase still challenging because of multiple barriers such as delayed initiation, 
fluid restriction, and interruptions as a result of perceived feeding intolerance and prolonged 
fasting around procedures.5 Independent of the need to provide high amounts of intake, a 
stepwise approach to deliver nutritional support can be considered (Table 3).27,49 This 
 
approach entails protein-energy dense and/or hydrolysed formulas. Ultimately, when enteral 
nutrition remains insufficient after the first week of critical illness, parenteral nutrition allows 
for substantial amounts of nutrient intake. However, almost 50%of children fully dependent 
of parenteral nutrition for a prolonged period are stunted.62-64 This is at least partially 
explained by maximum amount of macronutrient feasible to provide with parenteral 
nutrition, not allowing more than 2x REE, and the fact that caloric-dense lipids often have 
to be decreased because of intestinal failure-associated liver disease.65 Table 4 shows the 
energy recommendations in recovery phase of critical illness if (supplemental) parenteral  
nutrition is prescribed according the current Paediatric Gastroenterology Hepatology and 
Nutrition (ESPGHAN) guideline.19 One has to take into account that these are 
recommendations only for parenteral nutrition. When enteral nutrition is given, energy 
requirements are generally 10–20% higher compared with the parenteral route because 
splanchnic metabolism contributes significantly to whole body energy and protein turnover, 
and because some nutrients are excreted in the stool. 
 
Table 3. Stepwise approach for nutritional therapy in the PICU 
 Nutritional therapy   Consideration 
Step 1 Infants: standard polymeric 
formula/breastmilk 
Children: standard polymeric 
formula 
May result in nutritional deficits as a result of the 
lower energy and protein content of these 
formulas/breastmilk 
Step 2 Infants and children: polymeric 
protein:energy enriched formula  
Higher energy and protein content may 
overcome nutritional deficits especially in fluid 
restricted patients 
Step 3 Infants and children: (semi)-
elemental protein:energy 
enriched formula  
Absorption, tolerance and utilization of proteins 
and fats may be altered and (semi)-elemental 
feeds are considered as an alternative 
Step 4 If insufficient EN (<80%) or no 
EN possible >1 week after 
admission: start PN 
Especially in children with intestinal failure; 
appropriate growth and normal body 
composition difficult to achieve and risk for 





Table 4. Recommendations for energy intake with (supplemental) PN in recovery phase of 
critical illness 
Age group Kcal/kg/day 
0-1 yr 75-85 
1-7 yr 65-75 
7-12 yr 55-65 
12-18 yr 30-55 
 
Assessing the effects of high nutritional intake during the recovery phase 
The success of nutritional support during the recovery phase of paediatric critical illness will 
often be reflected by catch-up growth. However, catch-up growth may have some long-
term consequences, such as the development of obesity, metabolic syndrome, and related 
problems. Most of these associations have been described when catch-up growth developed 
in (very) low birth-weight neonates and after (semi)starvation during infancy.66,67 Whether 
catch-up growth after a period of growth restriction during critical illness has similar risks 
has not been investigated. However, adult healthy volunteers exposed to 6 months of 
undernutrition also showed a disproportionate gain in fat relative to lean body mass during 
their weight recovery.68 Therefore, the success of nutritional support should also take into 
account lean body mass, muscle mass and function, and functional status.69,70 Mobilization of 
patients might be an additive treatment. Although the role of (early) mobilization in 
maintaining lean body mass and improving muscle function in paediatric critical illness is 
unclear, there are some clear theoretical benefits.71 Physical activity and exercise are 
essential in allowing muscle protein anabolism and should be part of the nutritional recovery 
after critical illness. 
 
C O N C L U S I O N S 
Understanding that after the acute and stable phase of critical illness the recovery phase 
demands markedly higher nutritional intakes. Nutritional requirements increase because of 
increased activity and additional requirements for tissue repair and (catch-up) growth. In 
specific group of patients, a hypermetabolic state may persist up to a year after the initial 
insult. Restoration of the lean body mass and functional rehabilitation should be the hallmark 
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A B S T R A C T  
Background: Reaching an optimal nutritional intake is challenging in critically ill infants. 
One possible way to minimise nutritional deficits is the use of protein and energy-enriched 
(PE) - formulas. We aimed to describe weight achievement and gastrointestinal symptoms 
in infants admitted to the paediatric intensive care unit (PICU) while receiving PE-formula 
for a prolonged period. 
 
Methods: Records from infants admitted to a multidisciplinary PICU and using PE-formula 
were analysed retrospectively. Infants were eligible if they received PE-formula daily for at 
least 2 weeks. Weight achievement was determined as the difference between weight-for-
age (WFA) Z-scores at the start and end of PE-formula use. Gastrointestinal symptoms, 
including gastric residual volume, constipation and vomiting, were evaluated as tolerance 
parameters. 
 
Results: Seventy infants with a median [interquartile range (IQR)] age of 76 (30–182) days 
were eligible. The PICU duration was 50 (35–83) days during which they received PE-
formula for 30 (21–54) days. Predominant admission diagnoses were post-cardiac surgery, 
respiratory and cardiac diagnosis. A significant mean (SD) WFA Z-score increase of 0.48 
(1.10) (P<0.001) and a median (IQR) weight gain of 5.80 (3.28–9.04) g kg-1 day-1 was 
observed. Multivariate regression showed that a lower WFA Z-score at start was associated 
with a higher WFA Z-score increase during PE-formula use (b -0.35 (95% confidence interval 
= -0.50 to -0.19); P<0.001). The maximum 24-h gastric residual volume was 8.1 mL (IQR = 
2.2–14.3) for each 1 kg in bodyweight. Three (4%) infants were treated for diarrhoea and 
three infants were treated for vomiting. 
 
Conclusions: The majority of infants with a prolonged PICU stay showed weight 
improvement when using PE-formula. PE-formula was well tolerated because 







I N T R O D U C T I O N  
Critically ill children are at risk of developing malnutrition during a stay in a paediatric 
intensive care unit (PICU). Studies in Dutch populations have shown that 14% to 32% of 
critically ill infants already suffer from acute or chronic malnourishment upon admission to 
the PICU.1,2 Development of malnutrition during PICU stay is associated with increased 
mortality, length of mechanical ventilation and length of stay.3,4 Infants are particularly 
vulnerable to malnutrition because of their limited body reserves and their higher nutrient 
requirements for growth and development.4-6 Also, a prolonged PICU stay is associated with 
lower weight-for-age (WFA) Z-scores during and after admission in critically ill infants.2 
Therefore, providing optimal nutritional support is especially important in critically ill infants 
admitted for a prolonged time to the PICU.6,7  
 
This optimal nutritional support should account for the different phases (acute, stable and 
recovery) of critical illness.8 During the acute phase, there is a considerable risk of 
overfeeding and nutrient restriction might be beneficial in the early acute catabolic phase.9 
During the stable and recovery phase, there will be a shift from catabolism to anabolism and 
nutritional support should focus on increasing protein and energy intake to enable recovery, 
growth and catch-up growth.8 
 
The preferred route to meet energy and nutrient requirements is via enteral nutrition (EN). 
This is challenged by multiple barriers such as delayed initiation, fluid restriction, 
interruptions as a result of perceived feeding intolerance and prolonged fasting around 
procedures.6 The use of standard infant formulas may result in nutritional deficits as a result 
of the lower energy and protein content of these formulas. Previously, it has been shown in 
a small group of infants that protein balances were positive in the first days after admission 
with the use of protein and energy-enriched (PE)-formula compared to standard formula.10 
However, no data are available on the prolonged use of PE-formula on recovery and growth. 
The present study aimed to describe the feasibility of PE-formula in infants with a prolonged 
PICU admission by means of assessing gastrointestinal tolerance parameters and weight 
achievement. 
 
M E T H O D S  
Patients and setting 
This retrospective database study was conducted at a multidisciplinary tertiary PICU. All 
medical records of infants admitted from January 2007 until June 2017 using a PE-formula 
(Infatrini®; Nutricia, Zoetemeer, The Netherlands) were reviewed concerning demographic 






Inclusion criteria were: (i) age between 37 post-menstrual weeks and 12 months; (ii) a 
prolonged PICU stay defined as a PICU stay of ≥14 days; (iii) a minimum of 14 days enteral 
feeding with PE-formula; and (iv) at least 80% of energy intake from PE-formula on days with 
PE-formula use (energy intake provided by PE-formula divided by the total energy intake; 
enteral and parenteral). Exclusion criteria were: (i) oral intake other than human milk or 
formula; (ii) interruptions from PE-formula of more than 5 days or of more than 20% of the 
total duration of PE-formula use; and (iii) less than two weight measurements reported or 
weight measurements less than 14 days apart during the period of PE-formula. The study 
protocol was approved by the institutional review board of the Erasmus Medical Centre, 
Rotterdam, The Netherlands (MEC-2017-316). The committee waived informed consent as 
a result of the retrospective design. 
 
Nutritional intake 
The type of enteral feeding was mainly chosen on discretion of the clinician using a 
nutritional protocol in which fluid restriction was taken into account. Human milk was the 
first choice and preferred in all critically ill infants. In general, a PE-formula (100 kcal per 100 
mL; 2.6 g protein per 100 mL) was started if human milk was not available in mechanically 
ventilated children >3.5 kg and below the age of 12 months and in non-ventilated children 
on the discretion of the clinician. The preferred route was via a post-pyloric tube. EN was 
started as soon as possible after admission, preferably the day after admission. PE-formula 
was generally switched to standard formula after weaning from ventilation or when the 
weight goal was achieved. If EN was tolerated, feeding was increased until an energy target 
of twice the individual calculated resting energy expenditure (using the Schofield equation 
for weight) was achieved in all critically ill infants.11 
 
Anthropometric measurements 
Weight measurements were performed according to local protocol at the start and end of 
PE-formula use. Z-scores for WFA were calculated using Dutch reference standards 
(GROWTH ANALYSER RCT, version 4.0; https://growthanalyser.org).12 Changes in nutritional 
status were determined as the difference between WFA Z-scores at start and end of PE-
formula use. The age of the infants was corrected for prematurity for all measurements. A 
WFA Z-score < -2 was used to indicate acute malnutrition.13 Birth weight Z-scores were 
compared with WFA Z-scores at start and end of PE-formula use. Birth weight Z-scores 
were converted using the Fenton growth charts for preterm infants.14 As a result of the 
different standard values for expected growth, growth velocity in g kg-1 day-1 was calculated 








Gastrointestinal symptoms and tolerance 
There is no validated definition for feeding intolerance; therefore, gastrointestinal symptoms 
that are frequently used to describe feeding intolerance were used to determine tolerance 
to PE-formula. Parameters of enteral feeding tolerance were recorded each day during PE-
formula use and consisted of gastric residual volume (GRV) (mL kg-1 day-1; yes/no), vomiting 
(frequency) and defaecation (frequency), as well as treatment for vomiting, diarrhoea and 
constipation. Constipation was defined as 4 or more days without stools. According to 
protocol, GRV was checked every 4 h via a nasogastric tube. Gastric retention was defined 
as GRV exceeding more than 50% of the volume received in the previous 4 h when infants 
were continuously fed or of the previous bolus feeding volume when intermittently fed. 
When PE-formula was interrupted by the clinician because of signs of gastrointestinal 
symptoms, these were also recorded.  
 
Statistical analysis 
Data are reported as the number (%), mean (SD or SEM) if normally distributed or as the 
median [interquartile range (IQR)] if not normally distributed. A paired-sample t-test was 
used to evaluate the mean difference in WFA Z-scores between start and stop of PE-
formula. These measurements were also compared with the WFA Z-scores at birth. 
Stepwise multivariate linear regression analysis was used to identify which baseline and 
admission variables were associated with alterations in WFA Z-score during PE-formula use. 
Investigated variables were gender, birth weight Z-score, prematurely born infants, age and 
weight Z-score at start of PE-formula, diagnosis, reason to start PE-formula, post-pyloric 
feeding and caloric intake compared to the target. Variables were included in the model if 
the association with the outcome had a significance of P ≤ 0.1. Multicollinearity was assessed 
by the variance inflation factor (VIF) calculated through a linear regression between all 
included predictor variables. VIF was calculated by 1/(1 – r2), using the total r2 from the 
regression. Multicollinearity assumption is met if VIF is below 2.5. The constant, 
unstandardised beta values with their corresponding standard errors, 95% confidence 
intervals (CIs) and P-values were reported for multivariate linear regression model. All 
statistical analyses were performed using SPSS, version 24 (IBM Corp., Armonk, NY, USA). 
P<0.05 (two-tailed) was considered statistically significant. 
 
R E S U L T S  
Patients 
In total, 470 infants received PE-formula during PICU admission within the inclusion period 
of whom 70 infants were eligible for inclusion in the analysis. Reasons for exclusion were 
receiving PE-formula <14 days or <14 days between weight measurements (n=335); <37 





than 80% of total caloric intake (n=33); and an interruption of more than 20% of feeding 
duration (n=8). 
 
Of infants eligible for analyses, the median (IQR) PICU length of stay was 49.7 (34.9–83.1) 
days in which they received PE-formula for 29.2 (20.9–54.3) days. Predominant diagnostic 
groups were post-cardiac surgery (34%), respiratory diseases (19%), cardiac diseases (11%) 
and neurological conditions (6%) (Table 1).  
 
Nutritional intake  
The median (IQR) time between admission to the PICU and start of PE-formula was 8 (1–
24) days. Reasons to start PE-formula were 30 (43%) infants in accordance with the protocol 
for ventilated infants; 30 (43%) infants because of insufficient growth; three (4%) infants 
because of fluid restriction; five (7%) infants who had already started before admission; and 
four (6%) infants where the reason to start was not documented in the medical files. The 
reasons to stop PE-formula were discharge from PICU (n=32); reaching weight goal (n=12); 
signs of enteral feeding intolerance (n=8); and switching to standard formula after weaning 
from ventilation (n=3). In two (3%) infants, PE-formula was stopped because the infant died 
during admission and the remaining 13 (19%) infants had no documented or other reason 
to stop (Figure 1).  
 
The mean (SD) energy intake from PE-formula was 104.6 (19.4) kcal kg-1 day-1, which was 
100.9% (21.5%) of the energy target. Forty (57%) infants received the amount of energy 




The mean (SD) WFA Z-score at start of PE-formula was -1.93 (1.68);  3 (47%) infants had a 
WFA Z-score < -2. The changes in WFA Z-scores from birth to start of PE-formula and 
from start to stop of PE-formula are shown in Figure 2. A significant (P<0.001) increase in 
mean (SD) WFA Z-score of 0.48 (1.10) was noted during PE-formula use and, at the end of 
PE-formula, the number of infants with a WFA < -2 had decreased to 23 infants (33%). 
Overall, the median (IQR) increase in body weight during PE-formula use was 5.80 (3.28–
9.04) g kg-1 day-1 and 7.54 (4.70–10.47), 4.49 (1.48–5.82) and 3.88 (2.92–6.18) g kg-1 day-1 in 
infants between the age 0–3 months (n=40), 3–6 months (n=13) and 6–12 months (n=17) 
respectively. Multivariate regression showed that a lower WFA Z-score at start was 
associated with a higher increase in WFA Z-score during PE-formula use (r2 = 0.26; b -0.35; 
95% CI = -0.50 to -0.19; P<0.001). Other predictive baseline variables (e.g. WFA Z-score 
at birth, respiratory diagnosis, corrected age at start and reason to start) were not 






Gastrointestinal symptoms and tolerance 
Overall, five (7%) infants had constipation, whereas another 19 (27%) infants were treated 
for constipation at least once during PICU stay without fulfilling the criteria for constipation. 
In total, 47 (67%) infants vomited at least once during the period on PE-formula. Three 
infants (4%) were treated for vomiting with oral rehydration solution during the use of PE-
formula. GRV was measured in 43 (61%) infants receiving EN via gastric or combined (gastric 
and post-pyloric) route and in 22 (31%) infants receiving EN via a post-pyloric route. The 
median (IQR) daily GRV of infants receiving EN via gastric or combined route was 0.81 
(0.13–2.08) mL kg-1 per 24 h. The feeding was provided via boluses (n=10), continuous (n=5) 
or both continuous and boluses (n=28) in these 43 infants. Gastric retention occurred in 
two (5%) of the 43 infants via gastric of combined route, as well as in one (5%) infant 
receiving EN via a post-pyloric route. Parameters of gastrointestinal tolerance are 
summarised in Table 2.  
 
PE-formula was stopped in eight (11%) infants as a result of signs of enteral feeding 
intolerance, which comprised vomiting (n=4), gastric retention (n=2) and signs of discomfort 
(n=2) (Figure 1). Infants received PE-formula for a median (IQR) of 24.5 (15.9–55.0) days 
before PE-formula was stopped and switched to standard infant formula or an extensively 
hydrolysed (whey-based) protein and energy-enriched formula. 
 
D I S C U S S I O N  
The present retrospective study describes weight gain and parameters of enteral feeding 
tolerance in critically ill infants with a prolonged PICU stay and beyond the acute phase 
when using PE-formula. In the majority of the infants, an improvement of WFA Z-score was 
achieved and, overall, PE-formula was well tolerated. Before starting PE-formula, 47% of the 
critically ill infants were identified as acutely malnourished, emphasising the importance of 
adequate nutritional support in this patient group. Previous studies have reported difficulties 
with respect to achieving energy targets, with enteral intakes ranging from 12% to 38% of 
the prescribed targets.1,16-18 In the present study, using PE-formula, 57% of the infants were 







Table 1. Patient and admission characteristics  
Patient characteristics   Total group (n=70) 
Gender male  n (%) 36 (51) 
Birth weight (gr) (N=62) mean (±SD) 2448 (±855) 
Birth weight z-score (N=59) mean (±SD) -0.64 (±1.21) 
Gestational age (days) (N=63) median [IQR] 260 [242 - 270] 
Age at start (d)b median [IQR] 76.2 [30.0 - 181.8] 
Weight at start (gr) median [IQR] 3943 [3289 - 5803] 
WFA Z-score at start mean (±SD) -1.93 (1.68) 
HFA Z-score at start (N=14) median [IQR] -1.44  [-2.44 to -0.75] 
Admission duration (d) median [IQR] 49.7 [34.9 - 83.1] 
Nutritional intake     
Post-pyloric feeding  n (%) 45 (64) 
Feeding strategy n (%)   
    Continuous  27 (39) 
    Portion  10 (14) 
    Bothc  33 (47) 
Duration admission to start PE-formula (d) median [IQR] 8 [1 - 24] 
Duration PE-formula (d) median [IQR] 29.2 [20.9 - 54.3] 
Percentage of PE-formulad median [IQR] 98.9 [93.8 - 100] 
Diagnostic groups    
Reason for admission  n (%)   
    Respiratory insufficiency  30 (43) 
    Cardiac surgery  15 (21) 
    Cardiac insufficiency  10 (14) 
    Gl surgery    4 (6) 
    Surgery other  2 (3) 
    Sepsis/Infection  1 (1) 
    Neurology  1 (1) 
    Other  7 (10) 
Primary diagnosis  n (%)   
    Cardiac surgery  24 (34) 
    Respiratorye  13 (19) 
    Cardiac  8 (11) 
    Neurologyf  4 (6) 
    GI surgery  3 (4) 
    Surgery other  1 (1) 
    Infection / sepsis  1 (1) 
    Other  16 (23) 
aData are presented either as number of subjects(%), median[IQR] or mean(±SD) ; bAge at start 
was corrected for prematurity in case gestational age was below 37 weeks; cPatient received 
continuous drip and portion feeding during the period of PE-formula;  dPercentage of energy 
intake from PE-formula divided by total energy intake (PE-formula, EN and PN) eIncludes 
pneumonia, respiratory syncytial virus bronchiolitis and bronchopulmonary dysplasia; f Includes 
neurosurgery, neurotrauma and epilepsy. GI, gastrointestinal; EN, enteral nutrition; PN, 



























 Table 2. Gastrointestinal symptoms in infants using PE-formula 
Parameter  N (%) or Median [IQR] 
   
Defaecation Frequency per day 0.93 [0.85-1.00] 
N=70 Number of patients with constipationa 5 (7%) 
 Number of patients treated for constipation 24 (34%) 
 Number of patients treated for diarrhoea 1 (1%) 
Vomiting Number of patients with vomiting 47 (67%) 
N=70 Number of patients treated for vomiting 3 (3%) 
Retentionbc 
N=65 
   Infants with gastric EN (N=43)d  
Number of patients with retention 2 (5%) 
Average retention in 24 hours in ml kg-1 0.81 [0.13-2.08]  
Maximum retention in 24 hours in ml kg-1 8.11 [2.18-14.32]  
    Infants with post-pyloric EN (N=22)e  
 Number of patients with retention 1 (5%) 
 Average retention in 24 hours in ml kg-1 2.11 [0.75-4.29] 
 Maximum retention in 24 hours in ml kg-1 11.70 [6.64-19.62] 
a Constipation was defined as 4 or more days without defecation; b In 65 infants both gastric 
residual volume and weight were recorded; c Only days with measurement were included in the 
analyses; d Infants receiving EN through gastric route, including infants receiving EN through 
both gastric and post-pyloric route; e Infants receiving EN through post-pyloric route.  














Figure 2. Weight-For-Age Z-scores over time (N=70) 
 
 
Start moment of PE-formula and stop moment of PE-formula in 70 infants with minimum duration of PE-formula of two weeks;
 
a Median duration between 
two time points; • Value is significantly different when compared to WFA Z-score at birth p<0.001; † Value is significantly different when compared to 





Previous studies focusing on the effects of PE-formula compared to standard formula were 
performed in infants with viral bronchiolitis, infants after cardiac surgery and mechanically 
ventilated children aged 1 month to 16 years.10,19,20 In these studies, PE-formulas were well 
tolerated and a higher energy and protein intake and a positive nitrogen balance were 
achieved compared to standard formula. In all of these studies, no data were reported about 
the follow-up of these children and specifically not about growth. 
 
So far, only a limited number of studies have investigated weight achievement when using 
PE-formulas in non-critically ill children.21,22 In a study investigating infants with faltering 
growth receiving either a nutrient dense formula or an energy supplemented formula, the 
nutrient dense formula showed a trend toward better improvement in length compared to 
the energy supplemented formula after 6 weeks.21 Also, infants with complex medical 
conditions receiving extensively hydrolysed PE-formula for 28 days showed a significant 
increase in WFA Z-scores.22 To our knowledge, the present study is the first to examine 
the course of weight in critically ill infants using PE-formula for a longer period of time. In 
our study, weight gain was achieved in 93% of the infants, whereas, in 71% of the infants, an 
increase in WFA Z-score was observed. Moreover, it appeared that infants who had a lower 
WFA Z-score at start of the PE-formula benefited the most. However, catch-up growth 
during the recovery phase of critical illness and the implications for short-term and long-
term outcome have never been reported. Previously, our research group showed a 
decrease in WFA Z-score during PICU stay in critically ill infants and children that was 
related to cumulative negative energy and protein balances.2 In this previous study, no PE-
formula were used. Overall, median weight velocity was 5.80 g kg-1 day-1. Also, and as might 
be expected, weight velocity in infants aged 0 – 6 months was higher than in infants aged 6 
– 12 months. Compared with the normal weight velocity data for healthy infants, weight 
achievement in the present study was similar for the three age groups: 0 – 3 months, 3 – 6 
months and 6 – 12 month.15 Weight gain was achieved by following the nutritional protocol 
with energy target set at twice the resting energy expenditure (calculated with the Schofield 
equation for weight).11 Although indirect calorimetry is currently the golden standard for 
determining the individual energy requirement during critical illness in the acute phase and 
to detect over- or underfeeding23,24 in the stable and recovery phase of (critical) illness, an 
increase in the amount of energy to enable weight gain is recommended in those infants 
who have a prolonged stay in the PICU.8 Moreover, it is suggested to increase the protein-
energy ratio to enable adequate (catch-up) growth, especially in (critically) children with 
acute malnutrition.25-27 
 
Intolerance to EN is frequently reported in critical illness but, surprisingly, no uniform 
definition exists. To report tolerance to PE-formula, we decided to describe gastrointestinal 
symptoms that are frequently used in relation to EN intolerance in critically ill children, such 





well tolerated because signs of intolerance only occurred in few of the infants. This is in 
accordance with previous findings in which early administration of PE-formula in critically ill 
infants with viral bronchiolitis was also well-tolerated.10 GRV is one of the most routinely 
used parameters in the PICU despite a lack of evidence to support this parameter and 
current guidelines challenge the use of GRV as a marker for feeding intolerance.6,31 There is 
also no consensus for a standardised threshold for large GRV; however, the threshold of 
more than 50% of the feeding volume of the previous 4 h has been used in some studies 
and is the standard of care in our PICU.32,33 In the present study, gastric retention occurred 
in two infants receiving their feeding via a gastric route or a combined route and in one 
infant receiving EN via a post-pyloric route. We reported GRV separately for the two 
feeding routes because there is some evidence advising against the routine advancement of 
post-pyloric tubes. In these infants, large GRV might not indicate feeding intolerance or 
correlate with delayed gastric emptying. However, gastric aspiration might be useful for 
detecting tube dislocation when gastric retention does not solely consist of gastric 
secretion.34,35 The prevalence of constipation was 7%, which is much lower than previously 
reported in a study of critically ill children (prevalence of 46.7%).36 Of note, we did find a 
large number of infants (62%) who vomited at least once when on PE-formula. In this age 
group, some regurgitation could be physiological as a result of immaturity. We were not 
able to differentiate between physiological and non-physiological vomiting. In 11% of infants, 
the PE-formula was stopped because of signs of enteral feeding intolerance, with vomiting 
being the most reported reason. This percentage is relatively low compared to the 
prevalence of enteral nutrition discontinuation as a result of the feeding intolerance 
reported in literature (prevalence ranging from 7% to 29%).37-40 
 
The lack of a comparison group receiving (fortified) human milk or standard infant formula 
and the retrospective design are major limitations of the present study. It is therefore not 
known whether the same growth would have been achieved with human milk or standard 
formula. However, in clinical practice, it is known that achieving adequate nutritional goals 
is very difficult because these children frequently have fluid restriction, in addition to any 
consideration of the lower protein-energy ratios of these types of feeding. Other factors, 
such as intravenous fluid administration and the presence of oedema, might influence body 
weight and therefore the measured weight may not accurately display the alterations in lean 
body mass. Unfortunately, we were unable to account for these influencing factors, such as 
the presence of oedema, because no information was reported in the records. However, 
by using a long interval between measurements, in conjunction with our experience with 
respect to children often being oedematous at the start of admission to the PICU, we 
consider that the influence of possible fluid imbalances on our results was limited. Additional 
anthropometric measurements to assess the nutritional status, such as length and mid-upper 
arm circumference, could not be evaluated in this retrospective study. Infants with 





not taken into account. The final limitation is a possible selection bias in the description of 
enteral gastrointestinal parameters. Only infants with a prolonged PE-formula use were 
considered to be eligible in our analysis of the weight course. Consequently, infants in the 
present study already tolerated PE-formula for at least 2 weeks. 
 
C O N C L U S I O N S 
The majority of critically ill infants receiving protein and energy-enriched formula for a 
prolonged period gained weight and had an increase in WFA Z-score during PICU 
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A B S T R A C T  
Background: Enteral feeding is challenging in critically ill infants. Target intakes are often 
not achieved as a result of fluid restriction, procedural interruptions and perceived enteral 
feeding intolerance. In those infants perceived to have poor feeding tolerance, the use of a 
peptide nutrient-energy dense enteral feed (PEF) may improve nutritional intake and 
minimise feeding interruptions as a result of gastrointestinal symptoms. The aim of this 
observational study was to characterise the use of a PEF amongst critically ill infants in two 
paediatric intensive care units (PICUs). 
 
Methods: Records from critically ill infants aged <12 months admitted to two PICUs were 
retrospectively reviewed with a PICU length of stay (LOS) ≥ 7 days. Achievement of 
nutritional targets for the duration of PEF was reviewed. Gastrointestinal symptoms, 
including gastric residual volume, constipation and vomiting, were evaluated as tolerance 
parameters. 
 
Results: In total, 53 infants were included, with a median age on admission of 2.6 months. 
Median admission weight was 3.9 kg in PICU-1 and 4.7 kg in PICU-2. Median (interquatile 
range) energy intake in PICU-1 and PICU-2 was 68 (47-92) and 90 (63-124) kcal kg-1, 
respectively, and median (interquatile range) protein intake 1.7 (1.1-2.4) g kg-1 and 2.5 (1.6-
3.2) g kg-1, respectively. Feeding was withheld because of feeding intolerance in one infant 
(4%) on two occasions in PICU-1 for 2.5 h and in two infants (7%) on two occasions in 
PICU-2 for 19.5 h. Gastric residual mean (SD) volumes were 3.5 (5.4) mL kg-1 in PICU-1 
and 16.9 (15.6) mL kg-1 in PICU-2. 
 
Conclusions: Peptide nutrient-energy dense feeding in infants admitted to the PICU is 
feasible, well tolerated and nutritional targets are met. However, with this study design, it 
is not possible to draw any conclusions regarding the benefit of PEF over standard PE feed 






I N T R O D U C T I O N  
Feeding a critically ill child appropriately is difficult. There is often a discrepancy in what is 
prescribed and what is delivered and the cumulative deficits of protein and energy are 
associated with impaired outcome.1 Optimal nutritional support evolves with the acute, 
stable and recovery phase of critical illness. During the acute phase, energy intake to a 
maximum of the resting energy expenditure is recommended with increasing amounts of 
nutrition perceived to be required during stable and recovery phases.2 However, target 
intakes are often not achieved as a result of fluid restriction, procedural interruptions and 
perceived enteral feeding intolerance. 3,4 In those infants perceived to have poor feeding 
tolerance, the use of a peptide nutrient-energy dense enteral feed (PEF) may be tolerated 
better and improve nutritional intake.5 Limited research to date has focused on the optimal 
nutrition composition of nutrients during the time course of critical illness in children.6-8 
 
Traditionally polymeric enteral feeds are used as first line;8-9 however, the metabolic 
utilisation and assimilation of proteins, carbohydrates, fats and other nutrients during critical 
illness may be affected by hypoxaemia, dysbiosis and impoverishment of the microbiome.10-
12 As such absorption, tolerance and utilisation of protein13, fats and energy may be altered.14-
15 
 
Peptide feeds are usually considered as a second line when tolerance to complex feeds 
cannot be established,5,8,16 such as with ongoing diarrhoea, vomiting and abdominal 
distention resulting in feeding interruptions.8,17 Nutrient-energy dense whey based protein 
feeds have been successfully used in critically ill infants during the first week of admission, 
resulting in significantly higher de novo arginine synthesis and higher nutritional intakes 
compared to standard infant feeds alone.18,19 The aim of this retrospective observational 
study was to describe the use of a peptide nutrient-energy dense enteral feed amongst 
critically ill infants with a paediatric intensive care unit (PICU) length of stay ≥7 days, in two 
different PICUs, considering feasibility, tolerance and nutritional targets. 
 
M E T H O D S  
Subjects and setting  
A retrospective observational study was completed in two PICUs to investigate the 
feasibility and tolerance of a ready to use PEF (100 kcal and 2.6 g protein per 100 mL; 
Infatrini Peptisorb®; Nutricia, zoetermeer, The Netherlands), amongst critically ill infants 
<12 months of age in infants with a PICU length of stay (LOS) ≥ 7 days. In PICU-1, the 





PEF is provided to infants with gastrointestinal symptoms or perceived feeding intolerance. 
The units were comparable in size and number of patients admitted per year. PICU-1 and 
PICU-2 are both tertiary paediatric intensive care units and based in Southampton, UK 
(PICU-1) and Rotterdam, The Netherlands (PICU-2), respectively (Table 1).  
 
As a result of the different feeding practices, data collection time periods varied. 
Retrospective data were collected for a 2-year period from (2016–2018) in PICU-1 and a 
5-year period (2013–2018) in PICU-2 to identify all infants with a PICU LOS ≥ 7 days up to 
21 days who received PEF. Inclusion criteria were: children aged 0– 12 months and critically 
ill infants with a PICU stay ≥7 days. Exclusion criteria were premature infants ≤37 weeks 
gestational age at the time of admission (corrected age) and infants who had not received 
PEF or whose PICU LOS was ≤7 days. The University Hospital Southampton NHS 
Foundation Trust (UK) retrospective study was registered as a service evaluation within the 
NHS Trust (reference SEV03) and Erasmus University Medical Centre (The Netherlands) 
was the study protocol was approved by the institutional review board (MEC-2017-316). 
 
Fluid and nutrition management 
In PICU-1 and PICU-2, nutritional targets are based on the calculated resting energy 
requirements (REE) using Schofield equation for weight20 (Table 1). In PICU-1, energy target 
during the acute phase was calculated as 100% of REE and, in the stable and recovery phase, 
as 140% and 160% of REE, respectively. In PICU-2, PEF energy target was set at 200% of 
REE for the stable and recovery phases.20-22 
 
Anthropometric measurements 
Anthropometric measurements were performed and recorded in accordance with local 
Standardised Operating Procedures and World Health Organisation (WHO) guidelines,23 
weight was corrected for prematurity in those infants born ≤37 weeks. Infants ≤12 months 
of age were weighed naked and weight was measured to the nearest 0.001 kg using a digital 
scale. 
 
A dataset from each of the centres was downloaded into EXCEL (Microsoft Corp., 
Redmond, WA, USA). Z-scores were calculated using ANTHRO, version 3.3.3.24 WHO 
growth reference interpretation of cut-offs for malnutrition was used. Malnutrition was 
defined as a weight for age ≤ -2 Z-scores of the mean of the WHO child growth standards.23 
For ex-preterm infants, weight Z-scores were corrected using the Fenton growth charts 
for preterm infants.25 
 
Gastrointestinal symptoms 
Gastrointestinal symptoms were recorded each day from the start of PEF and included: 





as ≥4 days without stools. Medication for diarrhoea was also recorded in PICU-2. 
Furthermore, it was recorded when PEF was interrupted by the clinician because of signs of 
gastrointestinal symptoms.  
 
Statistical analysis  
Statistical analyses were performed in SPSS, version 24 (IBM Corp., Armonk; NY, USA). 
The results are expressed as the mean (SD) or the median with the interquartile range 
(IQR), and with the percentage and number for binary or categorical data. 
 
R E S U L T S  
Demographics of infant populations  
In total, 53 children met the study inclusion criteria of a PICU length of stay ≥7 days and 
receiving PEF. The median duration of mechanical ventilation was 168 h in PICU-1 and 143 
h in PICU-2. Mean (SD) length of stay was 9.9 (3.4) days in PICU-1 and 13 (2.9) days in 
PICU2. Predominant diagnostic groups were post-cardiac surgery, respiratory diseases and 
sepsis (Table 2). 
 
Nutrition support: energy intake 
The median (IQR) time between admission and start of PEF was 1 (1–1) days in PICU-1 and 
14 (1–30) days in PICU-2. Reasons to start PEF in PICU-1 were standard nutrition protocol 
(100%) and, in PICU-2, growth insufficiency (14%) started PEF prior to admission (18%), 
fluid restriction (3%) or clinician led decision (61%). The reason to stop PEF in PICU-1 was 
discharge from the unit (89%) or death (11%) and, in PICU-2, was discharge from the unit 
(50%), change to standard infant formula (7%), weight goal achieved (11%), resolved 
gastrointestinal symptoms (7%) or death (11%). Nutritional intake increased following the 
commencement of PEF in both centres (Table 3). 
 
Gastrointestinal symptoms 
The preferred route of feeding in PICU-1 was via a nasogastric route and PICU-2 via a post-
pyloric enteral tube. One infant admitted in PICU-2 fulfilled the criteria for constipation and 
required treatment. In PICU-1, vomiting occurred in 11 infants (40%) with a median (IQR) 
frequency of 2 (1–5) vomits per day. GRV was measured in 22 (88%) infants, with mean 
(SD) GRV of 3.5 (5.4) mL kg-1 day-1. Feeding was withheld for perceived feeding intolerance 
(e.g. nonspecific gastrointestinal symptoms) in one infant (4%) on two occasions for 2.5 h. 
In PICU-2, vomiting occurred in 23 infants (82%) with a median (IQR) frequency of0.3 (0.0–
1.2) vomits per day. GRV was measured in 28 (100%) infants, with mean (SD) GRV of 4.7 
(5.6) mL kg-1 day-1 and a maximum GRV over a 24-h period of 16.1 (15.8) mL kg-1 day-1.In 





mean (SD) GRV of 3.5 (2.9) mL kg-1 day-1 and post-pyloric fed infants a GRV of 5.4 (6.9) mL 
kg-1 day-1. Feeding was withheld for perceived feeding intolerance in two infants (7%) on two 
occasions for 19.5 h. In PICU-2, medication for the management of diarrhoea was prescribed 
to four infants (14%) on a median (IQR) of7 (3–14) occasions. 
 
Feeding interruptions: procedures  
In both centres, the most common non-feeding related interruptions were as a result of 
airway procedures, surgery or clinical deterioration e.g. escalation of inotropic support 
(Table 3). 
 
Change in weight for age Z-score during peptide nutrient-energy dense enteral 
feeding 
Mean (SD) weight for age Z-score on admission was -2.0 (2.2) in PICU-1 and -0.8 (2.5) in 
PICU-2. There was a positive change in weight for age Z-score during PICU stay amongst 
infants who were weighed during the observational study period (n=17). 
 
D I S C U S S I O N  
The results of the present observational study suggest that the use of peptide nutrient-
energy dense formula in critically ill infants in two centres with differing populations and 
feeding practices is feasible, without any major complications being found. Expert consensus 
recommend polymeric enteral feeds and the use of protocols to guide in the detection and 
management of feed intolerance,21,16 suggesting that peptide feeds be provided where there 
is failure to establish enteral feeding or in for those children who will not tolerate whole 
cow’s milk protein.16,26,27 The use of a PEF may further improve nutritional intake and 
minimise feeding interruptions as a result of gastrointestinal symptoms.  
 
In this observational study, there were two different approaches to enteral feeding. In PICU-
1, the approach was to gastrically feed infants proving PEF from admission with the aim of 
ameliorating episodes of perceived feeding intolerance. In PICU-2, infants were post-
pylorically fed, providing PEF only when there was perceived feeding intolerance.26,28 The 
predominant diagnostic group in this observational study was post-cardiac surgery in infants 
with congenital heart disease (CHD) on vasoactive inotropes. Infants with CHD are a 
notably challenging group to adequately nourish during the peri-operative period because 
they are often malnourished prior to surgery with poorer post-operative resilience29-31 and 
as a result of post-operative fluid restriction post-operatively32,33 and the use of inotropes 






Concerning the amount of energy provided, 135% and 213% of REE was achieved in PICU-
1 and PICU-2, respectively, indicating that, with the use of PEF, it was possible to meet 
recommended nutritional requirement amongst infants in the different phases of disease 
(PICU1, acute phase, PICU-2, stable and recovery phase). Previously, Gentles et al.35 
reported that only 54% of infants with CHD achieved REE during a PICU admission (median 
length of stay 5 days). More recently, Zhang et al.36 compared nutritional intake of post-
surgical infants with CHD who were randomised to receive standard infant formula or a 
polymeric protein-energy dense (PE) energy intake. Those who received PE formula had an 
higher average energy intake during the 7-day intervention period, suggesting that nutrient 
dense formula may better enable nutritional targets to be achieved {Zhang, 2018}. In other 
studies considering a mixed PICU population, energy goals are reported to be achieved in 
36%–76% of critically ill children up to day 10 of admission.1,37-40 A recent study evaluated 
the use of use of a PE formula in critically ill infants with a LOS ≥14 days and reported that 
57% of infants achieved energy targets calculated as twice the REE.41 
 
Inadequate intake and gastrointestinal symptoms are the most commonly used descriptors 
to describe feeding intolerance.42-44 Despite the lack of evidence to support the use of GRV 
as a surrogate for delayed gastric emptying,26,44,45 large GRV has been used as the most 
common reason for feeding interruptions.6,40,46 Both centres in the present study had similar 
criteria GRV as a surrogate marker of gastric emptying. GRV was measured in 88%–100% 
of infants, with mean (SD) GRV low measured volumes [3.5 (5.4) to 4.7 (5.6) mL kg-1 day-1]. 
It is debatable if routine assessment of GRV measurements should be used in infants 
receiving enteral nutrition via post-pyloric route, the standard route in PICU-2.47,48 
Therefore, GRV was reported separate for the post-pyloric [5.4 (6.9) mL kg-1 day-1] and 
gastric route [3.5 (2.9) mL kg-1 day-1] in PICU-2. In this study, enteral feeds were withheld 
for perceived feeding intolerance in 4% and 7% of infants in PICU-1 and PICU-2, respectively, 
which is lower than reported in other studies (11–19%).3,49 Therefore, our results suggest 
the use of a PEF for infants was suitable without increased GRV’s or feeding interruptions 
as a result of perceived feed intolerance compared to previous studies.  
 
Vomiting occurs common in critically ill children and is taken as a sign of feeding 
intolerance50 or iatrogenic withdrawal from sedation.51 Feeding is often withheld following 
episodes of vomiting because concerns of increased risk of aspiration.6 Both PICUs used 
morphine and midazolam as analgesic and sedation agents, although it was not possible to 
determine the causality of vomiting (e.g. feeding intolerance, or withdrawal from sedation 
arising from prolonged use).  
 
Malnutrition is associated with prolonged PICU-LOS, increased morbidity and 





present study, the incidence of moderate acute and persistent malnutrition was similar in 
both units with 16%–18%. The use of PE formula in critically ill children has been associated 
with improved weight for age Z-score during PICU stay.36-41 Although only 17 of the 53 
infants had serial weight measures completed during the observational period, in those in 
whom it was completed, there was a positive change in weight for age Z-score. Similar 
findings have been described with the use of PEF amongst non-critically ill infants with 
complex disease and growth faltering.27  
 
Our understanding of gastrointestinal function during critical illness is limited and although 
it is assumed a child’s gastrointestinal tract is completely functional and capable of normal 
digestion and absorption during acute illness, this may not be the case.6,58 Gastric emptying 
is complex and influenced by the type of food and form; for example, liquid over solid and 
feed composition,59 disease pathology and mode of feed delivery,61,61 and feed osmolality.62 
Both extensively hydrolysed protein and medium chain triglyceride rich infant feeds have 
been shown to empty from the stomach faster than respectively diets with whole protein 
and long chain fats.63,64 In a single-centre prospective cohort study in ill critically ill children 
(n=291), factors were analysed that were associated with peptide-based formula 
prescription. These factors were malnourishment, fasting >48 h as a result of feed 
intolerance and use of a-adrenergic drugs.5 In the present study in PICU-2, the reasons to 
start PEF were growth insufficiency, starting PEF prior to admission, fluid restriction or a 
decision by the clinician based on clinical judgement.  
 
There are a number of limitations to the present study, particularly with regard to the 
retrospective nature of the cohort, limited study numbers and the lack of a comparison 
group (e.g. standard infant or PE formula) and, as such, it is not known whether a similar 
nutritional intake would have been achieved or whether the incidence of gastrointestinal 
symptoms would have been any different. Also, the time periods for each cohort were 
different because of variances in unit practice and thus feeding strategies. As there is a 
paucity of comparative or prospective data within a randomised controlled study it is not 
possible to draw any causal relationships. However, from the results presented, the use of 
peptide-nutrient energy dense feeds in critically ill infants with a prolonged PICU-LOS 
appeared to be well tolerated and resulted in few interruptions as a result of feed 
intolerance, enabling recommended nutritional requirements to be met during critical 
illness. Further larger multicentre studies will be required to investigate the relationship of 






C O N C L U S I O N S 
Peptide feeding in two different centres with different population and feeding indications is 
feasible without any major complications found. Infants met nutritional targets and there 
were minimal feeding interruptions arising from feeding intolerance. There may be a role 
for the use of peptide nutrient-energy dense feed in critically ill infants who are difficult to 
feed as a result of feeding intolerance and gastrointestinal symptoms. However, with this 
study design, it is not possible to draw any conclusions regarding the benefit of PEF over 








Table 1. Description of standard practices in study units 
  PICU 1 PICU 2 
Unit size 16 PICU beds 
Admit 0 – 17 years 
24 PICU beds 
Admit 0 – 17 years 
Fluid allowance 12 – 24 hrs post admission 2 – 3 
ml/kg/hr (48-72ml/kg/day) and 
4ml/kg/hr (96ml/kg/day) on consecutive 
days; once extubated 5 – 6ml/kg/hr; 
restricted after (cardiac) surgery 
Depending on age fluid 5 – 7.5 
ml/kg/hr (120 – 180) 













Schofield equation (adjusted age, sex, 
weight) 
Schofield equation (adjusted 








Yes – every 4 hours 
Response to GRV If GRV > 4 hours or > 200ml, replace 
½ of the GRV and stop feed for 2 
hours. When GRV > 50% persists, 
feeding is halved 
If GRV > 50% of feeding 
volume in 4 hours, replace 
GRV and subtract from next 
feeding. When GRV > 50% 
persists, feeding is halved 
Feeding methods 
used 
Continuous feeds over 20 hours with 4 
hour break; 6am – 10m 
Continuous feeds over 24 
hours 
Target feed start 
time 
Within 6 hours Within 24 hours 
Feed advancement 
rate 
0.5 – 1ml/kg/hr depending on fluid 
allowance 
Non cardiac diagnosis: 
2ml/kg/hr 
Cardiac diagnosis: 0.6 – 2 
ml/kg/hr depending on fluid 
allowance 
Post-pyloric tubes Not first line, only if ongoing feed 
intolerance or high risk patients e.g. 
traumatic brain injury 
Standard practise 
Standard feed type Peptide nutrient-energy dense enteral 
feed (PEF)/ human milk 
Nutrient-dense polymeric feed/ 
human milk 





Table 1. Description of standard practices in study units 




100% extensively hydrolysed whey protein (short chain peptides/ free 
amino acids), lactose free, maltodextrin, 50% medium chain triglycerides 




6 hours prior to extubation, for transport depending on procedure 
Guidance on 
withholding feeds 
Mechanical bowel obstruction, suspected necrotising enterocolitis, 
significant gastrointestinal bleed, bowel ischaemia, significant abdominal 
distention; feeding intolerance (e.g. large GRV, vomiting) 
Usual sedation and 
analgesia for > 1 day 
ventilation 
Morphine and midazolam 
GRV, gastric residual volume, EETs, endotracheal tubes, RDA, recommended dietary allowance, 







Table 2. Patient demographics and feeding characteristics 
  PICU 1  
(N=25) 
PICU 2  
(N=28) 
Gender: Male – No. (%) 17 (43%) 13 (46%) 
Number of episodes of care (days) 254 513 




Congenital heart disease  












3 (2 - 4) 
Age (months) - median (IQR) 2.6 (0.03 - 6.0) 2.6 (0.4 - 3.6) 
Weight (kg) - median (IQR) 3.9 (3.5 - 4.7) 4.7 (3.3 - 5.7) 
Weight for age z score - mean (SD) 





PICU days - median (IQR) 9 (7 – 12) 13.5 (9 – 16) 
Mechanical ventilation hours - median (IQR) 168 (138 – 252) 143 (0 – 383) 
PIM2 score - median (IQR) 4.4 (1.2 – 8.9) Not recorded 
Inotropes days - No. (%) 132/254 (52%) 130/513 (25%) 
Mortality - No. (%) 3 (12%) 5 (18%) 












Day of admission where PEF feeding is 
started - median (IQR) 
1 (1 - 1) 14 (1 - 30) 
Kcal/kg intake - median (IQR) 68 (47 – 92) 90 (63 – 124) 
Protein g/kg intake day - median (IQR) 1.7 (1.1 – 2.4) 2.5 (1.6 – 3.2) 
Enteral Nutrition 
Day 1 – 5 of PEF  
Energy kcal/kg - median (IQR) 
% REE 
Protein g/kg - median (IQR) 
 
 
32 (6 - 57) 
61% (10% – 112%) 
0.9 (0.2 – 1.5) 
 
 
94 (37 - 114) 
152% (74% – 229%) 
2.0 (1.0 – 3.0) 
Day 6 – 10 of PEF 
Energy kcal/kg - median (IQR) 
%REE 
Protein g/kg - median (IQR) 
 
59 (42 - 84) 
118% (85% – 168%) 
1.6 (1.1 – 2.2) 
 
104 (70 - 138) 
209% (141% – 276%) 
2.7 (1.8 – 3.6) 
Day 11 – 21 of PEF 
Energy kcal/kg - median (IQR) 
%REE 
Protein g/kg - median (IQR) 
 
68 (49 - 92) 
135% (98% – 184%) 
1.8 (1.2 – 2.4) 
 
107 (77- 131) 
213 (155 – 262) 
2.8 (2.0 – 3.4) 
Gastric fed - No. (%) 





GRV ml/kg/d (total) – mean (SD) 
    Gastric feda  
    Post-pyloric fed  
3.5 (± 5.4) 4.7 (± 5.6) 
3.5 (± 2.9) 
5.4 (± 6.9) 
Vomiting per day - No. (%) 2 [IQR 1-5] 0.3 [IQR 0.0-1.2] 
Constipation- No. of infants (%) 0 (0%) 1 (3,6%) 
Feeding interruption hours - Median (IQR) 
Interruption reasons % of episodes - No. 
(%) 
    Extubation/ airway procedure 
    Ileus/ Abdominal distention 
    Surgery 
    Other/ deteriorating illness 












WAZ scores reported at - Median (IQR) 
    day 1 – 5  
    day 6 – 10  
    day >11  
WAZ change during PICU stay 
 
-1.6 (-3.0 - 0.1) (N=25) 
-1.2 (-2.5 - -0.6) (N=14) 
-1.2 (-2.4 - 0.0) (N=10) 
1.2 (0.7 - 1.6) (N=10) 
 
-0.6 (-2.2 - 0.9) (N=28) 
0.2 (-1.8 - 1.6) (N=10) 
0.3 (-1.1 - 1.3) (N=7) 
0.4 (-0.2 - 1.8) (N=7) 
a Infants receiving enteral nutrition via a gastric route, including infants receiving enteral nutrition 
via both a gastric and a post-pyloric route. GRV, gastric residual volume, PEF, nutrient and energy 
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A B S T R A C T  
The goal of nutritional support during critical illness is to provide the appropriate amount 
of nutrition accounting for the acute, stable and recovery phase in order to accelerate 
recovery and to improve short-term and long-term outcome. Although the preferred route 
to provide nutritional support during paediatric critical illness is via enteral route, reaching 
target intakes is often difficult due to (perceived) feeding intolerance, fluid restriction, and 
interruptions around procedures. Because undernourishment in these children has been 
associated with impaired outcome, parenteral nutrition (PN) has therefore been viewed as 
an optimal alternative for reaching early and high nutritional targets. However, PN 
recommendations regarding timing, dose and composition varied widely and were based on 
studies using intermediate or surrogate endpoints and observational studies. It was not until 
the paediatric early versus late PN in critically ill children (PEPaNIC) randomised controlled 
trial (RCT) that the advice to reach high and early macronutrient goals via PN was 
challenged. The PEPaNIC study showed that omitting supplemental PN during the first week 
of PICU admission as compared with early initiation of PN (<24 hours) reduced new 
acquired infections and accelerated recovery. The provision of amino acids in particular was 
negatively associated with short-term outcomes, probably explained by the suppression of 
the activation of autophagy. Autophagy is an evolutionary conserved intracellular 
degradation process and it is crucial for maintaining cellular integrity and function, which 
becomes even more important during acute stress. Results of the long-term PEPaNIC follow 
up study showed that withholding early PN did not negatively affect anthropometrics and 
health status but improved neurocognitive and psychosocial development two and four 
years later. Current guidelines therefore advise to consider withholding parenteral 
macronutrients for the first week of PICU admission, while providing micronutrients. 
Although parenteral restriction during the first week of critical illness has been found 
beneficial, further research beyond the acute phase is warranted to determine the best role 
of PN in terms of optimal timing, dose and composition in order to improve short-term 




I N T R O D U C T I O N  
Providing optimal nutrition is essential for normal growth, health and development of 
children. Nutrition is known to both cure and cause diseases, and with this viewpoint in 
mind, the role of parenteral nutrition (PN) has developed substantially over de last decade. 
During critical illness the child is subjected to hormonal and metabolic changes, commonly 
referred to as acute stress response, which temporarily inhibits the normal developmental 
process in order to survive. Furthermore, the gut is subjected to many adverse influences 
such as ischemia, altered blood flow, lack of enteral nutrition (EN )and medication. As such, 
the goal of nutritional support is to provide the appropriate amount of feeding during the 
different phases of disease in order to accelerate recovery and to have beneficial effects on 
short-term and long-term outcome. Nutritional requirements of critically ill children 
depends on many factors, including nutritional status on admission, the underlying and actual 
diagnosis. Furthermore, the awareness of the changes in amino acid, lipid, carbohydrate and 
micronutrient metabolism during the different phase of the acute stress response is essential 
in determining the dynamic metabolic and nutritional support, and thereby counteract 
malnourishment and overfeeding (Table 1). 
Nutritional support 
The preferred route to provide nutritional support during paediatric critical illness is via 
enteral route.2-5 Enteral nutrition or even trophic feeding is supposed to have a positive 
influence on reduction of oxidative stress and maintaining the immune response and 
gastrointestinal mucosal integrity limiting bacterial translocation via the gut. However, the 
clinical impact of these positive modulations of EN is unknown. Due to many reasons, such 
as (perceived) feeding intolerance, fluid restriction, fasting around (bedside) procedures, 
target caloric and protein goals are often not achieved via enteral route and discrepancies 
between the amounts prescribed and delivered ranges up to 60%.6-11  
Observational studies have found that malnourishment and underfeeding due to 
macronutrient deficits are associated with delayed wound healing, reduced immune 
response, malabsorption, bacterial overgrowth and increased morbidity and mortality.8,9,12,13 
Overfeeding in its turn may lead to intestinal failure associated liver disease (IFALD), 
hyperglycaemia and increased respiratory burden due to the increase in CO2 production 
present by lipogenesis from carbohydrates.14,15 Besides short-term consequences, both 
underfeeding and overfeeding have been associated with impaired growth, cognitive 
functioning and emotional and behavioural problems in non-critically ill children.16,17 Thus 
far, the long-term consequences of underfeeding and overfeeding in critically ill children 
have not been established.  
Due to the inability to achieve caloric and protein goals via EN, parenteral nutrition is often 
initiated in critically ill children. A world-wide survey investigating PN practises in the 




caloric targets, as well as estimation of energy requirements during critical illness and timing 
of initiation, amount and composition of PN.18,19 What should be considered as optimal PN 
during critical illness is controversial due to the majority of findings that are being derived 
from observational studies and the inability to provide a causal relationship between 
nutrition and short-term or long-term recovery and outcomes. To understand the optimal 
role of PN during paediatric critical illness, the following two fundamental questions should 
be answered:  
1) What is the optimal timing of parenteral nutrition?  
2) What is the optimal dose and composition of parenteral nutrition? 
 
Timing of parenteral nutrition 
Acute phase 
The paediatric early versus late parenteral nutrition in critically ill children (PEPaNIC) RCT, 
published in 2016 was the first randomised controlled trial (RCT) that aimed to determine 
optimal timing in critically ill children.20 This large multicentre RCT involving 1440 critically 
ill children showed that withholding supplemental PN for seven days (Late PN), as compared 
with initiating PN within 24 hours after admission (Early PN), improved short-term outcome 
such as new acquired infections and length of stay.20 EN was provided in both groups when 
possible and tolerated within 24 hours and PN was supplemented up to total caloric need 
following the randomisation groups. When more than 80% of total caloric need was reached 
enterally, supplemental PN was stopped. Weight deterioration during PICU admission was 
not affected by the intervention, however, a decrease in weight-for-age z-score itself was 
associated with worse clinical outcomes in both groups.21 Furthermore, secondary analyses 
of the PEPaNIC RCT showed that even term neonates and undernourished children upon 
admissions benefited from this intervention.22,23 The results of the PEPaNIC RCT had a great 
impact on international guidelines which currently advise to consider (supplemental) PN 
beyond day 7 of critical illness while providing micronutrients.2-5 So far, it is still the only 
RCT focussing on optimal initiation of PN in critically ill children in the first week of 
admission in the PICU.  
Stable and recovery phase 
Although restriction of PN during the acute phase of illness, continuing this course beyond 
the acute phase seems detrimental for short-term and long-term outcome. Currently, it is 
not known at which point in time safe parenteral restriction ends and the potential 
detrimental effects of macronutrient starvation starts.  
During the stable and recovery phases, PN should focus on allowing normal or even catch 
up growth and successful provision is usually monitored through anthropometric 
measurements, muscle strength and function) and tissue repair (e.g. wound healing). 
Nutritional needs can rise above normal requirements for healthy children,24 however, it is 




recommended while providing EN, however the guidelines do not provide 
recommendations for stepwise enhancement of PN.4  
Autophagy 
The leading explanation behind the counter-intuitive finding of the PEPaNIC RCT is the 
consequence of early and high nutritional intake to suppress the fasting response, which 
induces ketosis and activates autophagy.25-28 Autophagy is an evolutionary conserved 
intracellular degradation process and it is crucial for maintaining cellular integrity and 
function. This becomes even more important during acute stress, as children suffer from 
extensive cell and organ damage, leading to organ failure and muscle weakness. Animal 
studies showed that impaired autophagic control caused by early PN let to liver and skeletal 
muscle deficiency.27 This process was confirmed by a study in adults establishing that early 
PN did not prevent muscle wasting and even increased adipose tissue deposition in the 
muscle.25 These studies open perspectives for therapies that activate autophagy during 
critical illness. Although still controversial, possible endeavours can lie within 
pharmacological agents inducing autophagy. For instance an animal experiment found that 
stimulation of autophagy in the kidney with rapamycin correlated with protection of renal 
function.29  
Intermittent PN 
PN can be provided continuously over 24 hours as well as intermittently, meaning a period 
of withholding PN. Several intermittent techniques have been described, including cyclic 
feeding with a period of fasting (10-12 hours) throughout the night or day. A cyclic regime 
in non-critically ill children with long-term PN, i.e. children with short bowel syndrome or 
intestinal failure, has been used for many years and was shown not to change intestinal 
microbiome30 and decreased the risk of IFALD and cholestasis.31 Furthermore, a reduction 
of serum bilirubin levels and livers enzymes was seen, which was associated with a reduction 
in both hyperinsulinaemia and fat deposition in the liver.32,33 Metabolic studies showed that 
lipid oxidation was higher and dextrose use was lower during cyclic PN.34,35 Overall, cyclic 
PN was well tolerated without a higher risk for hypo- or hyperglycaemia, however, using a 
tapering technique can be considered in younger children as abrupt discontinuation had may 
cause hypoglycaemia.36 Based on this evidence cyclic PN is currently recommended in stable 
patients during and after hospital admission.37  
Also, there is currently no evidence for continuous versus cyclic PN in critically ill children. 
Cyclic feeding has some additional hypothetical benefits in critical ill children compared to 
continuous provision of nutrients, e.g. fasting induces activation of autophagy, preservation 
of the circadian rhythm and even enhanced protein synthesis.28,38 This strategy remains 
controversial, however, the findings in the non-critically ill paediatric population underpin 
the rationale for a cyclic feeding strategy opposed of continuous feeding which is standard 




to define an optimal fasting periods to allow autophagy and potentially improve clinical 
outcomes. 
Parenteral micronutrients 
Micronutrients, consisting of vitamins, trace elements and electrolytes, are considered to 
have an important role in body metabolism, immune response and tissue function, and are 
therefore essential during critical illness. While the current guidelines on parenteral 
nutrition in critically ill children recommended to consider withholding PN for the first week 
of admission, they advise to maintain supplementation of micronutrients during this time 
window.2-5 In addition, the ESPGHAN/ESPEN/ESPR/CSPEN guidelines recommend to 
provide micronutrients daily because this prohibits adverse reactions from transient high 
levels, except from vitamin K which can be provided weekly without harmful side effects.39-
41 
Dose of parenteral macronutrients 
Energy 
The actual energy requirement of the child will depend on many factors including 
medication, need for mechanical ventilation, temperature, (lack of) physical activity and on 
the phase of the disease. During the acute phase, endogenous energy production accounts 
for a substantial proportion of energy requirement (up to 75%) irrespective of the energy 
provision via exogenous source.42 Therefore, the energy requirement from EN or PN can 
be much lower than the calculated or measured resting energy expenditure (REE) (Figure 
1). During the recovery phase the focus shifts from acute interventions to optimising activity, 
tissue repair and physical and neurocognitive development. There is an increasing demand 
in energy during this phase to allow normal development of the child and even to catch 
up.2,4,43  
Amino Acids 
Amino acid dose requirement is lower via PN than EN due to the bypass of the utilization 
by the gastro-intestinal tract. A secondary analyses from the PEPaNIC study showed that 
during the acute phase higher doses of parenteral administered amino acids was negatively 
associated with PICU length of stay, new acquired infections and duration of mechanical 
ventilation.44 Even low doses of parenteral amino acids during the acute phase were found 
to be harmful, whereby a maximal risk of harm was reached with a median daily dose of 
1.15 g/kg for children < 10 kg, 0.83 g/kg for children between 10–20 kg, and 0.75 g/kg for 
children > 20 kg. Therefore, the current guidelines suggest to withhold amino acids via PN 
during the first week of illness.45  
After the acute phase muscle wasting often continues due to immobilization and 
undernourishment. Therefore, the ESPGHAN/ESPEN/ESPR/CPNN guidelines advise from 
day eight onwards to provide a minimum amino acid intake of 1.0 mg/kg/min in stable term 




balance while the maximum amino acid intake should not exceed 2.1 mg/kg/min in neonates, 
1.7 mg/kg/min in infants and children up to 3 years and 1.4 mg/kg/min in older children).45  
Specific amino acids 
Amino acids are classified into essential (cannot be synthesised from other elements), semi-
essential and non-essential (can be synthesise from other elements). There is little evidence 
regarding specific amino acids administration during critical illness. Moreover, the available 
evidence focusses primarily on (pre)term neonates. Although, trials in adults providing 
glutamine, a semi-essential amino acid, as a single nutrient or in combination with other 
nutritional supplements did find a reduction in sepsis and mortality46 and was found safe in 
19 infants after surgical interventions,47 there seems to be no evidence for glutamine in PN 
in infants and young children as this failed to show a beneficial effect on outcome and is 
currently not advised in PN in children up to 2 years.48-50 The semi-essential amino acid 
arginine has, among others, a role the endogenous nitric oxide synthesis. A small study in 
critically ill septic children aged 6-16 years found arginine to increase arginine oxidation for 
the production of nitric oxide without an effect on arginine synthesis.51 Nonetheless, due to 
the overall lack of evidence the SCCM/ESICM guidelines advised against the use of glutamine, 
arginine, supplementation in children with septic shock or sepsis-associated organ 
dysfunction. 
Carbohydrates 
Carbohydrates or glucose are one of the main and preferred energy sources during health 
and during critical illness. Glucose levels are among others influenced by the route 
carbohydrates are provided and administration of glucose outside of the main feeding 
sources, such as medication. Plasma glucose levels are a balance between glucose utilization 
and exogenous glucose intake and endogenous glucose production (glycogenolysis and 
gluconeogenesis). During critical illness glucose metabolism is affected due to insulin 
resistance and β-cell dysfunction, which increases the risk of developing hyperglycaemia. 
Due to the restricted glucose utilisation in the acute phase lower doses are advised during 
this acute phase compared to the acute and stable phase. Recommended doses per phase 
and weight are presented for children from 28 days to 18 years in Table 2.52 For term 
neonates it is recommended to start with 2.5-5 mg/kg/min gradually increasing towards 5-
10 mg/kg/min. Additionally, during stable and recovery phase the concomitant provision of 
protein and lipids should be incorporated in the amount of glucose provision. It is important 
to maintain normal plasma levels of glucose as hyperglycaemia and hypoglycaemia are both 
associated with impaired outcomes and carbohydrate tolerance should be controlled 






Table 1. Definitions of the three phases of the stress response in critically ill children1 including 
the nutritional considerations per phase 
 Definition Nutritional considerations 
Acute phase 
Catabolic 
First phase after event, 
characterised by 
requirement of (escalating) 
vital organ support. Phase 
when the patient requires 




1) Energy acquired via endogenous 
production. Intake requirement 
lower than REE. 
2) Start of enteral nutrition and 
accepting low and slowly inclining 
intakes up to 1 times REE, while 
monitoring patients EN tolerance. 
3) Withhold PN during the acute phase 
(fist 7 days) to allow autophagy and 
improve clinical outcomes.  





Stabilisation or weaning of 
vital organ support, while 
the different aspects of the 
stress response are not 
(completely) resolved. The 
patient is stable on, or can 
be weaned, from this vital 
support 
1) Stepwise inclining EN intakes, while 
monitoring patients EN tolerance. 
2) Provide PN from day 8 onwards 





Clinical mobilisation with 
normalisation of neuro-
endocrine, immunologic and 
metabolic alterations, 
characterised by a patient 
who is mobilising 
1) Higher caloric and protein 
requirements with EN and/or 
additional PN might be necessary to 
account for increasing physical 
activity, tissue repair, and long-term 
development. 
EN: enteral nutrition; IFALD: intestinal failure associated liver disease; PN: parenteral nutrition; 






Figure 1. Dynamic energy need during the different phases of critical illness  
EN: Enteral Nutrition; REE: resting energy expenditure; PN: Parenteral Nutrition 
 
Lipids 
Parenteral lipid provision should be a fundamental part of PN in critically ill children during 
stable and recovery phase. Normally, lipid intake accounts for 25-50% of the non-protein 
caloric intake in parenterally fed patients, however, critical illness can result in acceleration 
of the lipid metabolism. Providing lipid emulsions is essential because this allows a high 
energy supply without administering high doses of carbohydrates as an iso-osmolar solution 
in a low volume. The supply of fatty acids, with a minimum of linoleic acid intake of 0.1 
g/kg/day, is essential to prevent essential fatty acid deficiencies.53 The provided dosage of 
lipids should not exceed the capacity for lipid clearance and should be lowered in case of 
hyperlipidaemia (serum triglyceride level is >265 mg/dl (>3.0 mmol/L) in infants >400 mg/dl 
(>4.5 mmol/L) in children. It is currently advised not to exceed a lipid intake of 4g/kg/day 
and 3 g/kg/day via PN in infants and children respectively.  
Dose of parenteral micronutrients 
Comparable to the macronutrients, the micronutrient needs may also differ during the 
course of paediatric critical illness. During the catabolic acute phase energy expenditure is 
altered and protein breakdown is increased. The demand for trace elements and water-




Simultaneously, the cell breakdown results in release of intracellular elements ensuring the 
availability of many elements. During anabolic phase the micronutrient need rises to allow 
normal of even catch-up development and patients presenting with deficiencies are more 
likely during the anabolic phase after a prolonged catabolic phase.54,55 Increased losses e.g. 
zinc deficiency as a result of diarrhoea, potassium with vomiting, may also interfere with 
maintaining optimal levels. 
When depletions passed the subclinical phase, it may manifest in encephalopathy, muscle 
weakness, neuropathy, wound healing and affect cardiac and other organ functions and as a 
final stage result in death.54 Critical illness and inflammation are known to have an effect on 
the plasma levels of micronutrients and associations with deficiencies have been made with 
continuous renal replacement therapy and cardiac surgery. Low micronutrient levels are 
reported for thiamine, riboflavin, folate, vitamin B6, vitamin B12, vitamin A, b-carotene, zinc, 
selenium, iron and chromium, were high or unchanged levels were found for vitamin E, 
vitamin B6, copper and manganese.4 The clinical interpretation of blood plasma levels can 
be misleading during critical illness and might not reflect true intracellular deficiencies.56 
Furthermore, the actual relevance of micronutrient deficiencies or redistribution in critically 
ill children remains uncertain, nonetheless reported prevalence’s are high and associations 
have been made with adverse outcome.4,57-59 
Supplementation 
Adult studies in critically ill patients confirm the association between micronutrient 
deficiency and stress response, however, recent randomised controlled trials and meta-
analyses failed to find a causality between single or combination of supplemented 
micronutrients (i.e. selenium, copper, zinc, thiamine and vitamins vitamin B12, D, C & E) and 
clinical outcomes including mortality, length of stay and time to recover from sepsis.60-69 
Several recent studies have invested in the combination of vitamin C, thiamine and 
hydrocortisone as a potential therapy to accelerate recovery.68,70-74 An observational study 
in paediatric septic patients who received vitamin C, thiamine in addition to hydrocortisone 
showed improved short-term outcomes compared to hydrocortisone alone.70 Though, the 
benefit of this supplementation therapy was not confirmed by a RCT performed in adults.68 
Because there is currently no evidence for the optimal micronutrient doses accounting for 
paediatric critical illness,4 the recommendations provided in the guidelines for parenteral 
micronutrients are based upon dietary intake recommendations for healthy children and do 
not account for the phase of illness, potential increased demands or altered losses (Table 
3).4,57-59,75 
Some comments can be made for specific micronutrients:  
Sodium 
Critically ill children are at risk to develop hyponatremia. A meta-analysis showed that 




risk of developing hyponatraemia when compared with hypotonic intravenous fluids.76 The 
evidence suggest to use isotonic fluids for at least the first 24 hours of critical illness or 
post-operative care, while using the Holliday and Segar formula to calculate the amount of 
maintenance fluid required.77-79 In patients with excessive sodium losses sodium chloride 
solutions can be switched to sodium lactate or sodium acetate to decrease the chloride 
intake and thereby the risk of metabolic acidosis associated hyperchloraemia.79 
Iron  
Due to the risk of overload via PN iron is preferably provided enterally and in children 
receiving short-term PN (<3 weeks) iron supplementation is not recommended.40  
Calcium, phosphorus, magnesium, potassium and Vitamin B1 (Thiamine) 
Adequate threshold of calcium, phosphorus and magnesium are required for normal growth 
and bone mineralization. The risk of developing hypophosphatemia, hypomagnesemia, 
hypocalcaemia, and hypokalaemia is associated with the provision of nutrients. Especially 
high nutrient incline after a period of malnutrition placed critically ill children at risk of 
developing these depletions, commonly referred to as the refeeding syndrome. This 
syndrome is further characterised by hyperglycaemia and fluid retention causing oedema 
and can be managed by parenteral trace mineral supplementation and/or caloric feeding 
restriction.80 Vitamin B1 serve as a co-factor in the substrate oxidation and depletions are 
known to affect the neuro and cardiovascular system causing diseased as Beriberi, 
Wernicke’s and Korsakoff syndrome. During critical illness depletions in this micronutrient 
may occur after introduction of feeding after a period of malnutrition.81  
Zinc 
Zinc serves as a cofactor for over 300 body enzymes including DNA synthesis and RNA 
transcription and deficiency is characterised by impaired immune function, glucose 
homeostasis wound healing and growth retardation. Zinc supplementation during critical 
illness is the only element investigated in critical ill children with two RCTs. The first trial 
showed in 24 critically ill children that by providing 500 mcg/kg/d plasma levels could be 
restored to the near 50th percentile.82 While the second RCT providing whey protein, zinc, 
glutamine, selenium and metoclopramide versus whey protein in 298 critically ill children 
and found no differences on the immune status of these children. Additionally, this trial was 
terminated for futility before half the children were enrolled.83 
Selenium 
Selenium is an essential antioxidant and serves as a cofactor for glutathione peroxidase, an 
enzyme that is linked to resolving oxidative tissue damage. It is also involved in 
iodothyronine deiodinase and thioredoxin and thereby having a role in the thyroid 
metabolism which is affected in the acute phase of critical illness.84 Selenium deficiency has 
been associated with e.g. muscle weakness, immune disorders and carcinogenesis in adults, 




skin lesions, liver dysfunction and paralysis.85 The only RCT performed in critically ill children 
is the previously described RCT which included selenium as one of the added nutrients 
which showed no favourable outcomes of supplementation of selenium together with whey 
protein, zinc, glutamine and metoclopramide 83. Systematic reviews in preterm neonates and 
adults showed that supplementation of selenium resulted in decreased mortality and 
duration of ICU stay, however supplemented amounts and methods varied substitutional 
and no dose recommendations were extracted.65,86  
Vitamin B12, vitamin C and vitamin D 
The anti-inflammatory Vitamin B12 supports macronutrient metabolism and DNA synthesis 
in health and deficiencies may results in anaemia and neurodegenerative demyelination. The 
absorption of this vitamin can be affected by gastrointestinal surgery, feeding via post-pyloric 
tube and using proton pump inhibitors, all common in the PICU.87 Measured plasma levels 
are unreliable which hinders detecting deficiencies and clinical trials regarding optimal 
supplementation are non-existent. The isolated provision of Vitamin C has been investigated 
and high doses up to 66mg/kg/hour may lead to reduced duration of mechanical ventilation 
and vasopressor support in critically ill adults, without reporting adverse effects. However, 
no effect was seen of this antioxidant on mortality in a systematic review combining the 5 
RCTs.88 Vitamin D has been a topic of interest for many years in critical illness due to its 
important role in calcium and bone homeostasis, cardiovascular system and inflammation.89 
A recent systematic review including 52 studies in critically ill children found a deficiency 
prevalence of 55% which was indeed associated with mortality.90 Again, when the 6 available 
RCTs evaluating Vitamin D supplementation either enteral of parenteral in critically ill adults 
were combined in a systematic review, no benefit regarding recovery or mortality was 
found.  
Besides acknowledging the potential modulatory effect of micronutrients on the acute stress 
response, the risk of intoxication caused by over supplementing should not be dismissed. It 
is an uncommon reported phenomenon during critical illness, nonetheless, safe upper intake 
levels most be verified to find the balance between both deficiency and toxicity.91 The limited 
available paediatric research restrains the guidance for lower and upper levels in the 
different phases of illness, therefore it might be a practical solution to aim for future research 
on the micronutrients who require more routine measurements in instable patients. 
Currently, daily or weekly laboratory measurements are advised for electrolytes (sodium, 
potassium, chloride, calcium, phosphorus and magnesium), trace minerals (iron, selenium, 
zinc and copper) and vitamin B12.92  
Long-term consequences of Parenteral Nutrition  
Children requiring long-term PN 
Children requiring long-term PN are shorter and have an affected body composition and a 
higher fat mass compared to healthy subjects.93 Therefore, the success of PN support should 




mass and fat mass and accompanied with muscle mass function and functional status.94,95 
Furthermore. IFALD, cholestasis, metabolic syndrome and catheter-related bloodstream 
infections are commonly described long-term consequences of PN therapy in children 
requiring PN due to short bowel syndrome or low birth-weight infants.93,96-98 The 
pathogenesis is multifactorial, and association have been made with imbalances in amino 
acids composition, duration of PN and providing PN continuous (non‐cyclical).99  
In addition, the occurrence of cholestasis or IFALD is highly associated with intravenous 
lipid emulsions (ILEs) composition. Although there is no evidence suggesting an effect of 
different ILEs during short-term PN use on cholestasis or bilirubin levels, during long-term 
PN multicomponent ILEs (with fish oil) may contribute to a decrease in bilirubin levels and 
cholestasis.100 Furthermore, composite ILEs are found to be superior to pure soybean ILEs 
as they have less inflammatory properties, are immune modulating, have higher antioxidant 
content and prevent against cholestasis and IFALD,101,102 however no study have assessed 
the pro- and anti-inflammatory effects of these different ILEs in critically ill children. 
Therefore, for PN lasting longer than a few days, pure soybean ILEs should not be used and 
composite ILEs with or without fish oil are the first choice treatment.53 Provision of pure 
soybean oil ILEs can be considered in short-term PN with the knowledge that this may 
provide a less balanced nutrition than composite ILEs.Long-term neurocognitive 
development of children requiring long-term PN was investigated in 13 studies. The 
reported prevalence for normal neurocognitive development varied substantial and ranged 
between 29-100%, with 80-90% of the children in mainstream schools.97 There was no 
evidence favouring specific timing (cyclic or continuous) or other variables related to PN 
such as duration for its long-term consequences on neurocognitive development.  
Critically ill children 
Due to the advances in medical therapy and thereby increasing PICU survivorship, it 
becomes more and more important to consider long-term developmental outcomes of PN. 
Overall, studies investigating PICU survivors find lower scores for neurocognitive 
functioning as compared with a healthy population or normative scores. Additionally, health-
related quality of life, physical and mental health status can also be affected after PICU 
admission.103 Additional to the evaluation of body composition and commonly described PN 
complications, the effect of PN therapy on organ function and short-term and long-term 
consequences should be monitored when critically ill children are concerned.104  
Table 2. Advised parenteral glucose dose during acute, stable and recovery phase according to the 
ESGPHAN/ESPEN/ESPR/CSPEN guideline per age or weight class52 
  28d-10 kg 11-30 kg 31-45 kg >45 kg 
Acute phase  2-4 mg/kg/min  1.5-2.5 mg/kg/min  1-1.5 mg/kg/min  0.5-1 mg/kg/min  
Stable phase  4-6 mg/kg/min  2-4 mg/kg/min  1.5-3 mg/kg/min  1-2 mg/kg/min  





The PEPaNIC RCT was the first interventional study to investigate long-term developmental 
effects of a PN intervention. Two years after admission, PICU survivors had worse 
outcomes on anthropometrics, health status, and neurocognitive development as compared 
with matched healthy control children. Furthermore, the omission of PN during the acute 
phase of critical illness caused no harm and even resulted in better scores for visuomotor 
integration, and parent-reported executive functioning, in particular inhibitory control.105 
Due to the large number of young infants in this trial and the plasticity of the developing 
brain, a longer assessment period was warranted to investigate the effect on all long-term 
physical, neurocognitive, and psychosocial developmental domains. The four year post-
randomisation follow up study affirmed that omitting supplemental PN during the first week 
of critical illness caused no harm and even resulted in less parent-reported emotional and 
behavioural problems.103 These emotional and behavioural problems can arise from poor 
executive functioning, such as poor inhibitory control which was already affected at the two 
year post PICU time point.106,107 These clinical findings were supported by differences in 
telomere length and DNA methylation between children who received early-PN and late-
PN, which substantiates plausible molecular basis of detrimental long-term consequences of 
high and early provision of parenteral macronutrients.108,109 However, further research is 
needed to unravel the underlying mechanisms of the long-term harm caused by high and 
early parenteral nutrition.  
To be able to provide optimal parenteral nutrition beneficial for short-term and long-term 
outcomes, the timing, amount, composition and concomitant provision of enteral nutrition 
should be integrated into a comprehensive approach incorporating all these features. First, 
the optimal timing should be defined for the individual patient which is now based on the 
PEPaNIC RCT on day 7, followed by a steady stepwise incline towards energy and protein 
targets to avoid refeeding syndrome. 
C O N C L U S I O N S 
Enteral intake is often insufficient in critically ill children which might result in a need for 
parenteral nutrition. Understanding the course of metabolic needs during the acute stress 
response is essential before providing parenteral nutrition. Based upon the findings of the 
landmark PEPaNIC RCT, the current recommendations changed to withhold parenteral 
nutrition during the first week of admission while continue to provide micronutrients.2-5 
Although this parenteral macronutrient restriction during the acute phase has been found 
beneficial for critically ill children regarding physical and neurocognitive short-term and long-
term consequences, further research is required to obtain the optimal timing, dose and 
composition of parenteral nutrition during stable and recovery phase as well as the 
determination of the role of parenteral micronutrients. Furthermore, cyclic feeding or 





Table 3. Advised parenteral micronutrient dose according to the ESGPHAN/ESPEN/ESPR/CSPEN 
guideline per age class39-41,79 
Nutrient Term – 6 m 6 – 12 m > 12 m 
Sodium Day 1: 0-2 mmol/kg/d 
Day 2-4: 1-3 mmol/kg/d 
> d7: 2-3 mmol/kg/d 
2-3 mmol/kg/d 1-3 mmol/kg/d 
Potassium Day 1-3: 0-3 mmol/kg/d 
Dag 4-7: 2-3 mmol/kg/d 
> d7: 1.5-3 mmol/kg/d 
1-3 mmol/kg/d 1-3 mmol/kg/d 
Calcium 0.8-1.5 mmol/kg/d  0.5 mmol/kg/d 0.25-0.4 mmol/kg/d 
Magnesium 0.1-0.2 mmol/kg/d 0.15 mmol/kg/d 0.1 mmol/kg/d 
Phosphate 0.7-1.3 mmol/kg/d 0.5 mmol/kg/d 0.2-0.7 mmol/kg/d 
Chloride Day 1: 0-3 mmol/kg/d 
Day 2-4: 2-5 mmol/kg/d 
> d7: 2-3 mmol/kg/d 
2-4 mmol/kg/d 2-4 mmol/kg/d 
Iron Not recommended in 
short-term PN 
Not recommended in 
short-term PN 
Not recommended in 
short-term PN 
Zinc 250 µg/kg/d (term - 3 
months) 
100 µg/kg/d (3-6 
months) 
100 µg/kg/d  
(max 5mg/d) 
50 µg/kg/d  
(max 5mg/d) 
Copper 20 µg/kg/d  
(max 0.5 mg/d) 
20 µg/kg/d  
(max 0.5 mg/d) 
20 µg/kg/d  
(max 0.5 mg/d) 
Iodine At least 1 µg/kg/d At least 1 µg/kg/d At least 1 µg/kg/d 
Selenium 2-3 µg/kg/d 
(max 100 µg/kg/d) 
2-3 µg/kg/d 
(max 100µ/d) 
2-3 µg/kg/d  
(max 100µ/d) 
Manganese Max 1 µg/kg/d  Max 1 µg/kg/d  Max 1 µg/kg/d  
Molybdenum 0.25 µg/kg/d  
(max 5.0 µg/d) 
0.25 µg/kg/d  
(max 5.0 µg/d) 
0.25 µg/kg/d  
(max 5.0 µg/d) 
Chromium Not advised in PN Not advised in PN Not advised in PN 
Vitamin A 150-300 µg/kg/d  150-300 µg/kg/d 150 µg/d 
Vitamin D 400 IU/d 
(or 40-150 IU/kg/d) 
40-150 IU/kg/d 400-600 IU/d 
Vitamin E 2.8-3.5 IU/kg/d 2.8-3.5 IU/kg/d 11 IU/d 
Vitamin K 10 µg/kg/d 10 ug/kg/d 200 µg/d 
Vitamin C 15-25 mg/kg/d 15-25 mg/kg/d 80 mg/d  
Thiamine 0.35-0.5 mg/kg/d 0.35-0.5 mg/kg/d 1.2 mg/d  
Riboflavin 0.15-0.2 mg/kg/d 0.15-0.2 mg/kg/d 1.4 mg/d 
Pyridoxine 0.15-0.2 mg/kg/d 0.15-0.2 mg/kg/d 1.0 mg/d 
Niacin 4-6.8 mg/kg/d 4-6.8 mg/kg/d 17 mg/d 
Vitamin B12 0.3 µg/kg/d 0.3 µg/kg/d 1 µg/d 
Pantothenic 
acid 
2.5 mg/kg/d 2.5 mg/kg/d 5 mg/d 
Biotin 5-8 µg/kg/d 5-8 µg/kg/d 20 µg/d 
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A B S T R A C T  
Background & aims: Following the results of the paediatric early versus late parenteral 
nutrition in critical illness (PEPaNIC) multicentre, randomised, controlled trial (RCT), the 
new ESPGHAN/ESPEN/ESPR/CSPEN and ESPNIC guidelines recommend to consider 
withholding parenteral macronutrients for 1 week, while providing micronutrients, in 
critically ill children if enteral nutrition is insufficient. Critically ill children are suspected to 
be vulnerable to micronutrient deficiencies due to inadequate enteral nutrition, increased 
body’s demands and excessive losses. Hitherto, micronutrient requirements in PICU are 
estimated based on recommended daily intakes for healthy children and expert opinion. We 
aimed to provide an overview of the current practice of micronutrient administration and 
practical considerations in the three participating centres of the PEPaNIC study, and 
compare these therapies with the recommendations in the new 
ESPGHAN/ESPEN/ESPR/CSPEN guidelines. 
 
Methods: We describe the current composition and preparation of the prescribed 
parenteral micronutrients (consisting of vitamins, trace elements and electrolytes) in the 
three centres (Leuven, Rotterdam and Edmonton) that participated in the PEPaNIC RCT, 
and compare this per micronutrient with the ESPGHAN/ESPEN/ESPR/CSPEN guidelines 
recommendations. 
 
Results: The three centres use a different micronutrient supplementation protocol during 
the first week of critical illness in children, with substantial differences regarding the amounts 
administered. Leuven administers commercial vitamins, trace elements and electrolytes in 
separate infusions both in 4 hours. Rotterdam provides commercial vitamins and trace 
elements simultaneously via 8-hour infusion and electrolytes continuously over 24 hours. 
Lastly, Edmonton administers commercial vitamins and institutionally prepared trace 
elements solutions in 1 hour and electrolytes on demand. Comparison with the 
ESPGHAN/ESPEN/ESPR/CSPEN guidelines yields in differences between the 
recommendations and the administered amounts, which are most substantial for vitamins.  
 
Conclusion: The practice of intravenous micronutrient administration differed 
substantially between the three PEPaNIC centres and in comparison with the current 
guideline recommendations. This deviation is at least partially explained by the inability to 
provide all recommended amounts with the currently available commercial products and by 





I N T R O D U C T I O N  
Micronutrients play an important role in metabolism, immune response and maintenance of 
tissue function.1,2 Critically ill patients are suspected to be vulnerable to micronutrient 
deficiencies due to inadequate enteral nutrition, increased body’s demands and excessive 
losses.3 The relevance of micronutrient deficiencies in critically ill children remains unclear, 
although reported prevalence’s are high and associations with adverse outcome were 
found.4-6 It seems justifiable to provide micronutrients, i.e. vitamins, trace elements and 
electrolytes, early and adequately during critical illness. However, due to a lack of evidence, 
current recommendations are based upon expert opinion and dietary reference nutrient 
intake for healthy children. 
 
The provision of parenteral macronutrients during critical illness have been investigated in 
the landmark Paediatric Early versus Late Parenteral Nutrition in Intensive Care Unit 
(PEPaNIC) Randomised Controlled Trial (RCT). In this RCT, critically ill children (term 
neonates – 17 years) were randomly assigned to withholding macronutrient provision via 
parenteral nutrition (PN) during the first week (Late-PN) or to initiation of PN within 24 
hours (Early-PN) to reach caloric goals when enteral nutrition (EN) was insufficient.7,8 The 
major finding was that the later start of parenteral nutrition (i.e. the intervention arm), 
resulted in a better clinical outcome.8,9 However, parenteral micronutrients, including 
vitamins, trace elements and electrolytes, during this first week of critical illness were 
provided in both randomization groups within 24 hours when EN was insufficient, so that 
between group differences in outcome would be solely attributable to differences in 
macronutrient intake.  
 
The findings of the PEPaNIC RCT had a subsequent impact on the recently published 
ESPGHAN/ESPEN/ESPR/CSPEN and ESPNIC guidelines on parenteral nutrition in critically 
ill children, which now recommend to consider withholding parenteral macronutrients, 
meaning withholding amino acids and lipids provision, and substantial lower carbohydrate 
intake,  during the first week of paediatric critical illness while continuing micronutrient 
provision.10,11 In addition, the recent guidelines adapted part of the micronutrient 
recommendations compared to the previous guidelines which were valid during the 
PEPaNIC RCT. After publication of the recent guidelines and the PEPaNIC RCT, many 
practical difficulties on how to supplement parenteral micronutrients without 
simultaneously providing macronutrients persisted. Therefore, the primary aim of this study 
was to report the current protocols on composition and preparation of the prescribed 
parenteral micronutrients in the three centres that participated in the PEPaNIC RCT. 
Secondly, we performed a comparison between the three local parenteral micronutrient 
protocols and the recommendations according to the new ESPGHAN/ESPEN/ESPR/CSPEN 





M E T H O D S  
Protocols for nutrition in critically ill children were obtained from the three centres. One 
researcher (RDE) compared micronutrient doses and the technical organisation of their 
administration between centres and compared these with existing recommendations. For 
this study micronutrients were defined as both electrolytes as well as vitamins and trace 
elements. Parenteral macronutrient supplementation is currently withheld during the first 
week of critical illness in the three participating PICU sites, while providing parenteral 
micronutrients via standard protocols (University Hospitals Leuven, Leuven, Belgium – 
Erasmus MC-Sophia Children’s Hospital, Rotterdam, the Netherlands – Stollery Children’s 
Hospital, Edmonton, Canada). Each centre individually developed a micronutrient protocol 
to accommodate the micronutrient supplementation. In the present study, we first report 
the three protocols for the composition and preparation of the different micronutrient 
prescriptions, consisting of vitamins, trace elements and electrolytes, as they are currently 
used per research centre during the first PICU-week if EN is less than 80% of target intake. 
If the enteral intake exceeds 80% of target intake intravenous micronutrient 
supplementation is stopped in all three centres. Secondly, these protocols are compared 
with the new ESPGHAN/ESPEN/ESPR/CSPEN guidelines.10 
 
R E S U L T S  
Leuven 
The protocol aims at approaching the ESPGHAN/ESPEN/ESPR/CSPEN recommended 
intake through pragmatic administration of commercially available micronutrient 
preparations.10 Vitamins and trace elements are given daily in separate infusions and shielded 
from daylight. Vitamins are administered over a 4 hour period and diluted in a glucose 
infusion (Dextrose 5% or 10%), followed by trace elements which are administered via a 
similar 4 hour infusion. Different doses are used for term infants up to 10 kg, for children 
>10 kg and <30kg and for children >30kg. Vitamin K is administered weekly. The 
composition of the two infusions is described in Table 1 for the different weight categories.  
Electrolytes are administered via a nurse driven protocol to prevent and/or supplement 
depletion (e.g. potassium chloride and potassium phosphate). The maintenance fluids 
provide NaCl 0.9% at roughly 2ml/kg/h (~ 7.2 mmol/kg/day) (Appendix). Potassium 
phosphate (10 – 40 mg/kg/d ~0.32 mmol/kg/d) is administered distributed over a maximum 
of three 4-hours administrations per day to avoid simultaneous infusion and potential 
reaction with copper. Nurses titrate potassium to a target of 3.5 to 4.5 mmol/L, using 
infusions of 1mmol/kg over 1 hour. Magnesium sulphate (60 mg/kg/d ~ 0.24 mmol/kg/d) is 
divided over a maximum of three administrations daily as well and adjusted so that 





The provision of micronutrients is based upon the new ESPGHAN/ESPEN/ESPR/CSPEN 
recommendations.10 Micronutrients are administered daily via two infusions shielded from 
direct daylight. The first mixture contains trace elements and vitamins and is administered 
over an 8-hour infusion period. For this infusion, three commercially available products 
containing different vitamins and trace elements are mixed in a sodium chloride 0.9% bag 
and prescribed according to two different weight categories (term neonate – 12 kg and >12 
kg ) (Table 2). These commercial available products were tested stable during 24 hours at 
20-25°C both single and in combination when diluted in sodium chloride 0.9% by their 
pharmaceutical company. The second mixture contains glucose and electrolytes (sodium, 
potassium, calcium, magnesium and phosphate) and is administered continuously over 24 
hours/day. The electrolyte mixture differs according to two different weight categories (< 
5 kg and > 5kg). For preparing the electrolyte solution standard commercially available 
glucose and sodium chloride bags are used (glucose 5% - NaCl 0.45% < 5 kg or glucose 2.5% 
/ NaCl 0.45% >5 kg) (Appendix).  
 
Edmonton 
The provision of micronutrients is based upon the current American Society for Parenteral 
and Enteral Nutrition (ASPEN) guidelines recommendations.12-15 Vitamins and trace 
elements are prescribed in two different doses for infants up to 12 months and for children 
>12 months. Vitamins are provided via commercially available products and trace elements 
are prepared in the local hospital pharmacy (Table 3). The institutionally prepared trace 
element solution contains zinc, selenium, copper and iodine and is administered daily in a 
period of 30-60 minutes. The preparation and stability of the trace element solutions have 
been reported previously.16 Chromium and manganese are not provided in the solution, as 
they both exist as contaminants in other parenteral nutrition elements including 
electrolytes, and thereby meeting the amounts that are required. The trace element 
solutions were found physio-chemically stable up to 7 days when the needs for appropriate 
storage conditions were met.16 
The amount of maintenance fluid NaCl 0.9% is provided according to Holliday et al.17 and 
adjusted to diagnosis and clinical status (Apendix). The following amount of electrolytes are 
recommended for infants and children <50 kg: potassium 2-4 mmol/kg, magnesium 0.15-
0.25 mmol/kg, phosphorus 0.5-2 mmol/kg and calcium 0.25-2 mmol/kg. Electrolytes 
administered are prescribed on demand based on the patient’s condition and titrated based 
on laboratory values. The administration of calcium is limited by solubility and phosphate 
precipitation. Potassium chloride is added as 20 - 40 mmol/100ml to the maintenance fluid, 
or when severely depleted an extra potassium chloride 1 mmol/ml infusion is provided 
starting at 0.1mmol/kg/hr. In addition, in post-cardiac surgery patients magnesium sulphate 
is supplemented with a bolus of 0.10-0.20 mmol/kg per dose every 12 hours to aim for 




Comparison with ESPGHAN/ESPEN/ESPR/CSPEN guidelines 
Comparison between prescribed micronutrient doses and the current 
ESPGHAN/ESPEN/ESPR/CSPEN guidelines are provided in Tables 4-5.10 
Leuven 
For vitamins, the provision is defined as one fixed volume (1 or 2 ml per day) for each weight 
group (<10 kg and >10 kg). The ESPGHAN/ESPEN/ESPR/CSPEN recommendations, 
however, are defined in doses per kilograms per day in the children up to 12 months. 
Therefore, the prescribed amount – as compared to recommendations - could be low, high 
or adequate in range depending on the actual weight of the child. A relatively high provision 
of sodium, chloride, phosphate and magnesium was found in all age groups. Overall, the 
prescription of vitamins is considered to be below the recommended doses in younger 
children (<10 kg). In the older children (>10 kg) vitamin supplementation is in the range of 
the guidelines. However, vitamin A is provided above and vitamin D below 
recommendations. Trace elements zinc and copper are relatively low in young infants, while 
in older children zinc and molybdenum are provided above recommendations and the 
provision of copper is relatively low. Iron and chromium are provided in all children, which 




When comparing the current practice in Rotterdam to the ESPGHAN/ESPEN/ESPR/CSPEN 
guidelines, a relatively high provision of sodium and chloride is found in all age groups. The 
highest deviation is found for sodium, providing an amount of 11.1 mmol/kg/d in neonates. 
ESPGHAN/ESPEN/ESPR/CSPEN guidelines recommend sodium amounts provided via PN of 
1-3 mmol/kg/d in older non-critically ill children and 3-5 mmol/kg/d in neonates.18 In addition, 
the provision of water-soluble vitamins is above recommend doses in most age groups. In 
neonates, trace elements were in line with the guidelines, whereas in the older children 
provision of copper is relatively low. In the older children (>12 kg) the trace element 
mixture contained iron and chromium which is not recommended in short-term PN. 
Edmonton 
The micronutrient doses administered in Edmonton are based upon the ASPEN guidelines 
and literature.12-15 Nevertheless, when comparing the amounts provided with the new 
ESPGHAN/ESPEN/ESPR/CSPEN guidelines, most trace elements and vitamins are within the 
recommended range for children above 12 months. In the younger children the provision 
of most vitamins is difficult to compare due to the provision in different weight classes in 
doses/day and recommendations provided in doses/kg/day. In general, the provision of 
vitamin K is high and the provision of most water-soluble vitamins can be considered low. 
In compliance with the ESPGHAN/ESPEN/ESPR/CSPEN guidelines, iron and chromium are 




Table 1. Current micronutrient provision in critically ill children in Leuven, Belgium 
Weight class Electrolyte Infusion Vitamin infusion Trace element infusion 
< 10 kg Glucose 5% -NaCl 
0.9% (ratio: 60/40) 50 
ml/m2/hour 
(~2ml/kg/h) 
Cernevit® 1 ml/d 
Vitamine K 2 mg (1-2 
times per week) 
Addaven® 0.25 ml/kg (max 
10 ml/d) 
> 10 kg Glucose 5% -NaCl 
0.9% (ratio: 60/40) 50 
ml/m2/hour 
(~2ml/kg/h) 
Cernevit® 2.5 ml/d 
Vitamine K 5 mg (1-2 
times per week) 
Addaven® 0.25 ml/kg (max 
10 ml/d) 
> 30 kg Glucose 5% -NaCl 
0.9% (ratio: 60/40) 50 
ml/m2/hour 
(~2ml/kg/h) 
Cernevit® 5 ml/d 
Vitamine K 10 mg (1-
2 times per week) 
Addaven® 0.25 ml/kg (max 
10 ml/d) 






Table 2. Current micronutrient provision in critically ill children in Rotterdam, the Netherlands 
Weight class Electrolyte Infusion Vitamin and trace element 
infusion 
<  5 kg Glucose 5% - NaCl 0,45% 113 ml,  
KCl 15% (2 mmol/ml) 0,8 ml, Ca-
gluconate 10% (0,23 mmol/ml) 4 ml, 
Mg-sulphate 10% (0,4 mmol/ml) 0,50 
ml, Glycophos (1 mmol P/ml, 2 mmol 
Na/ml) 1,2 ml 
120 ml/kg/d as continuous infusion 
Soluvit® 1,5 ml/kg,  
Vitintra Infant® 2,5 ml/kg (max 10ml),  
Peditrace® 1 ml/kg,  




5 – 12 kg Glucose 2,5% - NaCl 0,45% 69 ml,  
KCl 15% (2 mmol/ml) 0,6 ml, Ca-
gluconate 10% (0,23 mmol/ml) 1,5 ml, 
Mg-sulphate 10% (0,4 mmol/ml) 0,25 
ml, Glycophos (1 mmol P/ml, 2 mmol 
Na/ml) 0,5 ml  
72 ml/kg/d as continuous infusion 
Soluvit® 1,5 ml/kg (max 8ml),  
Vitintra Infant® 10ml,  
Peditrace® 1 ml/kg (max 10ml),  
NaCl 0.9% 37 ml 
 
 
12 – 30 kg Glucose 2,5% - NaCl 0,45% 69 ml,  
KCl 15% (2 mmol/ml) 0,6 ml, Ca-
gluconate 10% (0,23 mmol/ml) 1,5 ml, 
Mg-sulphate 10% (0,4 mmol/ml) 0,25 
ml, Glycophos (1 mmol P/ml, 2 mmol 
Na/ml) 0,5 ml  
72 ml/kg/d as continuous infusion 
Soluvit® 8 ml,  
Vitintra Infant® 10 ml,  
Supliven® 0,25 ml/kg (max 10 ml),  




> 30 kg Glucose 2,5% - NaCl 0,45% 69 ml,  
KCl 15% (2 mmol/ml) 0,6 ml, Ca-
gluconate 10% (0,23 mmol/ml) 1,5 ml, 
Mg-sulphate 10% (0,4 mmol/ml) 0,25 
ml, Glycophos (1 mmol P/ml, 2 mmol 
Na/ml) 0,5 ml  
48 ml/kg/d as continuous infusion 
(max 2L/d) 
Soluvit® 8 ml,  
Vitintra Infant® 10 ml,  
Supliven® 0,25 ml/kg (max 10 ml),  










Table 3. Current micronutrient provision in critically ill children in Edmonton, Canada 
Age Electrolyte Infusion Vitamin infusion Trace element infusion 
< 12 months Glucose 5% -NaCl 
0.9%  
Rate according to 
Holliday et al.17 
MULTI-12/K1® 
2ml/kg/d (max 5ml/d) 
Zinc sulfate; 500 µg/ml, 
copper sulfate; 40 µg/ml, 
selenious acid; 4 µg/ml, 
sodium iodide; 2 µg/ml in 
sterile water 
0.5 ml/kg/d (max 10ml/d) 
> 12 months Glucose 5% -NaCl 
0.9%  
Rate according to 
Holliday et al.17 
MULTI-12/K1® 
5ml/d 
Zinc sulfate; 500 µg/ml, 
copper sulfate; 40 µg/ml, 
selenious acid; 4 µg/ml, 
sodium iodide; 2 µg/ml in 
sterile water 
0.25 ml/kg/d (max 10ml/d) 






Table 4. Comparison of the standard provision of micronutrients in infants < 5 kg and infants between 5-10 kg of the three PEPaNIC RCT centres 
and the ESPGHAN guidelines. 
 <  5 kg Infants 5-10 kg* 
Nutrient Leuven Rotterdam Edmonton ESPGHAN 
guidelines 



































2-4 mmol/kg 1-3 mmol/kg/d 


































































- - Not advised in 
short-term PN 
Zinc 126 µg/kg/d 250 µg/kg/d 250 µg/kg/d 250 µg/kg/d 
(term neonate 
until 3 months) 







Copper 9.5 µg/kg/d 20 µg/kg/d 20 µg/kg/d 20 µg/kg/d  9.5 µg/kg/d 20 µg/kg/d 20 µg/kg/d 20 µg/kg/d (max 
0.5 mg/d) 
Iodine 3.3 µg/kg/d 1.0 µg/kg/d 1.0 µg/kg/d At least 1 
µg/kg/d 
3.3 µg/kg/d 1.0 µg/kg/d 1.0 µg/kg/d At least 1 
µg/kg/d 
Selenium 2.0 µg/kg/d 2.0 µg/kg/d 2.0 µg/kg/d 2-3 µg/kg/d (max 
100 µg/kg/d) 
2.0 µg/kg/d 2.0 µg/kg/d 2.0 µg/kg/d 2-3 µg/kg/d 
(max 100µ/d) 




- 0.25 µg/kg/d 




- 0.25 µg/kg/d 
(max 5.0 µg/d) 
Chromium 0.25 
µg/kg/d - 









57 µg/kg/d -  23.8 
µg/kg/d 
57 µg/kg/d -  
Vitamin A 700 µg/d  173 µg/kg/d 690 µg/d  150-300 µg/kg/d  
 
700 µg/d 690 µg/d 690 µg/d  150-300 µg/kg/d 
Vitamin D 44 IU/d 100 IU/kg/d 400 IU/d 400 IU/d (or 40-
150 IU/kg/d) 
44 IU/d 400 IU/d 400 IU/d 40-150 IU/kg/d 
Vitamin E 2.24 IU/d 1.8 IU/kg/d 7 IU/d 2.8-3.5 IU/kg/d 2.24 IU/d 7.0 IU/d 7 IU/d 2.8-3.5 IU/kg/d 
Vitamin K 2000 - 4000 
µg/week 
50 µg/kg/d 200 µg/d 10 µg/kg/d 2000 - 4000 
µg/wk 
200 µg/d 200 µg/d 10 µg/kg/d 
Vitamin C 25 mg/d 
 








0.7 mg/d 0.38 mg/kg/d 1.2 mg/d 
0.35-0.5 mg/kg/d 




0.83 mg/d 0.54 mg/kg/d 1.4 mg/d 
0.15-0.2 mg/kg/d 




0.91 mg/d 0.60 mg/kg/d 1 mg/d 
0.15-0.2 mg/kg/d 
0.91 mg/d 0.60 mg/kg/d 1 mg/d 
0.15-0.2 mg/kg/d 
Niacin 9.2 mg/d 6.0 mg/kg/d 17 mg/d 4-6.8 mg/kg/d 9.2 mg/d 6.0 mg/kg/d 17 mg/d 4-6.8 mg/kg/d 






3.5 mg/d 2.25 mg/kg/d 5 mg/d 
2.5 mg/kg/d 
3.5 mg/d 2.25 mg/kg/d 5 mg/d 
2.5 mg/kg/d 
Biotin 23 µg/d 9.0 µg/kg/d 20 µg/d 5-8 µg/kg/d 23 µg/d 9.0 µg/kg/d 20 µg/d 5-8 µg/kg/d 
Folic acid 82.8 µg/d 60 µg/kg/d 80 µg/d 56 µg/kg/d 82.8 µg/d 60 µg/kg/d 80 µg/d 56 µg/kg/d 




Table 5. Comparison of the standard provision of micronutrients in children between 10-30 kg and children > 30 kg of the three PEPaNIC RCT 
centres and the ESPGHAN guidelines. 
 Children 10* – 30 kg Children > 30 kg 
Nutrient Leuven Rotterdam Edmonton ESPGHAN 
guidelines 




6.3 mmol/kg/d 11.5-15.4 
mmol/kg/d 









1.2 mmol/kg/d 2-4 
mmol/kg/d 





















0.1 mmol/kg/d 0.15-0.25 
mmol/kg/d 























7.0 mmol/kg/d 13.5-17.4 
mmol/kg/d 















Zinc 126 µg/kg/d 126 µg/kg/d 125 µg/kg/d 50 µg/kg/d 
(max 5mg/d) 
126 µg/kg/d 126 µg/kg/d 125 µg/kg/d 50 µg/kg/d 
(max 5mg/d) 
Copper 9.5 µg/kg/d 9.5 µg/kg/d 10 µg/kg/d 20 µg/kg/d 
(max0.5 mg/d) 
9.5 µg/kg/d 9.5 µg/kg/d 10 µg/kg/d 20 µg/kg/d 
(max 0.5 mg/d) 
Iodine 3.2 µg/kg/d 3.2 µg/kg/d 0.5 µg/kg/d At least 1 
µg/kg/d 
3.2 µg/kg/d 3.2 µg/kg/d 0.5 µg/kg/d At least 1 
µg/kg/d 
Selenium 2.0 µg/kg/d  2.0 µg/kg/d  1 µg/kg/d 2-3 µg/kg/d 
(max 100µ/d) 
2.0 µg/kg/d  2.0 µg/kg/d  1 µg/kg/d 2-3 µg/kg/d 
(max 100µ/d) 
Manganese 1.4 µg/kg/d 1.4 µg/kg/d - Max 1 µg/kg/d  1.4 µg/kg/d 1.4 µg/kg/d - Max 1 µg/kg/d  
Molybdenum 0.48 µg/kg/d  0.48 µg/kg/d  - 0.25 µg/kg/d 
(max 5.0 µg/d) 
0.48 µg/kg/d  0.48 µg/kg/d  - 0.25 µg/kg/d 
(max 5.0 µg/d) 
Chromium 0.25 µg/kg/d 0.25 µg/kg/d  Not advised in 
PN 





Fluor 23.8 µgl/kg/d 23.8 µg/kg/d -  23.8 µg/kg/d 23.8 µgl/kg/d -  
Vitamin A 1750 µg/d 690 µg/d 690 µg/d 150 µg/d 420 µg/d 3500 µg/d 690 µg/d 150 µg/d 
Vitamin D 110 IU/d 400 IU/d 400 UI/d 400-600 IU/d 80 IU/d 220 IU/d 400 UI/d 400-600 IU/d 
Vitamin E 5.6 IU/d 7.0 IU/d 7 UI/d 11 IU/d 4.48 IU/d 11.2 IU/d 7 UI/d 11 IU/d 
Vitamin K 5000-10.000 
µg/week 
200 µg/d 200 µg/d 200 µg/d 5000-10.000 
µg/week 
200 µg/d 200 µg/d 200 µg/d 
Vitamin C 62.5 mg/d 80 mg/d 80 mg/d 80 mg/d  50 mg/d 125 mg/d 80 mg/d 80 mg/d  
Thiamine B1 1.75 mg/d 2.0 mg/d 1.2 mg/d 1.2 mg/d  1.40 mg/d 3.51 mg/d 1.2 mg/d 1.2 mg/d  
Riboflavin B2 2.07 mg/d 2.9 mg/d 1.4 mg/d 1.4 mg/d 1.66 mg/d 4.14 mg/d 1.4 mg/d 1.4 mg/d 
Pyridoxine B6 2.265 mg/d 3.2 mg/d 1 mg/d 1.0 mg/d 1.81 mg/d 4.53 mg/d 1 mg/d 1.0 mg/d 
Niacin 23 mg/d 32 mg/d 17 mg/d 17 mg/d 18.4 mg/d 46 mg/d 17 mg/d 17 mg/d 
Vitamin B12 3 µg/d 4.0 µg/d 1 µg/d 1 µg/d 2.2 µg/d 6.0 µg/d 1 µg/d 1 µg/d 
Pantothenic 
acid 
8.625 mg/d 12 mg/d 5 mg/d 
5 mg/d 
6.9 mg/d 17.25 mg/d 5 mg/d 
5 mg/d 
Biotin 34.5 µg/d 48 µg/d 20 µg/d 20 µg/d 24 µg/d 69 µg/d 20 µg/d 20 µg/d 
Folic acid 207 µg/d 320 µg/d 80 µg/d 140 µg/d 165 µg/d 414 µg/d 80 µg/d 140 µg/d 




D I S C U S S I O N 
The micronutrient protocols in the three PEPaNIC centres varied widely, mostly due to 
practical considerations. As such, there are substantial differences in the administered 
vitamins, trace elements and electrolytes between the participating centres. The most 
prominent differences are: 1) different age or weight cut-off values determined by 
recommended age and weight limits of their used products; 2) Rotterdam is the only centre 
which included electrolytes within their micronutrient protocols as continuous infusion over 
24 hours, whereas the Leuven and Edmonton protocol for continuous electrolyte 
administration is adaptive and nurse driven and avoids simultaneous infusion of trace-
elements and phosphate; 3) vitamins and trace elements are administered either separately 
or simultaneously via 1-8 hours daily bolus; and 4) Edmonton is the only centre to 
institutionally prepare the trace elements mixtures, whereas in the other two centres 
commercially available products are administered. Nonetheless, these three protocols 
provide practical information, which can be valuable for PICUs worldwide.  
Comparison between the prescribed and ESPGHAN/ESPEN/ESPR/CSPEN guideline 
recommended amounts yielded substantial differences for electrolytes, vitamins and trace 
elements, which was most frequently observed for vitamins.8,10,11,18-25 Avoiding depletion of 
micronutrients seems essential during critical illness, as deficiencies have been associated 
with decreased organ dysfunction, muscle weakness, poor wound healing and altered 
immune status.1,3 Unfortunately, there is a paucity of evidence in critically ill children 
regarding the clinical consequences of insufficient micronutrient provision, low serum levels 
or true depletion of body stores. Moreover, the redistribution of micronutrients during 
critical illness and the interaction with oxidative stress preclude reliable identification of true 
deficiencies.11,26,27 Only two studies investigated the impact of zinc and selenium 
supplementation in critically ill children, unfortunately, the generated data was insufficient 
to provide recommendations on dose and timing of supplementation.26,28 For macronutrient 
prescription, the ESPGHAN/ESPEN/ESPR/CSPEN guidelines take the different phases of 
critical illness into consideration, but for micronutrients these phases are not taken into 
account. Currently, there are no specific recommendations for parenteral micronutrient 
provision in critically ill children and as such, the ESPGHAN/ESPEN/ESPR/CSPEN 
recommendations for amount and timing of parenteral micronutrient requirements are 
based on recommended daily intakes for healthy children and observational studies, limiting 
their value, particularly for PICU.  
When developing a protocol for parenteral micronutrient and electrolyte administration, 
several important aspects have to be addressed. First, one should consider the timing of the 
prescription (bolus vs. continuous / day vs. night / combined vs. separated / daily vs. non-
daily). Parenteral vitamins are usually administered as a mixture containing multiple vitamins, 




mixtures are administered at night and shielded from daylight or delivered within a short 
timeframe in the PEPaNIC centres. It is important to consider that bolus injection may 
increase urinary losses of water-soluble vitamins. In Edmonton and Leuven, the provision is 
separated for vitamins and trace element mixtures, whereas in Rotterdam these mixtures 
are provided simultaneously for practical reasons. It is important to consider that 
simultaneous provision can create a possible risk – among others - of vitamin C breakdown 
by copper,29 although the clinical importance of such effect has never been established. On 
the other hand, addition of selenium to a mixture can attenuate spontaneous vitamin C 
breakdown.30 All such interactions are obviously dependent on the volume of dilution and 
are under-investigated. Vitamin K in Leuven is the only micronutrient not given daily. The 
ESPGHAN/ESPEN/ESPR/CSPEN guidelines recommend against non-daily provision of 
vitamins as transiently high levels may provoke adverse effect. This is however not the case 
for vitamin K.21 For trace elements, the ESPGHAN/ESPEN/ESPR/CSPEN guidelines provide 
no strong recommendation whether these elements should be given daily or intermittently. 
Nonetheless, most dose recommendations are provided per day. The value of monitoring 
remains debated, since serum levels don’t reflect body stores.20 The 
ESPGHAN/ESPEN/ESPR/CSPEN strongly recommend against early administration of iron, 
which is reserved for long-term PN dependency (>3 weeks), due to the risk of iron overload 
when bypassing the homeostatic control of gastrointestinal iron absorption. In addition, iron 
is a pro oxidative agent. Because of the used commercial products, Leuven and Rotterdam 
deviate from the guideline, as iron is supplemented from day two onwards in all children in 
Leuven and in older children in Rotterdam. Moreover, iron overload is primarily reported 
in children receiving prolonged PN 
 
Second, the choice between provision of institutionally prepared mixtures and one of the 
available commercial preparations will determine the doses of vitamin and trace elements 
administered. Moreover, by elimination of lipid emulsion, the pharmaceutical companies are 
restricted by the solubility and stability of the vitamins in non-lipid emulsions. In the three 
PEPaNIC centres three different commercially available vitamin preparations are used, none 
of them fulfilling all guideline recommended requirements. Given the scarce data these 
guidelines are based on, it is difficult to judge the importance of such deviations.21 
 
Concerning the prescription of trace elements, commercially available mixtures are used in 
Rotterdam and in Leuven and institutionally prepared mixtures in Edmonton.16 The 
advantage of commercially available mixtures is the lower risk for microbial contamination 
and compounding errors prior to administration.31-33 Furthermore, the adequate 
infrastructure to secure and check the quality makes locally prepared products very costly.34 
This is why most institutions prefer standard solutions to institutional solutions. 
Unfortunately, the currently available commercial products are insufficient to fully comply 
with the guideline recommendations for each trace element. Nonetheless, the 




solutions when the nutritional requirements cannot be met by the available range of 
standard solutions, for example for critically ill children or metabolically unstable patients 
such as those with abnormal fluid and electrolyte losses.35 This is not in correspondence 
with the ASPEN guidelines, that state that the recommended intakes of trace elements can 
only be achieved using individualised trace element products.36 Hence, before prescribing 
commercial trace elements, one has to determine if the micronutrient mixtures are 
acceptable for the majority of their admitted patient population.35,37 
 
Regarding the administration of electrolytes, Rotterdam is the only centre that prescribes 
standard continuous electrolyte infusions, in contrast with Edmonton where electrolytes 
are prescribed on demand and Leuven, where intermittent electrolyte infusions were given 
in a nurse driven approach preventing or correcting deficiencies. In Rotterdam, electrolyte 
infusions are diluted in commercially available glucose and sodium chloride solutions and 
are, mainly to equally administer glucose over the day, administered continuously over 24 
hours. This practice results in higher sodium intake than the advised amounts via parenteral 
nutrition. Critical illness is characterised by a shift in metabolic pathways responsible for 
electrolyte and fluid balance. Because of several common critical illness related factors, such 
as impaired free water excretion, frequent administration of hypotonic fluids, and multiple 
morbidity and drug-related conditions, critically ill children are more susceptible to develop 
hyponatremia during PICU admission compared to non-critically ill children with PN 
dependency.38,39 Therefore, in clinical practice, the ESPGHAN/ESPEN/ESPR/CSPEN 
recommended amounts targeted for non-critically ill children are often not sufficient to 
prevent hyponatremia during the acute phase of critical illness and higher amounts can be 
tolerated.40  
C O N C L U S I O N S 
In conclusion, practices of parenteral micronutrient administration varied substantially 
between the PEPaNIC research centres, and deviated from the current guideline 
recommendations, most prominent for vitamin administration. Lack of hard clinical 
supportive evidence and the inability to administer all recommended amounts with the 
currently available commercial products hampers implementation of these new 
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A P P E N D I X  
Methods S1: Composition of the commercial supplements used in the PEPaNIC centres 
Addaven®  or Supliven®   
Vial (10ml) 
Chromic chloride hexahydrate  53.33 μg 
Cupric chloride dihydrate  1.02 mg 
Ferric chloride hexahydrate  5.40 mg 
Manganese chloride tetrahydrate  198 μg 
Potassium iodide  166 μg 
Sodium fluoride  2.10 mg 
Sodium molybdate dihydrate  48.5 μg 
Sodium selenite  173 μg 
Zinc chloride  10.5 mg 
  
Cernevit-12®   
Vial (5ml) 
Retinol palmitate corresponding to Retinol 
(Vitamin A)  
3500 IU 
 
Cholecalciferol (Vitamin D3)  200 IU 
DL a-tocopherol corresponding to  
    a-tocopherol (Vitamin E)  
10.2 mg 
11.2 IU 
Ascorbic Acid (Vitamin C)  125 mg 
Nicotinamide (Vitamin B3)  46 mg 
Dexpanthenol corresponding to      
    pantothenic acid (Vitamin B5)  
16.15 mg 
17.25 mg 
Pyridoxine hydrochloride corresponding to   
    pyridoxine (Vitamin B6)  
5.5 mg 
4.53 mg 
Riboflavin sodium phosphate corresponding 
to riboflavin (Vitamin B2)  
5.67 mg 
4.14 mg 
Cocarboxylase tetrahydrate   
    corresponding to thiamine (Vitamin B1)  
5.8 mg 
3.51 mg 
Folic Acid  414 µg 
D-Biotin  60 µg 
Cyanocobalamin (Vitamin B12)  5.5 µg 
Also contains: Glycine 250 mg,  Glycocholic acid 140 mg, Soybean lecithin 112.5 mg 
 
MULTI-12/K1®  
Vial 1 (4ml) 
Ascorbic acid  80 mg  
Vitamin A  2300 IU  
Vitamin D  400 IU  
Thiamine (as hydrochloride)  1.2 mg  
Riboflavin (as phosphate)  1.4 mg  
Pyridoxine hydrochloride  1 mg  
Niacinamide  17 mg  
d-Panthenol  5 mg  




Vitamin K1  0.2 mg  
Also contains: polysorbate 80, 1.4%, sodium hydroxide to adjust pH and water for injection.  
Vial 2  (1ml) 
Biotin  20 µg  
Folic Acid  140 µg  
Vitamin B12 (cyanocobalamin)  1 µg  






zinkchloride  5.21 mg  
koperchloride 2 H2O  537 µg  
mangaanchloride 4 H2O  36.0 µg  
natriumseleniet anhydraat  43.8 µg  
natriumfluoride  1.26 mg  
kaliumjodide  13.1 µg  
 
Soluvit ® N  
Vial (10ml) 
Thiamine nitrate  3.1 mg  
Sodium riboflavine phosphate    
     corresponding to Vitamin B2  
4.9 mg  
3.6 mg 
Nicotinamide 40 mg  
Pyridoxine hydrochloride  
    corresponding to Vitamin B6  
4.9 mg  
4.0 mg 
Sodium pantothenate  
    corresponding to Pantothenic acid  
16.5 mg  
15.0 mg 
Sodium ascorbate  
    corresponding to Vitamin C  
113 mg  
100 mg 
Biotin 60 µg  
Folic acid  400 µg  
Cyanocobalamin  5.0 µg  
Also contains: Glycine 300 mg, Sodium edetate 0,5 mg, Methyl 
parahydroxybenzoate 0,5 mg 
 
Vitintra Infant®   
Vial (10ml) 
Retinolpalmitate  
    corresponding to retinol  
135.3 μg 
69 μg 
Phytomenadione  20 μg 
Ergocalciferol  1.0 μg 






Table S1. Overview of the local fluid practices in the three PEPaNIC RCT centres  
Practices Leuven Rotterdam 
 
Edmonton 
Fluid allowance 100 ml/kg/d for the 
first 10 kg bodyweight, 
50 ml/kg/d for the next 
10 kg, and 20 ml/kg/d 
for the bodyweight > 
20 kg 
<3m: 150-180 ml/kg/d 
3-6m: 150 ml/kg/d 
6-9m: 140 ml/kg/d 
9-12m: 120 ml/kg/d 
> 1y: 100 ml/kg/d for 
the first 10 kg 
bodyweight, 50 
ml/kg/d for the next 
10 kg, and 20 ml/kg/d 
for the bodyweight > 
20 kg  
100 ml/kg/d for the 
first 10 kg 
bodyweight, 50 
ml/kg/d for the next 
10 kg, and 20 ml/kg/d 
for the bodyweight > 
20 kg  
Fluid allowance in 
restricted patients 
80-110 ml/kg/d Post-op cardiac 
patients: day 1 50% 
TFI and day 2 75% 
Other patients 
around 75%, however 
Individually adjusted 
75% TFI for intubated 
patients 
50% TFI for post-op 
cardiac patients 
Maintenance fluid NaCl 0.9% <5kg: glucose 5% - 
NaCl 0.45%  
>5kg: glucose 2.5% / 
NaCl 0.45%  
NaCl 0.9%  
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A B S T R A C T  
Background: The Paediatric Early versus Late Parenteral Nutrition in Critical Illness 
(PEPaNIC) multicentre, randomised, controlled trial showed that compared with early 
parenteral nutrition (Early-PN), withholding supplemental parenteral nutrition for 1 week 
in the paediatric intensive care unit (PICU; Late-PN) reduced infections and accelerated 
recovery from critical illness in children. We aimed to investigate the long-term impact on 
physical and neurocognitive development of early versus late parenteral nutrition (PN). 
 
Methods: In this preplanned 2-year follow-up study, all patients included in the PEPaNIC 
trial (which was done in University Hospitals Leuven, Belgium; Erasmus MC–Sophia 
Children’s Hospital, Rotterdam, the Netherlands; and Stollery Children’s Hospital, 
Edmonton, AB, Canada) were approached for possible assessment of physical and 
neurocognitive development compared with healthy children who were matched for age 
and sex, and who had never been admitted to a neonatal ICU or a PICU. Assessed outcomes 
comprised anthropometric data; health status; parent/caregiver-reported executive 
functions, and emotional and behavioural problems; and tests for intelligence, visual-motor 
integration, alertness, motor coordination, inhibitory control, cognitive flexibility, and 
memory. To address partial responses among the children tested, we did multiple data 
imputation by chained equations before univariable and multivariable linear and logistic 
regression analyses adjusted for risk factors.  
 
Findings: At the 2-years follow-up, 60 (8%) of 717 children who received Late-PN and 63 
(9%) of 723 children who received Early-PN had died (p=0.81). 68 (9%) of 717 children who 
received Late-PN and 91 (13%) of 723 children who received Early-PN were too disabled 
for neurocognitive assessment (p=0.059), and 786 patients (395 assigned to Late-PN and 
391 assigned to Early-PN) consented for testing. 786 patients and 405 healthy control 
children underwent long-term outcomes testing between August 4, 2014, and January 19, 
2018, and were included in the imputation model for subsequent multivariable analyses. 
Late-PN did not adversely affect anthropometric data, health status, or neurological 
functioning, and improved parent/caregiver-reported executive functioning (Late-PN vs 
Early-PN β estimate –2.258, 95% CI –4.012 to –0.504; p=0.011), more specifically inhibition 
(–3.422, –5.171 to –1.673; p=0.0001), working memory (–2.016, –3.761 to –0.270; p=0.023), 
and meta-cognition (–1.957, –3.694 to –0.220; p=0.027). Externalising behavioural problems 
(β estimate –1.715, 95% CI –3.325 to –0.106; p=0.036) and visual-motor integration (0.468, 
0.087 to 0.850; p=0.016) were also improved in the Late-PN group compared with the 
Early-PN group. After Bonferroni correction for multiple comparisons, the effect on 
inhibitory control remained significant (p=0.0001). 
Interpretation: Withholding early PN for 1 week in the PICU did not negatively affect 
survival, anthropometrics, health status, and neurocognitive development, and improved 




I N T R O D U C T I O N  
The Paediatric Early versus Late Parenteral Nutrition in Critical Illness (PEPaNIC) 
multicentre, randomised, controlled trial revealed that withholding parenteral nutrition 
(PN) for up to 1 week in the paediatric intensive care unit (PICU), when enteral nutrition 
(EN) was insufficient, was clinically superior to providing full nutrition up to caloric targets 
with supplemental PN.1 Indeed, not giving PN during the first week in PICU and thus, in 
most patients, accepting low caloric and macronutrient intake reduced the incidence of new 
infections and accelerated recovery.1 Despite these short-term clinical benefits, concerns 
have been raised about potential adverse long-term consequences of low caloric and 
macronutrient intake for the patients’ length, bodyweight, head circumference, health status 
and neurocognitive development.2,3 To evaluate long-term value for patients, patient-
reported outcomes or rather, in case of children, parent/caregiver-reported outcomes 
should also be investigated.4 Any such adverse patient-centred long-term consequences 
would discourage withholding PN early in the course of paediatric critical illness. Children 
who have been treated in the PICU tend to have adverse long-term developmental and 
neurocognitive outcomes.5 In view of the potential benefits of fasting-induced responses for 
removal of cell damage and prevention of neurodegeneration,6,7 we hypothesised that 
withholding PN early during the course of critical illness in children could also bring about 
beneficial effects in the long term, in particular for neurocognitive development.  
 
We aimed to investigate whether withholding supplemental PN during the first week in 
PICU, rather than giving PN to reach nutritional targets as soon as possible, while adequately 
providing micronutrients, has an impact on survival, health status, and anthropometrics, 
clinically assessed neurological function, and parent/caregiver-reported and clinically tested 
neurocognitive outcomes at the 2-year follow-up, compared with matched healthy children. 
 
M E T H O D S  
Study design and participants 
This study is the preplanned 2-year follow-up of the PEPaNIC trial, in which 1440 critically 
ill children admitted to the participating PICUs (University Hospitals Leuven, Belgium; 
Erasmus-MC Sophia Children’s Hospital, Rotterdam, Netherlands; Stollery Children’s 
Hospital, Edmonton, AB, Canada) had been enrolled between 2012 and 2015. The full study 
protocol and acute outcome results have been published.1,8  
 
Parents or legal guardians had provided written informed consent on admission to the PICU 
to contact them for long-term follow-up testing of their child. Survival status was 
determined by assessment of hospital notes, national registers, or contact with the general 




were first sent a standardised patient information letter. Subsequently, they were contacted 
by phone to obtain consent for scheduling an appointment for the medical and 
neurocognitive assessment. Participating patients (Appendix) were assessed either at the 
hospital or at home; the latter was offered whenever parents or caregivers considered the 
burden of coming to the hospital too high. Neonates and infants enrolled in the PEPaNIC 
trial were assessed at the age of 2.5 years because the youngest appropriate age for 
parent/caregiver-reported executive functioning (with the Behaviour Rating Inventory of 
Executive Function [BRIEF] and a general intelligence test, Wechsler Preschool and Primary 
Scale of Intelligence [WPPSI]) is 2.5 years.  
 
405 healthy control children were recruited for a medical and neurocognitive assessment 
similar to that of the PEPaNIC patients. These children were demographically matched to 
the patients for age and sex. To control as much as possible for genetic, socioeconomic, 
and environmental background, siblings and relatives of the patients were preferably 
recruited into this control group besides unrelated children recruited from the same 
geographical area. Exclusion criteria for the control group were previous admission to a 
neonatal ICU or a PICU, or hospital admission for at least 7 days with need for an 
intravenous line, history of suspicious or established inborn chronic metabolic diseases 
requiring a specific diet, such as diabetes, and history of short bowel syndrome on home 
PN or other conditions that require home PN.  
 
Written informed consent was obtained from the parents or legal guardians or from the 
adolescent according to local regulations. The institutional review boards at each 
participating site approved this follow-up study (ML8052; NL49708.078; Pro00038098). The 
protocol is available online. 
 
Procedures, randomization and masking 
In the PEPaNIC trial,1 after having obtained consent, children who were admitted to the 
PICU were randomly allocated (1:1) to receive Early-PN, which was initiating PN within 24 
hours of PICU admission to supplement EN whenever 80% of targeted calories per age and 
bodyweight categories was not reached, or Late-PN. Late-PN meant that, for up to 1 week, 
patients received a mixture of glucose 5% and sodium chloride 0.9% without other forms 
of PN (lipid or protein infusions) being administered, corresponding to no PN in the majority 
of children. After 1 week, for both groups equally, PN could be administered if necessary. 
When EN covered 80% or more of calculated targets, supplemental PN was discontinued. 
Total macronutrient doses administered on each of the first 7 days in PICU are shown in 
the appendix. EN was initiated early for both groups equally, and all patients received 
intravenous micronutrients until fully enterally fed.  
 
Outcome assessors were physicians and experienced paediatric psychologists who had not 




were strictly blinded for the randomised allocation to either Late-PN or Early-PN. Parents 
had not been masked during the time the child was treated in the PICU and were not 
actively informed about the initial PEPaNIC study results.  
 
Outcomes 
In this 2-year follow-up study, the primary outcomes assessed were growth, physical ability, 
health status, and clinical, neurological, and neurocognitive outcomes. Death and severe 
disability precluding neurocognitive testing were a priori defined as safety endpoints. 
Neurocognitive testability was determined by screening of the medical file or clinical 
judgment, before the start of the neurocognitive assessment, by the physician or 
psychologist and confirmed by the parents or caregivers. 
 
For children who were examined at follow-up, head circumferences, bodyweights, and 
heights were measured. A clinical neurological examination was done to assess gross 
neurological abnormalities. A structured interview with the parents or caregivers assessed 
whether the child had been diagnosed with a somatic or psychiatric illness, or had been 
admitted to a hospital for medical or surgical reasons during the preceding 2 years for 
healthy control children and during the 2 years following the index PICU admission for 
patients. 
 
Validated, internationally recognised questionnaires and clinical tests with adequate 
normative data were used to score performance for a broad range of neurocognitive 
functions.9 Patient-reported outcome questionnaires were completed by parents or 
caregivers. They reported executive functioning in their child with the BRIEF preschool 
version for children aged 2.5-5 years or BRIEF for patients aged 6-18 years. Overlapping 
scales of both questionnaires (inhibition, flexibility, emotional control, working memory, and 
planning and organization), the overlapping index (meta-cognition, comprising the scales 
working memory and planning and organization), and the total score were reported (T 
scores, with mean 50 [SD 10]).10,11 Parents or caregivers completed the Child Behaviour 
Checklist (CBCL 1.5–5 years or CBCL 6–18 years)12,13 to assess emotional and behavioural 
problems. Internalising, externalising, and total problems were analysed (T scores, with 
mean 50 [SD 10]).12,13  
 
Clinical tests were used to evaluate neurocognitive functions. General intellectual ability was 
assessed with use of age-appropriate versions of the Wechsler intelligence quotient (IQ). 
WPPSI-III-NL14 was used for children aged between 2.5 years and 5 years 11 months, the 
Wechsler Intelligence Scale for Children (WISC-III-NL)15 was used for children aged 
between 6 years and 16 years 11 months, and the Wechsler Adult Intelligence Scale (WAIS-
IV-NL)16 for adolescents or young adults who were 17 years or older. For all of these tests, 
total IQ, verbal IQ, and performance IQ scores (test mean 100 [SD 15]) were computed. 




2.5 years and older to assess the ability to integrate visual and motor functions (total scaled 
score, with test mean 10 [SD 3]). The validated computerised Amsterdam 
Neuropsychological Tasks (ANT) program was used to measure attention, motor 
coordination, and executive functions in children aged 4 years or older.18 ANT-Baseline 
Speed was used to evaluate alertness (reaction time and SD), ANT-Tapping to assess motor 
coordination (number of taps), and Response Organization Objects to measure inhibitory 
control and cognitive flexibility (differences in reaction time and in number of errors 
between tests of increasing demand). Memory was assessed with use of 4 tests from the 
Children’s Memory Scale (CMS) for children aged between 5 years and 16 years 11 
months.19 CMS-Numbers assessed short-term verbal memory span and verbal working 
memory load (scaled score, with test mean 10 [SD 3]). The CMS-Word Pairs assessed 
short-term and long-term verbal memory, and recognition; CMS-Picture Locations assessed 
immediate visual memory; and CMS-Dot Locations assessed immediate and delayed visual 
memory (proportion of correct responses, ranging from 0 to 1). The CMS-Learning index 
represents learning abilities of the child (standard score, with mean 100 [SD 15]). The 
extended description of the parent/caregiver-reported outcome questionnaires and of the 
clinical and neuropsychological test battery is available in the appendix.  
 
Statistical analysis  
After taking into account estimations for the safety endpoints (death and severe disability 
precluding neurocognitive testing), we estimated that about 30% of the patients among the 
critically ill patients who had been included in the PEPaNIC trial and who were alive and 
testable at the 2-year follow-up would be lost to follow-up, on the basis of earlier 
experience.9 We calculated that such a sample size had >80% power to detect, with a 
certainty of >95%, clinically relevant differences between the 2 randomization arms, in the 
same order of magnitude as those we had previously documented with blood glucose 
control in the PICU.9 For the healthy control group, we calculated that with a sample size 
of 405 children, we would be able to detect, with a power of >80% and certainty of >95%, 
outcome differences between patients and healthy children of the same order of magnitude 
as those previously documented.9    
 
The inability to fully complete any of the neurocognitive tests would introduce bias in 
univariable analyses of these test results, because this in itself might suggest poor function. 
Hence, to correctly address partial responses, multiple data imputation by chained equations 
was required,20 with use of all available data per individual (Appendix). For tests validated 
for a specific age range (alertness, motor coordination, inhibitory control and flexibility in 
children aged 4 years or older, and memory in children who are between 5 and 16 years 
old), we imputed data within these age ranges only. To avoid bias and instability in this 
imputation model, the percentage of missing data per variable could not exceed 30%20 and 




Comparison of the observed and imputed values and the imputation predictor are shown 
in the appendix. 
 
To analyses the differences in outcomes between PEPaNIC participants and healthy control 
children, and to investigate the long-term outcome differences between patients randomly 
allocated to Late-PN or Early-PN during PICU stay, we did multivariable linear and logistic 
regression analyses on the 31 imputed datasets with the β estimates or odds ratios reported 
as pooled results, preceded by a pooled univariable comparison with use of Fisher’s exact 
test, Student’s t test, or Wilcoxon rank-sum test as appropriate (Appendix). All multivariable 
analyses were adjusted for the following risk factors: age, centre, race,21 sex, geographic 
origin,21 language, hand preference, history of malignancy, diabetes, a predefined syndrome 
(Appendix), and the educational and occupational status of parents (Appendix). For the 
comparison between Late-PN and Early-PN groups, further adjustment was done for 
diagnosis and severity of illness (with the Paediatric Index of Mortality 3 and paediatric 
logistic organ dysfunction scores) on PICU admission, risk of malnutrition, and parental 
smoking behaviour before PICU admission. We calculated p values for interaction between 
age group and randomization to assess whether patients who were infants (aged <1 years) 
at randomization behaved differently from older children.  
 
We did explanatory statistical analyses with further adjustment to investigate whether any 
eventual impact of Late-PN versus Early-PN on the long-term outcomes might have been 
mediated by its acute effects on new PICU infections and duration of PICU stay, and thus 
possibly indirectly also number of post-randomization hypoglycemic events or the duration 
of post-randomization treatments such as mechanical ventilatory support, hemodynamic 
support, antibiotics, corticosteroids, opioids, benzodiazepines, hypnotics, and α2-agonists. 
Data are presented as β estimates and odds ratios with 95% CIs, means and SDs, or numbers 
and proportions, as appropriate. Statistical analyses were done with R version 3.4.3, MICE 
version 2.46.0, and JMP version 13.0.0. Two-sided p-values of 0.05 or less were considered 
statistically significant. Bonferroni corrections for the multiple comparisons (n=45) were 
done as a sensitivity analysis, which altered the required level of p value for significance to 
0.001 or less.  
 
R E S U L T S  
Of the total patient population (n=1440), 60 (8%) of 717 children in the Late-PN group and 
63 (9%) of 723 children in the Early-PN group had died 2 years after admission to a PICU 
(p=0.81; Figure 1). 68 (9%) patients in the Late-PN group and 91 (13%) patients in the Early-
PN group were identified as too disabled to assess for neurocognitive development 
(p=0.059). 372 (26%) patients survived, but declined participation or could not be reached. 




observed (p=0.27). 786 patients (395 assigned to Late-PN and 391 assigned to Early-PN) 
and 405 healthy controls underwent long-term outcome testing between August 4, 2014 
and January 19 2018, and were included in the imputation model for subsequent 
multivariable analyses. Of the healthy control children, 332 (82%) were assessed at the 
hospital compared with 502 (64%) PEPaNIC children (p<0.001), with similar proportions 
for the Early-PN 458 (64%) and Late-PN 461 (64%) groups being assessed at the hospital 
(p=0.79). Demographic and medical characteristics of PEPaNIC participants and healthy 
control children are shown in Table 1. Patients who were tested at follow-up were overall 
comparable to the initial PEPaNIC study population (Table 1).  
 
Overall, PEPaNIC participants had worse outcomes at the 2-year follow-up for height, body 
weight, and head circumference, for health status, clinically assessed neurological 
functioning, parent/caregiver-reported executive functioning, and emotional and behavioural 
problems, and for clinical tests for intelligence, visual-motor integration, alertness, and 
memory than did healthy control children, assessed via univariable and via multivariable 
comparisons (Table 2; Table 3).  
 
Patients in the Late-PN group and those in the Early-PN group were similar in terms of 
height, bodyweight, body-mass index, and head circumference, and for health status, and 
clinically assessed neurological functioning in univariable and multivariable analyses (Table 2; 
Table 3) However, in the univariable comparisons, patients in the Late-PN group performed 
better than did those in the Early-PN group on parent/caregiver-reported inhibitory control, 
working memory, meta-cognition, and overall executive functioning, and on clinical tests for 
visual-motor integration, verbal-auditory recognition, and for one motor coordination task 
(synchronous tapping; Table 2). Adjusted for multiple comparisons, the better inhibitory 
control of patients in the Late-PN group than that of patients in the Early-PN group 
remained significant (p=0.0001). After multivariable adjustment for risk factors, 
parents/caregivers of patients in the Late-PN group reported better overall executive 
functioning than did parents/caregivers of patients in the Early-PN group (β estimate –2.258, 
95% CI –4.012 to –0.504; p=0.011), more specifically for inhibition (–3.422, –5.171 to –
1.673; p=0.0001), working memory (–2.016, –3.761 to –0.270; p=0.023), and metacognition 
(–1.957, –3.694 to –0.220; p=0.027; Table 3; Figure 2). Furthermore, patients in the Late-
PN group had fewer externalising behavioural problems (–1.715, 95% CI –3.325 to –0.106; 
p=0.036) as reported by parents/caregivers and scored better on visual-motor integration 
(0.468, 0.087 to 0.850; p=0.016) than did patients in the Early-PN group (Table 3; Appendix). 
 
For overall executive functioning, inhibition, meta-cognition, and externalising problems as 
reported by parents/caregivers, patients in the Late-PN group were not different from 
healthy control children (p values of ≥0.12; Appendix). After further correction for multiple 
comparisons, the better inhibitory control of patients in the Late-PN group than of those in 




missing-at-random assumption and with imputing worst test scores for the severely disabled 
and thus non-testable children, as presented in the appendix, further supported the 
robustness of these results.  
 
The effects of Late-PN versus Early-PN were more pronounced in the subgroup of patients 
who were infants at randomization than in older children (interaction p values of ≤0.03): β 
estimates for Late-PN versus Early-PN among infants for parent/caregiver-reported overall 
executive functioning (-3.843, 95% CI -6.361 to -1.325; p=0.0029), meta-cognition (-3.749, 
-6.244 to -1.254; p=0.0034), and working memory (-3.594, -6.052 to -1.135; p=0.0043; 
Appendix).  
 
The impact of Late-PN versus Early-PN on long-term outcomes did not appear to be 
mediated by its acute effects on new PICU infections, duration of PICU stay, exposure to 
hypoglycemia, or duration of potentially hazardous post-randomization treatments during 
the PICU stay (Appendix). The use of benzodiazepines and of corticosteroids was 
independently associated with poorer outcomes, whereas treatment with α2 agonists was 
associated with better overall executive functioning and visual-motor integration 
(Appendix). 
 
D I S C U S S I O N  
Two years after inclusion in the PEPaNIC multicentre, randomised, controlled trial, PICU 
survivors had worse developmental outcomes than did healthy control children. However, 
no adverse effect of withholding PN during the first week in the PICU could be detected 
for survival, anthropometrics health status, and neurocognitive development. In fact, 
omitting Early-PN in the PICU improved parent/caregiver-reported executive functioning 2 
years later compared with Early-PN, in particular resulting in a better inhibitory control. 
Moreover, of the patients who survived, fewer were too disabled to be tested in the Late-
PN group than in the Early-PN group.  
 
The long-term legacy of problems in executive functioning, as reported in this article by 
parents or caregivers of patients admitted to the PICU, has been described previously, 







Figure 1. CONSORT flow diagram of the study participants 









Figure 2. Density estimates for inhibitory function as reported by parents or caregivers 
Each line corresponds to an imputed dataset. Densities, which correspond to the proportions of children with a certain score (equivalent to a 
smoothed histogram), are shown separately for healthy control children and for paediatric early versus late parenteral nutrition in critical illness 
(PEPaNIC) participants who had been randomly assigned to receive late parenteral nutrition (no parenteral nutrition in the first week after admission 
to a paediatric intensive care unit [PICU]) or early parenteral nutrition (within 24 h after PICU admission when enteral nutrition alone was 




Table 1. Demographics of patients and healthy control children, post-randomization treatments in the PICU, and acute outcomes 




























Demographic        
Age at 2-year follow-up - years 6.0 (4.7)  5.7 (4.5)  NA NA 5.7 (4.4) 5.6 (4.5) 
Sex        
     Female 186 (46%) 331 (42%)  331 (42%) 305 (43%) 161 (41%) 170 (43%) 
     Male 219 (54%) 455 (58%)  415 (57%) 412 (57%) 230 (59%) 225 (57%) 
Known non-white racec 33 (8%) 63 (8%)  50 (7%) 33 (5%) 38 (10%) 25 (6%) 
Known non-European originc 54 (13%) 152 (19%)  161 (22%) 128 (18%) 88 (23%) 64 (16%) 
Known not exclusive Dutch or English language 76 (19%5) 184 (23%)  122 (17%) 106 (15%) 95 (24%) 89 (23%) 
Socioeconomic status        
     Parentd educational level 1 13 (3%) 37 (5%)  NA NA 12 (3%) 25 (6%) 
     Parentd educational level 1.5 23 (6%) 54 (7%)  NA NA 28 (7%) 26 (7%) 
     Parentd educational level 2 55 (14%) 184 (23%)  NA NA 96 (25%) 88 (22%) 
     Parentd educational level 2.5 76 (19%) 131 (17%)  NA NA 60 (15%) 71 (18%) 
     Parentd educational level 3 215 (53%) 200 (26%)  NA NA 100 (26%) 100 (25%) 
     Parentd educational level unknown 23 (6%) 180 (23%)  NA NA 95 (24%) 85 (22%) 
     Parente occupational level 1 2 (<1%) 10 (1%)  NA NA 2 (<1%) 8 (2%) 
     Parente occupational level 1.5 25 (6%) 76 (10%)  NA NA 33 (8%) 43 (11%) 
     Parente occupational level 2 47 (12%) 127 (16%)  NA NA 61 (16%) 66 (17%) 
     Parente occupational level 2.5 26 (6%) 77 (10%)  NA NA 44 (11%) 33 (8%) 
     Parente occupational level 3 83 (21%) 121 (15%)  NA NA 54 (14%) 67 (17%) 
     Parente occupational level 3.5 40 (10%) 54 (7%)  NA NA 32 (8%) 22 (6%) 
     Parente occupational level 4 116 (29%) 108 (14%)  NA NA 53 (14%) 55 (14%) 
     Parente occupational level unknown 66 (16%) 213 (27%)  NA NA 112 (29%) 101 (26%) 
Infant (age<1y) at randomization NA 363 (46%)  328 (45%) 325 (45%) 177 (45%) 186 (47%) 
STRONGkids risk levelf        
     Medium NA 707 (90%)  644 (89%) 644 (90%) 351 (90%) 356 (90%) 




PeLOD score, first 24h in PICUg NA 20.0 (11.6)    19.7 (12.0) 20.1 (12.3) 20.0 (11.6)  20.0 (11.5) 
PIM3 scoreh NA –3.5 (1.4)   –3.2 (1.6) –3.2 (1.7)  –3.4 (1.4) –3.5 (1.3) 
PIM3 probability of death, %h NA 6.7 (11.8)  9.4 (15.9) 9.1 (17.4) 6.8 (12.0) 6.5 (11.6) 
Diagnostic category        
     Surgical: abdominal NA 70 (9%)  53 (7%) 60 (8%) 34 (9%) 36 (9%) 
     Surgical: burns NA 2 (<1%)  5 (<1%) 5 (<1%) 1 (<1%) 1 (<1%) 
     Surgical: cardiac NA 339 (43%)  279 (39%) 268 (37%) 173 (44%) 166 (42%) 
     Surgical: neurosurgery or traumatic brain injury NA 71 (9%)  63 (9%) 53 (7%) 39 (10%) 32 (8%) 
     Surgical: thoracic NA 42 (5%)  34 (5%) 27 (4%) 23 (6%) 19 (5%) 
     Surgical: transplantation NA 14 (2%)  7 (1%) 17 (2%) 4 (1%) 10 (3%) 
     Surgical: orthopedic surgery or trauma NA 23 (3%)  28 (4%) 26 (4%) 14 (4%) 9 (2%) 
     Surgical: other NA 27 (3%)  21 (3%) 27 (4%) 10 (3%) 17 (4%) 
     Medical: cardiac NA 26 (3%)  30 (4%) 31 (4%) 10 (3%) 16 (4%) 
     Medical: gastrointestinal or hepatic NA 3 (<1%)  2 (<1%) 4 (<1%) 1 (<1%) 2 (<1%) 
     Medical: oncologic or hematologic NA 8 (1%)  8 (1%) 7 (1%) 5 (1%) 3 (<1%) 
     Medical: neurologic NA 44 (6%)  51 (7%) 52 (7%) 21 (5%) 23 (6%) 
     Medical: renal NA 0 (0%)  1 (<1%) 1 (<1%) 0 (0%) 0 (0%) 
     Medical: respiratory NA 83 (11%)  99 (14%) 96 (13%) 38 (10%) 45 (11%) 
     Medical: other NA 34 (4%)  42 (6%) 43 (6%) 18 (5%) 16 (4%) 
Malignancy 0 (0.0) 42 (5%)  51 (7%) 33 (5%) 26 (7%) 16 (4%) 
Diabetes 0 (0.0) 1 (<1%)  3 (<1%) 0 (0%) 1 (<1%) 0 (0%) 
Syndromei 5 (1.2) 79 (10%)  123 (17%) 118 (16%) 34 (9%) 45 (11%) 
Known parental smoking between birth and PICU 
admission 
NA 149 (19%)  NA NA 72 (18%) 77 (20%) 
Acute effect of randomization and post-randomization treatment in PICU      
Duration of stay in the PICU - days NA 7.4 (15.1)    9.2 (21.3) 6.5 (10.0) 8.4 (18.4) 6.4 (10.8) 
Patients who acquired a new infection in PICU NA 105 (13%)  134 (19%) 77 (11%) 66 (17%) 39 (10%) 
Duration of mechanical ventilatory support - days NA 4.7 (11.0)   6.4 (18.6)  4.4 (7.3)  5.5 (13.9)  3.9 (7.1) 
No. of days with hypoglycemia <40mg/dl - days NA 0.1 (0.5)  0.1 (0.6) 0.2 (0.6) 0.1 (0.5) 0.2 (0.6) 
Duration of antibiotic treatment - days NA 5.1 (13.4)    6.7 (19.0) 4.6 (8.7)  5.8 (16.4)  4.3 (9.5) 
Duration of hemodynamic support - days NA 2.5 (7.2)      3.0 (7.4) 2.4 (6.2) 2.6 (7.6) 2.3 (6.8) 
Duration of treatment with opioids - days NA 4.7 (8.8)     6.1 (16.5) 4.1 (6.2) 5.4 (10.8)  4.1 (6.2) 
Duration of treatment with benzodiazepines - days NA 4.2 (9.8)   5.4 (16.7)  4.0 (8.8)  4.5 (9.9)  3.9 (9.7) 




Duration of treatment with α2-agonists - days NA 1.0 (6.4)    1.1 (8.7) 1.0 (6.0)  0.9 (5.9)  1.1 (6.8) 
Duration of treatment with corticosteroids) - days  NA 1.2 (3.7)   1.6 (4.3)  1.3 (3.9) 1.3 (4.2)  1.0 (3.1) 
Data are mean (SD) or n (%). BMI, body mass index; NA, not applicable (values only known when the patients were seen at follow-up, or not applicable 
for healthy control children); PeLOD, Paediatric Logistic Organ Dysfunction score; PICU, paediatric intensive care unit; PIM3, Paediatric Index of 
Mortality 3 score; PN, parenteral nutrition; SEM, standard error of the mean.  
a 708 (59%) of 1191 participating children were tested in Belgium, 463 (39%) in the Netherlands, and 20 (2%) in Canada.  
b No differences in demographics, allocation to Late or Early-PN, and PICU- or hospital-related primary and secondary study endpoints were observed 
between the PEPaNIC patients who were tested and those who survived, but declined participation or could not be reached (n=372; all p>0.15). 
c Participants were classified according to race and geographical origin by the investigators. These classifications were performed to capture ethnical and 
regional differences in the frequency of consanguinity, which may adversely affect cognitive performance. 
d The education level is the mean of the paternal and maternal educational level, and calculated on the basis of the 3-point scale (1=low, 2=middle, 3-
high; Appendix) subdivisions as made by the Algemene Directie Statistiek (Belgium) and the Centraal Bureau voor de Statistiek (The Netherlands). 
e The occupation level is the mean of the paternal and maternal occupation level, which is calculated on the basis of the International Isco System 4-
point scale for professions (Appendix). 
f STRONGkids scores range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score of 
4 to 5 indicating high risk. 
g PeLOD scores range from 0 to 71, with higher scores indicating more severe illness. 
h PIM3 probability of death, ranging from 0-100% with high percentage indicating a higher probability of death in PICU. 
i A prerandomization syndrome or illness a priori defined as affecting or possibly affecting neurocognitive development (Appendix)
 
 
Table 2. Pooled univariable analyses of the differences assessed at 2-year follow-up between patients and healthy control children and between Late-
PN and Early-PN patient groups 
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Body-mass index – kg/m3 















Head circumference – cm 















Diagnosed with a somatic illness 957 (81%) 140 (35%) 507 (65%) <0.0001  259 (66%) 248 (63%) 0.31 
Diagnosed with a psychiatric illness 1160 (98%) 16 (4%) 52 (7%) <0.0001  30 (8%) 22 (6%) 0.23 
Admitted to hospital for a medical 
or surgical reason 
1191 (100%) 72 (18%) 425 (54%) <0.0001  216 (55%) 209 (53%) 0.51 
Clinical neurological evaluation 
score  
(range 0-8)c 
1116 (94%) 0.22 (0.6) 0.71 (1.5) <0.0001  0.81 (1.6) 0.61 (1.3) 0.096 
Executive functioning as reported by parents/caregivers - T-scorec      
     Inhibition 850 (72%) 46.3 (11.5) 49.9 (15.2) <0.0001  51.4 (14.4) 48.4 (13.2) <0.0001 
     Flexibility 851 (72%) 46.7 (11.3) 49.9 (15.3) <0.0001  50.5 (14.3) 49.4 (13.3) 0.12 
     Emotional control 851 (72%) 47.7 (11.2) 49.7 (13.5) 0.0052  50.0 (12.7) 49.4 (12.4) 0.34 
     Working memory 845 (71%) 46.7 (12.1) 51.4 (16.7) <0.0001  52.3 (15.4) 50.6 (14.1) 0.055 
     Planning and organization 847 (72%) 46.9 (11.9) 50.3 (14.7) 0.0001  50.8 (13.8) 49.8 (12.9) 0.18 
     Meta-cognition index 842 (71%) 46.8 (12.5) 50.2 (15.2) <0.0001  51.0 (14.1) 49.5 (13.5) 0.059 
     Total score 841 (71%) 45.9 (11.6) 50.2 (15.4) <0.0001  51.1 (14.5) 49.3 (13.7) 0.029 
Emotional and behavioural problems as reported by 
parents/caregivers - T-scorec 
      
 
 
     Internalising problems  1014 (86%) 46.7 (10.7) 51.1 (13.5) <0.0001  51.4 (13.3) 50.8 (12.5) 0.53 
     Externalising problems  1014 (86%) 46.8 (10.1) 49.8 (13.2) <0.0001  50.5 (12.7) 49.1 (12.0) 0.11 
     Total problems  1014 (86%) 46.1 (10.4) 50.9 (13.2) <0.0001  51.6 (13.0) 50.2 (12.3) 0.12 
Intelligence (range 45-155)d         
     Total IQ 1066 (90%) 100.7 (13.0) 90.6 (16.5) <0.0001  90.3 (16.6) 90.9 (15.8) 0.57 
     Verbal IQ  1052 (89%) 100.8 (14.1) 92.0 (18.2) <0.0001  91.6 (18.2) 92.4 (17.3) 0.55 
Intelligence (range 45-155)d         
     Performance IQ 1071 (90%) 100.7 (13.8) 91.5 (16.4) <0.0001  91.4 (16.7) 91.7 (15.6) 0.54 
Visual-motor integration (range 0.9-
20)d 
1097 (93%) 9.6 (2.4) 8.2 (3.5) <0.0001  8.0 (3.5) 8.5 (2.9) 0.010 
Alertnessc, e         
     Reaction time right hand - ms 413 (78%) 480.8 
(290.2) 
561.1 (700.4) 0.0064  591.4 (581.8) 527.6 (489.9) 0.082 
               Within-person SD of 
repeated tests 
413 (78%) 219.3 
(176.0) 
278.8 (715.0) 0.056  296.3 (559.0) 259.5 (510.8) 0.29 
     Reaction time left hand - ms 418 (79%) 459.7 
(239.2) 
536.2 (538.1) 0.038  557.1 (460.6) 513.0 (412.5) 0.11 
               Within-person SD of 
repeated tests 
418 (79%) 217.3 
(222.4) 
287.4 (542.7) 0.063  196.0 (454.0) 177.8 (401.8) 0.23 
Motor coordination (number of taps in 10 s) d, e        
     Number of right hand taps 433 (82%) 41.4 (16.1) 37.9 (41.1) 0.095  37.2 (32.6) 38.8 (28.8) 0.29 
     Number of left hand taps      433 (82%) 36.3 (14.4) 34.9 (36.6) 0.30  33.7 (29.1) 36.2 (25.9) 0.19 
     Number of valid alternating taps
  
392 (74%) 18.3 (23.2) 18.6 (63.8) 0.35  17.4 (49.4) 20.0 (45.7) 0.36 
     Number of valid synchronous 
taps 
392 (74%) 23.9 (15.1) 21.9 (35.8) 0.19  20.4 (27.6) 23.5 (26.5) 0.041 
Inhibition and flexibilityc, e         
     Difference in reaction time 
(inhibition) - ms 
383 (72%) 234.5 
(411.0) 
264.2 (1207.6) 0.24  286.5 (937.0) 239.6 (826.2) 0.17 
     Difference in no of errors 
(inhibition) 
385 (73%) 2.1 (12.7) 4.1 (38.6) 0.053  4.2 (28..5) 4.0 (27.3) 0.73 
     Difference in reaction time 
(flexibility) - ms 
369 (70%) 427.9 
(445.3) 
445.8 (1149.2) 0.31  458.7 936.0) 431.6 (782.9) 0.49 
     Difference in numbers of errors 
(flexibility) 
370 (70%) 2.4 (10.8) 4.8 (35.7) 0.067  4.6 (26.8) 5.0 (24.8) 0.64 
 
 
Memoryd, e         
     Verbal-auditory         
          Numbers (range 1-19)         
               Memory span (forward) 331 (83%) 10.2 (2.9) 8.6 (5.7) <0.0001  8.6 (5.0) 8.7 (4.4) 0.66 
               Working memory 
(backward) 
318 (80%) 10.3 (3.0) 8.7 (4.5) <0.0001  8.9 (4.3) 8.4 (3.7) 0.38 
          Word pairs (% of correct 
responses) 
        
               Learning 287 (72%) 0.50 (0.2) 0.43 (0.8) 0.047  0.42 (0.7) 0.45 (0.5) 0.26 
               Immediate memory 285 (72%) 0.47 (0.2) 0.33 (0.6) <0.0001  0.31 (0.5) 0.35 (0.4) 0.13 
               Delayed memory 282 (71%) 0.40 (0.3) 0.31 (0.8) 0.0059  0.30 (0.7) 0.32 (0.5) 0.43 
               Recognition 279 (70%) 0.95 (0.2) 0.87 (0.5) 0.0003  0.85 (0.4) 0.89 (0.3) 0.043 
     Non-verbal, visual-spatial         
         Pictures (% of correct 
responses) 
319 (80%) 0.85 (0.1) 0.789 (0.3) 0.0001  0.77 (0.2) 0.79 (0.2) 0.29 
         Dots (% of correct 
responses) 
        
               Learning 305 (77%) 0.86 (0.2) 0.78 (0.5) 0.010  0.79 (0.4) 0.78 (0.4) 0.57 
               Immediate memory 305 (77%) 0.87 (0.2) 0.80 (0.8) 0.058  0.80 (0.6) 0.80 (0.5) 0.70 
               Delayed memory 299 (75%) 0.87 (0.2) 0.80 (0.8) 0.094  0.79 (0.6) 0.80 (0.5) 0.59 
     Learning index (range 50-150) 280 (71%) 100.2 (22.5) 92.2 (85.5) 0.025  91.9 (69.2) 92.5 (54.9) 0.50 
Results are the combined number (%) and means (SD) from 31 datasets generated by multiple data imputation by chained equations under a missing-at-
random assumption for the 786 post-PICU patients and 405 healthy control children. IQ, intelligence quotient; PN, parenteral nutrition. 
a Statistically significant after Bonferroni correction for multiple comparisons. 
b Age-specific and sex-specific SD scores were calculated with the use of reference data from the WHO Growth Charts. The mean change in Z-scores 
from admission to a PICU to 2-year follow-up in the tested PEPaNIC population was 0.073 (SD 0.781) for height, 0.533 (1.101) for bodyweight, and 
0.673 (1.393) for body-mass index. The mean change in Z-scores from PICU admission to 2-year follow-up for patients who received Late-PN versus 
those who received Early-PN in the tested PEPaNIC population was 0.027 (SD 1.899) versus 0.119 (1.656; p=0.84) for height, -0.366 (1.314) versus -
0.397 (1.316; p=0.34) for bodyweight, and 0.605 (1.429) versus 0.739 (1.355; p=0.31) for body-mass index. 
c Higher scores reflect worse performance. 
d Higher scores reflect better performance.  




Table 3. Multivariable linear and logistic regression analyses of the differences in the outcomes assessed at 2-year follow-up between patients and 
healthy control children and between Late-PN and Early-PN patient groups 
 
 






Beta-estimate or odds 
ratio (95% CI) for the 
comparison patients 
vs controls, adjusted 
for risk factorsa 
P-value Beta-estimate or odds 
ratio (95% CI) for the 
comparison Late-PN 
vs Early-PN, adjusted 




Height – cm 1126 (95%) -1.717 (-2.670;-0.763) 0.0004c -0.538 (-3.358;2.282) 0.70 
Weight – kg 1135 (96%) -0.318 (-1.052;0.417) 0.39 0.278 (-1.639;2.194) 0.77 
Body-mass index – kg/m3 1126 (95%)     
Head circumference – cm 1060 (89%) -0.461 (-0.701;-0.221) 0.0001c -0.150 (-0.496;0.197) 0.39 
Diagnosed with a somatic illness 957 (81%) 2.940 (2.199;3.931)d <0.0001
c 
0.881 (0.625;1.242)d 0.74 
Diagnosed with a psychiatric illness 1160 (98%) 2.137 (1.104;4.136)d 0.024 0.764 (0.403;1.448)d 0.40 
Admitted to hospital for a medical or surgical 
reason 
1191 (100%) 4.781 (3.485;6.559)d <0.0001
c 
0.867 (0.634;1.186)d 0.37 
Clinical neurological evaluation score (range 0-
8)e 




Executive functioning as reported by parents/caregivers - T-scoref     




     Flexibility 851 (72%) 1.611 (0.107;3.114) 0.035 -1.146 (-2.841;0.550) 0.18 
     Emotional control 851 (72%) 0.678 (-0.796;2.152) 0.36 -0.861 (-2.500;0.778) 0.30 




     Planning and organization 847 (72%) 2.008 (0.426;3.590) 0.031 -1.139 (-2.807;0.529) 0.18 








Emotional and behavioural problems as reported by parents/caregivers - T-scoree    
 
 












Intelligence (range 45-155)e      
















Alertnesse, g      
     Reaction time right hand - ms 413 (78%) 55.695 (6.319;105.071) 0.027 -55.418 (-121.649;10.813) 0.10 
               Within-person SD of repeated tests 413 (78%) 48.403 (0.632;96.174) 0.047 -34.167 (-91.313;22.978) 0.23 
     Reaction time left hand - ms 418 (79%) 54.996 (10.192;99.799) 0.016 -40.166 (-106.821;26.488) 0.23 
               Within-person SD of repeated tests 418 (79%) 49.624 (4.158;95.089) 0.032 -17.296 (-75.374;40.783) 0.55 
Motor coordination (number of taps in 10 s)f, g      
     Number of right hand taps 433 (82%) -2.429 (-5.171;0.314) 0.081 0.863 (-2.181;3.907) 0.57 
     Number of left hand taps      433 (82%) -1.536 (-4.077;1.004) 0.23 1.998 (-0.878;4.874) 0.17 
     Number of valid alternating taps  392 (74%) 0.707 (-4.391;5.805) 0.78 2.085 (-2.653;6.823) 0.38 




Inhibition and flexibilitye, g      
     Difference in reaction time (inhibition) - ms 383 (72%) 25.177 (-51.033;101.387) 0.51 -53.416 (-125.105;18.274) 0.14 
     Difference in numbers of errors (inhibition) 385 (73%) 1.422 (-0.788;3.632) 0.20 -0.326 (-2.145;1.492) 0.72 
     Difference in reaction time (flexibility) - ms 369 (70%) 40.680 (-47.657;129.017) 0.36 -22.794 (-110.737;65.148) 0.60 
     Difference in numbers of errors (flexibility) 370 (70%) 2.085 (-0.062;4.231) 0.056 0.631 (-1.083;2.344) 0.46 
Memoryf, g      
     Verbal-auditory      
 
 
          Numbers (range 1-19)      
               Memory span (forward) 331 (83%) -1.113 (-1.883;-0.342) 0.0048 0.037 (-0.859;0.933) 0.93 
               Working memory (backward) 318 (80%) -0.927 (-1.638;-0.216) 0.010 -0.393 (-1.286;0.500) 0.38 






               Learning 287 (72%) -0.065 (-0.121;-0.008) 0.025 0.039 (-0.027;0.104) 0.24 
               Immediate memory 285 (72%) -0.110 (-0.165;-0.055) 0.0001c 0.047 (-0.014;0.109) 0.13 
               Delayed memory 282 (71%) -0.078 (-0.132;-0.025) 0.0046 0.017 (-0.044;0.078) 0.57 
               Recognition 279 (70%) -0.058 (-0.096;-0.021) 0.0027 0.035 (-0.013;0.083) 0.14 
     Non-verbal, visual-spatial      
         Pictures (proportion of correct responses) 319 (80%) -0.056 (-0.088;-0.024) 0.0006c 0.009 (-0.033;0.052) 0.66 
         Dots (proportion of correct responses)      
               Learning 305 (77%) -0.050 (-0.095;-0.005) 0.029 -0.016 (-0.064;0.032) 0.51 
               Immediate memory 305 (77%) -0.051 (-0.114;0.012) 0.11 -0.013 (-0.077;0.052) 0.69 
               Delayed memory 299 (75%) -0.058 (-0.122;0.006) 0.073 -0.002 (-0.069;0.064) 0.94 
     Learning index (range 50-150) 280 (71%) -6.328 (-12.555;-0.101) 0.046 0.487 (-5.590;6.565) 0.87 
Results are the combined beta-estimates and odds ratios from 31 datasets generated by multiple data imputation by chained equations under a missing-
at-random assumption for the 786 post-PICU patients and 405 healthy control children. Sensitivity analyses to the missing-at-random assumption and 
with imputing worst test-scores for the severely disabled and thus non-testable children, as specified in the appendix, further supported the robustness 
of these results. IQ, intelligence quotient; PeLOD score, Paediatric Logistic Organ Dysfunction Score; PICU, paediatric intensive care unit PIM3 score, 
Paediatric Index of Mortality 3 score; PN, parenteral nutrition SD, standard deviation; STRONGkids, Screening Tool Risk On Nutritional Status and 
Growth. 
a Estimates and odds ratios were adjusted for the following risk factors: age, centre, race, sex, geographic origin, language, hand preference, history 
of malignancy, diabetes, a predefined syndrome, and the educational and occupational status of parents; b Estimates and odds ratios were adjusted 
for the following risk factors: age, centre, race, sex, geographic origin, language, hand preference, history of malignancy, diabetes, a predefined 
syndrome, the educational and occupational status of parents, PIM3 score and PeLOD score upon PICU admission, STRONGkids risk category, and 
parental smoking behaviour prior to PICU admission; c Statistically significant after Bonferroni correction for multiple comparisons;  d These values 
are odds ratios; e Higher scores reflect worse performance; f Higher scores reflect better performance; g For alertness, motor coordination, executive 
functions, applicable imputation was limited to relevant age ranges. 
 
 
Executive dysfunction comprises problems in complex decision making and goal-oriented 
behaviour with implications for daily life23 and has been associated with externalising 
problems such as antisocial and aggressive behaviour.10,24 Indeed, poor inhibitory control in 
children is known to contribute to impulsive and destructive behaviours that upset or harm 
others.24 Hence, the possible beneficial effects of delaying PN in paediatric critical illness on 
the longer-term parent/caregiver-reported inhibitory function, further supported by better 
scores for other executive functions, externalising behaviour, and visual-motor integration 
(comparisons that lost significance after Bonferroni correction), are relevant. Indeed, the 
consequences for daily life and for the social environment are otherwise difficult to quantify 
by existing clinical neurocognitive tests.  
 
The most robust protection of executive functioning of delayed PN was observed for the 
ability to suppress immediate responses, as measured by the  parent/caregiver- reported 
inhibition score; this finding suggests potential damage induced by Early-PN  to frontal lobe 
areas that coordinate inhibition.25 The frontal lobe appears to be particularly vulnerable to 
metabolic insults during critical illness, with inflammation and neuronal damage described, 
which can be partially prevented by avoiding excessive hyperglycaemia.26 A previous 
randomised, controlled trial9 that documented the long-term neurocognitive impact of 
preventing hyperglycemia in the PICU also found some improvement of executive 
functioning. We speculate that harm induced by Early-PN to executive functioning might 
also be a direct metabolic insult on the developing brains of young children, because it was 
not statistically explained by the acute effects of the intervention, such as increased 
incidence of new infections or delayed recovery, or by other potentially hazardous post-
randomization treatments given during the PICU stay, such as use of benzodiazepines. The 
larger benefit observed for critically ill infants than for older children provides support for 
this speculation. Whether other periods of age or development, such as puberty, also 
represent special vulnerability remains to be investigated. 
 
Unlike our current findings in patients admitted to the PICU early in life, studies in other 
paediatric settings and otherwise healthy children have shown that insufficient rather than 
abundant nutritional intake, both prenatally and during childhood, can result in impaired 
growth and neurocognitive development.27,28 These differing results could be explained by 
the context. Indeed, specifically in the context of critical illness, fasting-induced responses 
brought about during the first days after an insult might generate beneficial effects through 
(autophagy-induced) cell damage removal and prevention of neuronal loss.26,29 The early 
administration of amino acids, the most powerful suppressors of autophagy,29 rather than 
glucose or lipids was found to explain the short-term harm by Early-PN in critically ill 
children.30 However, the exact underlying mechanisms of any long-term effect of not 
forcefully feeding patients early during critical illness remain speculative. Among others, 
alterations in DNA methylation in promoters or bodies of genes involved in neuronal 
growth, axonal guidance, and signal transduction could play a part,31 since such epigenetic 
 
 
changes have been previously associated with executive dysfunction.23 Moreover, the 
potential involvement of telomere shortening, which has been shown to be accelerated by 
early initiation of PN during paediatric critical illness, should be further investigated.32 
 
This study has limitations. First, the young age of PEPaNIC patients precluded complete and 
reliable results for certain neurocognitive tests. For these tests, the statistical power and 
thus the odds of identifying a difference between treatment groups was reduced. Second, 
neuroimaging studies were not done. Third, information on physiotherapy in the PICU and 
on the regular ward (i.e., after PICU but before hospital discharge) was not recorded. 
Fourth, data on follow-up consultations and therapies beyond the study protocol were not 
systematically available for all centres and all diagnostic subgroups. Fifth, after conservative 
Bonferroni correction, only the impact of withholding PN early in the PICU on long-term 
inhibitory control remained significant. However, given that inhibition is an important 
cognitive function involved in many aspects of daily life, and given the absence of any harm, 
this finding is relevant for endorsing implementation of withholding early PN in the PICU. 
 
C O N C L U S I O N S 
Patients admitted to the PICU early in life had worse outcomes at the 2-year follow-up for 
anthropometrics, health status, and neurocognitive development than did healthy control 
children. Withholding early PN for 1 week in the PICU did not negatively affect survival, 
anthropometrics, health status and neurocognitive development, and improved inhibitory 
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A P P E N D I X  
Methods S1: Definition of educational and occupational level of parents 
Educational level of parents 
The education level is the average of the paternal and maternal educational level, and 
calculated based upon the 3-point scale subdivisions as made by the Algemene Directie 
Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal Bureau voor de Statistiek (The 
Netherlands; statline.cbs.nl): low (=1), middle (=2) and high (=3) educational level. 
 
Occupational level of parents 
The occupation level is the average of the paternal and maternal occupation level, which is 
calculated based upon the International Isco System 4-point scale for professions 
(http://www.ilo.org/public/english/bureau/stat/isco/).1 In case one of the parents filled in two 
jobs in the questionnaire, the highest Isco code level was used. In case “unemployed”, 
“disabled”, “student”, or “housewife/houseman” was filled in, an Isco code level of 1 was 
given to that parent. When the parents described their profession as “employee”, “worker”, 
“liberal profession”, or “retired”, they were given an Isco code level of 2. 
 
Methods S2: Definition of “Syndrome” 
A prerandomization syndrome or illness a priori defined as affecting or possibly affecting 
neurocognitive development, and which is subdivided in the following categories: 
• Genetically confirmed syndrome or pathogenic chromosomal abnormality 
• Clearly defined syndrome, association or malformation without (identified) genetic 
aberration 
• Polymalformative syndrome of unknown etiology 
• Clear auditory or visual impairment without specified syndrome 
• Congenital hypothyroidism due to thyroid agenesis 
• Brain tumor or tumor with intracranial metastatic disease 
• Pedopsychiatric disorder (e.g. autism spectrum disorder, (treatment for) attention 
deficit hyperactivity disorder) 
• Severe medical disorder, not primarily neurologic, but suspected to alter 
psychomotor and/or mental performance 
• Severe neonatal problem (e.g. severe asphyxia) 
• Severe craniocerebral trauma or near-drowning 
• Severe infectious encephalitis or drug-induced encephalopathy 
• Infectious meningitis, encephalitis or Guillain-Barré 
• Resuscitation and/or need for extracorporeal membrane oxygenation prior to 
randomization 




Methods S3: Detailed description of outcome measures 
Medical assessment 
Anthropometric data 
Height (in cm), body weight (in kg) and head circumference (in cm) were measured.  
 
Health status  
In an interview with the parents, the need for medical support of all kind during the past 
two years for healthy control children and during the 2 years following the index PICU 
admission for patients, was recorded. The hospital admissions because of surgery or a 
medical reason, and the occurrence of a psychiatric diagnosis were documented.  
 
Clinical neurological examination 
In order to assess whether there were gross neurological abnormalities, during a structured 
clinical neurological examination, signs of major neurologic dysfunction were detected in 
the following domains: interaction/language skills, gross motor function, involuntary 
movements, reflexes, coordination and balance, fine motor function, cranial nerves, and 
special senses (sensory, visual, and auditory function). These were all scored normal or 
abnormal. An abnormal result for each of these domains was given 1 point and the sum was 
made of all the abnormal results, with a range of 0-8. 
 
Neurocognitive testing 
A broad range of neurocognitive functions, including general intellectual functioning, visual-
motor integration, attention, motor coordination, inhibitory control and cognitive flexibility, 
verbal and visual-spatial learning, and memory were evaluated, as previously reported.2 
 
Patient/Parents-reported outcomes (PROs) 
Executive functioning was measured with the Behaviour Rating Inventory of Executive 
Function (BRIEF-P 2.5-5 years, BRIEF 6-18 years), filled out by the parents or caregivers of 
the child. Overlapping scales and indices of both questionnaires (Inhibition, Flexibility, 
Emotional Control, Working Memory, Planning and Organization, Meta-cognition) and a 
Total Score were analysed (T-scores, with mean 50 and SD 10).3,4 Emotional and behavioural 
problems were assessed by the parent or caregiver with the Child Behaviour Checklist 
(CBCL 1.5-5 years or CBCL 6-18 years).5,6 NREF 4 Internalising, externalising, and total 
problems were analysed (T-scores, with mean 50 and SD 10).5,6 
 
Intelligence 
General intellectual ability was assessed with use of age-appropriate versions of the 
Wechsler Intelligence Quotient (IQ) tests. The Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI-III-NL)7 was used for children aged 2.5 years to 5 years 11 months (one 
version for age range 2 years 6 months to 3 years 11 months, and another version for age 
range 4 years to 5 years 11 months), the Wechsler Intelligence Scale for Children (WISC-
 
 
III-NL)8 was used for children aged 6 years to 16 years 11 months, and the Wechsler Adult 
Intelligence Scale (WAIS-IV-NL)9 for adolescents who were 17 years or older. For all these 




We used the Beery Developmental Test of Visual-Motor Integration, 6th Edition (VMI) to 
assess the ability to integrate their visual and motor functions (total Scaled Score, Test-
mean 10, SD 3). This involves eye-hand coordination.10 
 
Alertness, motor-coordination, and executive functions 
To measure alertness, motor-coordination and executive function, the validated Amsterdam 
Neuropsychological Tasks (ANT) program was used.11 The ANT is a computer-aided 
assessment battery of reaction time (RT) tasks that allows for the systematic evaluation of 
information processing capacities.  
 
Children 4 years and older performed ANT-Baseline Speed (BS), ANT-Tapping (TP), and 
Response Organization Objects (ROO). The ANT-BS evaluated alertness by measuring 
simple RT to visual stimuli (mean RT and SD of RT were obtained for the right and left hand 
separately). The ANT-TP assessed motor coordination for the right hand, left hand, 
bimanual alternating, and bimanual synchronous. The ANT-ROO measured inhibitory 
control and cognitive flexibility by calculating the differences in RT and the differences in 
number of errors between tests of increasing demand. 
 
Memory 
Auditory/verbal memory and Visual-spatial/non-verbal memory were assessed with use of 
four tests from the Children’s Memory Scale (CMS) for children between 5 and 16 years 11 
months.12 As to verbal memory, CMS-Numbers assessed short-term verbal memory span 
(forward digit recall) and verbal working memory load (backward digit recall). The CMS-
Word Pairs (recall a list of word pairs) assessed short-term and long-term verbal memory, 
and recognition. As to non-verbal memory, CMS-Picture Locations (remembering and recall 
of pictures in various locations) assessed immediate visual memory. CMS-Dot Locations 
(remembering and recall of the location of dots) assessed immediate and delayed visual 
memory. For CMS-Numbers, raw scores for verbal memory span, CMS-numbers forward, 
and verbal working memory load, CMS-numbers backward were reported. For CMS-Word 
Pairs, CMS-Picture Locations, and CMS-Dot Locations, proportional scores were analysed 
(proportion of correct responses ranging from 0 to 1, with higher scores reflecting better 
performance). The CMS-Learning index is a standardised score of the sum of the three 
learning trials of the CMS-Word Pairs and the learning trial of the CMS-Dot Locations 






Methods S4: Imputation 
Missing data (excluding the deceased and the severely disabled whereby non-testable 
children) were handled by multiple data imputation with chained equations under 
a ‘missing at random’ assumption. There were no missing data in the baseline variables. 
Predictors for missing values included all covariates listed below, and were retained in the 
predictor models with a minimum correlation of 0.1 with the prediction target. Predictive 
mean matching13 was used for numeric variables except for factors with two levels (which 
were imputed based on logistic regression) and factors with more than two levels (for which 
polytomous (unordered) regression was used). A monotonous visiting scheme was used 
such that variables for imputation were visited in increasing order of the number of missing 
data. Imputation convergence was assessed visually and set at 70 iterations (Figure S1). Since 
there were no more than 30% missing observations for all variables, 31 complete imputed 
datasets were used in the analyses,14 and pooled results were obtained across datasets using 
Rubin’s rules.15 
 
Plausibility of the imputations was assessed visually via the densities of the observed 
data and that resulting from the imputed values (Figure S2). Sensitivity of results to the 
‘missing at random’ assumption was assessed with use of pattern mixture models 15-17 
assuming the original imputed values were either too high or too low by a factor of 0.1 for 
the main result of inhibition as reported by parents. Under this assumption, the obtained 
beta-estimates and P-values for randomization to Late-PN vs. Early-PN for the multivariable 
linear regression analyses performed to determine significant and independent associations 
between risk factors and inhibition as reported by the parents at two-year follow-up within 
the tested patient population (Table S1-1) ranged from -2.962 (p<0.0001) to -2.396 
(p=0.032). The effect-sizes thus remained of the same order of magnitude, sign, and 
statistical significance as were observed for the original imputed datasets, which suggested 
that the analyses were robust against the investigated ‘missing at random’ violation.  
 
To further evaluate the robustness of the main findings, the analyses were repeated 
after imputing a penalised test result for all severely disabled and thus non-testable 
patients, defined as the worst result in the observed patients or controls, plus or minus 
one, as appropriate for each test. In this case, the obtained beta-estimates (p-values) for 
randomization to Late-PN vs. Early-PN for the multivariable linear regression analyses were 
respectively: A) -3.382 (p<0.0001) for inhibition as reported by parents; B) -1.928 (p=0.031) 
for meta-cognition as reported by parents; C) -1.992 (P=0.026) for working memory as 
reported by parents; D) -2.224 (p=0.014) for overall executive functioning as reported by 
parents; E) -1.668 (p=0.045) for externalising emotional and behavioural problems as 
reported by parents; and F) 0.464 (p=0.017) for visual-motor integration. These sensitivity 
 
 
analyses corresponded closely to the primary results as reported in Table 2 of the main 
manuscript. 
 
All multiple data imputation analyses were performed with R version 3.4.3 and MICE version 
2.46.0.  
 
List of variables used for multiple data imputation by chained equations  
Demographics of patients and control children and patient characteristics upon PICU 
admission, Centre, randomization for Late-PN or Early-PN, patient vs. controls, race, 
gender, geographic origin, language, hand preference, history of malignancy, history of 
diabetes, a predefined “syndrome”, educational and occupational status of parents, 
diagnosis, PIM3 and PeLOD scores upon PICU admission, risk of malnutrition 
(STRONGkids category), parental smoking behaviour prior to PICU admission, age at 
randomization, age group at randomization. 
 
Acute effects of randomization and post-randomization treatments in PICU 
Acquisition of new PICU infections, duration of PICU stay, duration of mechanical 
ventilatory support, hypoglycemia, duration of treatment with hemodynamic support, 
antibiotics, corticosteroids, opioids, benzodiazepines, hypnotics and α2-agonists. 
 
At two-year follow-up 
Age, test location, height, weight, head circumference, composite endpoint “diagnosed with 
a somatic illness”, composite endpoint “diagnosed with a psychiatric illness”, composite 
endpoint “admitted to hospital for a medical or surgical reason”, clinical neurological 
examination, verbal IQ, performance IQ, total IQ, visual motor integration, reaction time 
left hand, reaction time right hand, within subject SD of reaction time left hand, within 
subject SD of reaction time left hand, number of unimanual taps right hand, number of 
unimanual taps left  hand, number of valid alternating taps, number of valid synchronous 
taps, delta reaction time inhibition, delta number of errors inhibition, delta reaction time 
flexibility, delta number of errors flexibility, numbers memory span forward, numbers 
working memory backward, word pairs learning, word pairs immediate memory, word pairs 
delayed memory, word pairs recognition, pictures, dots learning, dots immediate memory, 
dots delayed memory, learning index, executive functioning as reported by 
parents/caregivers (inhibition, flexibility, emotional control, working memory, planning and 
organization, meta-cognition index, and total score), emotional and behavioural problems 
as reported by parents/caregivers (internalising problems, externalising problems, and total 







Figure S1. Macronutrient doses during the first week in PICU administered to the tested population 
Daily amount of total energy in kcal/kg/day, and the daily amounts of total substrates in g/kg/day are shown for the first 7 days in the paediatric 
intensive care unit (PICU). Bars represent the mean and the whiskers represent the standard error of the mean (SEM). The red bars represent the 




Figure S2. Imputation convergence for selected neurocognitive test results 
Mean and standard deviation of imputed values in each of 31 datasets over 70 iterations for  
A) Executive functioning as reported by parents/caregivers - T-score: Inhibition;  
B) Meta-cognition index;  
C) Working memory;  
D) Total score;  
E) Emotional and behavioural problems as reported by parents/caregivers - T-score: Externalising 
problems;  






Figure S3. Density estimates of the observed and imputed values for selected neurocognitive test 
results 
Density estimated for observed values (in blue) and for each imputed dataset (in orange) for  
A) Executive functioning as reported by parents/caregivers - T-score: Inhibition;  
B) Meta-cognition index;  
C) Working memory;  
D) Total score;  




Figure S4. Multiple imputation predictor variables 
Missing values for the variables in each row are imputed based on models that use as predictors only 





Table S1-1. Multivariable linear regression analyses determining significant and independent associations between risk factors and inhibition as 
reported by the parents/caregivers at 2 years’ follow-up within the tested patient population  
 
Model adjusted for risk factors 
 
Model further adjusted for acute effects 










interval  P-value 
Randomization to late vs. early initiation of PN -3.422 -5.171 -1.673 0.00013 -3.373 -5.140 -1.605 0.00020 
Centre         
     Leuven vs. Edmonton 1.752 -5.864 9.369 0.65 2.306 -5.392 10.004 0.55 
     Rotterdam vs. Edmonton 1.683 -6.012 9.377 0.66 1.307 -6.456 9.069 0.74 
Male vs. female sex 1.098 -0.740 2.937 0.24 1.162 -0.675 2.999 0.21 
Right vs. left hand preference  0.280 -2.548 3.109 0.84 0.284 -2.492 3.060 0.83 
Medium vs. high STRONGkids risk levela 0.592 -2.543 3.726 0.71 0.562 -2.620 3.745 0.72 
Diagnostic category (as compared with Cardiac surgery)        
     Surgical         
          Abdominal -0.800 -4.510 2.911 0.67 -0.634 -4.338 3.070 0.73 
          Burns -1.969 -17.860 13.923 0.80 -3.540 -19.912 12.833 0.67 
          Neurosurgery - traumatic brain injury 1.988 -1.662 5.638 0.28 1.640 -2.005 5.285 0.37 
          Thoracic -1.293 -5.670 3.084 0.56 -1.225 -5.650 3.200 0.58 
          Transplantation 5.434 -2.598 13.465 0.18 3.995 -5.157 13.148 0.38 
          Orthopedic surgery-trauma 0.485 -5.186 6.157 0.86 0.184 -5.522 5.889 0.94 
          Other 3.419 -1.470 8.309 0.17 2.611 -2.369 7.591 0.30 
     Medical          
          Cardiac 2.694 -2.638 8.026 0.32 2.291 -3.295 7.877 0.42 
          Gastrointestinal-hepatic 10.927 -5.325 27.179 0.18 10.591 -5.610 26.792 0.19 
          Hematologic-oncologic 3.951 -4.925 12.828 0.38 0.637 -8.789 10.063 0.89 
 
 
          Neurologic 0.691 -3.535 4.918 0.74 -0.297 -4.658 4.064 0.89 
          Respiratory  0.374 -3.370 4.118 0.84 -0.161 -4.032 3.710 0.93 
          Other 0.096 -4.640 4.832 0.96 -0.307 -5.197 4.582 0.90 
Infant (age<1y) vs. child at randomization 0.315 -1.635 2.265 0.75 0.331 -1.719 2.382 0.75 
Malignancy vs. no malignancy -1.620 -5.794 2.554 0.44 -1.907 -6.129 2.314 0.37 
Diabetes vs. no diabetes -5.169 -28.229 17.890 0.65 -3.412 -26.465 19.642 0.77 
Syndrome vs. no syndromeb 3.447 0.314 6.581 0.031 3.727 0.571 6.884 0.020 
PIM3 score (per point added)c 0.071 -0.780 0.922 0.87 -0.006 -0.883 0.871 0.98 
PeLOD score first 24 hrs (per point added)d 0.067 -0.047 0.181 0.24 0.051 -0.064 0.167 0.38 
Known non-European origin vs. othere -0.582 -4.367 3.202 0.76 -0.625 -4.407 3.158 0.74 
Known non-Caucasian vs. othere -1.931 -6.585 2.724 0.41 -1.560 -6.231 3.112 0.51 
Known not exclusive Dutch or English language vs. 
other 0.359 -2.480 3.198 0.80 0.379 -2.456 3.214 0.79 
Socioeconomic status         
  Educational level parents (as compared with level 1)f         
          Educational level 1.5 -3.090 -8.471 2.292 0.25 -2.468 -7.907 2.970 0.37 
          Educational level 2 -2.097 -6.648 2.453 0.36 -1.634 -6.226 2.958 0.48 
          Educational level 2.5 -3.730 -8.625 1.164 0.13 -3.127 -8.047 1.792 0.21 
          Educational level 3 -4.590 -9.509 0.329 0.067 -4.043 -8.996 0.909 0.10 
          Educational level unknown -0.579 -6.400 5.242 0.84 -0.111 -5.963 5.742 0.97 
  Occupational level parents (as compared with level 1)g         
          Occupational level 1.5 3.634 -4.260 11.527 0.36 3.091 -4.810 10.992 0.44 
          Occupational level 2 3.086 -4.721 10.893 0.43 2.380 -5.448 10.208 0.55 
          Occupational level 2.5 3.803 -4.335 11.941 0.35 2.995 -5.176 11.166 0.47 
          Occupational level 3 3.047 -4.923 11.017 0.45 2.400 -5.583 10.382 0.55 
 
 
          Occupational level 3.5 0.490 -7.969 8.950 0.90 -0.224 -8.701 8.253 0.95 
          Occupational level 4 4.074 -4.163 12.312 0.33 3.139 -5.147 11.426 0.45 
          Occupational level unknown 2.458 -5.483 10.399 0.54 1.882 -6.074 9.839 0.64 
Parental smoking between birth and PICU admission vs. 
no smoking 1.530 -0.787 3.847 0.19 1.635 -0.671 3.942 0.16 
New infection vs. no new infection     -0.420 -3.898 3.058 0.81 
Duration of stay in the PICU (per day added)     0.033 -0.258 0.323 0.82 
Days with hypoglycemic event (per day added)     -0.331 -2.299 1.637 0.74 
Duration of mechanical ventilatory support (per day added)    -0.089 -0.291 0.113 0.38 
Duration of treatment with antibiotics (per day added)     -0.049 -0.321 0.223 0.72 
Duration of hemodynamic support (per day added)     -0.100 -0.305 0.104 0.33 
Duration of treatment with corticosteroids (per day added)    0.229 -0.101 0.558 0.17 
Duration of treatment with opioids (per day added)     -0.082 -0.368 0.204 0.57 
Duration of treatment with benzodiazepines (per day added)    0.323 0.056 0.590 0.017 
Duration of treatment with hypnotics (per day added)     0.073 -0.211 0.356 0.61 
Duration of treatment with α2-agonists (per day added)    -0.186 -0.449 0.078 0.16 
PeLOD, paediatric logistic organ dysfunction score; PICU, paediatric intensive care unit; PIM3, paediatric index of mortality 3 score; PN, parenteral 
nutrition. For inhibition as reported by parents, higher scores reflect worse performance. a Scores on the Screening Tool for Risk on Nutritional Status 
and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1-3 indicating medium risk, and a score 
of 4-5 indicating high risk.  b A prerandomization syndrome or illness a priori defined as affecting or possibly affecting neurocognitive development 
(Methods S2) c Paediatric Index of Mortality 3(PIM3) scores, with higher scores indicating a higher risk of mortality. d Paediatric Logistic Organ 
Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness.me Participants were classified according to race and 
geographical origin by the investigators. These classifications were performed to capture ethnical and regional differences in the frequency of 
consanguinity, which may adversely affect cognitive performance.18 f The education level is the average of the paternal and maternal educational level, 
and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal 
Bureau voor de Statistiek (The Netherlands; statline.cbs.nl):Low(=1), middle(=2) and high(=3) educational level (Methods S1). g The occupation level is 





Table S1-2. Multivariable linear regression analyses determining significant and independent associations between risk factors and working memory as 
reported by the parents/caregivers at 2 years’ follow-up within the tested patient population  
 
Model adjusted for risk factors 
 
Model further adjusted for acute 










interval  P-value 
Randomization to late vs. early initiation of PN -2.016 -3.761 -0.270 0.023 -1.961 -3.728 -0.194 0.029 
Centre         
     Leuven vs. Edmonton 0.686 -6.879 8.250 0.85 1.356 -6.400 9.112 0.73 
     Rotterdam vs. Edmonton 0.107 -7.564 7.779 0.97 -0.082 -7.943 7.778 0.98 
Male vs. female sex 1.266 -0.523 3.055 0.16 1.220 -0.564 3.005 0.17 
Right vs. left hand preference  0.222 -2.353 2.797 0.86 0.287 -2.274 2.849 0.82 
Medium vs. high STRONGkids risk level a -0.120 -3.331 3.092 0.94 0.180 -3.084 3.444 0.91 
Diagnostic category (as compared with Cardiac surgery)        
     Surgical         
          Abdominal -2.737 -6.574 1.100 0.16 -2.573 -6.423 1.277 0.18 
          Burns -1.793 -17.437 13.850 0.82 -2.819 -18.998 13.361 0.73 
          Neurosurgery - traumatic brain injury 2.159 -1.515 5.833 0.24 1.930 -1.752 5.612 0.30 
          Thoracic -3.357 -7.670 0.956 0.12 -3.286 -7.666 1.094 0.14 
          Transplantation 6.273 -1.387 13.934 0.10 5.872 -2.856 14.599 0.18 
          Orthopedic surgery-trauma 0.651 -4.851 6.153 0.81 0.536 -4.962 6.034 0.84 
          Other 4.021 -0.885 8.927 0.10 3.462 -1.543 8.467 0.17 
     Medical          
          Cardiac 3.986 -1.280 9.252 0.13 3.125 -2.477 8.727 0.27 
          Gastrointestinal-hepatic 13.673 -1.652 28.999 0.080 13.484 -1.816 28.784 0.083 
          Hematologic-oncologic -1.926 -10.690 6.838 0.66 -4.287 -13.541 4.967 0.36 
 
 
          Neurologic 0.246 -3.909 4.402 0.90 -0.369 -4.582 3.843 0.86 
          Respiratory  -2.172 -5.908 1.563 0.25 -2.735 -6.583 1.113 0.16 
          Other  -1.210 -5.913 3.493 0.61 -1.545 -6.405 3.314 0.53 
Infant (age<1y) vs. child at randomization -0.737 -2.690 1.216 0.45 -0.703 -2.721 1.315 0.49 
Malignancy vs. no malignancy 1.704 -2.413 5.821 0.41 1.688 -2.471 5.847 0.42 
Diabetes vs. no diabetes 0.527 -22.272 23.326 0.96 1.951 -20.856 24.757 0.86 
Syndrome vs. no syndromeb 5.298 2.181 8.414 0.00094 5.324 2.167 8.481 0.0010 
PIM3 score (per point added)c 0.280 -0.614 1.173 0.53 0.191 -0.737 1.120 0.68 
PeLOD score first 24 hrs (per point added)d 0.011 -0.101 0.124 0.84 -0.004 -0.118 0.110 0.94 
Known non-European origin vs. othere 1.118 -2.771 5.007 0.57 1.112 -2.781 5.005 0.57 
Known non-Caucasian vs. othere -3.969 -9.097 1.158 0.12 -3.744 -8.870 1.382 0.15 
Known not exclusive Dutch or English language vs. 
other 0.316 -2.338 2.970 0.81 0.365 -2.305 3.036 0.78 
Socioeconomic status         
 Educational level parents (as compared with level 1)f         
          Educational level 1.5 -3.391 -8.554 1.773 0.19 -2.870 -8.119 2.379 0.28 
          Educational level 2 -2.230 -6.603 2.144 0.31 -1.745 -6.159 2.669 0.43 
          Educational level 2.5 -3.950 -8.584 0.683 0.094 -3.314 -7.974 1.346 0.16 
          Educational level 3 -4.174 -8.873 0.524 0.081 -3.631 -8.376 1.114 0.13 
          Educational level unknown -1.527 -7.153 4.099 0.59 -1.042 -6.754 4.669 0.71 
 Occupational level parents (as compared with level 1)g         
          Occupational level 1.5 0.618 -7.159 8.394 0.87 0.162 -7.632 7.956 0.96 
          Occupational level 2 0.579 -7.203 8.362 0.88 0.055 -7.752 7.863 0.98 
          Occupational level 2.5 0.286 -7.808 8.381 0.94 -0.453 -8.571 7.665 0.91 
          Occupational level 3 -0.860 -8.803 7.082 0.83 -1.442 -9.390 6.506 0.72 
 
 
          Occupational level 3.5 -3.143 -11.577 5.292 0.46 -3.740 -12.188 4.708 0.38 
          Occupational level 4 0.358 -7.869 8.585 0.93 -0.426 -8.692 7.840 0.91 
          Occupational level unknown 0.378 -7.667 8.422 0.92 -0.162 -8.241 7.918 0.96 
Parental smoking between birth and PICU admission vs. 
no smoking 1.230 -1.255 3.715 0.32 1.315 -1.174 3.803 0.29 
New infection vs. no new infection     0.674 -2.783 4.131 0.70 
Duration of stay in the PICU (per day added)     0.001 -0.287 0.289 0.99 
Days with hypoglycemic event (per day added)     -0.166 -2.167 1.835 0.87 
Duration of mechanical ventilatory support (per day added)    -0.103 -0.300 0.095 0.30 
Duration of treatment with antibiotics (per day added)     0.034 -0.239 0.307 0.80 
Duration of hemodynamic support (per day added)     -0.066 -0.266 0.134 0.51 
Duration of treatment with corticosteroids (per day added)    0.095 -0.226 0.415 0.56 
Duration of treatment with opioids (per day added)     -0.150 -0.435 0.134 0.29 
Duration of treatment with benzodiazepines (per day added)    0.337 0.075 0.598 0.011 
Duration of treatment with hypnotics (per day added)     0.066 -0.214 0.346 0.64 
Duration of treatment with α2-agonists (per day added)     -0.207 -0.465 0.050 0.11 
PeLOD, Paediatric Logistic Organ Dysfunction score; PICU, paediatric intensive care unit; PIM3, Paediatric Index of Mortality 3 score; PN, parenteral 
nutrition. For working memory as reported by parents, higher scores reflect worse performance. a Scores on the Screening Tool for Risk on Nutritional 
Status and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, 
and a score of 4 to 5 indicating high risk.  b A prerandomisation syndrome or illness a priori defined as affecting or possibly affecting neurocognitive 
development (Methods S2). c Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality. d Paediatric Logistic 
Organ Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness. e Participants were classified according to 
race and geographical origin by the investigators. These classifications were performed to capture ethnical and regional differences in the frequency of 
consanguinity, which may adversely affect cognitive performance.18 f The education level is the average of the paternal and maternal educational level, 
and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal 
Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level (Methods S1). g The occupation level 





Table S1-3. Multivariable linear regression analyses determining significant and independent associations between risk factors and meta-cognition as 
reported by the parents/caregivers at 2 years’ follow-up within the tested patient population  
 
Model adjusted for risk factors 
 
Model further adjusted for acute effects 










interval  P-value 
Randomization to late vs. early initiation of PN -1.957 -3.694 -0.220 0.027 -1.914 -3.668 -0.159 0.032 
Centre         
     Leuven vs. Edmonton 1.562 -5.918 9.041 0.68 2.358 -5.310 10.026 0.54 
     Rotterdam vs. Edmonton 0.874 -6.632 8.380 0.81 0.959 -6.726 8.644 0.80 
Male vs. female sex 0.936 -0.884 2.755 0.31 0.883 -0.934 2.699 0.33 
Right vs. left hand preference  0.355 -2.296 3.006 0.79 0.456 -2.136 3.049 0.72 
Medium vs. high STRONGkids risk levela -0.073 -3.217 3.071 0.96 0.190 -3.019 3.398 0.90 
Diagnostic category (as compared with Cardiac 
surgery)         
     Surgical         
          Abdominal -2.385 -6.209 1.438 0.22 -2.290 -6.145 1.565 0.24 
          Burns -0.358 -16.758 16.043 0.96 -1.153 -18.197 15.892 0.89 
          Neurosurgery - traumatic brain injury 1.129 -2.417 4.674 0.53 0.907 -2.639 4.453 0.61 
          Thoracic -3.311 -7.540 0.919 0.12 -3.228 -7.490 1.034 0.13 
          Transplantation 5.501 -2.154 13.157 0.15 5.628 -3.204 14.460 0.20 
          Orthopedic surgery-trauma 1.015 -4.352 6.381 0.71 0.939 -4.431 6.310 0.73 
          Other 3.183 -1.648 8.015 0.19 2.623 -2.336 7.581 0.29 
     Medical          
          Cardiac 2.776 -2.502 8.053 0.30 2.040 -3.474 7.553 0.46 
          Gastrointestinal-hepatic 13.837 -1.403 29.076 0.074 13.620 -1.592 28.832 0.079 
          Hematologic-oncologic 0.069 -8.634 8.773 0.98 -1.756 -11.000 7.488 0.70 
 
 
          Neurologic -0.205 -4.378 3.967 0.92 -0.703 -4.941 3.536 0.74 
          Respiratory  -1.146 -5.067 2.776 0.56 -1.620 -5.670 2.430 0.43 
          Other -1.400 -6.082 3.282 0.55 -1.681 -6.540 3.179 0.49 
Infant (age<1y) vs. child at randomization -0.047 -1.996 1.901 0.96 -0.008 -2.034 2.017 0.99 
Malignancy vs. no malignancy 0.192 -3.858 4.243 0.92 0.267 -3.816 4.350 0.89 
Diabetes vs. no diabetes 2.021 -20.625 24.666 0.86 3.172 -19.481 25.826 0.78 
Syndrome vs. no syndromeb 4.615 1.484 7.746 0.0040 4.650 1.463 7.838 0.0044 
PIM3 score (per point added)c 0.140 -0.764 1.044 0.76 0.057 -0.887 1.002 0.90 
PeLOD score first 24 hrs (per point added)d 0.005 -0.111 0.121 0.93 -0.011 -0.128 0.106 0.85 
Known non-European origin vs. other e 1.902 -2.060 5.864 0.34 1.933 -2.039 5.904 0.33 
Known non-Caucasian vs. othere -4.294 -9.338 0.750 0.094 -4.159 -9.193 0.874 0.10 
Known not exclusive Dutch or English language vs. 
other -0.479 -3.185 2.227 0.72 -0.525 -3.243 2.193 0.70 
Socioeconomic status         
  Educational level parents (as compared with level 1)f         
          Educational level 1.5 -3.383 -8.510 1.743 0.19 -2.849 -8.040 2.342 0.28 
          Educational level 2 -2.252 -6.601 2.098 0.30 -1.850 -6.234 2.533 0.40 
          Educational level 2.5 -3.961 -8.586 0.663 0.092 -3.364 -8.009 1.280 0.15 
          Educational level 3 -3.754 -8.451 0.943 0.11 -3.251 -7.998 1.496 0.17 
          Educational level unknown -2.156 -7.533 3.221 0.42 -1.668 -7.105 3.770 0.54 
   Occupational level parents (as compared with level 1)g        
          Occupational level 1.5 1.617 -6.176 9.410 0.68 1.218 -6.597 9.034 0.75 
          Occupational level 2 1.903 -5.876 9.682 0.63 1.382 -6.410 9.174 0.72 
          Occupational level 2.5 1.416 -6.695 9.528 0.73 0.718 -7.412 8.847 0.86 
          Occupational level 3 0.828 -7.068 8.724 0.83 0.237 -7.661 8.135 0.95 
 
 
          Occupational level 3.5 -2.904 -11.297 5.489 0.49 -3.499 -11.894 4.896 0.41 
          Occupational level 4 1.026 -7.130 9.183 0.80 0.218 -7.962 8.399 0.95 
          Occupational level unknown 1.409 -6.541 9.359 0.72 0.899 -7.064 8.861 0.82 
Parental smoking between birth and PICU admission 
vs. no smoking 0.770 -1.592 3.131 0.51 0.858 -1.503 3.219 0.47 
New infection vs. no new infection     0.261 -3.320 3.843 0.88 
Duration of stay in the PICU (per day added)     -0.042 -0.328 0.244 0.77 
Days with hypoglycemic event (per day added)     -0.262 -2.237 1.714 0.79 
Duration of mechanical ventilatory support (per day added)    -0.090 -0.288 0.108 0.36 
Duration of treatment with antibiotics (per day added)    0.070 -0.206 0.346 0.61 
Duration of hemodynamic support (per day added)     -0.048 -0.249 0.153 0.63 
Duration of treatment with corticosteroids (per day added)    0.053 -0.279 0.386 0.75 
Duration of treatment with opioids (per day added)     -0.103 -0.389 0.183 0.48 
Duration of treatment with benzodiazepines (per day added)    0.328 0.067 0.590 0.014 
Duration of treatment with hypnotics (per day added)     0.032 -0.254 0.319 0.82 
Duration of treatment with α2-agonists (per day added)    -0.235 -0.495 0.025 0.076 
PeLOD, Paediatric Logistic Organ Dysfunction score; PICU, paediatric intensive care unit; PIM3, Paediatric Index of Mortality 3 score; PN, parenteral 
nutrition. For meta-cognition as reported by parents, higher scores reflect worse performance. a Scores on the Screening Tool for Risk on Nutritional 
Status and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, 
and a score of 4 to 5 indicating high risk.  b A prerandomisation syndrome or illness a priori defined as affecting or possibly affecting neurocognitive 
development (Methods S2). c Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality. d Paediatric Logistic 
Organ Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness. e Paarticipants were classified according to 
race and geographical origin by the investigators. These classifications were performed to capture ethnical and regional differences in the frequency of 
consanguinity, which may adversely affect cognitive performance.18 f The education level is the average of the paternal and maternal educational level, 
and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal 
Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level (Methods S1). g The occupation 
level is the average of the paternal and maternal occupation level, which is calculated based upon the International Isco System 4-point scale for 




Table S1-4. Multivariable linear regression analyses determining significant and independent associations between risk factors and overall executive 
functioning as reported by the parents/caregivers at 2 years’ follow-up within the tested patient population  
 
Model adjusted for risk factors 
 
Model further adjusted for acute effects 










interval  P-value 
Randomization to late vs. early initiation of PN -2.258 -4.012 -0.504 0.011 -2.181 -3.953 -0.409 0.015 
Centre         
     Leuven vs. Edmonton 3.856 -3.580 11.291 0.30 4.479 -3.043 12.001 0.24 
     Rotterdam vs. Edmonton 3.164 -4.370 10.699 0.40 2.874 -4.744 10.493 0.45 
Male vs. female sex 0.990 -0.826 2.806 0.28 0.977 -0.841 2.796 0.29 
Right vs. left hand preference  0.295 -2.397 2.986 0.82 0.404 -2.232 3.039 0.76 
Medium vs. high STRONGkids risk levela -0.324 -3.425 2.777 0.83 -0.053 -3.211 3.106 0.97 
Diagnostic category (as compared with Cardiac surgery)        
     Surgical         
          Abdominal -2.051 -5.824 1.722 0.28 -1.943 -5.732 1.847 0.31 
          Burns 1.883 -14.275 18.041 0.81 0.303 -16.376 16.983 0.97 
          Neurosurgery - traumatic brain injury 2.165 -1.441 5.770 0.23 1.896 -1.712 5.505 0.30 
          Thoracic -1.916 -6.216 2.383 0.38 -1.812 -6.154 2.529 0.41 
          Transplantation 6.550 -0.796 13.896 0.080 6.490 -1.812 14.793 0.12 
          Orthopedic surgery-trauma 0.235 -5.239 5.710 0.93 0.026 -5.466 5.517 0.99 
          Other 4.937 0.015 9.858 0.049 4.123 -0.923 9.168 0.10 
     Medical          
          Cardiac 2.858 -2.373 8.089 0.28 1.891 -3.581 7.362 0.49 
          Gastrointestinal-hepatic 13.977 -1.084 29.038 0.068 13.632 -1.377 28.640 0.074 
          Hematologic-oncologic 1.544 -7.245 10.333 0.73 -0.418 -9.711 8.875 0.92 
 
 
          Neurologic -0.445 -4.596 3.706 0.83 -1.077 -5.314 3.160 0.61 
          Respiratory  -0.999 -4.628 2.631 0.58 -1.492 -5.206 2.223 0.42 
          Other  -0.949 -5.599 3.701 0.68 -1.363 -6.189 3.464 0.57 
Infant (age<1y) vs. child at randomization 0.317 -1.608 2.242 0.74 0.386 -1.634 2.406 0.70 
Malignancy vs. no malignancy -0.038 -4.162 4.085 0.98 -0.131 -4.290 4.028 0.95 
Diabetes vs. no diabetes 2.475 -20.377 25.328 0.83 4.192 -18.640 27.025 0.71 
Syndrome vs. no syndromeb 5.082 2.013 8.152 0.0012 5.296 2.202 8.390 0.00086 
PIM3 score (per point added)c 0.194 -0.695 1.082 0.66 0.121 -0.805 1.048 0.79 
PeLOD score first 24 hrs (per point added)d 0.026 -0.089 0.140 0.66 0.009 -0.107 0.125 0.88 
Known non-European origin vs. othere 1.782 -2.000 5.563 0.35 1.779 -2.001 5.559 0.35 
Known non-Caucasian vs. othere -4.530 -9.283 0.222 0.061 -4.265 -9.022 0.492 0.078 
Known not exclusive Dutch or English language vs. 
other 0.066 -2.585 2.718 0.96 -0.003 -2.665 2.659 0.99 
Socioeconomic status         
 Educational level parents (as compared with level 1)f         
          Educational level 1.5 -3.958 -9.112 1.196 0.13 -3.283 -8.492 1.927 0.21 
          Educational level 2 -2.614 -7.009 1.782 0.24 -2.119 -6.552 2.314 0.34 
          Educational level 2.5 -4.118 -8.777 0.541 0.083 -3.422 -8.103 1.259 0.15 
          Educational level 3 -4.625 -9.360 0.111 0.055 -4.032 -8.806 0.742 0.097 
          Educational level unknown -0.202 -5.678 5.273 0.94 0.386 -5.139 5.910 0.89 
 Occupational level parents (as compared with level 1)g        
          Occupational level 1.5 2.929 -4.880 10.738 0.46 2.240 -5.573 10.053 0.57 
          Occupational level 2 3.469 -4.305 11.244 0.38 2.652 -5.129 10.433 0.50 
          Occupational level 2.5 3.334 -4.693 11.361 0.41 2.298 -5.752 10.348 0.57 
          Occupational level 3 2.959 -4.955 10.873 0.46 2.159 -5.758 10.077 0.59 
 
 
          Occupational level 3.5 -0.484 -8.917 7.948 0.91 -1.317 -9.760 7.125 0.75 
          Occupational level 4 3.326 -4.857 11.508 0.42 2.245 -5.979 10.468 0.59 
          Occupational level unknown  
2.792 -5.114 10.698 0.48 2.085 -5.836 10.006 0.60 
Parental smoking between birth and PICU admission 
vs. no smoking 1.022 -1.242 3.285 0.37 1.144 -1.108 3.396 0.31 
New infection vs. no new infection     -0.356 -3.782 3.070 0.83 
Duration of stay in the PICU (per day added)     0.045 -0.236 0.326 0.75 
Days with hypoglycemic event (per day added)     -0.670 -2.632 1.293 0.50 
Duration of mechanical ventilatory support (per day added)    -0.123 -0.323 0.076 0.22 
Duration of treatment with antibiotics (per day 
added)     -0.017 -0.282 0.247 0.89 
Duration of hemodynamic support (per day added)     -0.071 -0.272 0.130 0.48 
Duration of treatment with corticosteroids (per day added)    0.073 -0.251 0.396 0.65 
Duration of treatment with opioids (per day added)     -0.102 -0.381 0.177 0.47 
Duration of treatment with benzodiazepines (per day added)    0.368 0.111 0.625 0.0050 
Duration of treatment with hypnotics (per day added)     0.078 -0.206 0.363 0.58 
Duration of treatment with α2-agonists (per day added)    -0.260 -0.516 -0.003 0.047 
PeLOD, Paediatric Logistic Organ Dysfunction score; PICU, paediatric intensive care unit; PIM3, Paediatric Index of Mortality 3 score; PN, parenteral 
nutrition. For overall executive functioning as reported by parents, higher scores reflect worse performance. a Scores on the Screening Tool for Risk 
on Nutritional Status and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 in-dicating 
medium risk, and a score of 4 to 5 indicating high risk.  b A prerandomization syndrome or illness a priori defined as affecting or possibly affecting 
neurocognitive development (Methods S2). c Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality. d 
Paediatric Logistic Organ Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness. e Participants were 
classified according to race and geographical origin by the investigators. These classifications were performed to capture ethnical and regional 
differences in the frequency of consanguinity, which may adversely affect cognitive performance.18 f The education level is the average of the paternal 
and maternal educational level, and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; 
statbel.fgov.be/nl/) and the Centraal Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level 
(Methods S1). g The occupation level is the average of the paternal and maternal occupation level, which is calculated based upon the International 
Isco System 4-point scale for professions (Methods S1).http://www.ilo.org/public/english/bureau/stat/isco/. 
 
 
Table S1-5. Multivariable linear regression analyses determining significant and independent associations between risk factors and externalising 
problems as reported by the parents/caregivers at 2 years’ follow-up within the tested patient population  
 
Model adjusted for risk factors 
 
Model further adjusted for acute 
effects of Late-PN vs Early-PN and 









interval  P-value 
Randomization to late vs. early initiation of PN -1.715 -3.325 -0.106 0.036 -1.810 -3.441 -0.179 0.029 
Centre         
     Leuven vs. Edmonton 4.664 -1.959 11.287 0.16 4.377 -2.421 11.175 0.20 
     Rotterdam vs. Edmonton 3.024 -3.740 9.787 0.37 2.464 -4.455 9.383 0.48 
Male vs. female sex 1.483 -0.241 3.207 0.091 1.427 -0.303 3.157 0.10 
Right vs. left hand preference  0.103 -2.410 2.616 0.93 0.159 -2.327 2.645 0.89 
Medium vs. high STRONGkids risk levela -0.069 -2.880 2.742 0.96 0.170 -2.702 3.042 0.90 
Diagnostic category (as compared with Cardiac surgery)         
     Surgical         
          Abdominal 0.597 -2.874 4.068 0.73 0.672 -2.793 4.138 0.70 
          Burns 8.641 -6.396 23.679 0.25 8.965 -6.524 24.454 0.25 
          Neurosurgery - traumatic brain injury 3.809 0.528 7.089 0.022 3.699 0.412 6.985 0.027 
          Thoracic -1.001 -5.006 3.004 0.62 -0.765 -4.811 3.280 0.70 
          Transplantation 7.503 0.677 14.328 0.031 8.683 0.985 16.381 0.027 
          Orthopedic surgery-trauma -0.017 -5.137 5.102 0.99 -0.105 -5.263 5.053 0.96 
          Other 2.924 -1.639 7.487 0.20 2.192 -2.432 6.815 0.35 
     Medical          
          Cardiac 2.955 -2.044 7.954 0.24 2.199 -3.080 7.479 0.41 
          Gastrointestinal-hepatic 10.723 -4.646 26.091 0.17 10.571 -4.771 25.913 0.17 
 
 
          Hematologic-oncologic 7.972 -0.416 16.361 0.062 7.727 -1.147 16.600 0.087 
          Neurologic 2.384 -1.535 6.303 0.23 2.119 -1.908 6.146 0.30 
          Respiratory  1.392 -1.909 4.693 0.40 1.040 -2.386 4.467 0.55 
          Other 
-0.018 -4.367 4.330 0.99 -0.257 -4.787 4.273 0.91 
Malignancy vs. no malignancy -3.056 -7.042 0.931 0.13 -3.143 -7.173 0.887 0.12 
Diabetes vs. no diabetes 15.073 -6.806 36.951 0.17 15.892 -5.983 37.767 0.15 
Syndrome vs. no syndromeb 1.066 -1.763 3.895 0.45 1.180 -1.693 4.052 0.41 
PIM3 score (per point added)c 0.067 -0.752 0.886 0.87 -0.051 -0.904 0.801 0.90 
PeLOD score first 24 hrs (per point added)d 0.054 -0.052 0.161 0.31 0.041 -0.067 0.150 0.45 
Known non-European origin vs. othere -0.480 -4.171 3.210 0.79 -0.425 -4.123 3.272 0.82 
Known non-Caucasian vs. othere -2.054 -6.511 2.404 0.36 -1.933 -6.383 2.517 0.39 
Known not exclusive Dutch or English language vs. other 2.015 -0.467 4.496 0.11 1.989 -0.496 4.474 0.11 
Socioeconomic status         
     Educational level parents (as compared with level 1)f         
          Educational level 1.5 -1.008 -5.866 3.851 0.68 -0.433 -5.377 4.510 0.86 
          Educational level 2 0.382 -3.730 4.494 0.85 0.763 -3.413 4.939 0.71 
          Educational level 2.5 -1.791 -6.206 2.624 0.42 -1.300 -5.762 3.163 0.56 
          Educational level 3 -2.165 -6.604 2.274 0.33 -1.684 -6.184 2.815 0.46 
          Educational level unknown 1.718 -2.986 6.422 0.47 2.140 -2.621 6.900 0.37 
     Occupational level parents (as compared with level 1)g         
          Occupational level 1.5 0.469 -7.078 8.015 0.90 0.079 -7.465 7.624 0.98 
          Occupational level 2 2.858 -4.657 10.373 0.45 2.361 -5.147 9.869 0.53 
          Occupational level 2.5 1.806 -5.933 9.546 0.64 1.312 -6.437 9.060 0.73 
          Occupational level 3 1.638 -6.002 9.277 0.67 1.398 -6.242 9.039 0.71 
 
 
          Occupational level 3.5 -0.323 -8.366 7.719 0.93 -0.465 -8.512 7.583 0.90 
          Occupational level 4 0.810 -7.026 8.647 0.83 0.287 -7.581 8.154 0.94 
          Occupational level unknown 0.795 -6.737 8.326 0.83 0.450 -7.064 7.963 0.90 
Parental smoking between birth and PICU admission vs. no 
smoking 2.017 -0.063 4.096 0.057 2.142 0.071 4.214 0.042 
New infection vs. no new infection     -0.771 -3.886 2.344 0.62 
Duration of stay in the PICU (per day added)     0.112 -0.157 0.381 0.41 
Days with hypoglycemic event (per day added)     1.425 -0.477 3.328 0.14 
Duration of mechanical ventilatory support (per day added)     -0.113 -0.295 0.070 0.22 
Duration of treatment with antibiotics (per day added)     -0.062 -0.314 0.189 0.62 
Duration of hemodynamic support (per day added)     -0.101 -0.286 0.084 0.28 
Duration of treatment with corticosteroids (per day added)     -0.055 -0.363 0.253 0.72 
Duration of treatment with opioids (per day added)     -0.111 -0.371 0.150 0.40 
Duration of treatment with benzodiazepines (per day 
added)     0.304 0.064 0.544 0.013 
Duration of treatment with hypnotics (per day added)     0.042 -0.226 0.310 0.76 
Duration of treatment with α2-agonists (per day added)     -0.200 -0.446 0.046 0.11 
PeLOD, Paediatric Logistic Organ Dysfunction score; PICU, paediatric intensive care unit; PIM3, Paediatric Index of Mortality 3 score; PN, parenteral 
nutrition. For externalising problems as reported by parents, higher scores reflect worse performance. a Scores on the Screening Tool for Risk on 
Nutritional Status and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating 
medium risk, and a score of 4 to 5 indicating high risk.  b A prerandomisation syndrome or illness a priori defined as affecting or possibly affecting 
neurocognitive development (Methods S2). c Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality. d 
Paediatric Logistic Organ Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness. e Participants were classified 
according to race and geographical origin by the investigators. These classifications were performed to capture ethnical and regional differences in the 
frequency of consanguinity, which may adversely affect cognitive performance.18 f The education level is the average of the paternal and maternal 
educational level, and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and 
the Centraal Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level (Methods S1). g The 
occupation level is the average of the paternal and maternal occupation level, which is calculated based upon the International Isco System 4-point scale 
for professions (Methods S1).http://www.ilo.org/public/english/bureau/stat/isco/. 
 
 
Table S1-6. Multivariable linear regression analyses determining significant and independent associations between risk factors and visual-motor 
integration at 2 years’ follow-up within the tested patient population  
Variable 
Model adjusted for risk factors 
 
Model further adjusted for acute 
effects of Late-PN vs Early-PN and 








interval  P-value 
Randomization to late vs. early initiation of PN 0.468 0.087 0.850 0.016 0.422 0.037 0.807 0.031 
Centre         
     Leuven vs. Edmonton 5.647 3.729 7.566 <0.0001 5.449 3.506 7.391 <0.0001 
     Rotterdam vs. Edmonton 4.879 3.032 6.727 <0.0001 4.834 2.961 6.708 <0.0001 
Male vs. female sex -0.789 -1.178 -0.400 <0.0001 -0.794 -1.185 -0.403 <0.0001 
Right vs. left hand preference  0.544 -0.091 1.179 0.092 0.542 -0.101 1.185 0.098 
Medium vs. high STRONGkids risk levela 0.339 -0.334 1.013 0.32 0.270 -0.417 0.958 0.44 
Diagnostic category (as compared with Cardiac surgery)         
     Surgical         
          Abdominal 0.449 -0.358 1.255 0.27 0.372 -0.436 1.180 0.36 
          Burns 0.585 -3.065 4.235 0.75 1.054 -2.699 4.807 0.58 
          Neurosurgery - traumatic brain injury -0.037 -0.786 0.713 0.92 0.031 -0.717 0.778 0.93 
          Thoracic 0.630 -0.273 1.533 0.17 0.528 -0.380 1.436 0.25 
          Transplantation -1.738 -3.224 -0.253 0.021 -1.099 -2.725 0.527 0.18 
          Orthopedic surgery-trauma -2.207 -3.346 -1.069 0.00015 -2.236 -3.378 -1.094 0.00013 
          Other 0.245 -0.849 1.340 0.65 0.289 -0.817 1.395 0.60 
     Medical          
          Cardiac 0.128 -1.022 1.277 0.82 0.333 -0.894 1.560 0.59 
          Gastrointestinal-hepatic 0.245 -2.770 3.260 0.87 0.239 -2.761 3.239 0.87 
 
 
          Hematologic-oncologic 1.275 -0.776 3.326 0.22 1.891 -0.263 4.045 0.085 
          Neurologic -0.472 -1.371 0.427 0.30 -0.268 -1.189 0.652 0.56 
          Respiratory  0.506 -0.233 1.246 0.17 0.445 -0.315 1.206 0.25 
          Other 
-0.180 -1.188 0.827 0.72 -0.279 -1.324 0.767 0.60 
Infant (age<1y) vs. child at randomization 1.228 0.799 1.657 <0.0001 1.179 0.736 1.622 <0.0001 
Malignancy vs. no malignancy 0.014 -0.945 0.972 0.97 0.196 -0.771 1.163 0.69 
Diabetes vs. no diabetes 0.511 -4.802 5.823 0.85 -0.090 -5.383 5.204 0.97 
Syndrome vs. no syndromeb -1.336 -1.985 -0.687 <0.0001 -1.474 -2.125 -0.823 <0.0001 
PIM3 score (per point added)c 0.017 -0.169 0.203 0.85 0.028 -0.163 0.219 0.77 
PeLOD score first 24 hrs (per point added)d -0.015 -0.039 0.010 0.23 -0.012 -0.037 0.013 0.34 
Known non-European origin vs. othere -0.144 -0.901 0.613 0.70 -0.133 -0.888 0.622 0.72 
Known non-Caucasian vs. othere -0.278 -1.197 0.642 0.55 -0.333 -1.250 0.585 0.47 
Known not exclusive Dutch or English language vs. other 0.350 -0.231 0.932 0.23 0.381 -0.201 0.962 0.19 
Socioeconomic status         
     Educational level parents (as compared with level 1)f         
          Educational level 1.5 0.121 -1.036 1.279 0.83 0.029 -1.143 1.201 0.96 
          Educational level 2 0.500 -0.469 1.469 0.31 0.413 -0.565 1.391 0.40 
          Educational level 2.5 0.419 -0.614 1.451 0.42 0.319 -0.717 1.355 0.54 
          Educational level 3 0.988 -0.062 2.037 0.062 0.883 -0.173 1.939 0.10 
          Educational level unknown 0.235 -0.769 1.238 0.64 0.080 -0.931 1.091 0.87 
     Occupational level parents (as compared with level 1)g         
          Occupational level 1.5 0.643 -1.186 2.472 0.49 0.807 -1.015 2.630 0.38 
          Occupational level 2 0.687 -1.140 2.515 0.46 0.808 -1.016 2.631 0.38 
          Occupational level 2.5 0.899 -0.990 2.789 0.35 1.075 -0.812 2.961 0.26 
 
 
          Occupational level 3 1.079 -0.766 2.924 0.25 1.228 -0.610 3.065 0.19 
          Occupational level 3.5 0.669 -1.295 2.634 0.50 0.766 -1.193 2.725 0.44 
          Occupational level 4 0.392 -1.520 2.304 0.68 0.625 -1.286 2.536 0.52 
Parental smoking between birth and PICU admission vs. 
no smoking -0.247 -0.729 0.235 0.31 -0.293 -0.765 0.180 0.22 
New infection vs. no new infection     0.043 -0.672 0.759 0.90 
Duration of stay in the PICU (per day added)     -0.026 -0.089 0.037 0.41 
Days with hypoglycemic event (per day added)     0.256 -0.175 0.687 0.24 
Duration of mechanical ventilatory support (per day added)    0.026 -0.015 0.068 0.21 
Duration of treatment with antibiotics (per day added)     0.027 -0.033 0.086 0.37 
Duration of hemodynamic support (per day added)     -0.025 -0.068 0.019 0.26 
Duration of treatment with corticosteroids (per day added)    -0.078 -0.148 -0.007 0.030 
Duration of treatment with opioids (per day added)     0.022 -0.039 0.084 0.47 
Duration of treatment with benzodiazepines (per day added)    -0.035 -0.093 0.022 0.22 
Duration of treatment with hypnotics (per day added)     -0.053 -0.118 0.011 0.10 
Duration of treatment with α2-agonists (per day added)     0.078 0.021 0.134 0.0074 
PeLOD, Paediatric Logistic Organ Dysfunction score; PICU, paediatric intensive care unit; PIM3, Paediatric Index of Mortality 3 score; PN, parenteral 
nutrition. For visual-motor integration, higher scores reflect better performance. a Scores on the Screening Tool for Risk on Nutritional Status and 
Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score 
of 4 to 5 indicating high risk.  b A prerandomisation syndrome or illness a priori defined as affecting or possibly affecting neurocognitive development 
(Methods S2). c Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality. d Paediatric Logistic Organ 
Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness. e Participants were classified according to race and 
geographical origin by the investigators. These classifications were performed to capture ethnical and regional differences in the frequency of 
consanguinity, which may adversely affect cognitive performance.18 f The education level is the average of the paternal and maternal educational level, 
and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal 
Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level (Methods S1). g The occupation level 
is the average of the paternal and maternal occupation level, which is calculated based upon the International Isco System 4-point scale for professions 
(Methods S1).http://www.ilo.org/public/english/bureau/stat/isco/.
                        
 
Table S2. Comparison of patients randomised to late parenteral nutrition during PICU stay with 
healthy control children for the tests significantly affected by the randomised intervention 
Neurocognitive function P-value 
Visual-motor integration 0.00052 
Externalising problems as reported by parents/caregivers 0.34 
Inhibition as reported by parents/caregivers 0.66 
Working memory as reported by parents/caregivers 0.032 
Meta-cognition index as reported by parents/caregivers 0.34 




Table S3. Impact of late versus early parenteral nutrition in infants for tests showing a significant 
interaction P-value with age group 
Variable Beta-estimate Confidence interval P-value 
Overall executive functioning -3.843 -6.361 -1.325 0.0029 
Meta-cognition -3.749 -6.244 -1.254 0.0034 
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A B S T R A C T  
Background: PEPaNIC randomised controlled trial, which recruited 1440 critically ill 
infants and children in 2012–15, showed that withholding parenteral nutrition for 1 week 
(late-parenteral nutrition), compared with early supplementation within 24 h of admission 
to the paediatric intensive care unit (early-parenteral nutrition), prevented infections, 
accelerated recovery, and improved neurocognitive development assessed 2 years later. 
Because several neurocognitive domains can only be thoroughly assessed from age 4 years 
onwards, we aimed to determine the effect of late-parenteral nutrition versus early-
parenteral nutrition on physical, neurocognitive, and emotional and behavioural 
development 4 years after randomization. 
 
Methods: This is a preplanned, blinded, 4-year follow-up study of participants included in 
the PEPaNIC trial (done at University Hospitals Leuven, Belgium; Erasmus Medical Centre 
Sophia Children’s Hospital, Rotterdam, Netherlands; and Stollery Children’s Hospital, 
Edmonton, AB, Canada) and of matched healthy children. Studied outcomes were 
anthropometrics; health status; parent-reported or caregiver-reported executive functions, 
and emotional and behavioural problems; and clinical tests for intelligence, visual-motor 
integration, alertness, motor coordination, and memory. Through multivariable linear and 
logistic regression analyses, after imputation for missing values (≤30%) and adjustment for 
risk factors, we investigated the effect of early-parenteral nutrition versus late-parenteral 
nutrition.  
 
Findings:  Between March 8, 2016, and Nov 8, 2019, 684 children from the original 
PEPaNIC trial (356 from the late parenteral nutrition group and 328 from the early-
parenteral nutrition group) were assessed for neurocognitive development at 4-years 
follow-up. Compared with the control group (369 healthy children), children who had 
critical illness had lower height (β-estimate –2.11 [95% CI –3.15 to –1.06]; p<0.0001) and 
head circumference (–0.42 [–0.67 to –0.18]; p=0.00077); and worse health status (e.g., 
hospital admission odds ratio 4.27 [95% CI 3.12 to 5.84]; p<0.0001), neurocognitive (e.g., 
parent-reported or caregiver-reported total executive functioning β-estimate 3.57 [95% CI 
1.95 to 5.18], p<0.0001; total intelligence quotient –7.35 [–9.31 to –5.39], p<0.0001), and 
parent-reported or caregiver-reported emotional and behavioural developmental outcomes 
(internalising 2.73 [1.19 to 4.28], p=0.00055; externalising 1.63 [0.19 to 3.08], p=0.027; and 
total behavioural problems 2.95 [1.44 to 4.46], p=0.00013), adjusted for risk factors. 
Outcomes were never worse in the late-parenteral nutrition group compared with the 
early-parenteral nutrition group, but patients in the late-parenteral nutrition group had 
fewer parent-reported or caregiver-reported internalising (β-estimate –1.88 [95% CI –3.69 
to –0.07]; p=0.042), externalising (–1.73 [–3.43 to –0.03]; p=0.046), and total emotional and 
behavioural problems (–2.44 [–4.22 to –0.67]; p=0.0070) than patients who had received 
                                                                
 
early-parenteral nutrition, after adjusting for risk factors, and were no longer different from 
healthy controls for these outcomes. 
 
Interpretation: Omitting early parenteral nutrition use for critically ill children did not 
adversely affect long-term outcomes 4 years after randomization and protected against 




                                                                
 
I N T R O D U C T I O N  
Critical illness in children is associated with impaired physical, neurocognitive, emotional, 
and behavioural development, which often persists for years after discharge from the 
paediatric intensive care unit and hospital.1,2 Over the past decade, avoidable intensive care-
related factors contributing to some long-term effects have been identified; these include 
hyperglycemia, phthalates leaching into the blood from indwelling medical devices, and the 
use of early-parenteral nutrition.3–5 The multicentre randomised controlled PEPaNIC trial6 
showed that postponing parenteral nutrition for 1 week in the paediatric intensive care unit 
(late-parenteral nutrition) has benefits over initiating parenteral nutrition within 24 h after 
admission to supplement insufficient enteral nutrition (early-parenteral nutrition), such as 
improved intensive care outcomes, as well as better executive functioning and visual-motor 
integration and reduced externalising behavioural problems at 2 years after admission to 
the intensive care unit.5 The improvements in neurocognitive development in the late-
parenteral nutrition group were found to be mediated by the differential DNA methylation 
status, in particular of 37 CpG sites related to genes involved in brain development.7 
 
A methodological limitation of the 2-year follow-up study of the PEPaNIC trial5 was the 
large proportion of patients who were younger than 4 years old when tested 
neurocognitively. Because of rapid brain development during the first years of life, 
assessment of most neurocognitive domains is only possible when the child is 4 years of age 
or older.8,9 As the child develops, impairments in physical or neurocognitive domains that 
were observed at 2 years follow-up could persist or disappear and other problems might 
emerge. Taken together, assessments at a later time point after critical illness are of value. 
We therefore did a 4-year follow-up study of the children included in the PEPaNIC trial to 
assess their health status, neurocognitive development, and emotional and behavioural 
outcomes. We aimed to compare these outcomes with data from matched children who 
had not had a critical illness, and to investigate the longer term effects of late-parenteral 
nutrition compared with early-parenteral nutrition. 
 
M E T H O D S  
Study design and participants 
In the PEPaNIC trial,6 1440 critically ill infants and children admitted to the participating 
paediatric intensive care units at University Hospitals Leuven, Leuven, Belgium; Erasmus 
Medical Centre, Sophia Children’s Hospital, Rotterdam, Netherlands; and Stollery 
Children’s Hospital, Edmonton, AB, Canada were enrolled from 2012 to 2015. The study 
protocol has been published.10 This study represents the preplanned 4-year follow-up of 
the original PEPaNIC trial.6 
 
                                                                
 
As described previously,5 during admission to a paediatric intensive care unit, parents or 
legal guardians of the patients provided consent to contact them for long-term follow-up 
testing. First, survival status was assessed by reviewing hospital notes, obtained through the 
national register or through contact with the general practitioner or referring paediatrician. 
After receiving a standardised information letter, survivors and parents or caregivers were 
contacted by telephone to obtain consent for scheduling an appointment for the medical 
and neurocognitive assessment, either at the hospital or at the patient’s home. For patients 
who could not be reached by telephone, survival status was reassessed at the end of the 
study. 
 
For comparison, 369 healthy children, demographically matched to the patients for age and 
sex, were recruited to a control group and underwent identical medical and neurocognitive 
assessment. Alongside unrelated children, healthy siblings and relatives of the patients were 
included to control as much as possible for genetic, socioeconomic, and environmental 
background. Healthy children were only included if they had not been previously admitted 
to a neonatal or paediatric intensive care unit, or admitted to hospital with need for an 
intravenous line for 7 days or more. History of inborn chronic metabolic diseases requiring 
a specific diet, such as diabetes, and conditions that require home parenteral nutrition, such 
as short bowel syndrome, were additional exclusion criteria. 
 
Parents, legal guardians, or patients (if they were ≥18 years old), gave written informed 
consent according to local regulations. The institutional review boards at each participating 
site approved this follow-up study (ML8052; NL49708.078; Pro00038098). 
 
Procedures, randomization, and masking 
After obtaining informed consent, children in the PEPaNIC trial6 were randomly assigned 
(1:1) to receive early parenteral nutrition, with parenteral nutrition initiated within 24 h of 
admission to the intensive care unit to supplement enteral nutrition whenever 80% of 
targeted calories per age and weight categories had not been reached, or late-parenteral 
nutrition, which meant that all parenteral nutrition was withheld for up to 1 week in the 
intensive care unit. For the late-parenteral nutrition group, this corresponded to no 
parenteral nutrition in most children. When enteral nutrition covered more than 80% of 
calculated targets, supplemental parenteral nutrition was discontinued. Total macronutrient 
doses administered on each of the first 7 days of admission are shown in the appendix. After 
1 week in the paediatric intensive care unit, parenteral nutrition could be administered when 
necessary in both groups. Enteral nutrition was initiated early in both groups equally, and all 
patients received intravenous micronutrients until fully enterally fed. 
 
Outcome assessors of the 4-year follow-up study were physicians and experienced 
paediatric psychologists who had not been involved in the management of the patients 
during their stay in the paediatric intensive care unit and who were strictly masked to 
                                                                
 
treatment allocation. Parents and caregivers were not masked while the child was treated 
in the paediatric intensive care unit and they were not actively informed about the initial 
PEPaNIC study results or the 2-year outcome results (which only became available near the 
end of the inclusions in the 4-year follow-up study).6 
 
Outcomes 
As done in the 2-year follow-up study,5 at 4-year follow-up, head circumference, body 
weight, and height were measured. A clinical neurological examination was done to assess 
gross neurological abnormalities. We used structured interviews with the parents or 
caregivers to assess whether the children had been diagnosed with a somatic or psychiatric 
illness, and whether they had been admitted to a hospital for medical or surgical reasons 
during the past 4 years (for the control group) and during the 4 years following admission 
to the paediatric intensive care unit (for the PEPaNIC participants). Neurocognitive 
testability was determined by screening the medical file or on clinical judgement before the 
start of the neurocognitive assessment by the physician or psychologist and confirmed by 
the parents or caregivers. 
 
To score performance for a broad range of neurocognitive functions, validated 
internationally recognised questionnaires and clinical tests with adequate normative data 
were used. Parent-reported questionnaires included the Behaviour Rating Inventory of 
Executive Function11,12 (executive functioning, T scores, with mean 50 and SD 10) and the 
Child Behaviour Checklist13,14 (emotional and behavioural problems, T scores, with mean 50 
and SD 10). On both questionnaires, higher scores indicate more problems. Clinical tests 
consisted of the age-appropriate versions of the Wechsler Intelligence Quotient Scale15-17 
(intelligence, standard scores, with mean 100 and SD 15), the Beery Developmental Test of 
Visual-Motor Integration18 (visuomotor integration, scaled score, with mean 10 and SD 3), 
tasks of the Amsterdam Neuropsychological Task Battery9 (for children aged 4 years or 
older), and the Children’s Memory Scale8 (for children aged 5–16 years). Tasks of the 
Amsterdam Neuropsychological Task Battery consisted of Amsterdam Neuropsychological 
Task Battery-Baseline Speed (alertness and reaction time) and Amsterdam 
Neuropsychological Task Battery-Tapping (motor coordination as number of taps). Tasks 
of the Children’s Memory Scale were Children’s Memory Scale-Numbers (verbal short-term 
memory and working memory, scaled scores with mean 10 and SD 3), Children’s Memory 
Scale-Word Pairs (short-term and long-term verbal memory, and recognition, proportion 
of correct responses ranging from 0 to 1), Children’s Memory Scale-Picture Locations 
(short-term visual memory as the proportion of correct responses), and Children’s Memory 
Scale-Dot Locations (short-term and long-term visual memory proportion of correct 
responses). The Children’s Memory Scale-Learning index represents learning abilities of the 
child (standard score, with mean 100 and SD 15). For the clinical tests, a higher score 
indicates better functioning, with the exception of Amsterdam Neuropsychological Task 
                                                                
 
Battery-Baseline Speed. An extended description of the questionnaires and of the clinical 
and neuropsychological test battery is reported in the appendix. 
 
Statistical analysis 
For patients in the PEPaNIC trial who were alive and testable 4 years later, we estimated a 
loss to follow-up of about 30%, on the basis of previous studies.3,5 With this sample size, we 
calculated that we would have more than 80% statistical power to detect, with a certainty 
of more than 95%, a minimal clinically relevant four point difference in intelligence quotient 
(IQ) and clinically relevant differences of a median 5.8% (IQR 3.8–8.0) or mean of 7.6% (SD 
7.9) in the other outcomes between patients in the early-parenteral nutrition and late 
parenteral nutrition groups, based on previous data.3,5 For the healthy control group, a 
sample size of 369 allows detection, with a power of more than 80% and certainty of more 
than 95%, of a difference in IQ of four points with the patients and median differences 
between patients and the control group of 5.2% (IQR 3.5–7.3) and a mean difference of 
7.9% (11.2) in the other outcomes that were studied previously.3,5 
 
Inability to fully complete the neurocognitive test battery could indicate poor neurocognitive 
function and thus introduce bias. Similarly to the 2-year follow-up study,5 missing values 
were imputed by chained equations, with use of all available data for each individual 
(Appendix).19 Imputation of data for age specific tests was only done within the respective 
age group. Bias and instability of the imputation model was minimised by only including 
outcomes with no more than 30% missing data.19 The number of imputation models was set 
at 31 to avoid the loss of statistical power (Appendix).19 
 
Univariable comparison of the pooled data from the imputed models was done with the 
Fisher exact test, Student t test, or Wilcoxon rank-sum test as appropriate. Multivariable 
linear and logistic regression analyses were done on the 31 imputed datasets with the pooled 
β-estimates or odds ratios reported to investigate the differences in outcomes between 
patients and healthy control children, and to analyse the differences between the two groups 
in PEPaNIC.5 All multivariable analyses adjusted for covariates, as pre-specified in the 
statistical analysis plan, and the analyses were done as reported in the 2-year follow-up 
study.5,10 For the comparison of patients who were critically ill with children in the control 
group, the analyses adjusted for the baseline risk factors, age, treatment centre, sex, race, 
geographic origin, language, hand preference, history of malignancy, a predefined syndrome 
(Appendix), and the educational and occupational status of the parents and caregivers 
(Appendix). Additional adjustment for admission diagnosis, severity of illness upon paediatric 
intensive care unit-admission (paediatric index of mortality 3 and paediatric logistic organ 
dysfunction scores), risk of malnutrition (Screening Tool for Risk On Nutritional Status and 
Growth), and parental smoking behaviour before admission to the paediatric intensive care 
unit was done for the comparison of the late-parenteral nutrition group with the early-
parenteral nutrition group. Acute effects of the random allocation on acquisition of new 
                                                                
 
infections and on the duration of hypoglycemia, ventilatory support, and stay in the 
paediatric intensive care unit could potentially mediate any long-term effect and thus further 
adjustment for these factors was done in the multivariable models. In addition, further 
adjustment was done for other post-randomization treatments that could theoretically play 
a role (duration of hemodynamic support, treatment with antibiotics, corticosteroids, 
opioids, benzodiazepines, hypnotics, and α2-agonists). Statistical analyses were done with 
use of R (version 3.5.3), MICE (versions 3.4.0 and 3.6.0), and JMP (version 14.0.0). Two-
sided p values of 0.05 or less were considered statistically significant. As the studied 
developmental outcomes are not independent (Appendix), correction for multiple 
comparisons was not done.7,20  
 
R E S U L T S  
Of the children included in the original PEPaNIC trial, done between June 18, 2012, and July 
27, 2015, 71 (10%) of 723 patients in the early-parenteral nutrition group and 66 (9%) of 
717 patients in the late-parenteral nutrition group did not survive to 4 years follow-up 
(p=0.69; Figure 1). For 18 patients survival status was unknown. A total of 247 patients in 
the early-parenteral nutrition group and 222 patients in the late-parenteral nutrition group 
survived but declined participation or were not contactable (p=0.47). Hence, loss to follow-
up was 34% (487 of 1440). At follow-up, 73 (10%) patients in the early-parenteral nutrition 
group and 59 (8%) patients in the late parenteral nutrition group were too disabled for 
neurocognitive testing (p=0.21) and were excluded from the analyses. For transparency, any 
available clinical data or questionnaire results for these patients are provided in the 
appendix, (pp 15–17). 684 (48%) children from the original study and 369 healthy controls 
underwent neurocognitive testing between March 8, 2016, and November 8, 2019, and 
were included in the imputation models for subsequent multivariable analyses. 
Neurocognitive testing was done at the hospital for 442 (65%) children who had been 
critically ill and 301 (82%) children in the control group (p<0.0001), with no differences in 
the place of assessment between patients in the late-parenteral nutrition and the early-
parenteral nutrition groups (p=0.99). Demographics and medical characteristics of children 
who had been critically ill and children in the control group are shown in Table 1. Overall, 
random assignment and primary and secondary intensive care outcomes of patients who 
were tested at 4-year follow-up were similar to the initial PEPaNIC study population. 
 
In univariable and multivariable comparison, at 4-years follow-up children who had been 
critically ill had worse outcomes for height, weight, head circumference, health status, 
clinically assessed neurological functioning, parent-reported or caregiver-reported 
executive functioning and emotional and behavioural problems and clinical tests for 
intelligence, visual-motor integration, alertness, motor-coordination, and memory than 
children in the control group (Table 2).  
                                                                
 
Figure 1. Study profile 
PICU, paediatric intensive care unit. STRONGkids, Screening Tool Risk On Nutritional Status and 
Growth 
  
                                                                
 
Compared with patients who had been allocated to early parenteral nutrition, patients in 
the late-parenteral nutrition group had similar height, weight, body-mass index, and head 
circumference, and clinically assessed neurological functioning in univariable and 
multivariable analysis (Table 2). In univariable analyses, fewer patients in the late parenteral 
nutrition group were admitted to hospital and parents or caregivers of these children 
reported fewer internalising, externalising, and total emotional and behavioural problems 
and fewer problems regarding flexibility compared with patients who received early 
parenteral nutrition (Table 2; Figure 2). After adjustment for risk factors, the finding of fewer 
internalising, externalising, and total emotional and behavioural problems in the late 
parenteral nutrition group than in the early-parenteral nutrition group remained (Table 2; 
Appendix). For internalising and externalising problems as well as total emotional and 
behavioural problems, children in the late parenteral nutrition group were not different 
from children in the control group (Appendix). 
 
Differences in intensive care outcomes of the randomised intervention and other post-
randomization factors overall did not explain the observed differences at 4-years follow-up 
(Appendix). Of note, treatment with benzodiazepines was independently associated with 
worse outcome, whereas α2-agonist treatment was associated with better outcome. 
 
D I S C U S S I O N  
4 years after critical illness, children were found to still have a disease legacy characterised 
by broad abnormalities in all investigated developmental domains, including growth, health 
status, and neurocognitive, and emotional and behavioural functioning, a finding that 
confirmed previously reported observations.3 Our results show that omission of 
supplemental parenteral nutrition in the first week of the child’s time in the intensive care 
unit did not harm physical and neurocognitive development and that these patients had 
fewer emotional and behavioural problems compared with children who received early-
parenteral nutrition. 
 
At 4-year follow-up, the legacy of critical illness affected all developmental domains. The 
extent to which these abnormalities are acquired during intensive care remains debated.22 
However, the developmental legacy documented 4 years after critical illness was found to 
remain present after adjustment for all known baseline risk factors at intensive care unit 
admission. The documented developmental abnormalities are relevant because they are 
known to have direct implications for daily life and hamper future societal perspectives.2,23,24 
Moreover, the developmental impairment after paediatric critical illness is at least as 
pronounced as what has been reported for children who survived cancer25–27 and for 
children with chronic diseases such as type 1 diabetes and chronic kidney disease.28,29 
 
                                                                
 
Of note, the emotional and behavioural problems—such as internalising, externalising, and 
other issues—were preventable by omitting the use of early-parenteral nutrition in the 
paediatric intensive care unit. Internalising problems are evidenced by anxious and 
depressive symptoms, and by social withdrawal,13,14 which are the consequences of over-
controlling behaviour. Externalising problems are externally directed problems that affect 
the environment and become apparent in aggressive and delinquent behaviour, which result 
in conflicts with others. The total score for the emotional and behavioural problems includes 
internalising and externalising behavioural problems, sleep problems for younger children, 
and social, thinking, and attention problems for older children. Such issues are thought to 
be in part a consequence of poor development of executive functions, such as poor 
inhibitory control.30,31 This might explain why, at 2-year follow-up, we found that not being 
exposed to early-parenteral nutrition predominantly reduced abnormal inhibitory control;5 
whereas, 2 years later, the effect on the emotional and behavioural problems became more 
apparent.  
 
The developing brain of children thus appears vulnerable to metabolic insults during periods 
of critical illness. We previously showed that tight glycemic control during intensive care 
prevented impaired motor coordination 4 years after admission,3 an impairment that was 
less apparent in patients of the PEPaNIC trial, who had received at least some form of blood 
glucose control. In addition to avoiding pronounced hyperglycemia, omitting early-
parenteral nutrition during critical illness protected the normal development of other 
neurobiological pathways that coordinate emotions and behaviour. This indicates that the 
neurocognitive legacy of paediatric critical illness is multifactorial, and improvement can only 
be expected by a stepwise elimination of various causal factors. The stepwise elimination of 
harmful factors will need the support of clinical guidelines to help the implementation or 
de-implementation of certain interventions, such as the latest European Society for 
Paediatric Gastroenterology Hepatology and Nutrition, European Society for Clinical 
Nutrition and Metabolism, European Society for Paediatric Research, and Chinese Society 
of Parenteral and Enteral Nutrition joint guidelines on paediatric parenteral nutrition.32 
Nevertheless, even though progress has been made, our findings show that children who 
have been critically ill clearly still face important developmental problems. Thus, the setting 
up of a structured post critical illness follow-up consultation is necessary for these children, 
with referral to a specialised health-care professional (e.g., clinical psychologist or 
psychiatrist) who can initiate an appropriate intervention when warranted. 
 
This study has some limitations to highlight. First, for the clinical tests that assessed inhibition 
and flexibility, missing data for more than 30% of the population did not allow imputation 
and thus no information on differences between the groups could be provided. Second, 
neuroimaging studies were not done because of ethical and practical considerations. Third, 
we did not correct for multiple comparisons because the studied developmental outcomes 
are not independent, as shown by the correlations in the outcomes reported, which makes 
                                                                
 
use of the stringent Bonferroni correction inappropriate. Although the risk of false-positive 
findings cannot be completely excluded, we did find a significant effect of early-parenteral 
nutrition versus late-parenteral nutrition on caregiver-reported emotional and behavioural 
problems. The strengths of the study include the limited loss to follow-up compared with 
other long-term follow-up studies of children with critical illness33,34 and the broad 
assessment of the physical, neurocognitive, and emotional and behavioural development of 
patients and matched control children. 
 
C O N C L U S I O N S 
4 years after critical illness, an important physical, neurocognitive, and emotional and 
behavioural legacy was reported. The omission of early-parenteral nutrition did not harm 
any of the developmental domains and protected patients against parent-reported or 
caregiver-reported emotional and behavioural problems, which were no longer 
overrepresented in patients in the late parenteral nutrition group compared with healthy 
controls. These data support de-implementation of the use of parenteral nutrition early 
during critical illness in infants and children. The findings also open perspectives for future 
identification of other modifiable risk factors related to intensive care management. 
                                                                
 
Table 1. Demographics, post-randomization treatments in the PICU, and acute outcomes of patients and healthy control children 

















Demographics        
Age at 4-years’ follow-up -  yr 7.5 (4.3) 7.3 (4.3)  NA NA 7.4 (4.3) 7.2 (4.2) 
Sex  













   Female 167 (45.3%) 291 (42.5%) 308 (42.6%) 305 (42.5%) 141 (43.0%) 150 (42.1%) 
Known non-Caucasian racea 27 (7.3%)  53 (7.8%) 50 (6.9%) 33 (4.6%) 33 (10.1%) 20 (5.6%) 
Known non-European origina 45 (12.2%) 129 (18.9%) 161 (22.3%) 128 (17.9%) 73 (22.3%) 56 (15.7%) 
Known not exclusive Dutch or 
English language 
71 (19.2%) 158 (23.1%) 122 (16.9%) 106 (14.8%)  78 (23.8%) 80 (22.5%) 
Socioeconomic status         
     Educational level parentsb        
          Educational level 1 12 (3.3%) 30 (4.4%)  NA NA 10 (3.1%) 20 (5.6%) 
          Educational level 1.5 13 (3.5%) 51 (7.5%)  NA NA 29 (8.5%) 22 (6.2%) 
          Educational level 2 47 (12.7%) 157 (23.0%)  NA NA 75 (22.9%) 82 (23.0%) 
          Educational level 25 68 (18.4%) 116 (17.0%)  NA NA 53 (16.2%) 63 (17.7%) 
          Educational level 3 207 (56.1%) 183 (26.8%)  NA NA 86 (26.2%) 97 (27.3%) 
          Educational level unknown 22 (6.0%) 147 (21.5%)  NA NA 75 (22.9%) 72 (20.2%) 
     Occupational level parentsc        
          Occupational level 1 2 (0.5%) 7 (1.0%)  NA NA 1 (0.3%) 6 (1.7%) 
          Occupational level 1.5 20 (5.4%) 63 (9.2%)  NA NA 23 (7.0%) 40 (11.2%) 
          Occupational level 2 42 (11.4%) 108 (15.8%)  NA NA 50 (15.2%) 58 (16.3%) 
          Occupational level 2.5 25 (6.8%) 69 (10.1%)  NA NA 39 (11.9%) 30 (8.4%) 
          Occupational level 3 80 (21.7%) 118 (17.3%)  NA NA 52 (15.9%) 66 (18.5%) 
          Occupational level 3.5 40 (10.8%) 53 (7.8%)  NA NA 30 (9.2%) 23 (6.5%) 
          Occupational level 4 117 (31.7%) 102 (14.9%)  NA NA 44 (13.4%) 58 (16.3%) 
          Occupational level unknown 43 (11.7%) 164 (24.0%)  NA NA  89 (27.1%) 75 (21.1%) 
Patient characteristics upon PICU admission       
Infant (age<1y) at randomization   NA 331 (48.4%) 328 (45.4%) 325 (45.3%) 153 (46.7%) 178 (50.0%) 
STRONGkids risk leveld        
                                                                
 
     Medium NA 613 (89.6%) 644 (89.1%) 644 (89.8%) 291 (88.7%) 322 (90.5%) 
     High NA 71 (10.4%) 79 (10.9%) 73 (10.2%) 37 (11.3%) 34 (10.0%) 
PeLOD score, first 24h in PICU e NA 20.0 (11.6) 19.7 (12.0) 20.1 (12.3) 19.4 (11.6) 20.5 (11.5) 
PIM3 scoref NA -3.5 (1.4)  -3.2 (1.6) -3.2 (1.7) -3.4 (1.4) -3.5 (1.3) 
PIM3 probability of death - % g 
 
NA 6.6 (11.7) 9.4 (15.9) 9.1 (17.4) 6.9 (11.9) 6.4 (11.7) 
Diagnostic category        
     Surgical        
          Abdominal NA 68 (9.9%)  53 (7.3%) 60 (8.4%) 34 (10.4%) 34 (10.0%) 
          Burns NA 3 (0.4%)  5 (0.7%) 5 (0.7%) 2 (0.6%) 1 (0.3%) 
          Cardiac NA 291 (42.5%) 279 (38.6%) 268 (37.4%) 137 (41.8%) 154 (43.3%) 
          Neurosurgery-Traumatic brain 
injury 
NA 58 (8.5%)  63 (8.7%) 53 (7.4%) 31 (9.5%) 27 (7.6%) 
          Thoracic NA 38 (5.6%)  34 (4.7%) 27 (3.8%) 21 (6.4%) 17 (4.8%) 
          Transplantation NA  11 (1.6%)  7 (1.0%) 17 (2.4%) 3 (0.9%) 8 (2.3%) 
          Orthopedic surgery-Trauma NA 19 (2.8%)  28 (3.9%) 26 (3.6%) 12 (3.7%) 7 (2.0%) 
          Other NA 25 (3.7%)  21 (2.9%) 27 (3.8%) 11 (3.4%) 14 (3.9%) 
     Medical        
          Cardiac NA 23 (3.4%)  30 (4.2%) 31 (4.3%) 8 (2.4%) 15 (4.2%) 
          Gastrointestinal-Hepatic NA 2 (0.3%)  2 (0.3%) 4 (0.6%) 1 (0.3%) 1 (0.3%) 
          Oncologic-Hematologic NA 6 (0.9%)  8 (1.1%) 7 (1.0%) 2 (0.6%) 4 (1.1%) 
          Neurologic NA 42 (6.1%)  51 (7.1%) 52 (7.3%) 19 (5.8%) 23 (6.5%) 
          Renal NA 0 (0.0%)  1 (0.1%) 1 (0.1%) 0 (0.0%) 0 (0.0%) 
          Respiratory NA 70 (10.2%) 99 (13.7%) 96 (13.4%) 33 (10.1%) 37 (10.4%) 
          Other NA 28 (4.1%)  42 (5.8%) 43 (6.0%) 14 (4.3%) 14 (3.9%) 
Malignancy  0 (0.0%) 38 (5.6%)  51 (7.1%) 33 (4.6%) 22 (6.7%) 16 (4.5%) 
Diabetes  0 (0.0%)  0 (0.0%)  3 (0.4%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Syndromeh  2 (0.5%)  63 (9.2%) 123 (17.0%) 118 (16.5%) 26 (7.9%) 37 (10.4%) 
Known parental smoking between 
birth and PICU admission  
NA 151 (22.1%)  NA NA 69 (23.1%) 82 (24.5%) 
Acute effects of randomization in PICU       
Duration of stay in the PICU – days NA 7.8 (16.0) 9.2 (21.3) 6.5 (10.0) 9.3 (19.8) 6.5 (11.2) 
Patients who acquired a new 
infection in PICU  
NA 96 (14.0%) 134 (18.5%) 77 (10.7%) 59 (18.0%) 37 (10.4%) 
                                                                
 
Duration of mechanical ventilatory 
support – days 
NA 5.0 (11.7) 6.4 (18.6) 4.4 (7.3) 6.0 (15.0) 4.0 (7.4) 
Number of days with hypoglycemia 
<40 mg/dl – days 
NA 0.1 (0.5)  0.1 (0.6) 0.2 (0.6) 0.1 (0.5) 0.2 (0.6) 
Post-randomization treatments effects       
Duration of antibiotic treatment – 
days 
NA 5.4 (14.2) 6.7 (19.0) 4.6 (8.7) 6.6 (17.7) 4.4 (9.8) 
Duration of hemodynamic support – 
days 
NA 2.7 (7.7)  3.0 (7.4) 2.4 (6.2) 2.9 (8.2) 2.5 (7.3) 
Duration of treatment with opioids – 
days 
NA 5.0 (9.3) 6.1 (16.5) 4.1 (6.2) 5.8 (11.5) 4.2 (6.5) 
Duration of treatment with 
benzodiazepines – days 
NA 4.4 (10.2) 5.4 (16.7) 4.0 (8.8) 4.9 (10.5) 4.0 (10.0) 
Duration of treatment with hypnotics 
– days 
NA 1.5 (6.0)  1.8 (6.3) 1.3 (3.1) 1.8 (8.1) 1.1 (3.0) 
Duration of treatment with alpha-2-
agonists – days 
NA 1.1 (6.8)  1.1 (8.7) 1.0 (6.0) 1.1 (6.4) 1.1 (7.1) 
Duration of treatment with 
corticosteroids - days  
NA 1.2 (3.9)  1.6 (4.3) 1.3 (3.9) 1.4 (4.5) 1.1 (3.3) 
Data are n (%) or mean (SD). a Participants were classified according to race and geographical origin by the investigators. These classifications were 
performed to capture ethnical and regional differences in the frequency of consanguinity, which may adversely affect cognitive performance. b The 
education level is the average of the paternal and maternal educational level, and calculated based upon the 3-point scale subdivisions as made by the 
Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle 
(=2) and high (=3) educational level (Methods S4). c The occupation level is the average of the paternal and maternal occupation level, which is calculated 
based upon the International Isco System 4-point scale for professions (Methods S4). d Scores on the Screening Tool for Risk on Nutritional Status and 
Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a score 
of 4 to 5 indicating high risk. e Paediatric Logistic Organ Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe 
illness. f Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality. g Paediatric Index of Mortality 3 (PIM3) 
probability of death, ranging from 0% to 100%, with higher percentages indicating a higher probability of death in PICU. h A pre-randomization syndrome 
or illness a priori defined as affecting or possibly affecting neurocognitive development (Methods S3). BMI, body mass index; NA, not applicable (values 
only known when the patients were seen at follow-up, or not applicable for healthy control children); PeLOD, paediatric logistic organ dysfunction score; 
PICU, paediatric intensive care unit; PIM3, paediatric index of mortality 3 score; PN, parenteral nutrition; SD, standard deviation. i Overall, demographics 
upon PICU admission, allocation to late or early parenteral nutrition, and ICU or hospital-related primary and secondary study endpoints were 
comparable between the PEPaNIC patients who were tested (N=684) and those patients who survived, but declined participation or could not be 
reached (N=469, Table S2). 
                                                                
 
Table 2. Pooled univariable analyses of the differences in the outcomes assessed at 4 years’ follow-up between patients and healthy control 
children and between late-PN and early-PN patient groups 
  Tested populations Tested PICU population 


































Height – cm 1012 (96.1%) 124.7 (23.4) 121.1 (23.2) 0.02 122.1 (23.1)     120.8 
(23.2) 
0.26 
    Z-scoreb 1012 (96.1%) 0.40 (0.99) -0.03 (1.23) <0.0001 0.04 (1.22) -0.09 (1.25) 0.16 
Weight – kg 1004 (95.3%) 28.0 (16.5) 27.0 (17.1) 0.33 27.2 (16.5)  26.7 (17.5)  0.70 
     Z-scoreb 1004 (95.3%) 0.32 (0.87) 0.12 (1.17) 0.005 0.17 (1.18) 0.08 (1.17) 0.55 
BMI - kg/m2 1003 (95.3%) 16.68 (2.94) 16.86 (3.33) 0.69 16.84 (3.13) 16.89 (3.50) 0.56 
     Z-scoreb 1003 (95.3%) 0.12 (1.00) 0.21 (1.17) 0.25 0.17 (1.43) 0.09 (1.26) 0.19 
Head circumference – cm 1008 (95.7%) 52.5 (2.3) 52.0 (2.7) 0.001  52.1 (2.8) 51.8 (2.6) 0.27 
     Z-scoreb 1008 (95.7%) 0.49 (1.08) 0.13 (1.34) <0.0001 0.17 (1.43) 0.09 (1.26) 0.19 
Diagnosed with a somatic illness 840 (79.8%) 120 (32.4) 370 (54.0) <0.0001 180 (54.6) 190 (53.5) 0.70 
Diagnosed with a psychiatric illness 960 (91.2%) 16 (4.3) 63 (9.2) 0.005 32 (9.5) 31 (8.9) 0.81 
Admitted to hospital for a medical or 
surgical reason  
1011 (96.0%) 101 (27.3) 453 (66.2) <0.0001 230 (70.0) 223 (62.7) 0.05 
Clinical neurological evaluation score 
(range, 0-8)a 
970 (92.1%) 0.2 (0.6) 0.6 (1.3) <0.0001 0.7 (1.4) 0.5 (1.2) 0.09 
Executive functioning as reported by 
parents/caregivers - T-score a c 
       
                                                                
 
          Inhibition 918 (89.9%) 45.7 (9.8) 49.8 (13.2) <0.0001 50.8 (13.3) 49.0 (12.6) 0.07 
          Flexibility 919 (90.0%) 45.7 (8.5) 49.3 (11.8) <0.0001 50.2 (12.2) 48.5 (11.2) 0.05 
          Emotional control 919 (90.0%) 46.2 (9.4) 48.9 (11.2) <0.0001 49.5 (11.3) 48.4 (11.0) 0.18 
          Working memory 918 (89.9%) 46.4 (9.6) 51.9 (13.5) <0.0001 52.7 (13.7) 51.1 (12.6) 0.12 
          Planning and organization 917 (89.8%) 46.3 (9.5) 50.4 (12.8) <0.0001 50.6 (12.8) 50.2 (12.0) 0.60 
          Meta-cognition index 916 (89.7%) 45.6 (9.8) 50.6 (13.2) <0.0001 50.9 (13.5) 50.2 (12.4) 0.51 
          Total score 915 (89.6%) 44.8 (9.8) 49.9 (13.2) <0.0001 50.5 (13.3) 49.2 (12.5) 0.18 
        
Emotional and behavioural problems as 
reported by  
parents/caregivers - T-score a c 
      
 
          Internalising problems  940 (92.1%) 46.7 (10.5) 51.0 (12.3) <0.0001 52.1 (12.1) 50.0 (12.2) 0.02 
          Externalising problems  940 (92.1%) 45.6 (9.7) 48.8 (11.2) <0.0001 49.7 (11.0) 47.9 (11.1) 0.03 
          Total problems  940 (92.1%) 45.4 (9.9) 50.1 (11.9) <0.0001 51.5 (11.6) 48.8 (11.9) 0.003 
Intelligence (range, 45-155) a          
     Total IQ 940 (92.1%) 105.7 (13.4) 93.1 (18.2) <0.0001 93.2 (17.0) 93.0 (18.2) 0.89 
     Verbal IQ  940 (92.1%) 107.5 (14.4) 95.2 (19.0) <0.0001 93.2 (16.0) 92.5 (16.2) 0.56 
     Performance IQ 940 (92.1%) 102.7 (13.2) 92.9 (16.2) <0.0001 94.8 (18.3) 95.6 (18.6) 0.56 
Visual-motor integration (range, 0.9-20) a 1025 (97.3%) 10.0 (2.1) 8.7 (3.1) <0.0001 8.7 (3.1) 8.7 (2.7) 0.88 
Alertness and motor coordination a c         
     Alertness a c d        
          Reaction time right hand – Z-score 739 (72.0%) 0.8 (4.3) 1.7 (12.6) 0.03 1.7 (8.9) 1.7 (9.4) 0.65 
          Within subject SD of repeated 
tests – Z-score 
739 (72.0%) 1.1 (3.4) 2.0 (8.5) <0.0001 2.0 (6.1) 2.0 (6.4) 0.68 
          Reaction time left hand – Z-score 752 (73.3%) 0.3 (2.5) 1.0 (5.8) <0.0001 1.0 (4.3) 1.1 (4.5) 0.64 
                                                                
 
          Within subject SD of repeated 
tests – Z-score 
752 (73.3%) 1.0 (2.5) 1.7 (4.0) <0.0001 1.6 (3.3) 1.7 (3.2) 0.59 
     Motor coordination (No of taps in 
10s) a c 
       
          No of unimanual taps        
               Right hand 816 (79.5%) 34.6 (29.6) 32.6 (52.3) 0.12 32.7 (40.0) 32.5 (37.0) 0.76 
               Left hand  816 (79.5%) 30.5 (32.3) 28.9 (60.4) 0.18 29.1 (46.0) 28.7 (41.7) 0.65 
          No of valid alternating taps   742 (72.3%) 22.9 (30.0) 19.7 (56.8) 0.05 19.6 (43.8) 19.9 (40.7) 0.71 
          No of valid synchronous taps   785 (76.5%) 16.5 (18.3) 13.2 (27.9) <0.0001 12.9 (21.9) 13.5 (20.5) 0.47 
Memory a c        
     Verbal-auditory        
           Numbers (range, 1-19)        
               Memory span (forward) 418 (85.1%) 9.9 (3.1) 8.7 (4.3) <0.0001 9.0 (4.0) 8.5 (3.6) 0.18 
               Working memory (backward) 394 (80.2%) 10.3 (3.1) 9.5 (5.3) 0.01 9.7 (4.5) 9.3 (4.3) 0.24 
          Word pairs (proportion of correct responses)       
               Learning 350 (71.2%) 0.5 (0.2) 0.4 (0.4) <0.0001 0.4 (0.4) 0.4 (0.3) 0.67 
               Immediate memory 346 (70.5%) 0.4 (0.5) 0.4 (1.3) 0.07 0.4 (1.0) 0.4 (0.9) 0.55 
               Delayed memory 343 (69.9%) 0.4 (0.7) 0.4 (1.6) 0.12 0.4 (1.3) 0.4 (1.1) 0.43 
               Recognition  343 (69.9%) 0.9 (0.5) 0.9 (1.3) 0.15 0.9 (0.9) 0.9 (0.9) 0.46 
     Non-verbal, visual-spatial        
          Pictures (proportion of correct    
          responses) 
404 (82.2%) 0.8 (0.1) 0.8 (0.2) <0.0001 0.8 (0.2) 0.8 (0.2) 0.74 
      Dots (proportion of correct responses)       
               Learning 370 (75.4%) 0.9 (0.2) 0.8 (0.4) 0.001 0.8 (0.4)  0.8 (0.3) 0.26 
               Immediate memory 367 (74.7%) 0.9 (0.3) 0.8 (0.7) 0.01 0.8 (0.5) 0.8 (0.5) 0.27 
               Delayed memory 361 (73.5%) 0.8 (0.4) 0.7 (1.1) 0.004 0.7 (0.8) 0.7 (0.8) 0.66 
                                                                
 
     Learning index (range, 50-150) 341 (69.5%) 101.0 (22.6) 88.1 (33.2) <0.0001  88.5 (27.4) 87.7 (25.8) 0.65 
Results are presented in numbers with proportions (%) or mean (SD) from the 31 datasets combined generated by multiple data imputation by chained 
equations under a ‘missing at random’ assumption for the 684 post-PICU patients and 369 healthy control children.  a For the clinical neurological 
evaluation score, higher scores reflect worse performance. For parent-reported executive functioning and emotional and behavioural problems, higher 
scores reflect worse performance. For intelligence and visual-motor integration, higher scores reflect better performance. For reaction time alertness 
and within-subject SD of repeated tests, higher scores reflect worse performance. For motor coordination, higher scores reflect better performance. 
For memory tests, higher scores reflect better performance.  b Age- and gender-adjusted Z-scores, were calculated with the use of reference data from 
the World Health Organization Growth Charts: http://www.bcchildrens.ca/Services/SpecializedPediatrics/EndocrinologyDiabetesUnit/ 
ForProfessionals/AnthropometricCalculators.htm. c For alertness, motor coordination, executive functions, emotional and behavioural problems and 
memory, applicable imputation was limited to relevant age-ranges. d For alertness, age adjusted Z-scores were calculated and imputed in the dataset 




                                                                
 
Table 3. Multivariable linear and logistic regression analyses of the differences in the outcomes assessed at 4 years’ follow-up between patients and 
healthy control children and between late-PN and early-PN patient groups 
   
    







Beta-estimate or odds 
ratio    
(95% CI) for the 
comparison patients 
vs. controls,  
adjusted for risk 
factorsd P-value 
Beta-estimate or odds 
ratio   
(95% CI) for the 
comparison  
late PN vs. early PN,  




 N=1053     
      
Height – cm 1012 (96.1%) -2.108 (-3.152 to -1.063) <0.0001 -0.814 (-3.448 to 1.820) 0.54 
Weight – kg 1004 (95.3%)  -0.091 (-0.966 to 0.785) 0.83 0.129 (-2.047 to 2.304) 0.91 
Head circumference – cm 1008 (95.7%) -0.421 (-0.665 to -0.176) 0.0007 -0.113 (-0.461 to 0.234) 0.52 
Diagnosed with a somatic illness 840 (79.8%) 2.232 (1.635 to 3.047) e <0.0001 0.974 (0.683 to 1.390) e 0.88 
Diagnosed with a psychiatric illness 960 (91.2%) 2.465 (1.248 to 4.871) e 0.009 1.035 (0.562 to 1.905) e 0.91 
Admitted to hospital for a medical or surgical 
reason 
1011 (96.0%) 4.269 (3.120 to 5.842) e <0.0001 0.715 (0.501 to 1.020) e 0.06 
Clinical neurological evaluation score (range, 0-
8)a 
970 (92.1%) 0.237 (0.098 to 0.376) 
0.0008 
-0.098 (-0.275 to 0.079) 
0.28 
Executive functioning as reported by 





          Inhibition 918 (89.9%) 2.685 (1.059 to 4.310) 0.001 -1.665 (-3.643 to 0.313) 0.10 
          Flexibility 919 (90.0%) 2.706 (1.259 to 4.153) 0.0002 -1.487 (-3.283 to 0.309) 0.10 
                                                                
 
          Emotional control 919 (90.0%) 2.061 (0.601 to 3.520) 0.005 -1.189 (-2.938 to 0.560) 0.18 
          Working memory 918 (89.9%) 3.695 (2.096 to 5.293) <0.0001 -1.375 (-3.328 to 0.577) 0.17 
          Planning and organization 917 (89.8%) 2.866 (1.327 to 4.406) 0.0002 -0.380 (-2.270 to 1.511) 0.69 
          Meta-cognition index 916 (89.7%) 3.334 (1.714 to 4.954) <0.0001 -0.610 (-2.580 to 1.359) 0.54 
          Total score 915 (89.6%) 3.566 (1.950 to 5.183) <0.0001 -1.266 (-3.246 to 0.714) 0.21 
Emotional and behavioural problems as 





          Internalising problems  940 (92.1%) 2.730 (1.185 to 4.275) 0.0005 -1.880 (-3.690 to -0.071) 0.042 
          Externalising problems  940 (92.1%) 1.631 (0.185 to 3.076) 0.02 -1.731 (-3.433 to -0.028) 0.046 
          Total problems  940 (92.1%) 2.951 (1.443 to 4.459) 0.0001 -2.442 (-4.215 to -0.668) 0.007 
Intelligence (range, 45-155) a      
     Total IQ  937 (89.0%)  -7.349 (-9.311 to -5.387) <0.0001 -1.100 (-3.399 to 1.198) 0.35 
     Verbal IQ  931 (88.4%) -6.955 (-8.986 to -4.924) <0.0001 -0.126 (-2.493 to 2.241) 0.92 
     Performance IQ 943 (89.6%) -5.968 (-7.905 to -4.030) <0.0001 -1.645 (-3.902 to 0.612) 0.15 
Visual-motor integration (range, 0.9-20) a 1025 (97.3%)  -0.888 (-1.202 to -0.574 ) <0.0001 -0.081 (-0.448 to 0.286) 0.66 
Alertness and motor coordination a b        
     Alertness a b c      
          Reaction time right hand – Z-score 739 (72.0%) 0.668 (0.186 to 1.150) 0.007 0.077 (-0.334 to 0.489) 0.71 
               Within subject SD of repeated tests – 
Z-score 
739 (72.0%) 0.663 (0.254 to 1.071) 
0.001 
0.020 (-0.393 to 0.434) 
0.92 
          Reaction time left hand – Z-score 752 (73.3%) 0.498 (0.177 to 0.819) 0.002 0.141 (-0.221 to 0.502) 0.44 
               Within subject SD of repeated tests – 
Z-score 
752 (73.3%) 0.476 (0.168 to 0.784) 
0.002 
0.173 (-0.166 to 0.512) 
0.32 
     Motor coordination (No of taps in 10s) a b      
          No of unimanual taps      
               Right hand  816 (79.5%) -1.762 (-3.448 to -0.076) 0.04 0.240 (-1.844 to 2.325)  0.82 
                                                                
 
               Left hand  816 (79.5%) -1.720 (-3.415 to -0.024) 0.04 0.094 (-1.893 to 2.081) 0.93 
          No of valid alternating taps  742 (72.3%) -2.412 (-4.848 to 0.023) 0.05 0.503 (-2.202 to 3.209) 0.71 
          No of valid synchronous taps  785 (76.5%) -2.066 (-3.348 to -0.783) 0.001 0.354 (-1.192 to 1.901) 0.65 
Memory a b      
     Verbal-auditory      
           Numbers (range, 1-19)      
               Memory span (forward) 418 (85.1%) -0.644 (-1.270 to -0.019) 0.04 -0.601 (-1.371 to 0.168) 0.12 
               Working memory (backward) 394 (80.2%) -0.165 (-0.781 to 0.450) 0.59 -0.323 (-1.047 to 0.400) 0.38 






               Learning 350 (71.3%) -0.081 (-0.122 to -0.040) 0.0001 -0.021 (-0.060 to 0.019) 0.30 
               Immediate memory 346 (70.5%) -0.040 (-0.101 to 0.021) 0.19 -0.030 (-0.089 to 0.026) 0.31 
               Delayed memory 343 (70.0%) -0.034 (-0.098 to 0.029) 0.28 -0.012 (-0.088 to 0.064) 0.76 
               Recognition 434 (70.0%) -0.033 (-0.084 to 0.018) 0.20 -0.010 (-0.048 to 0.027) 0.58 
     Non-verbal, visual-spatial      
          Pictures (proportion of correct 
responses) 
404 (82.3%)  -0.029 (-0.056 to -0.003) 
0.02 
0.008 (-0.028 to 0.044) 
0.68 
          Dots (proportion of correct responses)      
               Learning 370 (75.4%) -0.046 (-0.080 to -0.012) 0.007 0.007 (-0.040 to 0.054) 0.77 
               Immediate memory 367 (74.7%) -0.053 (-0.102 to -0.003) 0.03 -0.012 (-0.073 to 0.050) 0.70 
               Delayed memory 361 (73.5%) -0.078 (-0.148 to -0.007) 0.03 0.005 (-0.071 to 0.080) 0.90 
     Learning index (range, 50-150) 341 (70.0%) -10.216 (-13.883 to -
6.549) 
<0.0001 
-1.383 (-5.351 to 2.585) 
0.49 
      
Results are the combined beta-estimates and odds ratios from 31 datasets generated by multiple data imputation by chained equations under a ‘missing 
at random’ assumption for the 684 patients and 369 healthy control children.  a For the clinical neurological evaluation score, higher scores reflect worse 
performance. For parent-reported executive functioning and emotional and behavioural problems, higher scores reflect worse performance. For 
                                                                
 
intelligence and visual-motor integration, higher scores reflect better performance. For reaction time alertness and within-subject SD of repeated tests, 
higher scores reflect worse performance. For motor coordination, higher scores reflect better performance. For memory tests, higher scores reflect 
better performance.  b For alertness, motor coordination, executive functions, emotional and behavioural problems and memory, applicable imputation 
was limited to relevant age-ranges. c For alertness, age adjusted Z-scores were calculated and imputed in the dataset d Estimates and odds ratios were 
adjusted for the following risk factors: age, centre, race, gender, geographic origin, language, hand preference, history of malignancy, a predefined 
“syndrome”, and the educational and occupational status of parents. e These values are odds ratios. f Estimates and odds ratios were adjusted for the 
following risk factors: age, centre, race, gender, geographic origin, language, hand preference, history of malignancy, a predefined “syndrome”, the 
educational and occupational status of parents, PIM3 score and PeLOD score upon PICU admission, STRONGkids risk category, and parental smoking 
behaviour prior to PICU admission. IQ, intelligence quotient; PeLOD score, paediatric logistic organ dysfunction score; PICU, paediatric intensive care 
unit PIM3 score, paediatric index of mortality 3 score; PN, parenteral nutrition SD, standard deviation; STRONGkids, Screening Tool Risk On 
Nutritional Status and Growth. Sensitivity analyses to the “missing at random’ assumption and with imputing worst test-scores for the severely disabled 
and thus non-testable children, as specified in the Methods S2, further supported the robustness of these results.    
 
                                                                
 
               
Figure 2. The effect of late-parenteral nutrition versus early parenteral nutrition on the development of long 
term emotional and behavioural problems. The figure represents the density estimates for total behavioural  
and emotional problems reported by parents or caregivers. Each line corresponds to an imputed dataset.  
Densities correspond to the proportions of children with a certain score (equivalent to a smoothed histogram). 
Higher scores indicate more total behavioural and emotional problems. PN: parenteral nutrition.
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A P P E N D I X  
Methods S1. Detailed description of outcome measures  
Medical assessment 
Anthropometric data 
At the beginning of the follow-up visit, height (in cm), body weight (in kg) and head 
circumference (in cm) were measured. 
 
Health status 
In an interview with the parents, the need for medical support of all kind during the past 
two years for healthy control children and during the 4 years following the index PICU 
admission for patients, was recorded. The hospital admissions because of surgery or a 
medical reason, and the occurrence of a psychiatric diagnosis were documented. 
 
Clinical neurological examination 
In order to assess whether there were gross neurological abnormalities, during a structured 
clinical neurological examination, signs of major neurologic dysfunction were detected in 
the following domains: interaction/language skills, gross motor function, involuntary 
movements, reflexes, coordination and balance, fine motor function, cranial nerves, and 
special senses (sensory, visual, and auditory function).  These were all scored normal or 
abnormal. An abnormal result for each of these domains was given 1 point and the sum was 
made of all the abnormal results, with a range of 0-8. 
 
Neurocognitive testing 
A broad range of neurocognitive functions, including general intellectual functioning, visual-
motor integration, alertness, motor coordination, verbal and visual-spatial learning, and 
memory were evaluated, as previously reported.1 
 
Patient/Parents-reported outcomes (PROs) 
Executive functioning was assessed with the Behaviour Rating Inventory of Executive 
Function in children aged years 6 months - 5 years 11 months with BRIEF-P, and in children 
6 years – 17 years 11 months with BRIEF, filled out by the parents/caregivers of the child. 
Overlapping scales and indices of both questionnaires (Inhibition, Flexibility, Emotional 
Control, Working Memory, Planning and Organization, Meta-cognition) and a Total Score 
were analysed (T-scores, with mean 50 and SD 10).2,3 Emotional and behavioural problems 
were assessed by the parent/caregiver with the Child behaviour Checklist (CBCL 1.5-5 years 
or CBCL 6-18 years).4,5 Internalising, externalising, and total problems were analysed (T-
scores, with mean 50 and SD 10).4,5 
 
Intelligence 
                                                                
 
General intellectual ability was assessed with use of age-appropriate versions of the 
Wechsler Intelligence Quotient (IQ) tests. The Wechsler Preschool and Primary Scale of 
Intelligence (WPPSI-III-NL)6 was used for children aged 3 years 6 months – 5 years 11 
months (one version for age range 3 years 6 months – 3 years 11 months, and another 
version for age range 4 years – 5 years 11 months), the Wechsler Intelligence Scale for 
Children (WISC-III-NL)7 was used for children aged 6 years – 16 years 11 months, and the 
Wechsler Adult Intelligence Scale (WAIS-IVNL) 8 for adolescents who were 17 years or 
older. For all these tests Total IQ, Verbal IQ, and Performance IQ scores (standard scores, 
with mean 100, SD 15) were computed. 
 
Visual-motor integration 
We used the Beery Developmental Test of Visual-Motor Integration, 6th Edition (VMI) to 
assess the ability to integrate visual and motor functions (scaled score, with mean 10 and 
SD 3). This involves eye-hand coordination.9 
 
Alertness and motor-coordination 
To measure alertness and motor coordination, the validated Amsterdam 
Neuropsychological Tasks (ANT) program was used.10 The ANT is a computerised 
assessment battery of reaction time (RT) tasks that allows for the systematic evaluation of 
information processing capacities. Children aged 4 years and older performed ANT-Baseline 
Speed (BS) and ANT-Tapping (TP). The ANT-BS evaluated alertness by measuring simple 
RT to visual stimuli (Z-scores of mean RT and SD of RT with mean 0 and SD 1 were obtained 
for the right and left hand separately). The ANT-TP assessed motor coordination for the 
right hand, left hand, bimanual alternating, and bimanual synchronous (number of taps,). 
 
Memory 
Auditory/verbal memory and Visual-spatial/non-verbal memory were assessed with use of 
four tests from the Children’s Memory Scale (CMS) for children aged between 5 and 16 
years 11 months.11 As to verbal memory, CMS-Numbers assessed short-term verbal 
memory span (forward digit recall) and verbal working memory load (backward digit recall). 
The CMS-Word Pairs (recall a list of word pairs) assessed short-term and long-term verbal 
memory, and recognition. As to non-verbal memory, CMS-Picture Locations (remembering 
and recall of pictures in various locations) assessed short-term visual memory. CMS-Dot 
Locations (remembering and recall of the location of dots) assessed short-term and long-
term visual memory. For CMS-Numbers, scaled scores (with mean 10 and SD 3) for verbal 
memory span, CMS-numbers forward, and verbal working memory load, CMS-numbers 
backward were reported. For CMS-Word Pairs, CMS-Picture Locations, and CMS-Dot 
Locations, proportional scores were analysed (proportion of correct responses ranging 
from 0 to 1, with higher scores reflecting better performance). The CMS-Learning index is 
a standardised score of the sum of the three learning trials of the CMS-Word Pairs and the 
                                                                
 
three learning trials of the CMS-Dot Locations subtests. The range of the score is 50-150, 
with a higher score representing a better learning ability. 
 
Methods S2. Imputation 
Missing data (excluding the deceased and the severely disabled whereby non-testable 
children) were handled by multiple data imputation with chained equations under a 
‘missing at random’ assumption. There were no missing data in the baseline variables. 
Predictors for missing values included all covariates listed below, and were retained in the 
predictor models with a minimum correlation of 0.1 with the prediction target. Predictive 
mean matching12 was used for numeric variables except for factors with two levels (which 
were imputed based on logistic regression) and factors with more than two levels (for which 
polytomous (unordered) regression was used). A monotonous visiting scheme was used 
such that variables for imputation were visited in increasing order of the number of missing 
data. Imputation convergence was assessed visually and set at 100 iterations (Figure S2) 31 
complete imputed datasets were used in the analyses,13 and pooled results were obtained 
across datasets using Rubin’s rules.14  
 
Plausibility of the imputations was assessed visually via the densities of the observed 
data and that resulting from the imputed values (Figure S3). Sensitivity of results to the 
‘missing at random’ assumption was assessed with use of pattern mixture models14-
16 assuming the original imputed values were either too high by a factor of 0.07 or too low 
by a factor of 0.1 for the main result of total emotional and behavioural problems as 
reported by parents/caregivers. Under this assumption, the obtained beta-estimates and P-
values for randomization to late-PN vs. early-PN for the multivariable linear regression 
analyses performed to determine significant and independent associations between risk 
factors and total emotional/behavioural problems as reported by the parents/caregivers at 
4 years’ follow-up within the tested patient population ranged from -1.98 (p=0.05) to -1.84 
(p=0.04). The effect-sizes thus remained of the same order of magnitude, sign, and statistical 
significance as observed for the original imputed datasets, which suggested that the analyses 
were robust against the investigated ‘missing at random’ violation. 
 
To further evaluate the robustness of the main findings, the analyses were repeated after 
imputing a penalised test result for all severely disabled and thus non-testable patients, 
defined as the worst result in the observed patients or controls, plus or minus one, as 
appropriate for each test. In this case, the obtained beta-estimates (P-values) for 
randomization to late-PN vs. early-PN for the multivariable linear regression analyses were 
respectively: A) -1.80 (p=0.05) for internalising emotional/behavioural problems as reported 
by the parents/caregivers B) -1.62 (p=0.06) for externalising emotional/behavioural 
problems as reported by the parents/caregivers and C) -2.36 (p=0.01) for total 
emotional/behavioural problems as reported by the parents/caregivers. These sensitivity 
analyses corresponded closely to the primary results as reported in Table 3 of the main 
                                                                
 
manuscript.  All multiple data imputation analyses were performed with R version 3.5.3 and 
MICE versions 3.4.0 and 3.6.0. 
 
List of variables used for multiple data imputation by chained equations 
Demographics of patients and control children and patient characteristics upon 
PICU admission 
Centre, randomization for late-PN or early-PN, patient vs. controls, race, gender, 
geographic origin, language, hand preference, history of malignancy, history of diabetes, a 
predefined “syndrome”, educational and occupational status of parents, diagnosis, PIM3 and 
PeLOD scores upon PICU admission, risk of malnutrition (STRONGkids category), parental 
smoking before, during and after pregnancy, age at randomization, age group at 
randomization. 
 
Acute effects of randomization and post-randomization treatments in PICU 
Acquisition of new PICU infections, duration of PICU stay, duration of mechanical 
ventilatory support, hypoglycemia, duration of treatment with hemodynamic support, 
antibiotics, corticosteroids, opioids, benzodiazepines, hypnotics and alpha-2-agonists. 
 
At 4-years’ follow-up 
Age, test location, height, weight, head circumference, composite endpoint “diagnosed with 
a somatic illness”, composite endpoint “diagnosed with a psychiatric illness”, composite 
endpoint “admitted to hospital for a medical or surgical reason”, clinical neurological 
examination, verbal IQ, performance IQ, total IQ, visual motor integration, Z-score reaction 
time left hand, Z-score reaction time right hand, Z-score within subject SD of reaction time 
left hand, Z-score within subject SD of reaction time left hand, number of unimanual taps 
right hand, number of unimanual taps left hand, number of valid alternating taps, number of 
valid synchronous taps, numbers memory span forward, numbers working memory 
backward, word pairs learning, word pairs immediate memory, word pairs delayed memory, 
word pairs recognition, pictures, dots learning, dots immediate memory, dots delayed 
memory, learning index, executive functioning as reported by parents/caregivers (inhibition, 
flexibility, emotional control, working memory, planning and organization, meta-cognition 
index, and total score), emotional and behavioural problems as reported by 
parents/caregivers (internalising problems, externalising problems, and total problems). 
 
 
Methods S3. Definition of “Syndrome” 
A pre-randomization syndrome or illness a priori defined as affecting or possibly affecting 
neurocognitive 
development, and which is subdivided in the following categories:17 
o Genetically confirmed syndrome or pathogenic chromosomal abnormality 
                                                                
 
o Clearly defined syndrome, association or malformation without (identified) genetic 
aberration 
o Polymalformative syndrome of unknown etiology 
o Clear auditory or visual impairment without specified syndrome 
o Congenital hypothyroidism due to thyroid agenesis 
o Brain tumor or tumor with intracranial metastatic disease 
o Paediatric psychiatric disorder (e.g. autism spectrum disorder, (treatment for) 
attention deficit hyperactivity 
o disorder) 
o Severe medical disorder, not primarily neurologic, but suspected to alter 
psychomotor and/or mental 
o performance 
o Severe neonatal problem (e.g. severe asphyxia) 
o Severe craniocerebral trauma or near-drowning 
o Severe infectious encephalitis or drug-induced encephalopathy 
o Infectious meningitis, encephalitis or Guillain-Barré 
o Resuscitation and/or need for extracorporeal membrane oxygenation prior to 
randomization 
o Severe convulsions or stroke prior to randomization 
 
Methods S4. Definition of educational and occupational level of parents 
Educational level of parents17 
The education level is the average of the paternal and maternal educational level, and 
calculated based upon the 3-point scale subdivisions as made by the Algemene Directie 
Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal Bureau voor de Statistiek (The 
Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level. 
 
Occupational level of parents17 
The occupation level is the average of the paternal and maternal occupation level, which is 
calculated based upon the International Isco System 4-point scale for professions.18 In case 
one of the parents filled in two jobs in the questionnaire, the highest Isco code level was 
used. In case “unemployed”, “disabled”, “student”, or “housewife/houseman” was filled in, 
an Isco code level of 1 was given to that parent. When the parents described their profession 
as “employee”, “worker”, “liberal profession”, or “retired”, they were given an Isco code 
level of 2. 
 
Methods S5. Correlation of physical, neurocognitive and psychosocial  
outcomes 
We computed a correlation matrix to investigate the univariate association between all 
pairwise combinations of the physical, neurocognitive and psychosocial outcomes evaluated 
at 4-year follow up. In all cases we used a Pearson correlation of pairwise complete 
                                                                
 
observations. This correlation matrix was then visualised directly with a colour-code 
indicating the sign and strength of the correlation. This analysis was performed with the 
“Corrr” package version 0.4.0. for R version 3.5.3. 
       
  
                                                                
 
       
Figure S1. Macronutrient doses during the first week in PICU administered to the tested population             




Figure S2. Imputation convergence for selected neurocognitive test results 
Mean and standard deviation of imputed values in each of 31 datasets over 100 iterations 
for A) Emotional and behavioural problems as reported by parents/caregivers — T-score: 
Internalising problems B) Externalising problems C) Total problems.  
                                                                
 
   
Figure S3. Density estimates of the observed and imputed values for selected 
neurocognitive test results Density estimated for observed values (in blue) and for each 
imputed dataset (in orange) for A) Emotional and behavioural problems as reported by  
parents/caregivers — T-score: Internalising problems B) Externalising problems C) Total 
problems.  












































Figure S4. Multiple imputation predictor variables 
Missing values for the variables in each row are imputed based on models that use as predictors only 
the column variables highlighted in blue. The predictor variables are selected as described in Methods 
S4 
                                                                
 
 
Figure S5. Correlation plot of physical, neurocognitive and psychosocial outcomes 
The correlation matrix shows the correlation between all physical, neurocognitive and  
emotional/behavioural outcomes. Blue shades represent a positive correlation, red shades  
represent inverse correlations. Darker coloured shading represents a strongercorrelation. 









                                                                
 
Table S1-1. Demographics and other patient characteristics upon PICU admission, acute outcomes 
and post-randomization treatments in the PICU of participating patients who were too disabled for 
neurocognitive testing and those who underwent neurocognitive testing   
    














    
    
Demographics    
Age at 4-years’ follow-up -  yr 9.0 (5.6) 7.3 (4.3) 0.008 
Sex  






   Female 35 (41.7%) 291 (42.5%)  
Known non-Caucasian racea 11 (13.1%)  53 (7.8%) 0.09 
Known non-European origina 20 (23.8%) 129 (18.9%) 0.27 
Known not exclusive Dutch or English 
language 
20 (23.8%) 158 (23.1%) 0.88 
Socioeconomic status     
     Educational level parentsb   0.001 
          Educational level 1 9 (10.7%) 30 (4.4%)  
          Educational level 1.5 4 (4.8%) 51 (7.5%)  
          Educational level 2 21 (25.0%) 157 (23.0%)  
          Educational level 2.5 11 (13.1%) 116 (17.0%)  
          Educational level 3 10 (11.9%) 183 (26.8%)  
          Educational level unknown 29 (34.5%) 147 (21.5%)  
     Occupational level parentsc   <0.0001 
          Occupational level 1 3 (3.6%) 7 (1.0%)  
          Occupational level 1.5 6 (7.1%) 63 (9.2%)  
          Occupational level 2 19 (22.6%) 108 (15.8%)  
          Occupational level 2.5 5 (6.0%) 69 (10.1%)  
          Occupational level 3 5 (6.0%) 118 (17.3%)  
          Occupational level 3.5 0 (0.0%) 53 (7.8%)  
          Occupational level 4 10 (11.9%) 102 (14.9%)  
          Occupational level unknown 36 (42.9%) 164 (24.0%)  
 
Patient characteristics upon PICU admission 
   
Randomization   0.11 
     Early PN 48 (57.1%) 328 (48.0%)  
     Late PN 36 (42.9%) 356 (52.1%)  
Infant (age<1y) at randomization   36 (42.9%) 331 (48.4%) 0.33 
                                                                
 
STRONGkids risk leveld   0.15 
     Medium 71 (84.5%) 613 (89.6%)  
     High 13 (15.5%) 71 (10.4%)  
PeLOD score, first 24h in PICU e 22.8 (12.4) 20.0 (11.6) 0.03 
PIM3 scoref -3.0 (1.5) -3.5 (1.4) 0.001 
PIM3 probability of death - % g 9.1 (13.6) 6.6 (11.7) 0.001 
Diagnostic category   <0.0001 
     Surgical    
          Abdominal 1 (1.2%) 68 (9.9%)  
          Burns 0 (0.0%) 3 (0.4%)  
          Cardiac 28 (33.3%) 291 (42.5%)  
          Neurosurgery-Traumatic brain injury 10 (11.9%) 58 (8.5%)  
          Thoracic 1 (1.2%) 38 (5.6%)  
          Transplantation 1 (1.2%)  11 (1.6%)  
          Orthopedic surgery-Trauma 12 (14.3%) 19 (2.8%)  
          Other 1 (1.2%) 25 (3.7%)  
     Medical    
          Cardiac 0 (0.0%) 23 (3.4%)  
          Gastrointestinal-Hepatic 2 (2.4%) 2 (0.3%)  
          Oncologic-Hematologic 0 (0.0%) 6 (0.9%)  
          Neurologic 9 (10.7%) 42 (6.1%)  
          Renal 0 (0.0%) 0 (0%)  
          Respiratory 11 (13.1%) 70 (10.2%)  
          Other 8 (9.5%) 28 (4.1%)  
Malignancy  3 (3.6%) 38 (5.6%) 0.44 
Diabetes  0 (0.0%)  0 (0.0%) >0.99 
Syndromeh  48 (57.1%)  63 (9.2%) <0.0001 
Known parental smoking between birth and 
PICU admission  
17 (20.2%) 151 (22.1%) 0.70 
 
Acute effects of randomization and post-randomization 
treatments in PICU 
  
Duration of stay in the PICU – days 7.5 (14.6) 7.8 (16.0) 0.57 
Patients who acquired a new infection in 
PICU  
10 (11.9) 96 (14.0%) 0.59 
Duration of mechanical ventilatory support – 
days 
5.2 (10.8) 5.0 (11.7) 0.72 
Number of days with hypoglycemia <40mg/dl 
– days 
0.2 (0.8) 0.1 (0.5) 0.97 
Duration of antibiotic treatment – days 4.9 (9.6) 5.4 (14.2) 0.81 
Duration of hemodynamic support – days 1.9 (3.6) 2.7 (7.7) 0.71 
Duration of treatment with opioids – days 3.2 (4.5) 5.0 (9.3) 0.01 
Duration of treatment with benzodiazepines 
– days 
4.2 (10.7) 4.4 (10.2) 0.35 
Duration of treatment with hypnotics – days 1.0 (1.9) 1.5 (6.0) 0.79 
                                                                
 
Duration of treatment with alpha-2-agonists 
– days 
0.9 (6.6) 1.1 (6.8) 0.22 
Duration of treatment with corticosteroids - 
days  
1.0 (1.9) 1.2 (3.9) 0.03 
Data are n (%) or mean (SD). a Participants were classified according to race and geographical origin by the 
investigators. These classifications were performed to capture ethnical and regional differences in the frequency of 
consanguinity, which may adversely affect cognitive performance. b The education level is the average of the 
paternal and maternal educational level, and calculated based upon the 3-point scale subdivisions as made by the 
Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal Bureau voor de Statistiek (The 
Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level (Methods S4). c The occupation 
level is the average of the paternal and maternal occupation level, which is calculated based upon the International 
Isco System 4-point scale for professions (Methods S4). d Scores on the Screening Tool for Risk on Nutritional 
Status and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a 
score of 1 to 3 indicating medium risk, and a score of 4 to 5 indicating high risk.19  e Paediatric Logistic Organ 
Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness.20  f Paediatric 
Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality.21  g Paediatric Index of 
Mortality 3 (PIM3) probability of death, ranging from 0% to 100%, with higher percentages indicating a higher 
probability of death in PICU.21  h A pre-randomization syndrome or illness a priori defined as affecting or possibly 
affecting neurocognitive development (Methods S3). BMI, body mass index; PeLOD, paediatric logistic organ 
dysfunction score; PICU, paediatric intensive care unit; PIM3, paediatric index of mortality 3 score; PN, parenteral 




                                                                
 
Table S1-2. Physical development and parent-reported outcomes at 4 years’ follow-up of 
participating patients who were too disabled for neurocognitive testing and those who underwent 
neurocognitive testing   
    
    
 
Participating patients 









    

















      
    
Height - cm 77 
(91.7%) 





Weight - kg 84 
(100.0%) 
25.6 (14.0) 647 
(94.6%) 
27.0 (17.1) 0.45 
BMI - kg/m2 77 
(91.7%) 
17.4 (3.7) 646 
(94.4%) 
16.9 (3.4) 0.13 
Head circumference - cm 83 
(98.8%) 
50.1 (3.7) 649 
(94.9%) 
51.9 (2.7) <0.0001 













11 (14.5%) 609 
(89.0%) 
53 (8.7%) 0.10 
Admitted to hospital for a 
medical or surgical reason  
81 
(96.4%) 






evaluation score (range, 0-8)a 
57 
(67.9%) 
4.3 (1.8) 616 
(90.1%) 
0.6 (1.3) <0.0001 
Executive functioning as 
reported by 
parents/caregivers  - T-
scorea 
     
          Inhibition 36 
(42.9%) 
61.8 (14.8) 556 
(81.3%) 
49.6 (11.8) <0.0001 
          Flexibility 36 
(42.9%) 
59.0 (14.8) 557 
(81.4%) 
49.1 (10.6) <0.0001 
          Emotional control 36 
(42.9%) 
56.1 (15.1) 557 
(81.4%) 
48.9 (10.5) 0.004 
                                                                
 
          Working memory 35 
(41.7%) 
67.5 (12.4) 557 
(81.4%) 
51.5 (11.8) <0.0001 




62.0 (17.4) 557 
(81.4%) 
50.2 (11.2) <0.0001 
          Meta-cognition index 35 
(41.7%) 
64.9 (15.7) 556 
(81.3%) 
50.3 (11.7) <0.0001 
          Total score 35 
(41.7%) 
64.1 (16.8) 555 
(81.1%) 
49.7 (11.8) <0.0001 
Emotional and behavioural 
problems as reported by  
parents/caregivers - T-scorea 
     
          Internalising problems  44 
(52.4%) 
55.7 (10.4) 565 
(82.6%) 
50.4 (11.2) 0.006 




53.4 (13.0) 565 
(82.6%) 
48.5 (10.3) 0.02 
          Total problems  44 
(52.4%) 
56.6 (12.2) 565 
(82.6%) 
49.7 (11.0) 0.0007 
a Higher scores reflect worse performance.  BMI, body mass index; IQ, intelligence quotient; PICU, paediatric 
intensive care unit; PN, parenteral nutrition SD, standard deviation 
 
  
                                                                
 
Table S2. Demographics and other patient characteristics upon PICU admission, acute outcomes 
and post-randomization treatments in the PICU of patients who were tested and those patients who 
survived, but declined participation or could not be reached. 
    















    
 
Patient characteristics upon PICU admission 
   
Randomization   0.11 
     Early PN 247 (52.7%) 328 (48.0%)  
     Late PN 222 (47.3%) 356 (52.1%)  
Sex  






   Female 200 (42.6%) 291 (42.5%)  
Infant (age<1y) at randomization   193 (41.2%) 331 (48.4%) 0.01 
STRONGkids risk levela   0.15 
     Medium 427 (91.0%) 613 (89.6%)  
     High 42 (9.0%) 71 (10.4%)  
PeLOD score, first 24h in PICU b 17.4 (11.6) 20.0 (11.6) 0.0004 
PIM3 scorec -3.5 (1.4) -3.5 (1.4) 0.95 
PIM3 probability of death - % d 6.5 (11.2) 6.6 (11.7) 0.95 
Diagnostic category   0.12 
     Surgical    
          Abdominal 40 (8.5%) 68 (9.9%)  
          Burns 7 (1.5%) 3 (0.4%)  
          Cardiac 173 (36.9%) 291 (42.5%)  
          Neurosurgery-Traumatic brain injury 32 (6.8%) 58 (8.5%)  
          Thoracic 19 (4.1%) 38 (5.6%)  
          Transplantation 12 (2.6%)  11 (1.6%)  
          Orthopedic surgery-Trauma 13 (2.8%) 19 (2.8%)  
          Other 18 (3.8%) 25 (3.7%)  
     Medical    
          Cardiac 23 (4.9%) 23 (3.4%)  
          Gastrointestinal-Hepatic 1 (0.2%) 2 (0.3%)  
          Oncologic-Hematologic 4 (0.9%) 6 (0.9%)  
          Neurologic 32 (6.8%) 42 (6.1%)  
          Renal 1 (0.2%) 0 (0%)  
          Respiratory 74 (15.8%) 70 (10.2%)  
                                                                
 
          Other 20 (4.3%) 28 (4.1%)  
Malignancy  17 (3.6%) 38 (5.6%) 0.15 
Diabetes  2 (0.4%)  0 (0.0%) 0.16 
Syndromee  66 (14.1%)  63 (9.2%) 0.01 
    
Acute effects of randomization and post-randomization 
treatments in PICU 
  
Duration of stay in the PICU – days 6.1 (8.2) 7.8 (16.0) 0.66 
Patients who acquired a new infection in PICU  51 (10.9) 96 (14.0%) 0.11 
Duration of mechanical ventilatory support – 
days 
4.2 (7.1) 5.0 (11.7) 0.59 
Number of days with hypoglycemia <40mg/dl 
– days 
0.8 (0.3) 0.1 (0.5) 0.08 
Duration of antibiotic treatment – days 4.4 (7.4) 5.4 (14.2) 0.70 
Duration of hemodynamic support – days 1.8 (3.8) 2.7 (7.7) 0.13 
Duration of treatment with opioids – days 4.1 (6.4) 5.0 (9.3) 0.19 
Duration of treatment with benzodiazepines – 
days 
3.5 (6.0) 4.4 (10.2) 0.49 
Duration of treatment with hypnotics – days 1.3 (2.1) 1.5 (6.0) 0.001 
Duration of treatment with alpha-2-agonists – 
days 
0.5 (2.4) 1.1 (6.8) 0.19 
Duration of treatment with corticosteroids - 
days  
1.2 (3.4) 1.2 (3.9) 0.04 
Data are n (%) or mean (SD). a Scores on the Screening Tool for Risk on Nutritional Status and Growth 
(STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating 
medium risk, and a score of 4 to 5 indicating high risk.19  b Paediatric Logistic Organ Dysfunction (PeLOD) scores 
range from 0 to 71, with higher scores indicating more severe illness.20  c Paediatric Index of Mortality 3 (PIM3) 
scores, with higher scores indicating a higher risk of mortality.21  d Paediatric Index of Mortality 3 (PIM3) probability 
of death, ranging from 0% to 100%, with higher percentages indicating a higher probability of death in PICU.21  e A 
pre-randomization syndrome or illness a priori defined as affecting or possibly affecting neurocognitive development 
(Methods S3). BMI, body mass index; PeLOD, paediatric logistic organ dysfunction score; PICU, paediatric intensive 
care unit; PIM3, paediatric index of mortality 3 score; PN, parenteral nutrition; SEM, standard error of the mean. 
  
                                                                
 
Table S3-1. Multivariable linear regression analyses determining significant and independent associations between risk factors and internalising problems 
as reported by the parents/caregivers at 4 years’ follow-up within the patient population that underwent neurocognitive testing 
 Model adjusted for risk factors 
Model further adjusted for 
acute effects of late-PN vs 
early-PN  
Model further adjusted for post-
randomization treatments 
Variable β estimate (95% CI) 
P-
value  β estimate (95% CI) 
P-
value β estimate (95% CI) 
P-
value 
Randomisation to late vs· early 
initiation of PN -1.880 (-3690; -0.071) 0.042 -1·702 (-3·541; 0·173) 0.070 -1.625 (-3.470; 0.219) 0.084 
Centre       
     Leuven vs Edmonton 0.019 (-8.653; 8.691) 0.997 -0.024 (-8.717; 8.668) 0.996 0.082 (-8.725; 8.888) 0.985 
     Rotterdam vs Edmonton 0.627 ( -7.840; 9.094) 0.884 0.424 (-8.050; 8.898) 0.922 0.292(-8.316; 8.899) 0.947 
Male vs female sex 1.165 (-0.681; 3.011) 0.216 1.062 (-0.789; 2.913) 0.260 1.187(-0.674; 3.049) 0.211 
Right vs left hand preference  -0.130 (-2.867; 2.608) 0.926 -0.230 (-2.981; 2.522) 0.870 -0.063 (-2.831; 2.706) 0.964 
Medium vs high STRONGkids 
risk levela -3.074 (-6.178; 0.031) 0.052 -2.727 (-5.867; 0.413) 0.089 -2.667 (-5.893; 0.559) 0.105 
Diagnostic category (as compared with cardiac surgery)      
     Surgical       
          Abdominal 0.627 (-3.109; 4.363) 0.742 0.631 (-3.103; 4.365) 0.740 0.530 (-3.258; 4.317) 0.783 
          Burns -2.005 (-14.952; 10.942) 0.761 -2.825 (-15.865; 10.215) 0.671 -2.919 (-16.09; 10.255) 0.664 
          Neurosurgery - 
traumatic brain injury 1.887 (-1.990; 5.764) 0.339 1.848 (-2.028; 5.725) 0.349 1.689 (-2.200; 5.577) 0.394 
          Thoracic -1.197 (-5.380; 2.986) 0.574 -1.233 (-5.422; 2.955) 0.563 -0.961 (-5.192; 3.270) 0.655 
          Transplantation -0.617 (-8.396; 7.162) 0.876 -1.493 (-9.446; 6.461) 0.712 -1.241 (-10.413; 7.930) 0.790 
          Orthopedic surgery-
trauma -0.573 (-6.724; 5.577) 0.855 -0.821 (-6.987; 5.346) 0.794 -0.917 (-7.153; 5.318) 0.772 
          Other 1.849 (-3.448; 7.147) 0.761 1.418 (-3.947; 6.783) 0.604 0.920 (-4.527; 6.368) 0.740 
     Medical        
          Cardiac -0.611 (-6.202; 4.980) 0.830 -1.314 (-6.929; 4.300) 0.646 -1.436 (-7.200; 4.328) 0.625 
                                                                
 
          Gastrointestinal-hepatic -4.742 (-25.519; 16.035) 0.652 -4.641 (-25.442; 16.160) 0.659 -4.818 (-25.658; 16.022) 0.648 
          Hematologic-oncologic -2.598 (-12.953; 7.758) 0.622 -2.529 (-12.915; 7.857) 0.633 -2.829 (-13.968; 8.309) 0.618 
          Neurologic -2.208 (-6.747; 2.331) 0.339 -2.106 (-6.655; 2.444) 0.363 -2.322 (-7.005; 2.361) 0.330 
          Respiratory  -1.383 (-4.996; 2.230) 0.452 -1.414 (-5.059; 2.231) 0.446 -1.294 (-5.025; 2.437) 0.496 
          Other -0.106 (-4.796; 4.585) 0.965 -0.255 (-4.953; 4.443) 0.915 0.177 (-4.795; 5.148) 0.944 
Infant (age<1y) vs child at 
randomization -4.643 (-6.591; -2.694) 
<0.000
1 -4.610 (-6.602; -2.618) 
<0.000
1 -4.874 (-6.911; -2.836) 
<0.000
1 
Malignancy vs no malignancy 2.107 (-2.272; 6.486) 0.345 2.061 (-2.328; 6.450) 0.357 2.049 (-2.421; 6.519) 0.368 
Syndrome vs no syndromeb 1.699 (-1.521; 4.919) 0.300 1.520 (-1.732; 4.772) 0.359 1.906 (-1.400; 5.211) 0.258 
PIM3 score (per point added)c 0.526 (-0.364; 1.416) 0.246 0.401 (-0.529; 1.330) 0.397 0.326 (-0.607; 1.260) 0.492 
PeLOD score first 24 hrs (per 
point added)d 0.000 (-0.117; 0.117) 0.995 -0.007 (-0.125; 0.110) 0.906 -0.014 (-0.133; 0.105) 0.822 
Known non-European origin 
vs othere 0.166 (-3.549; 3.881) 0.930 0.073 (-3.652; 3.798) 0.969 0.024 (-3.707; 3.755) 0.990 
Known non-Caucasian vs 
othere -2.306 (-7.355; 2.743) 0.368 -2.178 (-7.227; 2.872) 0.396 -2.025 (-7.097; 3.047) 0.431 
Known not exclusive Dutch or 
English language vs other 1.709 (-1.020; 4.438) 0.219 1.922 (-0.830; 4.673) 0.171 1.794 (-0.968; 4.555) 0.202 
Socioeconomic status       
     Educational level parents (as compared with level 1)f      
          Educational level 1.5 -2.778 (-8.831; 3.274) 0.367 -2.491 (-8.585; 3.603) 0.422 -2.240 (-8.415; 3.935) 0.476 
          Educational level 2 -1.811 (-7.261; 3.639) 0.514 -1.374 (-6.880; 4.133) 0.624 -1.536 (-7.121; 4.049) 0.589 
          Educational level 2.5 -4.396 (-10.040; 1.248) 0.126 -4.025 (-9.707; 1.657) 0.164 -3.934 (-9.700; 1.803) 0.178 
          Educational level 3 -4.973 (-10.619; 0.672) 0.084 -4.540 (-10.228; 1.149) 0.117 -4.629 (-10.387; 1.128) 0.115 
          Educational level 
unknown -2.630 (-8.386; 3.125) 0.369 -2.324 (-8.109; 3.462) 0.429 -2.354 (-8.182; 3.474) 0.427 
     Occupational level parents 
(as compared with level 1)g        
                                                                
 
          Occupational level 1.5 1.679 (-7.871; 11.229) 0.730 1.529 (-8.054; 11.113) 0.754 1.092 (-8.523; 10.706) 0.824 
          Occupational level 2 0.238 (-9.230; 9.706) 0.961 0.149 (-9.361; 9.659) 0.975 -0.395 (-9.928; 9.138) 0.935 
          Occupational level 2.5 -2.341 (-12.174; 7.492) 0.640 -2.473 (-12.346; 7.400) 0.623 -2.704 (-12.618; 7.209) 0.592 
          Occupational level 3 -0.226 (-9.745; 7.492) 0.963 -0.300 (-9.840; 9.239) 0.951 -0.660 (-10.210; 8.890) 0.892 
          Occupational level 3.5 1.781 (-8.264; 11.826) 0.728 1.651 (-8.423; 11.725) 0.747 1.442 (-8.654; 11.538) 0.779 
          Occupational level 4 -1.396 (-11.172; 8.379 ) 0.779 -1.547 (-11.359; 8.265) 0.757 -2.074 (-11.907; 7.759) 0.679 
          Occupational level   
           unknown 1.793 (-7.686; 11.273) 0.710 1.682 (-7.850; 11.214) 0.729 1.478 (-8.060; 11.017) 0.761 
Parental smoking between 
birth and PICU admission vs 
no smoking 0.827 (-1.321; 2.974) 0.450 0.863 (-1.290; 3.016) 0.431 0.950 (-1.203; 3.103) 0.386 
New infection vs no new infection  1.333 (-1.910; 4.576) 0.420 0.436 (0.802; -2.972) 3.844 
Duration of stay in the PICU (per day added)  0.083 (-0.055; 0.220) 0.237 0.164 (0.279; -0.134) 0.461 
Days with hypoglycemic event (per day added)  -0.049 (-1.813; 1.714) 0.956 -0.369 (0.708; -2.298) 1.561 
Duration of mechanical ventilatory support (per day added)  -0.094 (-0.276; 0.088) 0.310 -0.095 (0.340; -0.291) 0.101 
Duration of treatment with antibiotics (per day added)    -0.127 (0.375; -0.407) 0.154 
Duration of hemodynamic support (per day added)    -0.013 (0.898; -0.215) 0.188 
Duration of treatment with corticosteroids (per day added)    0.020 (0.905; -0.316) 0.357 
Duration of treatment with opioids (per day added)    -0.001 (0.996; -0.284) 0.282 
Duration of treatment with benzodiazepines (per day added)    0.173 (0.227; -0.108) 0.454 
Duration of treatment with hypnotics (per day added)    -0.012 (0.931; -0.286) 0.262 
Duration of treatment with alpha-2-agonists (per day added)    -0.183 (0.153; -0.434) 0.068 
For internalising problems as reported by parents, higher scores reflect more problems. a Scores on the Screening Tool for Risk on Nutritional Status 
and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a 
score of 4 to 5 indicating high risk.19  b A pre-randomization syndrome or illness a priori defined as affecting or possibly affecting neurocognitive 
development (Methods S3) c Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality.21  d Paediatric Logistic 
Organ Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness.20  e Paarticipants were classified according to 
                                                                
 
race and geographical origin by the investigators. These classifications were performed to capture ethnical and regional differences in the frequency of 
consanguinity, which may adversely affect cognitive performance.22,36 f The education level is the average of the paternal and maternal educational level, 
and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal 
Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level (Methods S4). g The occupation level 
is the average of the paternal and maternal occupation level, which is calculated based upon the International Isco System 4-point scale for professions 
(Methods S4).18  PeLOD, paediatric logistic organ dysfunction score; PICU, paediatric intensive care unit; PIM3, paediatric index of mortality 3 score; 
PN, parenteral nutrition. 
  
                                                                
 
Table S3-2. Multivariable linear regression analyses determining significant and independent associations between risk factors and externalising problems 
as reported by the parents/caregivers at 4 years’ follow-up within the patient population that underwent neurocognitive testing  
 Model adjusted for risk factors 
Model further adjusted for 
acute effects of late-PN vs 
early-PN  
Model further adjusted for 
post-randomization 
treatments 
Variable β estimate (95% CI) 
P-
valu
e  β estimate (95% CI) 
P-
valu




Randomization to late vs. early initiation 
of PN -1.731 (-3.433; -0.028) 0.046 -1.645 (-3.379; 0.090) 0.063 -1.51 (-3.242; 0.219) 0.086 
Centre       
     Leuven vs Edmonton -3.194 (-11.275; 4.886) 0.438 -3.337 (-11.463; 4.790) 0.420 -2.708 (-10.865; 5.449) 0.51 
     Rotterdam vs Edmonton -4.080 (-11.970; 3.811) 0.310 -4.365 (-12.279; 3.549) 0.279 -4.168 (-12.145; 3.809) 0.30 
Male vs female sex 1.987 (0.306; 3.667) 0.021 1.922 (0.235; 3.609) 0.026 2.058 (0.362; 3.754) 0.017 
Right vs left hand preference  0.299 (-2.443; 3.041) 0.830 0.284 (-2.452; 3.020) 0.838 0.526 (-2.236; 3.287) 0.70 
Medium vs high STRONGkids risk levela -1.276 (-4.212; 1.660) 0.394 -1.211 (-4.189; 1.766) 0.424 -1.380 (-4.461; 1.700) 0.37 
Diagnostic category (as compared with cardiac surgery)      
     Surgical       
          Abdominal -1.137 (-4.542; 2.268) 0.512 -1.150 (-4.562; 2.263) 0.508 -1.192 (-4.630; 4.711) 0.496 
          Burns 2.862 (-4.331; 5.632) 0.643 2.764 (9.451; 14.978) 0.657 1.044 (-11.235; 13.322) 0.867 
          Neurosurgery - traumatic brain  
          injury -0.836 (-9.256; 14.980) 0.653 -0.807 (-4.459; 2.846) 0.665 -1.174 (-4.826; 2.477) 0.527 
          Thoracic -0.543 (-4.486; 2.813) 0.786 -0.545 (-4.479; 3.390) 0.786 -0.359 ( -4.292; 3.575) 0.857 
          Transplantation -4.324 (-4.465; 3.379) 0.241 -4.343 (-11.742; 3.056) 0.249 -6.763 (-15.230; 1.770) 0.119 
          Orthopedic surgery-trauma -2.478 (-11.568; 2.921) 0.385 -2.524 (-8.144; 3.096) 0.378 -2.685 (-8.333; -2.964) 0.350 
          Other 0.650 (-4.331; 5.632) 0.798 0.453 ( -4.575to 5.480) 0.860 -0.359 (-5.428; 4.711) 0.889 
                                                                
 
     Medical        
          Cardiac 0.085 (-5.026; 5.195) 0.974 -0.210 (-5.378; 4.957) 0.936 -0.280 (-5.636; 5.075) 0.918 
          Gastrointestinal-hepatic -6.568 (-24.963; 11.828) 0.482 
-6.447 (-24.862; 
11.968) 0.490 -6.618 (-24.971; 11.734) 0.477 
          Hematologic-oncologic -5.302 (-14.848; 4.245) 0.276 -5.263 (-14.876; 4.350) 0.283 -7.950 (-18.288; 2.388) 0.131 
          Neurologic -3.142 (-7.219; 0.934) 0.130 -3.122 (-7.217; 0.973) 0.135 -3.883 (-8.063; 0.297) 0.068 
          Respiratory  -1.308 (-4.669; 2.052) 0.445 -1.575 (-4.970; 1.820) 0.362 -1.416 (-4.878; 2.045) 0.421 
          Other -2.207 (-6.608; 2.195) 0.325 -2.468 (-6.881; 1.946) 0.273 -2.788 (-7.433; 1.858) 0.238 
Infant (age<1y) vs child at randomization 0.085 (-3.814; -0.112) 0.038 -1.929 (-3.820; -0.039) 0.046 -1.930 (-3.864; 0.003) 0.050 
Malignancy vs no malignancy -1.963 (-1.993; 6.212) 0.313 2.077 (-2.034; 6.188) 0.321 1.233 (-2.948; 5.414) 0.562 
Syndrome vs no syndromeb 1.045 (-0.206; 1.471) 0.139 0.861 (-2.032; 3.754) 0.559 1.754 (-1.173; 4.682) 0.239 
PIM3 score (per point added)c 0.632 (-0.118; 0.098) 0.851 0.567 (-0.303; 1.438) 0.201 0.497 (-0.373; 1.367) 0.262 
PeLOD score first 24 hrs (per point 
added)d -0.010 (-5.192; 1.861) 0.353 -0.010 (-0.119; 0.099) 0.854 -0.028 (-0.234; 0.114) 0.498 
Known non-European origin vs othere -1.665 (-4.125; 5.649) 0.758 -1.591 (5.129; 1.946) 0.377 -3.444 (-8.677; 1.789) 0.196 
Known non-Caucasian vs othere 0.762 (-0.483; 4.868) 0.108 0.824 (-4.064; 5.713) 0.739 0.165 (-6.148; 6.479) 0.958 
Known not exclusive Dutch or English 
language vs other 2.192 (-3.814; -0.112) 0.038 2.243 (-0.441; 4.926) 0.101 -2.959 (-6.951; 1.033) 0.146 
Socioeconomic status       
     Educational level parents (as compared 
with level 1)f       
          Educational level 1.5 -0.738 (-6.223; 4.747) 0.792 -0.787 (-6.313; 4.739) 0.780 0.169 (-5.412; 5.751) 0.952 
          Educational level 2 0.941 (-3.973; 5.855) 0.707 1.121 (-3.845; 6.087) 0.657 1.720 (-3.280; 6.719) 0.499 
          Educational level 2.5 -2.784 (-7.912; 2.345) 0.286 -2.608 (-7.774; 2.557) 0.321 -2.013 (-7.196; 3.171) 0.445 
          Educational level 3 -4.599 (-9.875; 0.678) 0.087 -4.448 (-9.759; 0.862) 0.100 -3.841 (-9.179; 1.497) 0.157 
          Educational level unknown -1.506 (-6.824; 3.813) 0.578 -1.378 (-6.726; 3.970) 0.612 -0.718 (-6.076; 4.640) 0.792 
                                                                
 
     Occupational level parents (as 
compared with level 1)g       
          Occupational level 1.5 -2.079 (-10.773; 6.615) 0.639 -2.325 (-11.046; 6.397) 0.601 -3.048 (-11.746; 5.650) 0.492 
          Occupational level 2 0.088 (-8.613; 8.789) 0.984 -0.177 (-8.922; 8.568) 0.968 -0.847 (-9.576; 7.883) 0.848 
          Occupational level 2.5 -2.387 (-11.413; 6.639) 0.604 -2.712 (-11.774; 6.351) 0.557 -3.471 (-12.537; 5.595) 0.452 
          Occupational level 3 0.527 (-8.275; 9.329) 0.906 0.344 (-8.483; 9.171) 0.939 -0.141 (-8.941; 8.660) 0.974 
          Occupational level 3.5 -0.920 (-10.204; 8.365) 0.846 -1.190 (-10.505; 8.125) 0.802 -1.568 (-10.882; 7.746) 0.740 
          Occupational level 4 -1.592 (-10.639; 7.454) 0.730 -1.904 (-10.989; 7.181) 0.681 -2.735 (-11.812; 6.341) 0.554 
          Occupational level unknown -0.963 (-9.764; 7.838) 0.830 -1.260 (-10.107; 7.587) 0.780 -1.575 (-10.400; 7.251) 0.726 
Parental smoking between birth and PICU 
admission vs. no smoking 1.797( -0.309; 3.903) 0.094 1.781 (-0.332; 3.893) 0.098 
 
1.895 (-0.203; 3.993) 0.076 
New infection vs no new infection   -0.648 (-3.674; 2.378) 0.674 -2.044 (-5.248; 1.160) 0.210 
Duration of stay in the PICU (per day added)  0.046 (-0.077; 0.170) 0.461 0.086 (-0.187; 0.359) 0.536 
Days with hypoglycemic event (per day added)  -0.231 (-1.904; 1.441) 0.786 -0.449 (-2.265; 1.367)  0.627 
Duration of mechanical ventilatory support (per day added)  -0.008 (-0.174; 0.158) 0.924 -0.057 (-0.237; 0.122) 0.527 
Duration of treatment with antibiotics (per day added)    -0.096 (-0.355; 0.163) 0.466 
Duration of hemodynamic support (per day added)    0.017 (-0.168; 0.202) 0.859 
Duration of treatment with corticosteroids (per day added)    0.244 (-0.077; 0.566) 0.135 
Duration of treatment with opioids (per day added)    -0.015 (-0.266; 0.236) 0.906 
Duration of treatment with benzodiazepines (per day added)    0.176 (-0.073; 0.425) 0.646 
Duration of treatment with hypnotics (per day added)    0.214 (-0.038; 0.466) 0.095 
Duration of treatment with alpha-2-agonists (per day added)    -0.273 (-0.504; -0.043) 0.020 
For internalising problems as reported by parents, higher scores reflect more problems. a Scores on the Screening Tool for Risk on Nutritional Status 
and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating medium risk, and a 
score of 4 to 5 indicating high risk.19  b A pre-randomization syndrome or illness a priori defined as affecting or possibly affecting neurocognitive 
development (Methods S3) c Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality.21  d Paediatric Logistic 
                                                                
 
Organ Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness.20 e Participants were classified according to 
race and geographical origin by the investigators. These classifications were performed to capture ethnical and regional differences in the frequency of 
consanguinity, which may adversely affect cognitive performance.22 f The education level is the average of the paternal and maternal educational level, 
and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and the Centraal 
Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level (Methods S4). g The occupation level 
is the average of the paternal and maternal occupation level, which is calculated based upon the International Isco System 4-point scale for professions 
(Methods S4).18 PeLOD, paediatric logistic organ dysfunction score; PICU, paediatric intensive care unit; PIM3, paediatric index of mortality 3 score; PN, 
parenteral nutrition. 
  
                                                                
 
Table S3-3. Multivariable linear regression analyses determining significant and independent associations between risk factors and total emotional and 
behavioural problems as reported by the parents/caregivers at 4 years’ follow-up within the patient population that underwent neurocognitive testing 
 Model adjusted for risk factors 
Model further adjusted for 
acute effects of late-PN vs 
early-PN  
Model further adjusted for 
post-randomization 
treatment effects 
Variable β estimate (95% CI) 
P-
valu
e  β estimate (95% CI) 
P-
valu




Randomization to late vs early initiation 
of PN -2.442 (-3.433; -0.028) 0.046 -2.242 (-4.043; -0.4043) 0.015 -2.163 (-3.960; -0.365) 0.019 
Centre       
     Leuven vs Edmonton -2.834 (-11.275; 4.886) 0.438 -2.687 (-11.115; 5.742) 0.531 -2.172 (-10.667 6.324) 0.616 
     Rotterdam vs Edmonton -2.360 (-11.970; 3.811) 0.310 -2.476 (-10.732; 5.742) 0.556 -2.506 (-10.848; 5.837) 0.555 
Male vs female sex 1.483 (0.306; 3.667) 0.021 1.411 (-0.360; 3.183) 0.118 1.558 (-0.224; 3.339) 0.086 
Right vs left hand preference  0.019 (-2.443; 3.041) 0.830 -0.067 (-2.865; 2.731) 0.962 0.190 (-2.625; 3.004) 0.894 
Medium vs high STRONGkids risk levela -2.630 (-4.212; 1.660) 0.394 -2.369 (-5.452; 0.713) 0.132 -2.445 (-5.610; 0.721) 0.130 
Diagnostic category (as compared with 
cardiac surgery)       
     Surgical       
          Abdominal -0.652 (-4.542; 2.268) 0.512 -0.679 (-4.249; 2.891) 0.709 -0.703 (-4.301; 2.895) 0.701 
          Burns 1.540 (-9.256; 14.980) 0.643 0.682 (-12.001; 13.365) 0.916 -0.229 (-12.993; 12.536) 0.972 
          Neurosurgery - traumatic brain 
injury 0.503 (-4.486; 2.813) 0.653 0.433 (-3.290; 4.157) 0.819 0.086 (-3.633; 3.805) 0.964 
          Thoracic -1.323 (-4.465; 3.379) 0.786 -1.354 (-5.435; 2.727) 0.515 -1.091 (-5.197; 3.015) 0.602 
          Transplantation -2.856 (-11.568; 2.921) 0.241 -3.506 (-11.188; 4.176) 0.370 -4.678 (-13.497; 4.141) 0.298 
          Orthopedic surgery-trauma -0.542 (-8.086; 3.129) 0.385 -0.778 (-6.692; 5.137) 0.796 -0.892 (-6.840; 5.056) 0.768 
          Other 0.705 (-4.331; 5.632) 0.798 0.379 (-4.881; 5.640) 0.887 -0.426 (-5.742; 4.891) 0.875 
     Medical        
                                                                
 
          Cardiac -1.239 (-5.026; 5.195) 0.974 -1.771 (-7.124; 3.582) 0.516 -1.964 (-7.501 ; 3.573) 0.486 
          Gastrointestinal-hepatic -5.844 (-24.963; 11.828) 0.482 -5.716 (-24.994; 13.563) 0.559 -5.919 (-25.143; 13.305) 0.544 
          Hematologic-oncologic -5.495 (-14.848; 4.245) 0.276 -5.668 (-15.844; 4.507) 0.274 -7.908 (-18.814; 2.998) 0.155 
          Neurologic -4.072 (-7.219; 0.934) 0.130 -3.963 (-8.229; 0.303) 0.069 -4.661 (-9.032; -0.289) 0.037 
          Respiratory  -2.226 (-4.669; 2.052) 0.445 -2.311 (-5.835; 1.214) 0.198 -2.282 (-5.887; 1.323) 0.214 
          Other -2.103 (-6.608; 2.195) 0.325 -2.285 (-6.863; 2.293) 0.327 -2.352 (-7.170; 2.466) 0.338 
Infant (age<1y) vs child at randomization -4.487 (-3.814; -0.112) 0.038 -4.406 (-6.347; -2.464) 
<0.00
01 -4.536 (-6.517; -2.553) 
<0.00
01 
Malignancy vs no malignancy 3.260 (-1.993; 6.212) 0.313 3.273 (-0.978; 7.524) 0.131 2.827 (-1.492; 7.145) 0.199 
Syndrome vs no syndromeb 2.110 (-1.819; 3.909) 0.474 1.892 (-1.198; 4.983) 0.229 2.610 (-0.519; 5.738) 0.102 
PIM3 score (per point added)c 0.582 (-0.206; 1.471) 0.139 0.450 (-0.451; 1.351) 0.327 0.375 (-0.527; 1.276) 0.414 
PeLOD score first 24 hrs (per point 
added)d -0.007 (-0.118; 0.098) 0.851 -0.014 (-0.128; 0.100) 0.807 -0.029 (-0.144; 0.086) 0.615 
Known non-European origin vs othere -0.459 (-5.192; 1.861) 0.353 -0.513 (-4.143; 3.118) 0.781 -0.575 (-4.201; 3.050) 0.755 
Known non-Caucasian vs othere -0.943 (-4.125; 5.649) 0.758 -0.850 (-5.866; 4.166) 0.738 -0.582 (-5.609; 4.445) 0.819 
Known not exclusive Dutch or English 
language vs other 1.987 (-0.483; 4.868) 0.108 2.172 (-0.532; 4.876) 0.115 2.133 (-0.572; 4.837) 0.122 
Socioeconomic status        
     Educational level parents (as 
compared with level 1)f       
          Educational level 1.5 -1.687 (-6.223; 4.747) 0.792 -1.543 (-7.337; 4.252) 0.601 -0.819 (-6.677; 5.040) 0.784 
          Educational level 2 -0.445 (-3.973; 5.855) 0.707 -0.095 (-5.296; 5.106) 0.971 0.126 (-5.125; 5.377) 0.962 
          Educational level 2.5 -4.285 (-7.912; 2.345) 0.286 -3.979 (-9.365; 1.407) 0.147 -3.577 (-9.000; 1.846) 0.195 
          Educational level 3 -5.469 (-9.875; 0.678) 0.087 -5.138 (-10.638; 0.362) 0.067 -4.864 (-10.405; 0.677) 0.085 
          Educational level unknown -2.716 (-6.824; 3.813) 0.578 -2.467 (-8.024; 3.091) 0.383 -2.127 (-7.708; 3.453) 0.453 
     Occupational level parents (as 
compared with level 1)g        
                                                                
 
          Occupational level 1.5 1.882 (-10.773; 6.615) 0.639 1.757 (-7.374; 10.888) 0.706 1.105 (-8.007; 10.217) 0.812 
          Occupational level 2 1.570 (-8.613; 8.789) 0.984 1.513 (-7.619; 10.644) 0.745 0.781 (-8.335; 9.897) 0.866 
          Occupational level 2.5 -0.537 (-11.413; 6.639) 0.604 -0.636 (-10.101; 8.829) 0.895 -1.220 (-10.689; 8.248) 0.800 
          Occupational level 3 1.799 (-8.275; 9.329) 0.906 1.736 (-7.453; 10.925) 0.711 1.242 (-7.921; 10.405) 0.790 
          Occupational level 3.5 1.154 (-10.204; 8.365) 0.846 1.011 (-8.701; 10.723) 0.838 0.678 (-9.025; 10.381) 0.891 
          Occupational level 4 0.701 (-10.639; 7.454) 0.730 0.546 (-8.937; 10.028) 0.910 -0.254 (-9.721; 9.214) 0.958 
          Occupational level unknown 1.571 (-9.764; 7.838) 0.830 1.481 (-7.699; 10.661) 0.751 1.142 (-8.012; 10.296) 0.806 
Parental smoking between birth and 
PICU admission vs. no smoking 1.450 (-0.309; 3.904) 0.094 1.451 (-0.677; 3.579) 0.181 1.571 (-0.547; 3.689) 0.146 
New infection vs no new infection   1.215 (-1.941; 4.370) 0.450 -0.185 (-3.501; 3.131) 0.913 
Duration of stay in the PICU (per day added)  0.057 (-0.071; 0.186) 0.380 0.105 (-0.180; 0.389) 0.471 
Days with hypoglycemic event (per day added)  -0.343 (-2.051; 1.366) 0.694 -0.517 (-2.380; 1.346) 0.586 
Duration of mechanical ventilatory support (per day added)  -0.046 (-0.218; 0.127) 0.601 -0.080 (-0.266; 0.107) 0.401 
Duration of treatment with antibiotics (per day added)    -0.115 (-0.386; 0.155) 0.402 
Duration of hemodynamic support (per day added)    -0.017 (-0.209; 0.174) 0.858 
Duration of treatment with corticosteroids (per day added)    0.166 (-0.161; 0.493) 0.320 
Duration of treatment with opioids (per day added)    -0.054 (-0.317; 0.210) 0.690 
Duration of treatment with benzodiazepines (per day added)    0.277 (0.011; 0.543) 0.041 
Duration of treatment with hypnotics (per day added)    0.134 (-0.129; 0.398) 0.316 
Duration of treatment with alpha-2-agonists (per day added)    -0.281 (-0.523; -0.039) 0.023 
For total emotional and behavioural problems as reported by parents, higher scores reflect more problems. a Scores on the Screening Tool for Risk on 
Nutritional Status and Growth (STRONGkids) range from 0 to 5, with a score of 0 indicating a low risk of malnutrition, a score of 1 to 3 indicating 
medium risk, and a score of 4 to 5 indicating high risk.19  b A pre-randomization syndrome or illness a priori defined as affecting or possibly affecting 
neurocognitive development (Methods S3) c Paediatric Index of Mortality 3 (PIM3) scores, with higher scores indicating a higher risk of mortality.21 d 
Paediatric Logistic Organ Dysfunction (PeLOD) scores range from 0 to 71, with higher scores indicating more severe illness.20  e Participants were 
classified according to race and geographical origin by the investigators. These classifications were performed to capture ethnical and regional differences 
in the frequency of consanguinity, which may adversely affect cognitive performance.22  f The education level is the average of the paternal and maternal 
                                                                
 
educational level, and calculated based upon the 3-point scale subdivisions as made by the Algemene Directie Statistiek (Belgium; statbel.fgov.be/nl/) and 
the Centraal Bureau voor de Statistiek (The Netherlands; statline.cbs.nl): Low (=1), middle (=2) and high (=3) educational level (Methods S4). g The 
occupation level is the average of the paternal and maternal occupation level, which is calculated based upon the International Isco System 4-point scale 
for professions (Methods S4).18 PeLOD, paediatric logistic organ dysfunction score; PICU, paediatric intensive care unit; PIM3, paediatric index of 
mortality 3 score; PN, parenteral nutrition. 
 
                                                                
 
Table S4. Comparison of patients randomised to late-PN during PICU stay with healthy 
control children for the tests significantly affected by the randomised intervention 
Neurocognitive testing P-value 
Internalising problems as reported by parents/caregivers 0.103 
Externalising problems as reported by parents/caregivers 0.313 
Total behavioural and emotional problems as reported by parents/caregivers 0.085 
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I N T R O D U C T I O N 
Optimal nutritional support in critical illness remains controversial and this thesis highlighted 
several important considerations in the ongoing debate; what is optimal nutrition in critically 
ill children? The primary focus was to provide more insight in nutritional therapy for critically 
ill children concerning the route, timing and amount during acute, stable and recovery phase, 
with a special focus on a conceptual insight of the barriers to provide such optimal nutrition. 
Major barriers who were thought to inhibit enteral intake achievement during the different 
phases of illness, and management of these barriers, were investigated i.e. feeding 
intolerance, fluid restriction and non-invasive ventilator support.1  
Then, if we are able to overcome these barriers, the question concerning the optimal 
amount during the different phases arises. The knowledge of the neuro-endocrine stress 
response is critical for the nutritional recommendations. During the acute phase 
(parenteral) nutrient restriction appears beneficial for short-term and long-term outcome, 
while during stable and recovery phase inclining nutrient intake should be considered.  
Identification of barriers on the PICU 
To allow an early identification of barriers for enteral nutrition (EN) during PICU admission, 
a paediatric quality improvement survey tool was developed. We executed a survey among 
920 physicians, nurses and dieticians across 57 countries which showed that many perceived 
barriers to enteral feeding are still an important concern in PICUs worldwide (Chapter 2). 
This survey tool did not only focus on the patient related factors, but included possible 
barriers in the organisation and infrastructure. The main perceived barriers for EN delivery 
in PICU were related to feeding interruptions around procedures, lack of dietician coverage, 
inadequate training and education on multiple levels. These appear to be caused by a general 
lack of prioritization of nutrition during paediatric critical illness. More education in 
recognizing and resolving PICU related barriers and training of staff abilities are key, 
whereby the individual role of the physician, nurse and dietician should be determined. 
Hence, future education and interventions to improve nutritional support must involve all 
three health care professions as well as an active role in addressing these barriers. With 
improved education, prioritizing and infrastructure we will finally be able to address difficult 
barriers and misconceptions around longstanding perceived barriers such as feeding 
intolerance, fluid restriction and non-invasive ventilator support; and strategies to overcome 
these barriers. 
Feeding intolerance 
Feeding intolerance with a median prevalence of 19% is a highly relevant problem in 
achieving enteral intake, and is presumed to have a considerable impact on morbidity and 
mortality during critical illness (Chapter 4). Still, feeding intolerance is perceived differently 
from health care professional to health care professional, and assessment of feeding 
intolerance is in clinical practise largely based upon the amount of gastro residual volume 
                                                                
 
(GRV), despite the lack of evidence supporting this bed-side decision making process.2,3 A 
GRV below cut-off thresholds or a single presentation of vomiting often results in 
withholding EN, whereas it is questionable if this is justified. Studies comparing PICU sites 
with and without routine GRV measurements did not find differences in aspiration or 
complications, while it did result in lower EN intake.4,5 
Our systematic review revealed numerous definitions of feeding intolerance in the literature 
all using different parameters. The inconsistent use of signs and symptoms to define feeding 
intolerance limits the ability to find causes and identify strategies to overcome feeding 
intolerance. Based upon this systematic review, we proposed a definition to be used in 
future research, which includes the presence of vomiting, diarrhoea, large GRV and 
abdominal distention/ischemia together with the inability to enhance enteral feeding 
(Chapter 4). A uniform evaluation is key to not only identify whether feeding intolerances 
truly exist, moreover, it is a tool to start to unravel this descriptive term. 
Feeding intolerance may be considered a symptom of yet another organ failing during critical 
illness. The gastrointestinal tract comprises of more than its nutrient absorption and 
digestion function and plays an important role in the first line immunologic defence and gut-
brain-microbiome axis. The underlying question here is what feeding intolerance comprises. 
As most research is focussed on nutrient absorption, we fail to incorporate these other 
essential functions, which both presumably have a considerable impact on the patient, into 
one overall organ dysfunction. By focussing on only one mechanism we remain incapable to 
comprehend the complete pathophysiological mechanisms.6 
Also, whether gastrointestinal failure independent of enteral nutrition intake determines 
clinical outcomes remains in interesting question. Hence, more detailed knowledge on the 
short-term and long-term health consequences of these major gastrointestinal functions is 
required. Moreover, an early identification and management is key in optimizing EN support.  
Mechanism behind feeding intolerance 
Both the gastrointestinal morphology and function can be altered leading to feeding 
intolerance.7 Having a better understanding of the pathophysiology of feeding intolerance 
during the different phases of critical illness may lead towards novel diagnostic and 
therapeutic management. 
Motility 
Important pathophysiologic parameters of feeding tolerance are delayed gastrointestinal 
motility, intestinal inflammation and decreased enterocyte function. In health, gastric 
emptying is regulated by a network of neural and humoral (circulating or hormonal) 
mechanisms which modulate the intrinsic myogenic activity. The motility is evoked by 
depolarisation initiated by a network of interstitial cells embedded in the GI tract.8 The 
activity of the gut is different between fasting and fed state. During fasting state the gut 
                                                                
 
enters in several phases migrating the nutrients along the gastrointestinal tract.9,10 The vagus 
nerve plays an important extrinsic influence and can increase the motility via 
parasympathetic pathway. Furthermore, numerous hormones are related to the gut motility 
i.e. ghrelin, motilin, secretin, neurotensin, gastrin, gastrin-releasing peptide, cholecystokinin, 
peptide YY and glucagon like peptide-1. Dysfunction of these gastrointestinal hormones, 
identified by altered plasma levels, have been associated with feeding intolerance in non-
critically ill populations. There are also indications that these hormones are altered during 
paediatric critical illness,11-16 however, our systematic review showed that studies relating 
these hormone profiles with feeding intolerance are sparse and highly needed (Chapter 4). 
In critical ill patients presenting with delayed gastric emptying, the upper gastrointestinal 
tract is frequently impaired in both the fasting and fed state.9,10,17 Abnormal functions seen 
during the fed state are often contributed to the somatic function i.e. delayed fundal 
relaxation, reduced antral motility and increased isolated pyloric activity. These 
abnormalities are already pronounced when minimal amounts of nutrients are provided.18 
The duodenal function often remains, however this may be disorganised and even showing 
retrograde peristaltic contractions.  
Gut integrity 
Other mechanisms affecting feeding intolerance are the intestinal enterocyte function or 
inflammation. Besides the absorption of nutrients the gut plays in important role in the 
body’s first line immunologic defence. There are reports that during critical illness the gut 
integrity is disrupted with hyperpermeability and increased epithelial apoptosis, with 
decreased epithelial proliferation and mucus integrity.19,20 Furthermore, there is a direct 
correlation between thinning of the mucus layer and reduction of villus height, making the 
intestinal epithelium more exposed to injury from digestive enzymes.21 
Several hypothesis have been formed on how the association between disrupted gut 
integrity and sepsis and organ failure exist. The general hypothesis is via direct translocation 
of intact bacteria into the systemic circulation, however, the evidence surrounding this 
hypothesis is mainly from preclinical models.22,23 A new theory hypothesised that the effect 
on organ failure occurs from toxic mediators migrating from the gut travel via the 
mesenteric lymphatics into the system causing among others severe long damage.24,25 
Several markers have been identified in association with impaired gastrointestinal function 
and inflammation in non-critically ill children such as citrulline, Intestinal fatty-acid binding 
protein (I-FABP), Clauding-3 and faecal calprotectin or faecal interleukin (IL)-8. As discussed 
in Chapter 4, abnormal concentrations of these gastrointestinal hormones have been found 
in critically ill children,11,15 especially presenting with feeding intolerance, indicating the 
importance of these hormones as a possible mediator. 
Microbiome 
                                                                
 
The gut microbiome plays an important role in the synthesis and absorption of macro- and 
micronutrient and production of short-chain fatty acids. Studies show that the microbiome 
is severely altered during illness due to the use of antibiotics, intestinal ischemia, fasting or 
altered EN, infections and abnormal intestinal motility, into a virulent pathobiome, inhibiting 
its normally health promoting function.19,26,27 Faecal samples from critically adults patients 
collected at admission and discharge showed fast deterioration of the health-promoting 
organisms with overgrowth of pathogens as compared with healthy subjects, which makes 
patients vulnerable for new acquired infections, sepsis, and organ failure.28,29 
Gut-brain-microbiome axis  
Though still unrecognised during critical illness, there seems to be a bidirectional pathway 
between the central and enteric nervous system affecting the emotional and cognitive 
centres of the brain (figure 1). Recent evidence suggest that the gut microbiome plays in 
central role in this interaction and it is known to influence anxiety, depression, cognition 
and visceral pain recognition.30,31 Because of its many functions, i.e. nutrient absorption, 
immune system and microbiome, the gut has been hypothesised to be the ‘‘motor’’ of the 
systemic inflammatory response in critical illness.19,20,32,33 
 
 
Figure 1. The brain-gut-microbiome axis 
Bidirectional interactions between the brain, gut and microbiome. Interactions entail the 
central nervous system, gastrointestinal system, endocrine system and immune systems 
combined. MEN, minimal enteral nutrition 
                                                                
 
 
Preservation of the gastrointestinal functions 
Enteral nutrition is considered safer, more physiological and protective for gastrointestinal 
mucosal integrity and motility as compared with parenteral nutrition (PN).34,35 Maintenance 
of gut integrity is presumable an important indicator for the beneficial effect of EN. 
Prolonged enteral fasting leads to negative consequences on intestinal morphology and 
microbial diversity possible leading to feeding intolerance.36 Even short-term fasting may 
impact the function of Paneth cells, allowing to an increase in bacterial translocation and 
following its infectious consequences.37 Paneth cells are located in the small intestine and 
are important in the production of antimicrobial proteins in the gut. EN generally consisted 
of processed liquid formulas with limit microbial diversity. These formulas are often 
absorbed in the proximal part of the gastrointestinal tract leaving the distal tract open for 
the severe consequences of fasting. Therefore, EN is less effective in comparison to an oral 
diet. Nonetheless, even trophic feeding, the practice of feeding small volumes of enteral feed 
termed as minimal enteral nutrition (MEN), is thought to already stimulate normal enzyme 
activity, hormone release, blood flow, motility and microbial flora, and the development of 
the immature gastrointestinal tract in infants. Unfortunately, there is currently no evidence 
indicating the minimum or maximum amount of EN needed to maintain gastrointestinal 
integrity, Paneth cell function and minimise the risk of harm and positively affect outcomes. 
Identification of dysbiosis during illness in faecal samples may lead to novel treatment 
options. Adding antioxidants or probiotics to EN could hypothetically limit the development 
of a pathobiome, however, thus far it has not led to an altered feeding intolerance 
symptomology in critically ill children (Chapter 4). Researchers have called this strategy 
rather naïve, as the complex microbiome cannot be saved by adding only a few commensal 
probiotic organisms.38 Although the Firmicutes and Bacteroidetes microorganism have the 
largest impact on gut integrity and might be a promising place to start. Furthermore, faeces 
microbiota transplantations are increasingly used in the non-critically ill population to adapt 
the microbiome. In critically ill patients only 4 case reports were published, making it 
impossible to form any premature conclusions.39 
Fluid restriction  
Fluid restriction due to renal, hepatic, or cardiac failure often precludes the use of large fluid 
volumes and the ability to achieve feeding goals either enteral or parenteral. Our survey 
showed that 29% of the respondents classified severe fluid restriction as an important 
barrier for EN (Chapter 2) ranking this barrier 6 out of 25 possible barriers.  
During stable and recovery phase protein and energy-dense formula may be considered to 
support achievement of nutritional requirements to allow normal development, growth and 
preservation of lean body mass (Chapter 6). This formula allowed for a lower fluid intake 
deriving from EN, while maintaining target caloric and macronutrient intake. In Chapter 7 
we examined 70 critically ill infants receiving protein and energy-dense formula for at least 
                                                                
 
14 days and found that realising the target of approximately 2 times of resting energy 
expenditure (REE) was possible. This resulted in normal growth as comparable with healthy 
subjects and even a significant weight-for-age z-score of +0.48 enabling catch-up growth in 
the majority of infants. These findings have yet to be extrapolated to older children. 
There are some signs that dense formulas affect nutrients absorption by delaying gastric 
emptying.40 However, previous observational studies in critically ill children have seen similar 
tolerance when compared to standard polymeric feeding.41,42 In our study (Chapter 7), 
limited gastrointestinal symptoms occurred, comprising of large GRV, vomiting, diarrhoea 
and obstipation while using protein and energy-dense formula. However, comparison with 
standard formula regarding these gastrointestinal symptoms were not made in this particular 
study.  
There is still a paucity of evidence favouring specific feeding formulas in critically ill children. 
In general, nutritional studies focus on the first period after admission. This is unfortunate 
as much harm can be caused by prolonged underfeeding of overfeeding during stable and 
recovery phase. Thus, when strict fluid restriction or feeding intolerance inhibits full enteral 
feeding in children, protein and energy dense-formula should be considered. 
Non-invasive ventilation 
Non-invasive ventilator support (e.g. high-flow nasal cannula, bilevel positive airway pressure 
and continuous positive airway pressure) is often perceived as a barrier to start or incline 
EN by clinicians due to the suggested increased risk for pulmonary aspiration and potential 
need for intubation. Our multicentre retrospective cohort study showed that, although 
there was a large centre difference in ventilatory support and feeding protocol, children 
admitted to the PICU tolerated feeding well, with relatively limited feeding related 
complications or presence of gastrointestinal symptoms (Chapter 3). Especially the 
occurrence of respiratory aspiration was rare, however, further prospective trials are 
needed to determine both the optimal timing and feeding method in critically ill children 
receiving non-invasive ventilatory support. 
Medication 
Several medications are known to influence gastrointestinal motility, including sedatives, 
analgesics, antibiotics and vasoactive drugs administered to critically ill patients, can 
potentially affect gastrointestinal motility. Analgesics (opioids) impact gastric emptying and 
upper gastrointestinal tract through the central and peripheral opioid receptors, whereas 
sedatives delay gastric emptying, increase gastrointestinal transit time, and affect the 
gastrointestinal motility. Subsequently, gastrointestinal symptoms such as vomiting may also 
be a sign of factors not related to the gastrointestinal function such as sedation withdrawal 
with subsequent agitation, rather than a direct results of sedative on feeding intolerance and 
delayed gastric emptying.43 Our study showed that children who received antibiotics had an 
overall lower enteral intake (Chapter 5). Antibiotics play a role in many aspects of critically 
                                                                
 
illness, apart from the relationship with inflammation, it can have both a pro-kinetic function 
and results in negative effects such as diarrhoea. Moreover, the effect on the 
impoverishment of the microbiome has been established in multiple studies all contribution 
to worse outcomes.27,44,45 The ‘’motor’’ of the gut is also controlled by the adrenergic and 
dopaminergic nerve system, thereby catecholamines can lead to feeding intolerance. Often 
these drugs are prescribed simultaneously and are associated with the degree of illness. 
After correction for confounders, the provision of inotropic agents as compared with 
antibiotics, sedatives and analgesics was found to influence EN intake the most (Chapter 5).  
Management of barriers 
Numerous factors contribute to the pathogenesis of feeding intolerance, meaning that 
approaches to its prevention and management are most likely multifaceted. 
 
Medication 
In addition to medication causing feeding intolerance, they also serve a role in its therapeutic 
management. Dopamine receptor antagonists (metoclopramide and domperidone), motilin 
agonists (erythromycin) and 5-HT4 receptor agonists (prucalopride) promote 
gastrointestinal motility.46 Although not uncommonly used in critically ill children, current 
RCTs in paediatric critical care are lacking to support the use of drugs to reduce feeding 
intolerance. Moreover, these drugs may have serious side effects in young children. Novel 
prokinetic agents such as opiate receptor antagonists, CCK receptor antagonist and Ghrelin 
agonist have (hypothetical) promising effects, however, the efficacy of in the management of 
feeding intolerance has not been formally assessed during critical illness.47 
Post-pyloric feeding 
There is ongoing debate on the optimal feeding route in critically ill children. Enteral 
nutrition, via nasogastric tube, is often perceived to lead to large GRV and pulmonary 
aspiration in children who are intolerant to feeding, increasing the risk of nosocomial 
pneumonia. These risks may be decreased when using a post-pyloric feeding tube. However, 
the difficulty of inserting a post-pyloric feeding tube may cause a delayed start with 
subsequent inability to achieve nutritional targets.48,49  
Based on the lack of evidence favouring a specific route and the difficulties of inserting a 
post-pyloric tube, recent guidelines did not indicate that post-pyloric feeding is superior to 
gastric feeding.50-53 Nevertheless, in centres with sufficient expertise and training, post-
pyloric feeding was associated with a higher achievement of nutritional goals as compared 
with gastric feeding (Chapter 5). Although this finding was corrected for confounders, this 
conclusion still pertains to observational research and could be subjected to bias. However, 
strengths of this study were the multicentre nature and the large cohort size (n=690). The 
higher achievement of EN via post-pyloric route in Chapter 5 is pertained to the acute phase 
of illness, whether this therapy is also more successful in the stable and recovery phase 
remains speculative.  
                                                                
 
It is remarkable that there is currently only one RCT investigating feeding intolerance in 
gastric versus post-pyloric feeding in 74 critically ill children. In contradiction to 
observational studies, this RCT found no significant differences for aspiration, vomiting, 
diarrhoea or abdominal distention, which could lie in the small number of participants. In 
children with a successful post-pyloric tube placement a higher achievement of caloric goals 
was possible, however, in 29% of the children tube placement was unsuccessful.54 Additional 
training to health care professional is highly needed to improve the success of post-pyloric 
tube placement, which consequently could improve enteral intake. 
Feeding formula 
A possible strategy to overcome feeding intolerance is the changing the type of feeding. 
Adding fibre or switching to peptide feeding (Chapter 8) are relative easy and non-invasive 
strategies which have been explored in observational studies. Peptide feeding is frequently 
used in children suffering from cow’s milk allergy, but also in medical conditions without 
evidence‐based research supporting its use.55 In our multicentre observational study, protein 
and energy-dense peptide feeding was feasible and safe in 50 critically ill infants, however, 
the study did not compare this formula with other types of formula (Chapter 8). A 
retrospective observational study in critically ill children investigating signs of feeding 
intolerance before and after implementation from peptide to polymeric diet identified no 
differences. Currently, expert consensus stated that polymeric feeding is first choice and 
peptide feeding should be considered to improve tolerance and advancement of enteral 
feeding in children who present with signs of intolerance to polymeric feeding.51 In addition, 
diarrhoea can be treated or prevented by adding fibres to the feeding formula, with a gaining 
interest for specific fibre blends, including soluble fibres and prebiotics.56 
 
Overcoming barriers 
For decades it was believed that low enteral intake resulted in worse clinical outcomes, as 
many observation studies showed an association between these two factors.57,58 Therefore, 
research has focussed on removing barriers to allow a higher intake. This viewpoint has 
been challenged in the current debate on the nutritional requirements during paediatric 
critical illness.  
The investigated barriers might be related to different concepts and as such be addresses in 
a different way. Barriers such as non-invasive ventilation and delays in gaining small bowel 
excess are partially the results of inadequate education and knowledge and should be 
addresses as such.  
Feeding intolerance and the inability to achieve enteral intake might be an adaptive response 
to stress. Interfering with this adaptive response to stress, by adding more nutrient content 
than the body can metabolise, could potentially even have harmful consequences. This leaves 
the question, if we can improve the management of barriers, should we? 
                                                                
 
What are optimal nutritional targets? 
When discussing nutritional requirements during paediatric critical illness it is probably 
essential to take the phase of illness into account. Although arbitrarily, these phases of illness 
are divided into three phases; acute, stable and recovery. During the acute phase the body 
turns into a catabolic state altering its energy expenditure and use of energy substrates.59 
During stable and recovery phase the catabolic response adapts into an anabolic state 
restoring the protein balance.  
The acute phase 
This phase is characterised by protein wasting and loss of lean body mass, leading to 
increases impaired morbidity and mortality. Nutritional support was thought to partially 
ameliorate protein wasting during the catabolic response and historically artificial nutrition, 
including EN and PN, was recommended to be provided as early as possible and as high as 
possible.  
Enteral nutrition 
The guidelines and recommendations have changed substantial over the past years, 
however, they still pertain to observational research. The new guidelines recommend to 
achieve 67%-100% of REE via EN by the end of the first week.50,51,53,60. Moreover, there is a 
strong consensus to start artificial nutrition via enteral route with an early initiation (< 24-
48 hours) i.e. for the maintenance of gut integrity. This advice is primarily based upon low 
grade evidence were an earlier and higher achievement of nutritional targets is associated 
with improved outcome in observational designs, without incorporating the heterogeneity 
of the PICU population and variances in the severity of illness.57,58,61-63 Furthermore, the 
beneficial effect of early and higher EN has been found in animal models and laboratory 
studies using surrogate outcome markers.42,64-71 However, the conclusions made from these 
observational and laboratory studies need to be carefully interpreted due to unmeasured 
confounders.  
The observational designs on which the guidelines are based need careful interpretation, as 
association does not imply proof for causation. Additionally, when many variables need to 
be taken in to account in the analyses, spurious associations may occur. The magnitude of 
illness deterioration is associated to the amount of feeding intolerance,17,72 as critically ill 
children who are able to achieve higher feeding goals, might have an overall lesser amount 
of organ failure and thereby inherently have an improved outcome. To avoid premature 
conclusions between EN intake and improved outcome, confounding variables contributing 
to enteral adequacy such as age, diagnosis, malnutrition, type and method of feeding, 
medication, systemic laboratory inflammation markers and illness severity scores should be 
encountered (Chapter 5). Previous observational paediatric studies fail to correct for these 
important confounders and there are currently no RCT’s published addressing different 
macronutrient contents or artificial nutrition targets to improve outcome in children.  
                                                                
 
Chapter 5 shows that during the acute phase, higher achievement of nutritional targets via 
EN was no longer beneficial after multivariable correction for these important confounders. 
This provides a new hypothesis whereby achieving high caloric goals early during critical 
illness does not automatically result in favourable outcomes; and even that the use of trophic 
feeding and permissive underfeeding may be beneficial. This hypothesis is supported by a 
small retrospective study showing improved outcomes with underfeeding as compared with 
overfeeding.73 This might be partially related to the adverse outcomes of the inability to use 
the exogenous substrates. Thereby, in the acute phase, energy intake provided to critically 
ill children should not exceed the metabolic abilities of the patients. Unfortunately, causal 
evidence on the optimal EN target in critically ill children is lacking.  
Systemic inflammation 
In Chapter 5 we showed that the degree of illness severity assessed by validated scores and 
systemic inflammation markers were associated with the amount of enteral intake. This 
finding supports previous studies associating illness severity with enteral intake or with the 
presence of gastrointestinal symptoms.17,58,72 Whether this reflects a causal link or merely 
adaptation to the underlying illness remains a topic of debate.  
An induced epithelial apoptosis is found in patients with sepsis together with a decrease in 
crypt proliferation, which reduces the nutrient absorption function of the gut, but also the 
first line defence mechanism allowing systemic inflammation.20,32,33 This alteration was also 
found in patients with non-infectious inflammation such as trauma, burns, and haemorrhage. 
Hence, systemic inflammation should be seen as more than a just simple confounder.  
As systemic inflammation could be one of the indicators for gastrointestinal organ failure, 
this may be incorporated into the bed-side decision around feeding practices. However, a 
more complete picture including biomarkers for gut motility and integrity is needed to allow 
individual targeted nutritional support.  
Specific populations 
The PICU population is quite heterogeneous, whereby specific populations may respond 
differently to nutritional interventions. For instance, patients admitted after traumatic brain 
injury often experience large GRV and vomiting due to the increased intracranial pressure 
to delay gastric motility via the autonomic nervous system.74 In our study we found that 
admission for neurology or neurosurgery led to normal or higher intake (Chapter 5). 
Children admitted due to gastrointestinal surgery were the only subgroup which significant 
lower EN intake, which is likely influenced by the clinician or surgeon deeming the gut 
unsuitable or contraindicated for feeding rather than actual feeding intolerance.  
Based upon low grade evidence, guidelines currently only recommend to postpone or 
withhold early EN in hemodynamically instable patients with a high risk of impaired 
splanchnic perfusion and subsequent bacterial translocation or gut ischemia.50-53 Conversely, 
                                                                
 
delaying EN in instable patients may lead to undernutrition and reduction of this 
gastrointestinal barrier function. Both sides have been associated with poorer clinical 
outcomes. Hence, whether early initiation in hemodynamically instable patients causes 
beneficial or deleterious effects remains controversial. However, no evidence suggests that 
EN should not be attempted in stable patients, including children receiving extra corporal 
membrane oxygenation, and may even be attempted in instable patients under certain 
precautions. The presence of uncontrollable shock, hypoxaemia, acidosis or severe signs of 
‘feeding intolerance’ including GI bleeding, exceedingly large gastric residue, bowel ischemia 
or obstruction are strong signs to delay EN. However, MEN may play a role in these patients 
due to the many favourable effects and small burden on the gut. Overall, early initiation of 
EN seems valuable in the majority of critically ill children.  
What can we learn from adults ICU studies? 
Recently, the TARGET study showed that approximately 100% (±1900 kcal/d) compared 
with 70% (±1300 kcal/d) of recommended caloric intake did not result in improved short-
term clinical outcomes, or quality of life and functional outcomes six months after ICU 
admission in 3957 mechanically ventilated adults.75,76 During this trials the amount of protein 
was comparable between the two groups resulting in a differences between carbohydrate 
and lipid amounts. The EDEN RCT compared trophic feeding (± 400kcal/d) with full enteral 
feeding (±1300kcal/d) for the first six days in 1000 patients within 48 hours of developing 
acute lung injury and found no differences.77 Also, the PermiT RCT showed that receiving 
800 kcal/d versus 1300 kcal/d for the first 14 days of admission did not affect outcome.78 
Furthermore, secondary analyses from the EPaNIC study involving 4640 adults found that 
the group of patients who received <30% of recommended target was associated with 
improved recovery, regardless of the administration route, and higher amounts of amino 
acids primarily explained the harm.79 Thus, the historic believe that higher enteral 
achievement would benefit the patient has not been confirmed by a RCT. 
Parenteral nutrition 
The landmark PEPaNIC RCT80 had a large impact on the paediatric guidelines, which now 
recommend to withhold parenteral nutrition during the first week of admission while 
continue to provide micronutrients50-53. Subjects included in the PEPaNIC trial were all 
critically ill children with an expected admission duration >24 hours and a medium or high 
nutritional risk score assessed by the STRONGkids score. The critically ill population is 
heterogeneous, whereby some subpopulations are thought to be more at risk for 
macronutrient restriction, such as children who are undernourished upon admission or 
neonates. Though, these subgroups showed similar beneficial effects.81,82 
Macronutrients 
Secondary analyses of the PEPaNIC RCT confirmed the adult result, whereby higher doses 
of amino acid administration were associated with worse outcome, while the effect of lipids 
and carbohydrates were neutral of even beneficial.83 Higher glucose administration did not 
                                                                
 
negatively affect outcome, however, a higher blood glucose concentration is known to cause 
worse short-term and long-term outcomes.84,85  
Recommended minimum amino acid amount in critically ill children is 1.0 g/kg/d (children) 
up to 1.5 g/kg/d (term infants) according to the European guidelines86 and a minimum of 1.5 
g/kg/d according to the American guidelines which might be even higher in young infants and 
children50. These advices are the results of the threshold needed to acquire a positive 
nitrogen balance in children, which has been associated with improved outcomes. The 
PEPaNIC study showed that the harm from amino acids was already present at amounts 
starting at 40–50% of reference doses for age and weight, which increased with higher doses 
of amino acids. The maximum risk of harm was already established when amino acid 
amounts of 0.75 kg/g/d in older children and 1.15 kg/g/d in children <10kg was provided, 
which is considerably lower than recommended. 
Hence, the negative impact of amino acids was identified even at low macronutrient 
amounts, whereby the impact was primarily investigated per dose, rather than feeding 
route.79,83 In two recent large RCTs involving adult ICU patients feeding provided via enteral 
route did not reduce mortality or the risk of new acquired infections compared to 
parenteral provided feeding. However, there was a greater risk of gastrointestinal 
complications in the EN group. Importantly, in both studies feeding was provided at 
isocaloric doses and similar between the two randomisation groups.87,88 Hypothesis 
generating, the amount of nutrients provided, and thereby allowing overfeeding rather than 
permissive underfeeding, could be more important than the feeding route nutrients are 
provided.  
Mechanism behind beneficial caloric and macronutrient restriction 
The leading hypothesis behind the counter-intuitive findings is the consequence of 
nutritional intake to suppress the fasting response, which induces ketosis and activates 
autophagy.89-92 Autophagy is an evolutionary conserved intracellular degradation process and 
it is crucial for maintaining cellular integrity and function, which of course becomes even 
more essential during acute stress. Starvation-induced autophagy is an important 
evolutionary response during acute illness against intracellular pathogens and improves 
survival.  
Mice studies dating back to 1979 already found that force-fed mice had worse survival 
compared to mice who were allowed to feed ad libitum or underwent a 72 starvation period 
when infected with bacteria.93,94 Remarkably, survival rates were highest in mice who lost 
the most weight, while achieving weight gain is still a surrogate outcome measure of benefit. 
More recent, animal models have shown that providing artificial nutrients, in particular 
amino acids, are a strong suppressor of autophagy. While revolutionary steps are performed 
in laboratory research, in vivo human studies are complicated by the inability to measure 
                                                                
 
autophagy. In the absence of a ‘‘golden standard’’, secondary parameters, such as the 
presence of ketone bodies, are currently used.  
Micronutrients 
Reintroduction of feeding potentially results in a shift of micronutrients. Micronutrient 
depletions are often seen in critically ill children which is associated with impaired morbidity 
and mortality. Although no trials showed an advantageous effect of micronutrient 
supplementation, it seems logical to provide micronutrients during all phases of critical 
illness. However, due to a lack of evidence, current recommendations are based upon 
expert opinion and dietary reference nutrient intake for healthy children without 
incorporation of the phase of the disease. In Chapter 10 we showed the lack of clinical 
evidence supporting supplementation and the inability to provide all recommended amounts 
with the current commercial products hampers the implementation of current guideline 
recommendations.95-98 Although the ESPGHAN/ESPEN/ESPR/CSPEN guidelines advise to 
use commercial products due to the lower risk for microbial contamination and 
compounding errors99,100, the ESPGHAN/ESPEN/ESPR/CSPEN and ASPEN guidelines both 
acknowledge the recommended intakes can only be accomplished using individualised 
micronutrient products in critically ill children.99,101 It would greatly improve the healthcare 
system if pharmaceutical companies are able to provide micronutrient products in 
adherence to the guidelines, and in adherence to the paediatric critically ill population. 
The difficulties in assessment and interpretation of micronutrient status and management of 
depletions lies in the different methods used to determine depletions. Most often serum 
levels are used, however other methods entail clinical signs of deficiencies, dietary 
assessment or intracellular depletion measurements. All methods have their pitfalls, as 
clinical signs are often not differentiated from critical illness itself and for serum and 
intracellular measurements paediatric reference standards are lacking.102 Furthermore, 
cautions interpretation of thresholds is needed during the acute inflammatory response, as 
levels are significantly lowered during inflammation.103 
Stable and recovery phase 
Taking into consideration that biomarkers determining the timing of transition from acute 
to stable to recovery phase are lacking, currently the transition towards the anabolic phase 
is arbitrarily assumed to be by the end of the first week.60 Unquestionably, this is highly 
dependent on the individual acute stress response to critical illness, and more knowledge is 
needed on how to determine these transition points. Besides the clinical status of the child, 
additional information on inflammation status, metabolic markers and neuro-endocrine 
stress response hormones may help to differentiate these phases on an individual level in 
the future, and guide the nutritional requirements according to these phases.  
During the stable and recovery phase the bodies’ acute response to prioritise the delivery 
of energy substrates to vital tissues from endogenous production has faded, and resynthesis 
                                                                
 
of lost tissue follows. The body is more capable to digest and process exogenous nutrients 
and energy requirements increase. The provided intake should incorporate physical activity, 
rehabilitation and (catch-up) growth (Chapter 6). In specific diagnoses the requirement may 
rise up to twice the recommended daily intake for healthy children. There is an increased 
risk of undernutrition which is detrimental for short-term and long-term outcome. We 
know that worldwide prolonged undernutrition places a large long-term burden on children 
with approximately 113.4 million children being undernourished and 3.1 million children 
dying from undernutrition each year mostly in low-income and middle-income 
countries.104,105 Long-term adverse effects in these children consist of poor learning ability 
and school performances which influence the societal perspectives.106 The Minnesota 
Starvation Experiment (1944-1945) showed that a semi-starvation period of six months 
reducing the daily intake with 50% in healthy adults led to neurocognitive and psychiatric 
problems only after a few weeks of starvation.107 Therefore, a transition in nutrient regime 
is needed to counteract the detrimental consequences of (long-term) macronutrient 
deficits. 
Hence, the stepwise manner to increase EN intake should be guided by the metabolic stress 
response and patients tolerance, which could mean modification to a protein and energy-
dense formula or other management of barriers. When patients remain unable to achieve 
macronutrient goals adequately due to many barriers identified on the PICU, supplemental 
PN start to play an important role. As these recommendations are withdrawn from 
observational evidence, it is important to allow individual circumstances and patient 
characteristics to take precedence over the guidelines advised nutritional targets.  
Long-term developmental outcomes 
The development of feeding intolerance as well as nutritional support is suspected to have 
prolonged impact after discharge from the PICU, as both undernutrition and overfeeding 
during childhood are associated with impaired neurocognitive and behavioural 
development.108,109 The impact of caloric adequacy during PICU admission on long-term 
development is currently unknown. The adult ICU TARGET study was one of the first to 
assess recommended enteral intake (100%) versus lower than recommended intake (70%) 
during the acute phase and could not identify any differences in survival, functional outcomes 
or altered quality of life at six month follow-up.75,76 
Nonetheless, studies have indicated that even short-term metabolic intervention during 
PICU admission has an impact on physical and neurocognitive development.85 Therefore, 
the children who participated in the PEPaNIC RCT were assessed for long-term physical, 
neurocognitive, and emotional and behavioural development two and four year after 
admission to investigate the impact of parenteral nutrition provided during the acute phase. 
On both time points, an important physical, neurocognitive, and emotional and behavioural 
burden was reported in comparison with matched healthy control children (Chapter 11 and 
12).  
                                                                
 
Two points specifically warranted careful and extensive investigation of long-term 
neurocognitive and psychical development in this vulnerable patient group. First, during the 
PEPaNIC RCT, a large proportion of children allocated to the late PN group had no or 
minimal enteral intake, resulting in substantial lower macronutrient intakes than 
recommended by the former guidelines.110 Despite the short-term clinical benefits of 
omitting PN during the first week of illness, concerns were raised about potential adverse 
long-term consequences of below recommended macronutrient intake for the patients’ 
anthropometric, health status, neurocognitive and psychosocial development. Second, the 
occurrence of hypoglycaemia (glucose level <40 mg/dl or <2.2 mmol/L) was higher in the 
late PN group (9.1% late PN versus 4.8% early PN), however, this had no effect the short-
term outcomes of providing late PN. Indeed, severe or recurrent hypoglycaemia, especially 
in neonates and infants, have been associated with worse long-term neurocognitive 
outcomes.111,112 However, a short and transitory hypoglycaemic occurrence during critical 
illness did not cause harm on long-term neurocognitive development two to four years after 
PICU admission in neonates and children who participated in the PEPaNIC RCT or three 
years after a tight glucose control RCT.85 
The omission of PN did not harm any of the physical and neurocognitive developmental 
domains and protected the ability for normal development on several (executive) domains 
2 years after (Chapter 11) and neurobiological pathways that coordinate emotions and 
behaviour 4 years after PICU admission (Chapter 12), which were no longer over 
represented in patients in the late PN group compared with healthy controls. These data 
support de-implementation of the use of parenteral nutrition early during critical illness in 
infants and children. The findings also open perspectives for future identification of other 
modifiable risk factors related to intensive care management.113 
Epigenetics 
Unravelling the mechanism behind this beneficial long-term effect is needed to comprehend 
this complex adaptation and provide new insights in possible therapeutic options. 
Epigenetics is the genetic control, other than the individual's DNA sequence, that alters and 
may switch genes ‘‘on’’ or ‘‘off’’ and subsequently determine which proteins are and are not 
transcribed. Examples of epigenetic control are DNA methylation, histone modification and 
noncoding RNAs, all of have been shown to alter by metabolic or lifestyle interventions.114 
Epigenetic regulation may have a substantial impact on the outcomes long after critical 
illness. Specifically, DNA Methylation or demethylation which is a chemical process that 
alters gene expression and thereby alters the biological processes, could alter the 
development of physical and neurocognitive functioning.115  
Epigenetic analyses from the PEPaNIC study showed that a total of 159 functionally relevant 
de novo alterations in DNA methylation partially explained the long-term harm, and 37 of 
these were related to early-PN. The DNA methylations occurred in genes know to be 
involved in brain development and signalling as well as in growth and metabolism. The harm 
                                                                
 
was most prominently elucidated by early administration of amino acids, rather than 
carbohydrates or lipids.116 Furthermore, these alteration were already present within the 
first 3 days of PICU admission and maintained or deteriorated during the course of 
admission.117 Therefore, it seems sensible for future studies to aim at intervention starting 
early during PICU admission.  
Epigenetics is modifiable in response to stimuli and a longer follow-up is warranted to 
examine if these alteration are permanent. Furthermore, the DNA methylation alterations 
within the PEPaNIC RCT were investigated in leucocytes, whether this is mirrored in other 
cells needs to be investigated. A special concern should be placed on the reproductive 
organs cells, as this could potentially have consequences continuing for generations.  
Identification of subgroups 
While in the heterogenetic PEPaNIC population based-level no harm was identified, a similar 
beneficial effect of this interventional in children who are thought to be more at risk for 
metabolic insults e.g. neonates, malnourished children upon admission and children who 
develop hypoglycaemia has to be further investigated regarding long-term consequences. 
Furthermore, specific diagnostic or age groups could respond differently to the omission of 
PN. This hypothesis was confirmed by a secondary analyses form the PEPaNIC RCT 
identifying that children between 1 and 11 months old were most vulnerable for the 
development of long-term consequences of early PN.118 
Furthermore, in view of the potential benefits of fasting-induced responses for removal of 
cell damage and prevention of neurodegeneration, withholding PN early during the course 
of critical illness in children brings beneficial effects in the short-term and long-term, in 
particular for neurocognitive development. Maturation of the brain takes place in different 
stages of life. During the first 5 years the brain rapidly develops and alters, which continues 
into adulthood. These first years lay the foundation for future learning, health and life 
successes. It is currently unknown if and how omitting PN affects their future societal 
perspectives for which a longer follow-up period is warranted.  
  
                                                                
 
F U T U R E   P E R S P E C T I V E S 
The PEPaNIC study shows that improvements made in national support have a substantial 
impact on daily life years after PICU admission. Unfortunately, recommendations for 
nutritional support in critically ill children is still largely driven by low-grade evidence i.e. 
observational studies and expert opinions. To allow further optimization this thesis asks and 
answers some important considerations leading to future research perspectives in the 
following fields: 
- Unravel the mechanism behind feeding intolerance to allow early assessment and 
management 
- Assessment of nutritional requirements for optimal short-term and long-term 
outcome during acute, stable and recovery phase; and the role of amino acids 
herein.  
- Explore the impact of micronutrient deficiencies and supplementation 
- Building a model towards individual tailored nutritional support by further 
exploring specific populations 
Feeding intolerance 
The proposed uniform definition to screen for feeding intolerance needs to be validated in 
clinical practice. This definition currently fails to incorporate several essential factors 
affecting patients’ tolerance, such as prescribed medication, pre-existing nutritional 
impairments and electrolyte imbalances impairing gastrointestinal motility e.g. 
hyperglycaemia, hypokalaemia and hypomagnesaemia or the use of hyperosmolar diluent.119 
With a validated definition clinicians and researcher will be able to identify the causes and 
consequences of feeding intolerance to one benchmark; and allow comparison of different 
feeding intolerance managements. 
Gastrointestinal biomarkers 
Studies exploring the mechanism behind feeding intolerance are warranted, not only in 
regards to improve body composition or short-term outcomes, but also its impact for long-
term health. In addition to clinical screening of GI symptoms and EN enhancement, 
laboratory markers could help to identify patients at risk for feeding intolerance. There is 
currently no marker to identify critically ill children who are tolerant to feeding, however, 
several makers have been identified in association with altered gastrointestinal function in 
other (paediatric) populations. Additionally, (systemic) inflammation markers and the 
microbiota could help to guide nutritional practices and individualise nutritional support in 
critically ill children. Figure 2 highlights some of the markers that have been associated with 
gastrointestinal dysfunction and could potentially lead to an early screening of feeding 
intolerance during critical illness, or indicate when the gastrointestinal tract is able to 
recover its normal functions. 
  
                                                                
 
Figure 2. Factors affecting feeding tolerance to enteral feeding and possible markers for 
determining these factors during critical illness. 
CCK, Cholecystokinin; CRP, C-reactive protein; GIP, Gastric Inhibitory 
Polypeptide; I-FABP; Intesntial Fatty Acid-Binding Protein  IL, interleukin; PYY, Peptide YY; 
TNF, Tumor necrosis factor 
 
 
Nutritional requirements  
Several large and sufficiently powered RCTs did not support evidence for high enteral caloric 
goals to affect patients’ outcomes. This should heighten our awareness of the lack of high 
quality evidence addressing the question of amino acid requirements in critical illness. 
Optimal amino acid requirements remain controversial during the acute phase. Guidelines 
recommendations are mainly based on maintaining muscle mass and avoid a negative 
nitrogen balance, both common in the critically ill, and associated with increased morbidity 
and mortality. New insights have shown that amino acids were the primary substrate 
explaining harm. In addition, parenteral nutrients restriction has led to a more efficient 
activation of autophagic quality control of myofibres and reduced muscle weakness.89 
                                                                
 
Therefor, determination of low vs normal or high amino acid intake, timing and the 
combination with early mobilisations are currently in the highest scoring research 
priorities.78,120 
Besides finding optimal macronutrient targets, more research is needed to investigate the 
range within feeding can be provided with a special interest towards minimal enteral 
nutrition. Hence, what amount of feeding is required to maintain gut function? 
In addition, the variation in illness severity, heterogeneity of the population and PICU 
confounders make it difficult to comprehend the metabolic processes to nutritional 
interventions.121,122 The diversity in metabolic, genetic, epigenetic response have been 
investigated on population-bases level, but the lack of biomarkers inhibits the investigation 
of individualised patient-level approach. The need to better understand de individual 
malnutrition risk and metabolic heterogeneity has led to several biomarkers in nutrition. 
Screening for malnutrition upon admission i.e. STRONGkids malnutrition score, illness 
severity scores (PIM, PELOD, PRISM) and systemic inflammatory have been well recognised 
in paediatric research as important patient-level biomarkers, still observational studies often 
fail to incorporate these in their conclusions. Furthermore, established biomarkers for 
nutrient absorption and metabolic response are the whole body protein balance measured 
via calculation of the nitrogen balance, metabolic substrates such as albumin, retinal binding 
protein, transthyretin and transferrin and measurement of body composition. These 
biomarkers could help the translation towards patient-level, however, little is known to 
what extent these surrogate outcomes markers affect clinical outcomes.121 
Lastly, strategies to enhance caloric intake, such as post-pyloric feeding tube, dense formula 
or medication, should be critically reviewed during the acute phase, as this hypothetically 
could result in unfavourable consequences. 
Macronutrients 
Not all macronutrients have an equal effect on body’s immunologic and metabolic stress 
response. As most harm was identified from amino acids substrates, future studies may have 
to rethink the amount of supplementation provided. Doses as low as 40-50% of currently 
recommended amounts resulted in harm during the acute phase, thereby studies comparing 
of the effect of different protein contents via enteral or parenteral route are highly needed. 
Contrariwise, the provision of non-protein sources could protect critically ill children 
against harm, as higher glucose doses from admission onwards and lipids from day 4 onwards 
resulted in faster recovery. This sets a basis for research adapting macronutrient 
supplementation towards different time points, rather than recognising it as one sustenance. 
Micronutrients 
While substantial improvements have been made for macronutrient supplementation, 
research for optimal micronutrient provision is lacking behind.51 Current gaps of knowledge 
                                                                
 
are the interpretation of serum micronutrient levels in comparison with actual intracellular 
depletions, the prognostic value of electrolyte disturbances after reintroduction of feeding, 
such as refeeding hypophosphatemia, and the impact of micronutrient supplementation on 
short-term and long-term outcomes. The advancements in micronutrient research is 
complicated by the difficulties of multiple assessment methods. In the most optimal situation 
research should include a multiple approach model including all forms of assessment i.e. 
clinical, dietary intake and laboratory serum and intracellular makers.  
Other feeding patterns 
While autophagy as a result of macronutrient restriction is thought to determine the 
beneficial effect of late PN, prolongation of this period of starvation seems detrimental. A 
possible solution to allow autophagy while also providing full amounts of nutrients is to 
mimic the fasting response in an intermittent or cyclic feeding pattern. No human naturally 
eats continuously for 24 hrs a day and the gastrointestinal tract is designed for intermittent 
ingestion of nutrients a few times a day including intermitted hormonal release. Indeed, the 
normal gastrointestinal hormonal response to feeding almost disappeared when continuous 
tube feeding is provided.123,124 Cyclic feeding has been used for many years in children with 
bowel diseases, however this has never been investigated in critically ill children. Animal 
models have shown that cyclic feeding, and thereby allowing autophagy, was beneficial for 
age-related diseases and resulted in an older age. A recent trial showed that a fasting period 
of 12 hours was sufficient to develop a metabolic fasting response in adult critically ill 
patients.92  
The next step in research lies in determination of the optimal duration of fasting to allow 
autophagy and improve clinical outcome, while limit the risk of feeding intolerant 
complication due to high feeding provision during the feeding window and monitor 
hyperglycaemic and hypoglycaemic insults. While cyclic/intermitted feeding begins to mirror 
the gastrointestinal digestion process in health, it could hypothetically also result in a 
normalisation of the circadian rhythm. Due to a lack of studies invested in this topic, this 
feeding methods is currently not advices in acutely ill children, hence, cyclic feeding allowing 
autophagy is still a controversy to overcome. 
Epigenetics 
Epigenetics might help to unravel the biological basis behind the impact of metabolic 
interventions to affect the outcome after critical illness. Alterations in the DNA methylation 
associated with long-term disturbances in physical and neurocognitive development can be 
induces by both internal en external factors and have been associated with undernutrition 
and overfeeding. Providing a biological basis will help to implement or de-implement certain 
intervention which might feel counterintuitive.  
A total of 37 of the 159 methylation alterations in the PEPaNIC RCT were related to the 
early-PN randomisation, resulting in 122 DNA methylation alterations unaccounted for. It 
                                                                
 
would be interesting to investigate if these alterations are the result of critical illness itself 
or potential other modifiable factors. Hence, the identification of DNA methylation as an 
important mediator for long-term development affected by the early provision of PN opens 
perspectives for other factors contributing to the legacy of critical illness to be investigated.  
Identification of subgroups 
A (metabolic) insult may not have a similar effect on physical, neurocognitive and emotional 
and behavioural development in all critically ill children. Identification of subgroups at risk 
to experience difficulties in specific developmental domains might help to individualise 
therapy or treatment for deficits before that are experienced in daily life. Hence, a predictive 
individualise model is needed, to allow early identification and targeted treatment, to reduce 
impairments following critical illness. 
Finally, future research should focus on building models which help to individualise 
nutritional support. This model should include clinical characteristics such as different age 
groups and diagnosis, (bio) markers for neuro-endocrine, immunologic and inflammatory 
stress response and gastrointestinal function. This model should help to guide: 1) the 
amount of EN the gut can appropriately tolerate and is desirable; and 2) when the 
endogenous energy supply alters and safe starvation is no longer preferred. In order to build 
a nutritional guidance model, the nutritional research field needs to incorporate results from 
a system biology approach (e.g. genomics/transcriptomics, proteomics and metabolomics) 
creating more extensive knowledge on the individual response to a nutritional therapy.125 
Ultimately, you would like to deliver the child the most optimal nutritional therapy with the 
lowest impact possible from critical illness in order to provide the best future.  
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Chapter 1 describes the important role of nutritional therapy in critically ill children in 
accelerating recovery and maintaining normal physical and neurocognitive development. The 
awareness of the changes in metabolism during the different phases of critical illness is 
essential in determining metabolic and nutritional support. As both underfeeding and 
overfeeding are known to affect outcome during the complete course of admission.  
Furthermore, chapter 1 focuses on the gastrointestinal tract as the preferred route for 
nutritional support. Enteral nutrition (EN) is considered safe, cost-effective and more 
physiologic compared to parenteral nutrition (PN). However, recommended caloric and 
protein targets are often not achieved via enteral feeding, and discrepancies between the 
amount prescribed and the amount delivered range up to 60%. Numerous studies have been 
carried out to investigate these discrepancies, with (perceived) feeding intolerance as a 
result of gut failure, fluid restriction, fasting around extubation and (bedside) procedures, 
and ventilatory support most frequently reported. 
The chapter ends with the aims of this thesis, which is to provide insight into optimal 
nutritional therapy for critically ill children concerning the route, timing, and amount during 
acute, stable and recovery phase, with special attention to a conceptual insight into the 
barriers that restrict such optimal nutrition. 
The Acute phase 
In Chapter 2, we developed a survey tool to allow clinicians (i.e. physicians, nurses and 
dieticians) to assess and address the barriers for EN in their Paediatric Intensive Care Unit 
(PICU). This resulted in a large worldwide survey to identify perceived barriers that hamper 
the delivery of EN in PICUs. The prominent barriers identified, related to fasting for 
procedures, dietician coverage, inadequate education, care priorities and delays in gaining 
small bowel access. Hence, most of the primary perceived barriers for EN were related to 
                                                                
 
an overall lack of prioritising nutrition during paediatric critical illness. This further warrant 
education as a tool to improve awareness of the existing evidence regarding these perceived 
barriers.  
In Chapter 3, we retrospectively explored EN practices in critically ill children receiving 
non-invasive respiratory support in four centres across Europe. Due to concerns about the 
potential need for escalation of treatment, subsequent intubation, and of the risk of 
aspiration, non-invasive respiratory support was thought to be one of the major factors for 
delaying EN. In this observational study, children received a median of 56% of their energy 
goals compared to a benchmark target of 85% of the recommended dietary allowance, 
whereby feeding was well tolerated, with relatively few gastrointestinal complications. 
Despite the variations found between the four centres in terms of non-invasive respiratory 
support use, nutrition targets and delivery practices, our study supports that enteral 
nutrition is possible at an early stage during non-invasive respiratory support. However, 
prospective trials are required to determine the optimal timing and feeding method for 
these children.  
In Chapter 4, a systematic literature search was performed to evaluate the definitions of 
feeding intolerance used in critically ill children and to investigate the prevalence, predictors 
and outcomes of feeding intolerance. Our literature search revealed a median prevalence 
of 20%. Moreover, feeding intolerance was inconsistently defined throughout the literature 
overview, and no causes, therapies or consequences could be identified. Due to the lack of 
a standardised definition, we proposed a definition for feeding intolerance for future 
research, entailing the inability to achieve enteral nutrition target intakes in combination 
with the presence of gastrointestinal symptoms indicating gastrointestinal dysfunction. Such 
a standardised definition is needed for both clinical and research purposes to determine the 
consequences of feeding intolerance and to identify therapeutic options in relation to short-
term and long-term consequences. 
For decades, it is believed that low enteral intake results in increased morbidity and 
mortality, as many observation studies show an association between these two factors. The 
observational design of these studies calls for cautiousness in assuming a relationship 
between higher EN achievement and improved outcomes, as children who tolerate EN 
might become less critically ill and inherently have a better outcome. Chapter 5 presents 
data involving 690 critically ill children, and it was found that enteral nutrition was low in 
the majority of critically ill children, whereby only 32% achieved their energy goals compared 
to a benchmark target of 100% of resting energy expenditure during the first seven days of 
admission. Gastrointestinal surgery diagnosis, gastric feeding tubes, treatment with inotropic 
agents and large gastric residual volumes were negatively associated with successfully 
achieving EN using multivariable mixed models. Univariable analyses supports the frequently 
reported association between higher achievement of enteral intake and improved clinical 
outcome during the acute phase. However, after multivariable adjustment, these 
                                                                
 
associations were no longer present, suggesting that the impact on clinical outcome 
reported in previous studies reflects insufficient adjustment for confounders such as illness 
severity. These data substantiate the requirement of sound multivariable adjustment in 
observational nutritional support research and the necessity for randomised controlled 
trials (RCTs) investigating optimal EN. 
The stable and recovery phase 
Chapter 6 provides an overview of the literature on strategies and considerations for 
nutritional support during the recovery phase. Although (parenteral) nutrient restriction 
during the acute phase appears to be beneficial, persisting this course of nutrient restriction 
after the metabolic stress response resolves has detrimental short-term and long-term 
consequences. The caloric requirements increase markedly during the stable and recovery 
phase towards at least twice the resting energy expenditure to enable recovery, 
preservation of lean body mass, and (catch-up) development and growth in children. Such 
large amounts of intake demand for an alternate approach, especially when feeding 
intolerance or fluid restriction constitute a barrier for full enteral feeding. This approach 
includes a protein and energy-dense and / or hydrolysed formula. In addition, mobilisation 
and exercise are essential to achieve catch-up growth with an optimal body composition.  
Chapter 7 highlights the use of polymeric protein and energy-dense feeding formula in 
infants with a prolonged admission duration (>2 weeks). On average, 100% of their energy 
target was accomplished during admission, and the majority of the 70 infants receiving this 
formula showed (catch-up) weight gain (median +0.48 weight-for-age z-score). This was 
most prominent in infants with a low weight-for-age Z-score at admission to the PICU. 
Furthermore, the polymeric protein and energy-dense feeding formula was well tolerated 
based on the limited gastrointestinal symptoms observed. 
Expert consensus recommends hydrolysed feeding when establishing enteral feeding fails, 
or in children who do not tolerate polymeric protein. Chapter 8 describes the use of 
hydrolysed protein and energy-energy dense enteral feeding in critically ill infants in two 
different PICUs, taking into consideration feasibility, tolerance and nutritional targets. The 
53 infants met their nutritional targets, enabling weight gain and minimal feeding 
interruptions arising from feeding intolerance were observed. Therefore, this formula may 
further improve nutritional intake and minimise feeding interruptions as a result of 
gastrointestinal symptoms. 
Parenteral nutrition: macronutrients and micronutrient supplementation 
Chapter 9 presents an overview of the current role of PN in paediatric critical care. Despite 
the strategies to improve enteral intake, EN often remains insufficient in critically ill children 
which might result in a need for parenteral nutrition. The paediatric early versus late 
parenteral nutrition in critical illness (PEPaNIC) multicentre RCT showed that omitting 
supplemental PN during the first week of PICU admission as compared with early initiation 
                                                                
 
of PN (<24 hours) reduced new infections and accelerated recovery in term neonates, 
infants and children, independent of their nutritional status during admission. The leading 
explanation behind the counter-intuitive findings is the consequence of nutritional intake, 
especially amino acids, to suppress the fasting response, which induces ketosis and activates 
autophagy. These findings of the landmark PEPaNIC RCT had a considerable impact on the 
new guidelines. Although parenteral macronutrient restriction during the acute phase has 
been found beneficial for critically ill children, further research is required to determine the 
optimal timing, dose and composition of parenteral nutrition during stable and recovery 
phase as well as the determination of the role of parenteral micronutrients.  
Following the results of the PEPaNIC RCT, the new nutritional guidelines recommend 
considering withholding parenteral macronutrients for one week, while providing 
micronutrients, in critically ill children if enteral nutrition is insufficient.  
Chapter 10 provides an overview of the current practice of micronutrient administration 
and practical considerations in the three participating centres of the PEPaNIC RCT, and 
compares these therapies with the recommendations in the new guidelines. It was found 
that the lack of hard clinical evidence and the inability to administer all recommended 
amounts with the currently available commercial products hampered the implementation of 
these new recommendations.  
Long-term developmental outcome of parenteral nutrition 
Despite the short-term clinical benefits of withholding PN during the first week of paediatric 
critical illness, concerns have been raised about potential adverse long-term consequences 
of low caloric and macronutrient intake for the patients’ bodyweight, length, head 
circumference, health status, neurocognitive, emotional and behavioural development. Any 
adverse patient-centred long-term consequences would discourage withholding PN early in 
the course of paediatric critical illness. In Chapter 11, the two-year long-term developmental 
outcomes of the PEPaNIC RCT were investigated. The study showed that patients who 
were admitted to the PICU early in life compared to healthy control children had worse 
outcomes on all developmental domains e.g. anthropometrics, health status and 
neurocognitive development. Withholding supplemental PN for one week in the PICU did 
not negatively affect survival, anthropometrics, health status and neurocognitive 
development two years later, and protected the children against problems with their 
inhibitory control. 
Several neurocognitive domains can only be fully investigated from age 4 onwards. Because 
the PEPaNIC RCT involved a large proportion of young infants, a longer assessment period 
was needed in addition to the two-year follow-up. Chapter 12 presents the four-year follow-
up study. Again, the burden of critical illness was clearly seen when comparing the critically 
ill children to healthy control children. Omitting PN in critically ill children did not adversely 
affect long-term outcomes four years after randomisation and even decreased parent-
                                                                
 
reported internalising, externalising and total emotional and behavioural problems. These 
problems could arise from difficulties with inhibitory control found at the two-year follow-
up. Therefore, the two- and four-year long-term follow-up data supports the de-
implementation of PN during the first week of admission. 
Chapter 13 discusses the key findings of this thesis in light of current knowledge. In general, 
our findings underline the necessity of a uniform assessment of barriers inhibiting enteral 
feeding and the increased need to individualise nutritional support during the different 
phases of the acute stress response. The need to better understand the metabolic 
heterogeneity of the PICU population and pathophysiology of gastrointestinal failure during 
critical illness has led to the following future research perspectives:  
- Unravel the mechanism behind feeding intolerance to allow early assessment and 
management 
- Assessment of nutritional requirements for optimal short-term and long-term 
outcomes during acute, stable and recovery phase and the role of amino acids.  
- Explore the impact of micronutrient deficiencies and supplementation 
- Build a model towards tailored nutritional support by further exploring specific 
populations 
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Kinderen die worden opgenomen op de intensive care (IC) afdeling zijn kritiek ziek en 
kunnen daardoor meestal niet zelfstandig eten of drinken. Optimale voeding is belangrijk 
voor het herstel van de kinderen, maar ook voor het in stand houden van normale groei en 
ontwikkeling. Daarom wordt al vroeg tijdens de opname kunstmatige voeding gestart. 
Voeding kan via een sonde in de maag worden gegeven (enterale voeding) of via een infuus 
direct in de bloedbaan (parenterale voeding). 
In Hoofdstuk 1, de inleiding van dit proefschrift, wordt het belang van optimale voeding 
benadrukt. Hoeveel voeding een kritiek ziek kind nodig heeft is afhankelijk van veel factoren, 
zoals diagnose, leeftijd en ernst van ziekzijn. Nadat een kind ernstig ziek is geworden, 
ondergaat het lichaam meerdere fases naar herstel. Deze fases zijn onderverdeeld in een 
acute-, een stabiele- en een herstelfase, maar zowel de duur als de ernst van de fase verschilt 
per kind. Tijdens elke fase zijn de optimale voeding strategieën verschillend. In dit 
proefschrift willen we per fase onderzoeken wat de beste voedingsstrategie is, waarbij we 
met name geïnteresseerd zijn in wanneer we enterale en parenterale voeding moeten 
starten en in welke hoeveelheid. Het is belangrijk om in elke fase niet te veel of te weinig 
voeding geven, want zowel overvoeding als ondervoeding zijn nadelig voor het kind.  
Enterale voeding via het maagdarmkanaal wordt gezien als de betere manier van voeding 
geven, omdat het veilig, kosteneffectief en meer fysiologisch dan parenterale voeding is. De 
aanbevolen calorie- en eiwitdoelstellingen worden echter vaak niet via de enterale route 
bereikt. Er wordt tot wel 60% minder toegediend dan door de arts wordt voorgeschreven. 
Er zijn talloze onderzoeken geweest die de redenen voor dit verschil beschrijven, waarbij 
(vermeende) voedingsintolerantie als gevolg van falen van het maagdarmkanaal, 
vochtbeperking, vasten rond extubatie, procedures en niet-invasieve 
beademingsondersteuning het vaakst worden gemeld. Om deze redenen zal in sommige 
gevallen toch gekozen worden parenterale voeding te geven.  
 
                                                                
 
De acute fase 
In Hoofdstuk 2 hebben we een vragenlijst ontwikkeld waarmee clinici (o.a. artsen, 
verpleegkundigen en diëtisten) de belemmeringen voor enterale voeding op hun kinder-IC 
kunnen beoordelen en aanpakken. Om een goed beeld te krijgen van de wereldwijde 
belemmeringen hebben we deze vragenlijst tevens rondgestuurd. In totaal hebben 920 clinici 
uit 57 landen deze vragenlijst ingevuld. De barrières die het meest voorkwamen waren 
vasten rondom behandeling, afwezigheid van diëtisten, onvoldoende opleiding en training, 
lage zorgprioriteiten en problemen bij het plaatsen van een voedingssonde in de dunne darm. 
Hierbij zou de lage prioritering van voedingszorg een rol kunnen spelen. Dit is opmerkelijk 
gezien voeding erg belangrijk is voor het herstel van zieke kinderen.  
Vanwege bezorgdheid over de mogelijke noodzaak van intensivering van de behandeling en 
daaropvolgende intubatie én vanwege het risico op overgeven en aspiratie, werd 
aangenomen dat niet-invasieve ademhalingsondersteuning één van de belangrijkste factoren 
was voor het uitstellen van enterale voeding. In Hoofdstuk 3 hebben we retrospectief in 
vier centra in Europa onderzocht of kinderen goed enterale voeding konden verdragen 
terwijl ze niet-invasieve ademhalingsondersteuning ontvingen. De kinderen bereikten 
gemiddeld 56% van hun calorische doelstelling. Deze hoeveelheid voeding werd goed 
verdragen met relatief weinig gastro-intestinale symptomen. Omdat de voedingsprotocollen 
en manieren van niet-invasieve ademhalingsondersteuning erg verschilden tussen de vier 
centra, was het lastig om een eenduidige conclusie te vormen. Ons onderzoek toonde wel 
aan dat het meestal mogelijk is om spoedig enterale voeding te starten tijdens niet-invasieve 
ademhalingsondersteuning. Er zijn echter prospectieve onderzoeken nodig om de optimale 
timing en voedingsmethode voor deze kinderen te bepalen. 
Eén van de grootste barrières tijdens het geven van enterale voeding is het ontstaan van 
voedingsintolerantie. Omdat bijna elke clinicus of onderzoeker een ander beeld heeft bij 
wat voedingsintolerantie is, maakt dit onderzoek doen naar dit begrip lastig. In Hoofdstuk 4 
hebben we een systematisch literatuuronderzoek uitgevoerd om de definities van 
voedingsintolerantie die gebruikt werden bij kritiek zieke kinderen te evalueren en om de 
prevalentie, oorzaken en gevolgen van voedingsintolerantie te onderzoeken. In de literatuur 
was voedingsintolerantie inconsistent gedefinieerd en er konden geen oorzaken, 
behandelingen of gevolgen worden geïdentificeerd. Wel werd het vaak geobserveerd 
(mediane prevalentie van 20%). Vanwege het ontbreken van een gestandaardiseerde definitie 
in de literatuur én om geen appels met peren te blijven vergelijken, hebben we een definitie 
voor voedingsintolerantie voorgesteld, welke gebruikt kan worden in toekomstig 
onderzoek. De voorgestelde definitie omvat twee factoren. Allereerst moeten de kinderen 
minder dan 2/3 van hun voedingsdoel kunnen bereiken. Ten tweede moeten er gastro-
intestinale symptomen zoals overgeven, buikpijn en vertraagde maagontlediging aanwezig 
zijn, die de verlaagde enterale inname verklaren. Voor zowel klinisch- als 
onderzoeksperspectief is een dergelijke gestandaardiseerde definitie  nodig om de gevolgen 
van voedingsintolerantie te bepalen én om therapeutische opties te identificeren. 
                                                                
 
Decennia lang werd aangenomen dat een lage voedingsinname leidt tot een slechter herstel 
in de acute fase van ziekzijn, aangezien veel observationele studies een verband tussen deze 
twee factoren lieten zien. De observationele methode van deze onderzoeken vraagt om 
voorzichtigheid bij het aannemen van een verband tussen hogere voedingsinname en beter 
herstel, omdat kinderen die voeding beter tolereren mogelijk minder ernstig ziek zijn en 
alleen daarom al een beter herstel hebben. Om deze reden hebben we in Hoofstuk 5 in 690 
kritiek zieke kinderen onderzocht of het verband tussen voeding en herstel nog steeds 
aanwezig is als je corrigeert voor aanvullende factoren zoals de ernst van ziekzijn. Het viel 
ons op dat gemiddeld slechts 32% van het calorische voedingsdoel gehaald werd gedurende 
de eerste 7 dagen van opname. Een significant lagere voedingsinname werd gezien bij 
kinderen die opgenomen werden na gastro-intestinale chirurgie, voeding kregen via een 
sonde in de maag in vergelijking met dunne darm, bloeddrukverhogingen middelen 
(inotropica) ontvingen of een te grote maagresidu hadden. In onze studie zagen ook wij het 
bekende verband tussen meer voedingsinname en verbeterd herstel, echter was dit verband 
niet meer aanwezig na correctie van aanvullende factoren die van invloed zijn op herstel 
zoals de ernst van ziekzijn. Dit ondersteunt de noodzaak van een gedegen correctie in 
observationeel voedingsonderzoek en de noodzaak van gerandomiseerde gecontroleerde 
studies (RCT) die optimale caloriedoelen onderzoeken. 
De stabiele en herstel fase 
Hoofdstuk 6 is een literatuuroverzicht over de optimale voeding strategieën en 
overwegingen tijdens de herstelfase van kritiek ziek zijn. Hoewel (parenterale) voeding 
restrictie tijdens de acute fase gunstig lijkt te zijn, kan het aanhouden van deze restrictie 
nadat de acute metabole stressrespons is verdwenen, nadelige gevolgen hebben op zowel 
korte als lange termijn. De benodigde hoeveelheid calorieën kan zelfs oplopen tot twee keer 
meer dan normaal voor een gezond kind. Deze hoeveelheid is nodig om herstel, behoud 
van vetvrije massa en (inhaal) ontwikkeling en groei bij kinderen mogelijk te maken. Ook in 
deze fase is het behalen van de relatief hoge doelen lastig door onder andere 
voedingsintolerantie en vochtbeperking. Het geven van eiwit- en energierijke voeding en / 
of intensief gehydrolyseerde voeding (verknipte eiwitten zodat deze makkelijk te verteren 
zijn) kan mogelijk helpen. Daarnaast zijn mobilisatie en beweging essentieel om bij een 
optimale lichaamssamenstelling een inhaalgroei te realiseren. 
Hoofdstuk 7 belicht het gebruik van eiwit- en energierijke zuigelingenvoeding bij kritiek zieke 
zuigelingen tijdens de herstelfase (opnameduur > 2 weken). Gemiddeld werd 100% van de 
energiedoelstelling behaald tijdens de opname en de meerderheid van de 70 patiënten die 
deze zuigelingenvoeding kreeg vertoonde gewichtstoename (mediaan gewicht-voor-leeftijd 
SD-score +0,48). De gewichtstoename was het meest prominent aanwezig bij zuigelingen 
met een lage SD-score bij opname op de kinder-IC. Bovendien werd de zuigelingenvoeding 
goed verdragen en waren er weinig gastro-intestinale symptomen aanwezig. 
                                                                
 
De Europese richtlijnen raden aan om intensief gehydrolyseerde voeding te geven indien 
standaard enterale voeding niet goed verdragen wordt, echter was deze voeding type nog 
niet onderzocht bij kritiek zieke kinderen. Hoofdstuk 8 beschrijft het gebruik van intensief 
gehydrolyseerde zuigelingenvoeding die tevens verrijkt is met eiwitten en energie tijdens de 
herstelfase op twee verschillende kinder-IC afdelingen. De 53 zuigelingen die observationeel 
werden onderzocht, bereikten hun voedingsdoelen en vertoonden gewichtstoename. Ook 
zagen we minimale voedingsonderbrekingen als gevolg van voedingsintolerantie. Deze 
resultaten tonen voorzichtig aan dat deze zuigelingenvoeding resulteert in een goede 
voedingsopname en dat voedingsonderbrekingen als gevolg van gastro-intestinale 
symptomen tot een minimum worden beperkt in kritiek zieke kinderen. 
Parenterale voeding: macronutriënten en micronutriënten 
Hoofdstuk 9 geeft een literatuuroverzicht van de huidige rol van parenterale voeding op de 
kinder-IC. Ondanks de behandelingen om de opname van enterale voeding te verbeteren, 
blijft dit vaak onvoldoende bij kritiek zieke kinderen, waardoor parenterale voeding gestart 
moet worden. Kinderen die geen parenterale voeding ontvangen hebben anders een 
beperkte inname van voedingsstoffen. Omdat meerdere observationele studies hebben 
aangetoond dat ondervoeding schadelijk is, werd van oudsher vroeg gestart met het geven 
van parenterale voeding. De pediatrische vroege versus late parenterale voeding bij kritieke 
ziekte (PEPaNIC) multicentre RCT toonde echter aan dat het weglaten van parenterale 
voeding tijdens de eerste week van opname in vergelijking met de vroege start van 
parenterale voeding (<24 uur) zorgde voor minder nieuwe infecties en sneller ontslag van 
de kinder-IC. Wachten met parenterale voeding is dus beter op de kinder-IC. Dit lijkt 
tegenstrijdig, maar de verklaring ligt in het natuurlijke opruimsysteem van de cellen. Kritieke 
ziekte veroorzaakt schade aan de cellen van alle belangrijke orgaansystemen. Beschadigde 
delen van cellen worden opgeruimd door een proces dat autofagie heet. Dit opruimsysteem 
wordt geactiveerd door vasten en simultaan onderdrukt door voedingsstoffen. Met name 
het geven van eiwitten leek de boosdoener te zijn in dit proces. Hoewel deze restrictie van 
parenterale voeding (suiker, eiwitten en vetten) tijdens de acute fase gunstig is bevonden 
voor kritiek zieke kinderen, is verder onderzoek nodig om de optimale timing, dosering en 
samenstelling van parenterale voeding tijdens de stabiele en herstelfase te weten te komen. 
De bevindingen van de PEPaNIC RCT hebben een aanzienlijke impact op de nieuwe 
parenterale voeding richtlijnen gehad. Deze adviseren nu om macronutriënten (suiker, 
eiwitten en vetten) gedurende 1 week achterwege te laten, terwijl micronutriënten 
(elektrolyten, vitamines en mineralen) wel voldoende gegeven dienen te worden bij kritiek 
zieke kinderen die te weinig enterale voeding ontvangen. Hoofdstuk 10 geeft een overzicht 
van de huidige klinische praktijk en beperkingen in het geven van elektrolyten, vitamines en 
mineralen in de drie deelnemende centra van de PEPaNIC RCT. De lokale protocollen 
werden met elkaar en met de aanbevelingen in de nieuwe parenterale voedingsrichtlijn 
vergeleken. We ontdekten dat het gebrek aan hard klinisch bewijs en het onvermogen om 
                                                                
 
alle aanbevolen hoeveelheden toe te dienen met de momenteel beschikbare commerciële 
producten, de uitvoering van deze nieuwe aanbevelingen belemmerden in alle drie de centra. 
Lange termijn resultaten van parenterale voeding 
Ondanks het gunstige effect van het onthouden van parenterale voeding op de korte termijn, 
is het belangrijk om na te gaan hoe deze kinderen op de lange termijn presteren. In theorie 
kan het geven van minder voedingsbouwstoffen een nadelig effect hebben op de groei, de 
gezondheidstoestand, de neurocognitieve ontwikkeling en de emotionele- en 
gedragsontwikkeling van patiënten. Indien dit het geval is, zouden we opnieuw kritisch naar 
deze behandeling moeten kijken. 
In Hoofdstuk 11 werden de ontwikkelingsresultaten 2 jaar na deelname aan de PEPaNIC 
RCT onderzocht. De lange termijn studie toonde aan dat kinderen die werden opgenomen 
op de kinder-IC in vergelijking met gezonde kinderen een slechtere ontwikkeling hadden op 
alle vlakken. Het onthouden van parenterale voeding gedurende 1 week in de kinder-IC had 
geen negatieve invloed op overleving, groei, gezondheidstoestand en neurocognitieve 
ontwikkeling 2 jaar later, en beschermde de kinderen tegen problemen met hun 
impulscontrole. 
Verschillende ontwikkelingsaspecten kunnen pas volledig worden onderzocht vanaf de 
leeftijd van 4 jaar. Omdat bij de PEPaNIC RCT een groot deel van de kinderen jonger dan 
1 jaar was bij opname, was naast de follow-up van 2 jaar een langere beoordelingsperiode 
nodig om een goed beeld te krijgen van de kinderen. Hoofdstuk 12 presenteert de essentiële 
4-jaar vervolgstudie. Opnieuw werd het nadelige effect van kritieke ziekte duidelijk in 
vergelijking met gezonde kinderen. Het weglaten van parenterale voeding bij kritiek zieke 
kinderen had geen nadelige invloed op de langetermijnresultaten 4 jaar na deelname aan de 
studie. Daarbij had deze behandeling een positief effect op de emotionele- en 
gedragsproblemen die vaak gezien worden na IC opname. Emotionele- en 
gedragsproblemen kunnen het gevolg zijn van problemen met impulscontrole die werden 
gevonden bij het 2 jaar vervolgonderzoek. 
Samenvattend ondersteunen de 2 en 4 jaar lange termijn vervolgstudies de nadelige impact 
van een opname op de kinder-IC én bevestigt dit de noodzaak tot het niet geven van 
parenterale voeding tijdens de eerste week van opname.  
Hoofdstuk 13 bediscussieert de belangrijkste bevindingen van dit proefschrift. Onze 
bevindingen benadrukken het belang van optimale voeding tijdens de verschillende fases van 
ziekzijn voor het herstel en de ontwikkeling van het kind tot 4 jaar na opname. Voor 
optimale voeding is het belangrijk om alle barrières die enterale voeding tegengaan te 
herkennen, een beter begrip van voedingsintolerantie te krijgen en zorgen voor restrictie 
van (parenterale) tijdens de acute fase.  
 
                                                                
 
Dit proefschrift stelt voor dat toekomstig onderzoek zich richt op de volgende essentiële 
onderwerpen: 
- Ontrafelen van het mechanisme achter voedingsintolerantie om vroege 
beoordeling en behandeling mogelijk te maken. 
- Vaststellen van de voedingsbehoeften tijdens de acute-, stabiele- en herstelfase 
voor een optimaal herstel op korte en lange termijn. 
- Onderzoeken van de rol van individuele macronutriënten tijdens kritieke ziekte 
(suiker, eiwitten en vetten). 
- Onderzoeken van de rol van micronutriënten tijdens kritieke ziekte (elektrolyten, 
vitamines en mineralen). 
- Een model bouwen voor individuele voedingsondersteuning met inachtneming van 
de grote diversiteit van de kinder-IC populatie. 
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D A N K W O O R D  
Bij het schrijven van dit dankwoord realiseer ik me hoe leuk, bijzonder, intensief, mooi, 
gezellig en vooral leerzaam de afgelopen 4 jaar zijn geweest. Omdat je promoveren niet 
alleen kan doen, wil ik een aantal mensen in het bijzonder bedanken voor hun steun en 
begeleiding om de figuurlijke top van de promotieberg te bereiken. 
Allereerst wil ik alle patiënten en ouders bedanken die bereid waren om meerdere malen 
vanuit het hele land naar het Sophia te komen om mee te doen met het onderzoek. Zonder 
eigenbelang, maar wel gepakt met een dosis interesse. Dit is de reden waarom ik elke dag 
gemotiveerd naar werk ging. Daarnaast hebben meer mensen dan op te noemen deel 
uitgemaakt bij het uitvoeren van onderzoek op de poli en op de afdeling. Alle 
verpleegkundige, artsen, secretaresses, zorgassistenten, balie- en polimedewerkers, 
psychologen en diëtisten bedankt voor jullie bijdragen. Het bewijs dat je onderzoek niet 
alleen doet is te zien aan de lijst van 42 coauthers. Ik wil iedereen dan ook bedanken voor 
de prettige samenwerking. Annemarie Zimmermann-Oosting em Annemiek Goedhart, ik 
heb jullie betrokkenheid als enorm waardevol beschouwd en geleerd hoe verschillende 
instanties ook kunnen samenwerken. 
 
Om vanuit 020 promotieonderzoek te verrichten in 010 vindt plaats onder de nodige gevate 
opmerkingen en voetbaltermen. Waarvan één in het bijzonder een rode draad in mijn 
promotie heeft gevormd: the Champions League. Ik ben blij en vereerd dat ik heb mogen 
samenwerken met veel inspirerende, scherpe en kritische begeleiders.  
  
Prof. Dr. Joosten, beste Koen. Niemand is beter geschikt om de rol als coach binnen de 
champions league te vervullen. Je weet op de juiste plek te stimuleren, de juiste mensen bij 
elkaar te zetten en blijft gevoel houden voor de persoon. Je betrokkenheid, efficiëntie (het 
was uitzonderlijk als ik niet binnen 48 uur een volledig geredigeerd manuscript terugkreeg) 
en kritische blik zorgde ervoor dat ik mij als wetenschapper optimaal heb kunnen 
ontplooien. Niet alleen binnen het ziekenhuis, maar ook daarbuiten maak je je hard voor 
optimale voedingszorg. Deze gedrevenheid hoop ik ook over te mogen dragen. 
  
Prof. Dr. De Hoog, beste Matthijs, ik heb het gedurende mijn promotie erg fijn ervaren dat 
de mogelijkheid om aan te kloppen er altijd was. Rondom het afronden van mijn promotie 
heb ik gemerkt dat een andere visie enrom verhelderend kan werken. Ook bedankt voor 
uw hulp bij het solliciteren voor die gehoopte AIOS plek. 
  
Dr. Verbruggen, beste Sascha, coach, trainer, aanvoerder, welke rol had je eigenlijk niet? De 
hoeveelheid ballen die jij hooghoudt is benoemenswaardig, maar desondanks stond jij 
vooraan bij elke inclusie of probleem. Als ik vastliep, wanneer dit ook maar was, mocht ik 
                                                                
 
altijd even aankloppen. De hoeveelheid energie en nieuwe ideeën waarmee ik dan weer naar 
buiten liep heeft me enorm veel geholpen.  
  
Prof. Dr. Van den Berghe, beste Greet, uw compassie voor wetenschap is ongeëvenaard. 
De samenwerking met het labo in Leuven was inpirerend en het is uiterst indrukwekkend 
hoeveel onderzoek u onder uw hoede heeft. Bedankt voor uw scherpe en gemotiveerde 
blik. Tevens bedankt voor uw deelname aan de grote commissie. 
 
Prof. Dr. Utens, beste Lisbeth, uw enthousiasme en motivatie voor onderzoek is 
aanstekelijk, daarbij is uw expertise voor de pediatrische psychologie bewonderingswaardig. 
Daarmee wil ik u bedanken voor de bereidheid om plaats te nemen in de grote commissie.  
 
Prof. Dr. Rings, Prof. Dr. Van Woensel en Prof. Dr. Van Zanten, bedankt voor het 
beoordelen van dit proefschrift en ik vind het een eer dat u allen bereid bent om deel te 
nemen in de commissie. 
 
Dr. Hulst en Dr. De Koning, beste Jessie en Barbara, vanaf het begin was het duidelijk dat 
naast de vele vergaderingen, inspanningen en nog meer besprekingen, een gezellige kop 
koffie of etentje op een congres net zo belangrijk zijn. Bedankt voor jullie kritische blik en 
secure aanpassingen zodat het project 10 keer beter werd. Jessie, bedankt dat je altijd extra 
vroeg opstond om vanuit Canada in te bellen. Esther, bedankt dat je mij hebt ingewerkt in 
de wondere wereld van de MDL markers en natuurlijk voor de gezelligheid tijdens de 
ESPGHAN congressen met de mede MDL onderzoekers. 
  
Karolijn, jouw waarde voor het PEPaNIC FU project is onbeschrijfelijk. Niet alleen 
inhoudelijk of door het zien van de vele patiënten, vooral vanwege je empathie en de fijne 
mentale ondersteuning die je soms nodig hebt bij het doen van onderzoek.  
 
Naast inspirerende begeleiders heb ik mogen samenwerken met een grote groep aan 
gedreven onderzoekers. Esther, ik had het project van geen betere onderzoeker kunnen 
overnemen. Jouw harde werk en excel sheets hebben ervoor gezorgd dat de follow-up tot 
het einde gestructureerd verliep. Maar wat hebben wij toch een hoogte en dieptepunten 
meegemaakt. Van nat tot onze enkels alle samples redden uit de vriezer tot de vele 
congressen waar we gezellig de glutenvrije tentjes ontdekte en (extra) wijntjes dronken. 
José, zonder jouw tomeloze inzet was het project een stuk minder succesvol geweest. Van 
Maastricht tot de noordelijke provincies, daar zat je weer uren in de auto. En wat konden 
we toch heerlijk verbaasd zijn over onze patiënten, met name hoe opgegeven casussen toch 
opeens kwamen opdagen. Wie weet rennen we nog een keer samen de bruggenloop, of nog 
beter langs de Seine.  
  
                                                                
 
Sharon en Jolanda, wat fijn dat jullie als onderzoeksassistente vele uren hebben gebeld en 
patiënten hebben gezien. En dan vergeet ik nog al het harde werk rondom het sluiten van 
de datasets. Maar ook de psychologische en medische stagiairs enorm bedankt voor jullie 
inzet. Bedankt Charlotte (eigenlijk heb jij mij ingewerkt), Jeroen (wanneer gaan we nu 
klimmen?), Marissa (wat leuk dat we nu weer samen werken), Eline, Floortje, Lotte, Fien en 
Laura. 
  
Het is bewonderenswaardig hoeveel werk verzet kan worden in één kwartaal. Bedankt 
Pieter, Ilse, Fabian, Sören, An, Ines, Liese, Sandra, Hanna, Astrid, Cettina en Shakira voor de 
fijne samenwerking en gastvrijheid. Elke trip naar Leuven zorgde voor een boost aan 
inspiratie.  
  
Na het afronden van de PEPaNIC follow up, stond het volgende grote project op het 
programma: ContInNuPIC. Arnout en Karlien, in slechts een paar maanden hebben jullie 
het hele project op poten weten te zetten en ik ben heel benieuwd naar de komende tijd. 
Jullie maakte het laatste (corona) jaar een stuk gezelliger en laten we vooral snel weer een 
diner met wijn erbij houden. Ellen en Mirjam, het nut van verpleegkundige in een 
onderzoeksgroep is mij goed duidelijk geworden, jullie nemen ontzettend veel werk uit 
handen. Ook Maud (mis onze koffiemomentjes nu al) en Melissa bedankt voor jullie inzet en 
gezelligheid. 
  
Natuurlijk gaat mijn dank ook uit naar alle ICK poule onderzoekers, die de PEPaNIC, en 
later de ContInNuPIC overnamen. Nienke, Shelley, Gerdien, Christine, Joppe, Sophie en 
Sophie. En natuurlijk was zo af en toe en poule uitje ook niet verkeerd.  
 
Joke, jij hoort eigenlijk onder alle kopjes. Ontzettend bedankt voor al je hulp en het ad rem 
meedenken met alle problemen. Je bent een grote steun voor alle ICK onderzoekers. 
 
Ik kan elke (medische) promovendus aanraden om in ieder geval een deel van de tijd te 
spenderen tussen psychologen. Naast psychosociale ondersteuning, is er op de KJPP afdeling 
geen gebrek aan statistische en wetenschappelijke kennis. De research lunches, borrels, 
kantoorcavia-gesprekken, theeleut-rondes en sportieve uitstapjes zoals de bruggenloop en 
bootcamp waren een fijne afwisseling. Suus, mijn enige eilandgenoot, wat heerlijk om naast 
jou te werken. Zonder jou was mijn promotie een stuk saaier geweest (en minder sportief), 
maar ik wil je vooral bedanken dat je altijd de moeite nam een antwoord op mijn vragen te 
vinden. Vanaf heden leid ik je in ieder geval niet meer op dagelijkse basis af.  
 
Roomies, fijne collega’s maken het werk pas echt leuk en bij ons was er geen gebrek aan 
gezelligheid. Wat ga ik onze koffierondes, escape room uitjes, kroketbuffets en do/vrijmibo’s 
missen. Naast hard werken heb ik ook enorm met jullie gelachen, waarvan sommige mooie 
uitspraken nog steeds op de deur staan. Ik zal ze hier maar niet herhalen. 
                                                                
 
Wyts, al die lekkere (natuur)wijntjes hebben uiteindelijk geleidt tot de inspiratie voor de 
design van dit boekje. Op naar vele meer, afgewisseld met een sportief lesje. 
 
Lieve, Heidi, Jeroen, Marjolijn, Ivar, Masha, Jimmy, Gusta en Martijn, en de uitbreiding Xam, 
Keo, Pux en Mika. Hoe lang zijn we nu al vrienden? Ik raak elke keer de tel kwijt, maar het 
voelt alsof jullie er altijd al waren. In het begin nog voorzichtig Sinterklaas-spelletjes spelen, 
lekker puberen in de kroegen van Noordwijk. Inmiddels hebben we allemaal een ander pad 
genomen. We zijn zo verschillend, maar matchen zo goed. Bedankt voor jullie steun en dat 
julie er altijd voor mij zijn, of de situatie nu om ijs, thee of wat sterkers vraagt. 
 
Vanaf dag één op de VU was het raak en wat is het fijn dat we nog steeds zulke goede 
vriendinnen zijn. Wat heerlijk om te zien dat idereen een andere kant op is gegaan en een 
prachtige baan heeft weten te bemachtigen. Lieve, Violet, Truc My, Jessica en Emma, jullie 
begrijpen als geen ander hoe het is om te promoveren, maar vooral ook hoe je van het 
leven moet genieten. Ik kijk uit naar de feestjes, bruiloten, vele etentjes en (ski)vakanties die 
nog zullen volgen.  
 
Lieve Eske, onze vriendschap begon op de long en geriatrie afdeling in het UZ Leuven. Met 
als traditie nog steeds onze jaarlijkste stedentripjes samen met Emma waarbij we meestal 
terug naar Leuven gaan. Weekendjes Rottedam/Zeeland, bbq’s, festivalletjes met Mara. Dit 
dankwoord zou niet compleet zijn zonder jullie nadrukkelijk te bedanken voor jullie steun 
rond alle hoogte- en dieptepunten (lees Maleisië). Ik gun iedereen zo’n hechte vriendschap 
zoals ik met jullie heb! 
 
Lieve Masha, wat fijn dat jij als paranimf aan mijn zijde staat. Vanaf moment één was je super 
enthousiast over het doen van onderzoek. Je hebt mij dan ook door alle momenten heen 
gesteund. De promotieoutfit was al besteld alvorens je uberhaupt de datum wist. Ik heb 
bewondering voor hoe jij in het leven staat en wat voor goede moeder je bent.  
 
In slechts enkele jaren zijn wij gegroeid van collega’s bij de CTC naar ontzettend goede 
vriendinnen en mogen wij vlak na elkaar aan elkaars zijde staan als paranimf. Wie o wie zal 
het eerst zijn? Maakt niet uit, zoalg de gepersonaliseerde Jimmy’s maar binnen zijn. Bedankt 
voor je steun, het sparren en de gezamelijke schrijfsessies onder het genot van een 
kaasplankje en wijn. Ik heb onwijs genoten van de afgelopen jaren. Indonesië, Ibiza en Zuid-
Afrika waren toch wel hele mooie hoogtepunten.  
 
Wat is het een genot om af te dalen naar de Brabantse gezelligheid voor de schoonfamilie. 
Mijn tweede date was niet voor niets op de bank van “os” ma. Lekker curry eten, proper 
English tea drinken en vooral heel veel geklets en gezelligheid. Annette, haal dat schoon 
maar weg voor familie. Je ontvangt iedereen met open armen en geen verzoek is te gek. 
Wat fijn dat jij ons altijd uit de brand helpt en Murphy altijd welkom is. Dad, ik hou ervan 
                                                                
 
dat we samen kunnen genieten van koken, maar vooral van het daarna opeten. Brad, hoe 
vaak heb jij wel niet op onze bank geslapen? Gamen tot in de late uurtjes en onze favoriet 
burrito’s eten. De traditie van spelletjes spelen zullen we nog lang volhouden nu Marjolein 
en Bram erbij zijn. 
 
In een totaal niet medische familie blijft promoveren toch een abstract begrip. Eigenlijk weet 
ik het nog steeds niet goed uit te leggen. Wanneer ben je nu klaar? Toch zijn jullie elke keer 
benieuwd naar nieuwe artikelen. Mam, de hoeveelheid liefde die jij aan Amanda en mij geeft 
is onbeschrijfelijk. Nog steeds kan ik het beste winkelen met jou (sorry Lies)en staan we 
nog altijd graag in de Duitse kroegen gluhwijn te drinken. Pap, de waarde van hard werken 
en daarvan de vruchten plukken heb ik van jou geleerd. Van klein meisje in de veilingbak 
tussen de rozen, naar een promotiefeest had ik niet kunnen bereiken zonder een goede 
basis. Lieve Amanda, wat ben ik trots op je! Gewoon een studie naast je fulltimebaan 
oppakken. Gelukkig is het latten met Ram tussen Nederland en Nepal nu eindelijk voorbij! 
 
Lief, wat hou ik toch ontzettend veel van je! Ik denk dat er weinig partners zijn die hun vrije 
dagen opgeven om in het ziekenhuis urenlang voedingsdata in een database over te nemen 
of 1000 vragenlijsten op juistheid contoleren. En juist dat vind ik zo mooi aan ons. Er altijd 
voor elkaar zijn. Het meest gelukkig ben ik als ik bij jou ben (liefst al reizend in een ver land 
of juist met de honden op de bank).  
 
 
